sentences,filename
"2021 Performance Report Advancing Science for LifePatient spotlight: Arnold Vargas Gonzalez Not long after joining Boston Scientific, Arnold Vargas Gonzalez sensed it would be more than just a job.",2021_boston_scientific_performance_report.pdf
"“The Boston Scientific quality culture inspired me right away,” says the 39-year-old, who is based in Coyol, Costa Rica.",2021_boston_scientific_performance_report.pdf
"Arnold worked hard to progress from product builder to quality inspector, and with encouragement and support from his leaders and colleagues, he pursued a degree in industrial engineering to advance his career in quality.",2021_boston_scientific_performance_report.pdf
"After earning a promotion to quality engineer, Arnold suffered gallbladder complications, which led to a critical surgery.",2021_boston_scientific_performance_report.pdf
"When doctors showed him the stent they were using, he knew he would make a full recovery.",2021_boston_scientific_performance_report.pdf
“I saw the Boston Scientific logo and it gave me such peace of mind.,2021_boston_scientific_performance_report.pdf
I believed in the device because we built it.” Arnold was soon back on the quality front lines and to his studies.,2021_boston_scientific_performance_report.pdf
"In 2021, amid global uncertainty, Arnold and his team stood strong — along with 41,000 Boston Scientific colleagues around the world.",2021_boston_scientific_performance_report.pdf
"Across the company, our people innovated to improve patient outcomes, stay connected with customers and deliver solutions wherever they were needed.",2021_boston_scientific_performance_report.pdf
The collective resolve of our global team accelerated our progress as a business and as a corporate citizen.,2021_boston_scientific_performance_report.pdf
"We found new ways to support our communities, protect the environment we all share and make care more equitable.",2021_boston_scientific_performance_report.pdf
"Like Arnold, we believe — in the power of doing our part, always working for a better future and advancing science for life.",2021_boston_scientific_performance_report.pdf
"Arnold Vargas Gonzalez engineer, Quality Assurance and Boston Scientific patient“ I knew my future would be here, making our products — always with the patient in mind.” Arnold and his wife Eimy, who also works in manufacturing at our Coyol site, are inspired to make life better for patients every day.",2021_boston_scientific_performance_report.pdf
2 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix This report has been prepared in reference to the Global Reporting Initiative guidelines and the SASB standards for the Medical Equipment & Supplies industry.,2021_boston_scientific_performance_report.pdf
"Unless otherwise indicated, data in this 2021 Performance Report and appendix are as of December 31, 2021, or for the year ended December 31, 2021, as applicable.",2021_boston_scientific_performance_report.pdf
Please refer to the appendix for detailed metrics and key definitions used within this report.,2021_boston_scientific_performance_report.pdf
"Reporting on other matters specific to financial performance of the company and its subsidiaries can be found in our 2021 Annual Report.Table of contents Patient spotlight: Arnold Vargas Gonzalez 2 A message from our Chairman and Chief Executive Officer 4 Our mission and values 6 Boston Scientific: 2021 at a glance 7 Our ESG strategy: Advancing science for life 8 2021 highlights 11 Awards and recognition 12 Transforming care 13 Innovating to meet more patient needs 14 Ensuring quality, health and safety 17 Improving access and outcomes through digital solutions 19 Investing in our people 20 Our diverse, equitable and inclusive workplace 21 Attracting, developing and retaining talent 25 Employee well-being, rewards and safety 28 Accelerating possibilities 31 Improving health equity and access 32 Confronting inequities 35 Supporting our communities 36Protecting the environment 39 Reducing our environmental impact 40 Managing climate risk 45 Advancing product stewardship 46 Creating value responsibly 48 Good governance reflects our values 49 Compliance, ethics and integrity 50 Protecting human rights across our company and supply chain 51 Keeping our supply chain resilient and reliable 52 Risk management and global security 53 Keeping our products and patient data secure 54 Appendix 55 Stakeholder engagement 56 Metrics summary 57 Global Reporting Initiative (GRI) index 68 Sustainability Accounting Standards Board (SASB) index 75 United Nations Sustainable Development Goals (SDGs) 77 3 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix A message from our Chairman and Chief Executive Officer We remain confident in our progress and committed to transforming care, investing in our people, accelerating possibilities, protecting the environment and creating value responsibly.",2021_boston_scientific_performance_report.pdf
Our 2021 performance report is one example of our efforts to be transparent and accountable to the public and our many stakeholders.,2021_boston_scientific_performance_report.pdf
"We are committed to understanding and managing environmental, social and governance (ESG) opportunities and risks in our business practices.",2021_boston_scientific_performance_report.pdf
"Overall, performance across Boston Scientific businesses remains strong and our future is promising.",2021_boston_scientific_performance_report.pdf
We’ve accomplished a great deal as we learned to manage through the pandemic.,2021_boston_scientific_performance_report.pdf
"In 2021, we invested more than $1 billion in research and development and launched 90 new products to advance patient care.",2021_boston_scientific_performance_report.pdf
We strengthened our digital capabilities to enhance patient engagement to facilitate remote education and training for health care providers.,2021_boston_scientific_performance_report.pdf
"Our teams conducted 145 global clinical trials and received approximately 1,250 market approvals that expand access to our technologies.",2021_boston_scientific_performance_report.pdf
"Above all, we improved the lives of more than 30 million patients.At Boston Scientific, we have always been dedicated to advancing science for life.",2021_boston_scientific_performance_report.pdf
"Now more than ever — at a time when we face continued challenges and uncertainty as a global community — we are hopeful and united by our mission and values to create a healthier, brighter future for one another and for our planet.",2021_boston_scientific_performance_report.pdf
"Mike Mahoney Chairman and Chief Executive Officer, Boston Scientific“ Working together, we can continue to transform lives around the world through innovative medical solutions.” 4 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Addressing inequities in workplaces, communities and health care systems The inequities in our workplaces, communities and health care systems have been starkly revealed over the last few years — by the pandemic, polarizing political environments, racial and social injustice and economic uncertainty.",2021_boston_scientific_performance_report.pdf
"We have committed to support diversity, address health inequities and combat systemic racism and injustice both within Boston Scientific and our communities.",2021_boston_scientific_performance_report.pdf
"In 2021, we made progress toward our goals by taking the following actions: • Deepened our diversity programs aimed at eliminating bias, racism and other forms of discrimination in our workplace as part of our 3Up by 2023 initiative, which is aimed at increasing representation of women and multicultural talent at the management level.",2021_boston_scientific_performance_report.pdf
• Introduced a human capital scorecard as part of our 2021 annual bonus program to hold ourselves accountable for building a more diverse and inclusive workplace and achieving our environmental goals.,2021_boston_scientific_performance_report.pdf
"• Expanded relationships with certified companies that share our dedication to improving customer and patient care, which included investing more than $865 million in small and diverse suppliers to help us meet our business objectives through external collaborations.",2021_boston_scientific_performance_report.pdf
"• Extended our advocacy across 28 national and local organizations as part of the second year of a $3.5 million multiyear strategy to combat inequity, systemic racism and injustice in the U.S. • Increased diversity in medical research and partnered with community health care providers to expand awareness of health disparities and address them through our Close the Gap health equity initiative.",2021_boston_scientific_performance_report.pdf
"• Contributed more than $75 million in corporate donations to fund medical research, fellowships, education and charitable organizations globally.Taking action for a healthier planet By protecting the planet’s health, we protect human health.",2021_boston_scientific_performance_report.pdf
That’s why sustainable and inclusive business practices are central to our work to transform lives.,2021_boston_scientific_performance_report.pdf
We are on track to achieve carbon neutrality by 2030 in all manufacturing and key distribution sites.,2021_boston_scientific_performance_report.pdf
"In 2021, we committed to setting new science-based targets and reaching net-zero carbon emissions across our entire value chain by 2050.",2021_boston_scientific_performance_report.pdf
"So far, we’ve cut our energy usage by investing in and increasing energy efficiency at all of our sites.",2021_boston_scientific_performance_report.pdf
This includes new construction that meets the highest climate standards.,2021_boston_scientific_performance_report.pdf
Nearly half of Boston Scientific real estate — more than 4 million global square feet — currently meets International Organization for Standardization (ISO) and Leadership in Energy and Environmental Design (LEED) energy and environmental standards.,2021_boston_scientific_performance_report.pdf
We are also converting to renewable energy.,2021_boston_scientific_performance_report.pdf
"In 2021, 73% of our electricity came from renewable sources (exceeding our interim goal of 50% by 2021) and we aim to source or generate 100% of our electricity from renewable sources by 2024.1,2 We are also pursuing efforts to better manage or reduce waste, conserve water and increase medical device recycling to minimize environmental impact of our products and packaging.",2021_boston_scientific_performance_report.pdf
"To better protect our business and customers from climate-related disruption, our climate risk approach entails oversight, risk management and mitigation efforts throughout our business.",2021_boston_scientific_performance_report.pdf
"Creating a healthier, more equitable future We have much work to do but we are making meaningful progress.",2021_boston_scientific_performance_report.pdf
The spirit and commitment of our global team has enabled us to succeed during uncertain times.,2021_boston_scientific_performance_report.pdf
"We have a robust portfolio and pipeline, ambitious research and development, the highest quality standards and a deeply talented global team.",2021_boston_scientific_performance_report.pdf
"Working together, we can continue to transform lives around the world through innovative medical solutions.",2021_boston_scientific_performance_report.pdf
"Mike Mahoney Chairman and Chief Executive Officer, Boston Scientific 1 Inclusive of all manufacturing and key distribution sites only.",2021_boston_scientific_performance_report.pdf
"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
5 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Our mission and values Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.,2021_boston_scientific_performance_report.pdf
"Our work is guided by core values that define the Boston Scientific culture and empower our employees.Meaningful innovation We foster an environment of creativity to transform new ideas into breakthrough services and solutions that create value for patients, customers and employees.",2021_boston_scientific_performance_report.pdf
"Diversity We embrace diversity and value the unique talents, ideas and experiences of our employees.High performance We strive for high performance to benefit our patients, clinicians and shareholders.",2021_boston_scientific_performance_report.pdf
"Winning spirit We adapt to change and act with speed, agility and accountability to further improve patient care.Caring We act with integrity and compassion to support patients, customers, our communities and each other.",2021_boston_scientific_performance_report.pdf
Global collaboration We work collaboratively to pursue global opportunities that extend the reach of our medical solutions.,2021_boston_scientific_performance_report.pdf
"6 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix U.S. $6,901 EMEA (Europe, Middle East and Africa) $2,518 APAC (Asia-Pacific) $2,070 LACA (Latin America and Canada) $386 Medical Devices1 $11,875 Specialty Pharmaceuticals2 $13 Net Sales $11,888Boston Scientific: 2021 at a glance Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.",2021_boston_scientific_performance_report.pdf
"As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care.",2021_boston_scientific_performance_report.pdf
"2021 net sales by region (dollars in millions)2021 net sales by business (dollars in millions) 1 We have three historical reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices.",2021_boston_scientific_performance_report.pdf
"In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients.",2021_boston_scientific_performance_report.pdf
"Following the reorganization, we have aggregated our core businesses, into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices.",2021_boston_scientific_performance_report.pdf
"2 On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business.",2021_boston_scientific_performance_report.pdf
Our consolidated net sales include Specialty Pharmaceuticals up to the date of the closing of the transaction.,2021_boston_scientific_performance_report.pdf
Specialty Pharmaceuticals net sales were substantially U.S. based and presented as a stand-alone operating segment alongside our Medical Device reportable segments.,2021_boston_scientific_performance_report.pdf
"$11,888 million To learn more about our category leadership strategy and growth opportunities, visit our Investor Relations website.Minimally invasive devices for diagnosing and treating gastrointestinal and airway conditionsSolutions for urological diseases including stone disease, men’s health and women’s healthGroundbreaking technologies that treat irregular heart rhythms and heart failure and help protect against sudden cardiac arrestA broad range of mapping and treatment technologies for diagnosing and treating heart rhythm disordersElectronic implantable technologies that help patients manage debilitating chronic pain and neurological conditionsMinimally invasive innovations that help improve the lives of patients living with heart and vascular conditionsLeading devices for diagnosis and minimally invasive treatments of peripheral vascular disease and cancer$2,141 $1,583 $2,019 $365 $909 $3,038 $1,820 Rhythm and Neuro MedSurg Endoscopy Electrophysiology Neuromodulation Cardiac Rhythm Management Urology and Pelvic Health Cardiovascular Interventional Cardiology Peripheral Interventions 7 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Linking compensation to ESG performance We introduced a human capital scorecard as part of our 2021 annual bonus program for all eligible employees.",2021_boston_scientific_performance_report.pdf
This is intended to reinforce our ESG focus and hold ourselves accountable to our goals in a measurable way.,2021_boston_scientific_performance_report.pdf
The human capital scorecard is weighted at 15% of our total bonus pool funding and equally divided among three ESG performance metrics.,2021_boston_scientific_performance_report.pdf
"Performance metric 2021 results Diversity, equity and inclusion (DE&I) • Increased representation of women in supervisor and manager roles globally to 41.1% and multicultural employees in the U.S. and Puerto Rico to 21.6%.",2021_boston_scientific_performance_report.pdf
"Our 2021 goals were 41.5% and 22.2%, respectively.",2021_boston_scientific_performance_report.pdf
Employee engagement and retention• Conducted an employee engagement survey and executed against our multi‐year enterprise action plan.,2021_boston_scientific_performance_report.pdf
• Met key employee retention rate goals.,2021_boston_scientific_performance_report.pdf
"Environmental • Increased renewable electricity use to 73% and decreased carbon footprint to 52.3k metric tons.1,2 Our 2021 goals were 70% and 55.0k metric tons, respectively.Human capital scorecard Learn more about our stakeholder engagement in the Appendix.For more information on our compensation programs, including the human capital scorecard, please see the Compensation Discussion and Analysis section of the company’s 2022 Proxy Statement.1 Inclusive of all manufacturing and key distribution sites only.",2021_boston_scientific_performance_report.pdf
"2 Reflects adjustments to previously reported figures of 72% renewable electricity and 53.7k metric tons CO2 in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
"8 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Our ESG strategy: Advancing science for life We believe in the life-changing potential of science for health care providers, their patients and communities.",2021_boston_scientific_performance_report.pdf
Our focus on improving patient health comes with a responsibility to have a positive impact on the world we share.,2021_boston_scientific_performance_report.pdf
"We are committed to understanding, managing and integrating environmental, social and governance (ESG) risks and opportunities into our business practices.",2021_boston_scientific_performance_report.pdf
"Guided by these insights and our values, we are making measurable progress.",2021_boston_scientific_performance_report.pdf
"Our people in approximately 115 countries are the driving force behind our initiatives aimed at addressing the world’s most pressing challenges, including inequity, economic disparity, climate change and environmental protection.",2021_boston_scientific_performance_report.pdf
Subject matter experts from across the company serve on our global ESG council and champion our ESG priorities.,2021_boston_scientific_performance_report.pdf
"The council’s efforts are directed by our ESG steering committee, composed of senior leaders and led by a member of our executive committee.",2021_boston_scientific_performance_report.pdf
"These members help shape our enterprise strategy and provide regular updates to our board of directors and its Nominating and Governance Committee, which has responsibility to monitor developments and oversee the company’s practices and policies related to environmental and social issues, and other matters impacting our standing as a responsible corporate citizen.",2021_boston_scientific_performance_report.pdf
"Within this framework, everyone in the organization has responsibility for and contributes to ESG progress.Stakeholder engagement for ESG progress Our ESG strategy, priorities and practices are informed by conversations with diverse stakeholders inside and outside the company — locally, nationally and globally.",2021_boston_scientific_performance_report.pdf
"In our collaborations and other business relationships, we work with organizations that share our commitment to better understand and improve environmental, social and economic progress.",2021_boston_scientific_performance_report.pdf
"Importance to stakeholdersOur ESG materiality matrix Human capital attraction and developmentEmployee well-being, engagement and safety Corporate governancePatient outcomes Product quality and customer health and safety Diversity, equity and inclusion/anti-racism Greenhouse gas emissions/energySupply chain managementHealth equity and access Climate risk managementProduct stewardship ComplianceTransparency Data securityInnovation for patient needs Corporate philanthropy, community outreach and volunteerism Other air and water emissions Customer relationship management Ethics in research and development /animal testing Public policy and lobbyingBiodiversityRisk and crisis managementLabor and compensationAnti-corruption and anti-competitive behaviorHuman rights Impact on economy, environment and societyhigh criticalcritical Key Material1 ImportantAssessing our ESG priorities We can better focus our efforts to reduce risk and drive positive impact when we fully understand the ESG topics most important to our stakeholders and our business.",2021_boston_scientific_performance_report.pdf
"In 2021, we engaged with an independent third-party consulting firm to update our materiality1 assessment.",2021_boston_scientific_performance_report.pdf
"The work to examine our priority topics involved in-depth interviews, peer benchmarking and guidance from internationally recognized sustainability frameworks and standards.",2021_boston_scientific_performance_report.pdf
"After consulting with internal subject matter experts on the topics identified by the assessment, the Boston Scientific ESG Steering Committee, Executive Committee and Board of Directors reviewed the findings.",2021_boston_scientific_performance_report.pdf
Taking direction from our stakeholders We worked with our outside experts to assess research and benchmarking results and distill more than 100 potential material topics to 31.,2021_boston_scientific_performance_report.pdf
"Based on this process and input gathered from stakeholder outreach, we scored potential topics on two dimensions: importance to stakeholders and impact on the economy, environment and society.",2021_boston_scientific_performance_report.pdf
"Informed by our materiality assessment and our values, we prioritized 15 material topics that would have the greatest impact.",2021_boston_scientific_performance_report.pdf
Our teams will be working to further prioritize and integrate these findings into our ESG strategy.,2021_boston_scientific_performance_report.pdf
We will continue to regularly monitor and assess progress to ensure we remain focused on the issues of greatest importance to our stakeholders.,2021_boston_scientific_performance_report.pdf
"1 Throughout this report, we use the Global Reporting Initiative Standards definition of materiality in order to identify and prioritize ESG topics for the company.",2021_boston_scientific_performance_report.pdf
"This standard is different from the definition and concept of materiality within the securities laws that we use to assess, among other things, required disclosure in Securities and Exchange Commission filings.",2021_boston_scientific_performance_report.pdf
"ESG topics identified as “material” for purposes of this report may not be considered material to the Company as a whole, including for SEC reporting purposes.",2021_boston_scientific_performance_report.pdf
9 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Our ESG framework We have organized our areas of focus under five pillars that reflect our ongoing dedication to ESG as we pursue our commitment to advance science for life.,2021_boston_scientific_performance_report.pdf
"In some cases, they overlap across our pillars, which is represented in the graphic to the right: Protecting the environmentInvesting in our peopleCreating value responsiblyTransforming care Product quality and customer health and safety Diversity, equity and inclusion Greenhouse gas emissions and energyAccelerating possibilitiesProduct stewardshipSupply chain managementHealth equity and access Patient outcomesInnovation for patient needs Climate risk management Corporate governanceTransparency Data securityCompliance Employee well-being, engagement and safety Human capital attraction and development 10 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix 2021 highlights Transforming care Protecting the environmentAccelerating possibilities Creating value responsibly Investing in our people $1+ billion invested in R&D for products to advance patient care41.1% of supervisor and manager roles held by women globally; 21.6% by multicultural employees in the U.S. and Puerto Rico70 hospitals and providers acted to address inequities in specialty care through Close the Gap partnerships68% reduction in greenhouse gas emissions since 2009 (Scope 1 and 2)1~35 million products delivered 99%+ pay equity$75+ million in contributions for medical research, fellowships, education and charitable organizations globally73% of electricity consumed generated from renewable sources, surpassing our interim goal of 50% by 20211, 2$865+ million spent on small and diverse suppliers30+ million patients served 1 Inclusive of all manufacturing and key distribution sites only.",2021_boston_scientific_performance_report.pdf
"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
"11 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Awards and recognition Newsweek America’s Most Responsible Companies (2020, 2021)Forbes Best Employers for Diversity (2018 – 2022) Clarivate Analytics Top 100 Global Innovators (2017 – 2021) Glassdoor Employees’ Choice Best Places to Work (2018, 2019, 2022) FTSE4Good Index (2016 – 2021)Fast Company Best Workplaces for Innovators (2020, 2021) Newsweek America’s Most Loved Workplaces (2021) Catalyst Award (2022)Disability Equality Index (DEI) Best Place to Work for Disability Inclusion (2016 – 2021) Forbes World’s Top Female Friendly Companies (2021) Seramount Inclusion Index Leading Company (2021)Human Rights Campaign (HRC) Best Places to Work for LGBTQ Equality (2015 – 2022) Bloomberg Gender-Equality Index (GEI) (2019 – 2022) Dow Jones Sustainability Index North America (2020, 2021) FORTUNE World’s Most Admired Companies (2016 – 2022) JUST Capital and CNBC’s America’s Most JUST Companies (2020 – 2022) Visit our website for more information on our recent awards and recognitions.",2021_boston_scientific_performance_report.pdf
"12 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from our Chairman and Chief Executive Officer Our mission and values Boston Scientific: 2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Transforming care Our work in health care is about addressing patients’ critical needs, expanding access to care and helping improve outcomes so people can lead longer, better lives.When we challenge the status quo, we advance breakthrough ideas to transform lives.",2021_boston_scientific_performance_report.pdf
"$1+ billion invested in R&D for products to advance patient care30+ million patients served 13 2021 Performance ReportIntroduction Transforming care Overview and 2021 highlights Innovating to meet more patient needs Ensuring quality, health and safety Improving access and outcomes through digital solutions Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Overview and 2021 highlights Amid significant disruption and uncertainty in a prolonged pandemic, our teams challenged what was possible.",2021_boston_scientific_performance_report.pdf
We developed new capabilities and adapted to stay connected with customers who were frequently faced with treating patients in challenging settings.,2021_boston_scientific_performance_report.pdf
"Our people upheld rigorous quality processes, delivered market-leading solutions around the world and collaborated with providers and communities to expand health care access.",2021_boston_scientific_performance_report.pdf
"To increase the impact of our work, we enhanced our digital platforms that support our products and help keep us engaged with physicians and their patients.",2021_boston_scientific_performance_report.pdf
Innovating to meet more patient needs Our teams are always reaching for breakthrough solutions that will make a meaningful difference for patients and health care providers.,2021_boston_scientific_performance_report.pdf
"Our products help physicians diagnose and treat complex cardiovascular, vascular, digestive, oncological, neurological, urological and pelvic health diseases and conditions.",2021_boston_scientific_performance_report.pdf
"We work across the company and with trusted experts and providers to deepen our portfolio in these areas and continue to create value for patients, physicians and payers.",2021_boston_scientific_performance_report.pdf
"Our innovations are the result of organic research, collaborations, tuck-in acquisitions, investments in emerging technologies and strategic partnerships.",2021_boston_scientific_performance_report.pdf
"Research and development (R&D) to advance innovative care We pursue scientific advances through a uniform, global approach that combines business, technical and quality processes.",2021_boston_scientific_performance_report.pdf
"This allows us to monitor products over their life cycles, from concept and commercialization through next-generation designs.",2021_boston_scientific_performance_report.pdf
The data we gather and analyze help us develop solutions to address unmet customer and patient needs.,2021_boston_scientific_performance_report.pdf
"In 2021, we invested more than $1 billion in R&D and launched 90 new products to advance patient care.",2021_boston_scientific_performance_report.pdf
"Thirty-five percent of total company revenue flowed from products released between 2019 and 2021, which we believe represents a strong pace of innovation.We have research and development sites in the United States, the European Union, Costa Rica, India and China.",2021_boston_scientific_performance_report.pdf
Some of the sites also serve as R&D Centers of Excellence where we identify successful practices and share them across the company to strengthen our overall R&D capability.,2021_boston_scientific_performance_report.pdf
One example of how these R&D Centers of Excellence teams work together to inspire continuous innovation is our growing line of drug-eluting devices.,2021_boston_scientific_performance_report.pdf
"Since introducing drug-eluting coronary stents in the early 2000s, our teams have advanced the technology and developed new devices to address a broader range of conditions.",2021_boston_scientific_performance_report.pdf
"We offer our customers both a drug-coated balloon and a drug-eluting stent, providing a comprehensive set of therapies to treat patients with peripheral artery disease in major markets.Randy Schiestl vice president, R&D, Global Technology“ Since our founding, creating something new that makes a difference in patients’ lives is at the heart of how we innovate.”$1+ billion invested in R&D 10.1% R&D spend as percent of sales 90 new products 35% sales generated from new products launched over the last three years 2021 innovation results 14 2021 Performance ReportIntroduction Transforming care Overview and 2021 highlights Innovating to meet more patient needs Ensuring quality, health and safety Improving access and outcomes through digital solutions Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Seeking new opportunities to deliver breakthrough solutions Through our venture portfolio and strategic acquisitions, we invest in early-stage and commercial-stage companies to identify technologies that expand our ability to diagnose and treat complex diseases and conditions.",2021_boston_scientific_performance_report.pdf
"In 2021, Boston Scientific announced five acquisitions that we anticipate will help us advance outcomes and strengthen our pipeline.",2021_boston_scientific_performance_report.pdf
Learn more about each acquisition on our website .,2021_boston_scientific_performance_report.pdf
"Partnering to accelerate scientific progress Our teams work closely with external research organizations, academic institutions and practitioners to evaluate ideas, develop medical device designs and conduct feasibility studies.",2021_boston_scientific_performance_report.pdf
"For instance, through our Motion Medical joint innovation accelerator with the Mayo Clinic, engineers from Boston Scientific work with physicians to develop prototypes and treatments for conditions that impede quality and longevity of life.",2021_boston_scientific_performance_report.pdf
Here are some highlights from our collaborations.,2021_boston_scientific_performance_report.pdf
gBETA MedTech Black Founder Accelerator: The first gBETA MedTech program specifically for early-stage Black-owned businesses announced its initial cohort of five health care start-ups.,2021_boston_scientific_performance_report.pdf
PracticePoint Alliance: Our engineers worked with Worcester Polytechnic Institute (WPI) faculty and students to develop robotics concepts and test endoscopy and urology prototypes.,2021_boston_scientific_performance_report.pdf
"MEDX Xelerator: The medical device and digital health- focused incubator announced its first million-dollar challenge for physicians and engineers pursuing novel ways to meet health care needs.~$1 billion invested in venture portfolio over the past decade ~35 active venture investments in 2021 3 out of 5 of our 2021 acquisitions announced came from our venture portfolio 15 2021 Performance ReportIntroduction Transforming care Overview and 2021 highlights Innovating to meet more patient needs Ensuring quality, health and safety Improving access and outcomes through digital solutions Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Jenifer Levinson vice president, Global Health Economics and Market AccessAddressing health economics to improve market access To increase patient access to needed medical therapies globally, our Health Economics and Market Access (HEMA) team studies the health economics associated with using our devices.",2021_boston_scientific_performance_report.pdf
HEMA economists use clinical outcomes and real-world data to demonstrate the economic value of our medical solutions and share that clinical and economic evidence to support payer and provider decision-making.,2021_boston_scientific_performance_report.pdf
"The HEMA team worked closely with our Close the Gap initiative in 2021, using health disparity analytics to engage providers and advocate for clinical trial reimbursement policies that support more diverse representation.",2021_boston_scientific_performance_report.pdf
"As a result of the HEMA team’s efforts in 2021, we made the following advances to improve patient access to treatment: “ It’s all about access.",2021_boston_scientific_performance_report.pdf
"If a health care provider believes their patient is going to benefit from a procedure, we want to make sure it is affordable and covered by the payer so the patient receives the care they need.”Access in the U.S.",2021_boston_scientific_performance_report.pdf
Most insurance plans in the U.S. now cover approved use of the WATCHMAN FLX™ left atrial appendage closure device.,2021_boston_scientific_performance_report.pdf
"The U.S. Centers for Medicare & Medicaid Services granted new payment terms for single-use duodenoscopes, including the Boston Scientific EXALT™ Model D, increasing patient access to medical technology that substantially improves diagnosis and treatment.",2021_boston_scientific_performance_report.pdf
"Providers now have access to a device for the 40% of Medicare patients who need treatment for problems in the liver, gallbladder, bile ducts and pancreas.",2021_boston_scientific_performance_report.pdf
"Access in South Africa Nearly 3 million patients now have access to procedures utilizing the AXIOS™ Stent and Delivery System, which enables physicians to treat patients endoscopically instead of surgically.Access in Korea In Korea, patients now have access to procedures involving the SpyGlass™ DS direct visualization system and TheraSphere™ therapy for hepatocellular carcinoma (HCC).",2021_boston_scientific_performance_report.pdf
Global evidence generation The HEMA team published eight peer-reviewed health economics manuscripts and 24 peer-reviewed abstracts to contribute to the global evidence base for payer and other purchasing decision-makers.,2021_boston_scientific_performance_report.pdf
"Pre-clinical science and clinical trials Before Boston Scientific products proceed to human clinical trials, we use stringent pre-clinical standards to conduct extensive research into new devices.",2021_boston_scientific_performance_report.pdf
"After clinical trials generate safety and efficacy data, we publicly report the outcomes.",2021_boston_scientific_performance_report.pdf
"In 2021, we continued to strengthen and refine our operating procedures to ensure we met or exceeded all European Union Medical Device Regulation (EU MDR) requirements.",2021_boston_scientific_performance_report.pdf
"To learn more about progress we have made advancing diversity in clinical trials, go to Accelerating possibilities.",2021_boston_scientific_performance_report.pdf
"145 active clinical trials with 14,000 patients enrolled globally Active clinical trials 16 2021 Performance ReportIntroduction Transforming care Overview and 2021 highlights Innovating to meet more patient needs Ensuring quality, health and safety Improving access and outcomes through digital solutions Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Everyone makes an impact Our quality culture is reinforced through annual Everyone Makes an Impact (EMAI) virtual events where patients and caregivers share how Boston Scientific devices improved their lives.Ensuring quality, health and safety Health care providers and their patients deserve transparency about the quality of our solutions.",2021_boston_scientific_performance_report.pdf
That is why a comprehensive quality infrastructure guides our work through the life cycle of each Boston Scientific product.,2021_boston_scientific_performance_report.pdf
"Our global quality and safety teams diligently oversee the processes and systems for everything we do — from research, development and design to product building, supply chain operations and distribution.",2021_boston_scientific_performance_report.pdf
"Our annual bonus plan includes a quality metrics modifier, which allows the Executive Compensation and Human Resources Committee of the Board to reduce annual bonus plan funding for failure to meet quality goals and to reinforce accountability across the company.",2021_boston_scientific_performance_report.pdf
"• The Boston Scientific Best4 strategy is the framework our teams follow to deliver industry-leading quality through a patient-centric culture, agile quality processes, a relentless focus on product performance and global regulatory compliance.",2021_boston_scientific_performance_report.pdf
• Our global quality system continuously integrates customer feedback and enables us to adapt to changing global regulatory requirements.,2021_boston_scientific_performance_report.pdf
• Quality improvement projects are prioritized companywide to ensure that our products meet the highest performance and safety standards and achieve excellent patient outcomes.,2021_boston_scientific_performance_report.pdf
• Boston Scientific quality system training is mandatory for all employees and compliance is monitored through quality management oversight.,2021_boston_scientific_performance_report.pdf
"At EMAI 2021, Brooke Thomas discussed how receiving an implantable cardioverter defibrillator (ICD) changed her life.",2021_boston_scientific_performance_report.pdf
Boston Scientific Quality teams collaborated with Human Resources to reinforce our quality focus through companywide incentives.,2021_boston_scientific_performance_report.pdf
"For example, we launched the Quality Catch recognition program for product builders at all manufacturing sites.",2021_boston_scientific_performance_report.pdf
Employees who raise system or process concerns that lead to quality improvements are recognized by supervisors and peers for contributions such as “Eagle Eye” and “Raise Your Hand” catches.,2021_boston_scientific_performance_report.pdf
"To learn more, visit our newsroom.",2021_boston_scientific_performance_report.pdf
"17 2021 Performance ReportIntroduction Transforming care Overview and 2021 highlights Innovating to meet more patient needs Ensuring quality, health and safety Improving access and outcomes through digital solutions Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Successfully implemented all process and system requirements for EU MDR compliance by May 26, 2021 Zero findings resulting in action following more than 400 external audit daysCompliance Adhering to Global Quality System compliance excellence and executing EU MDR Quality Management System (QMS)Performance Driving continuous improvement in product performance, patient experience7% reduction in overall complaint rate in 2021 compared to 2020, with a 39% overall reduction in complaint rate since 2017 98%+ effectiveness in CAPA metrics and on-time approvalsAgility Removing complexity, improving systems$39 million in cost avoidance through quality system improvements Implemented Quality System structure for remote case supportThe “Best4” strategy — which includes a focus on culture, agility, performance and compliance — is the companywide framework for our patient-centric quality culture.",2021_boston_scientific_performance_report.pdf
It is a key pillar in our Delivering Excellence strategy to uphold cohesive quality across our global supply chain.,2021_boston_scientific_performance_report.pdf
All Boston Scientific manufacturing and distribution sites use a shared set of metrics to ensure the highest quality standards are met throughout the company’s operations and supply chain.,2021_boston_scientific_performance_report.pdf
"Best4 Taking a comprehensive quality approach Our Corrective and preventative action (CAPA) efforts in 2021 included investing in systems, training and processes focused on preventative action.",2021_boston_scientific_performance_report.pdf
We also made measurable progress identifying and reducing risks through a combination of corrective actions and process improvements.,2021_boston_scientific_performance_report.pdf
Our practice of conducting limited market releases for key products demonstrates how we are adapting our processes to further support the responsible development and expansion of new markets.,2021_boston_scientific_performance_report.pdf
"For example, with the launch of the EXALT™ Model B device in the United States and Europe, this approach allowed us to closely monitor and evaluate device use and adjust for any additional training needs prior to the full launch.",2021_boston_scientific_performance_report.pdf
"The company increased post-market surveillance activities across our product portfolio and participated in more than 400 days of external quality system audits involving the U.S. Food and Drug Administration, EU MDR bodies such as DEKRA, the British Standards Institute (BSI) and TÜV SÜD as well as several country-specific regulators.",2021_boston_scientific_performance_report.pdf
"Since 2017, Boston Scientific has recorded a 39% year-over-year complaint rate reduction.",2021_boston_scientific_performance_report.pdf
"In the rare event that we do detect an issue, we act swiftly and with patient safety in mind.",2021_boston_scientific_performance_report.pdf
"2021 recalls: • Class I recalls: 3 • Class II recalls: 8Metric Results Culture Establishing a preventative quality culture26% of CAPAs considered preventativequality strategy Best4quality results 18 2021 Performance ReportIntroduction Transforming care Overview and 2021 highlights Innovating to meet more patient needs Ensuring quality, health and safety Improving access and outcomes through digital solutions Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Additional details on product quality and safety data are available in our Appendix.Connected patient challenge The sixth Boston Scientific Connected Patient Challenge featured telehealth solutions to improve patient care and connectivity while also addressing the gap in treatment disparities.",2021_boston_scientific_performance_report.pdf
"After receiving a record number of submissions, first place went to Kalia Health for KAL-PDx, a home-based early detection test for preeclampsia.",2021_boston_scientific_performance_report.pdf
"Improving access and outcomes through digital solutions For a health care solution to make a meaningful difference, it must reach the patients who need treatment.",2021_boston_scientific_performance_report.pdf
"In 2021, we made significant investments in physician digital education and engagement.",2021_boston_scientific_performance_report.pdf
"Approximately 20,000 providers accessed the Boston Scientific EDUCARE platform for on-demand learning modules, interactive training tools, clinical overviews and case studies.",2021_boston_scientific_performance_report.pdf
The platform includes medical education and training courses that support health care professionals in the delivery of patient care around the globe and is the primary access point to the company’s professional education for health care professionals.,2021_boston_scientific_performance_report.pdf
"To address treatment inequities, inconsistent outcomes and COVID-19 safety concerns, we also introduced targeted technologies for improving patient care.Protecting product data and patient privacy We continued to invest in heightened data security and privacy.",2021_boston_scientific_performance_report.pdf
"Our data security experts took action to mitigate potential vulnerabilities, expand cybersecurity monitoring and strengthen mandatory employee training.",2021_boston_scientific_performance_report.pdf
"For network- connected Boston Scientific systems, we implemented advanced security testing to discover vulnerabilities and quickly address them, along with a robust security risk assessment process.",2021_boston_scientific_performance_report.pdf
"Safe, secure remote assistance The MyLATITUDE™ app enables patients with Boston Scientific pacemakers and defibrillators to stay connected with their providers through LATITUDE™ in-home monitoring.",2021_boston_scientific_performance_report.pdf
"In 2021, data from the ISO 27001 and 27018 certified LATITUDE system helped providers safely and remotely monitor approximately 1 million patients with implanted devices, to quickly detect and treat certain heart conditions.SpaceOAR certification for physicians in Hong Kong Our Asia Pacific digital team developed a compliant virtual certification program for physicians using our SpaceOAR™ Hydrogel.",2021_boston_scientific_performance_report.pdf
The pilot program for providers treating patients undergoing prostate cancer radiation therapy will serve as a prototype for virtual certification programs in other medical fields.Measuring chronic pain with artificial intelligence (AI) As the opioid epidemic amplified the need for reliable pain measurement — especially in telehealth settings — we work with IBM Research on technology to objectively measure pain.,2021_boston_scientific_performance_report.pdf
"Our collective team of scientists, engineers, device designers and clinicians are using a custom AI and cloud platform to discover new biomarkers that will help clinicians assess patients and offer personalized chronic pain care.For more on our work to safeguard patient data and product security, see Creating value responsibly .",2021_boston_scientific_performance_report.pdf
"19 2021 Performance ReportIntroduction Transforming care Overview and 2021 highlights Innovating to meet more patient needs Ensuring quality, health and safety Improving access and outcomes through digital solutions Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Investing in our people As a business and as a global citizen, Boston Scientific is defined by the talent and collective passion of our people.",2021_boston_scientific_performance_report.pdf
"We strive to make our company a place where employees are valued and feel they belong — and where diversity of thought, skills and life experience leads to breakthroughs.When we challenge ourselves to embrace differences, we advance innovation.",2021_boston_scientific_performance_report.pdf
"41.1% of supervisor and manager roles held by women globally; 21.6% by multicultural employees in the U.S. and Puerto Rico99%+ pay equity for employees across gender globally and for multicultural talent in the U.S. and Puerto Rico 20 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Overview and 2021 highlights Our people continued to address unmet clinical needs with innovative medical technology.",2021_boston_scientific_performance_report.pdf
Teams across Boston Scientific adapted to new ways of working to deliver on our commitments to providers and patients around the world.,2021_boston_scientific_performance_report.pdf
"We prioritized a diverse and inclusive workplace where employees learn and grow, have access to resources to support their well-being and receive equitable rewards for their contributions.",2021_boston_scientific_performance_report.pdf
"Our diverse, equitable and inclusive workplace At Boston Scientific, we know diverse insights lead to new and better answers.",2021_boston_scientific_performance_report.pdf
"That’s why we work to create an inclusive, open and equitable culture for all employees no matter where they sit or what role they hold.",2021_boston_scientific_performance_report.pdf
"Our people collaborate in ways that foster new approaches to tough problems, demonstrate our core values and reflect our commitment to diversity, equity and inclusion (DE&I).",2021_boston_scientific_performance_report.pdf
The result is innovation that helps improve patient care.,2021_boston_scientific_performance_report.pdf
"To achieve DE&I that endures, our aspirations and progress must be transparent and measurable.",2021_boston_scientific_performance_report.pdf
Our 3Up by 2023 goals aim to increase the representation of women and multicultural talent in our workforce through policies and practices that give everyone equitable opportunities for career growth.,2021_boston_scientific_performance_report.pdf
"Wendy Carruthers executive vice president, Human Resources“ When we create a workplace where all employees feel they belong, are valued and have opportunities to grow, we will advance health care to many more patients.”Boston Scientific wins premier Catalyst Award for DE&I excellence We have been honored with a 2022 Catalyst Award, the premier award for DE&I initiatives that improve gender representation across ranks and advance women and other underrepresented groups.",2021_boston_scientific_performance_report.pdf
"Boston Scientific was recognized for its multi- year, global initiative to address barriers women and diverse employees may face in the workplace.",2021_boston_scientific_performance_report.pdf
The effort accelerated a cultural shift within Boston Scientific.,2021_boston_scientific_performance_report.pdf
"“We applaud Boston Scientific for its commitment to diversity, equity and inclusion and to fostering career advancement for women and everyone,” said Lorraine Hariton, president and chief executive officer, Catalyst.",2021_boston_scientific_performance_report.pdf
"Increase our goal for representation of women at the supervisor and manager level by 3 percentage points or more, to at least 43% globally Increase our goal for representation of multicultural talent at the supervisor and manager level by 3 percentage points or more, to at least 23% in the U.S. and Puerto Rico Continue to be a top 10% globally recognized leader for workplace inclusion 21 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Board of director representationAccelerating our DE&I progress Unconscious bias training is required for all Boston Scientific employees.",2021_boston_scientific_performance_report.pdf
"We expanded initiatives to support equitable opportunities for growth, including diverse hiring practices and development programs for women and multicultural leaders.",2021_boston_scientific_performance_report.pdf
"To equip employees with additional skills and tools to recognize and address systemic racism, bias and prejudice, we introduced Anti-Racism & Cultural History (ARCH) training in the United States.",2021_boston_scientific_performance_report.pdf
"The ARCH curriculum advances workplace understanding of race, culture and identity through three learning paths customized for individual contributors, people leaders and senior leaders.",2021_boston_scientific_performance_report.pdf
The program is required for people leaders and recommended for individual contributors.,2021_boston_scientific_performance_report.pdf
"ARCH training will be adapted and made available in all regions starting in 2023.“ I have been promoted eight times in my career with Boston Scientific, and I have never felt held back from obtaining my goals.",2021_boston_scientific_performance_report.pdf
"My company’s focus on increasing women in leadership has created a culture that has accelerated career opportunities for all genders.” Becky Knutson director, Research and Development Supervisor and manager level representation1Representation at all levels Women (global)2Women (global)2Multicultural (U.S. and Puerto Rico)3Multicultural (U.S. and Puerto Rico)3 2018 2019 2020 202146.5%47.0%47.4%48.3% 2018 2019 2020 202138.4% 38.1%39.9%41.1% 2018 2019 2020 202131.7%33.2%34.0%35.7% 2018 2019 2020 202119.6%20.8%21.4% 21.6%30% of board of director members self- identify as women, 30% self-identify as ethnically diverse 1 Supervisors and managers: includes all levels that are supervisor, manager I and manager II.",2021_boston_scientific_performance_report.pdf
2 Gender: includes all employees globally where gender is identified.,2021_boston_scientific_performance_report.pdf
"Excludes any employees where gender is ""undeclared"" and ""unknown.""",2021_boston_scientific_performance_report.pdf
"3 Multicultural talent: in the U.S. and Puerto Rico, defined as African American/Black, Asian, Hispanic/Latino, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races.",2021_boston_scientific_performance_report.pdf
"Excludes any employees who choose not to self-identify.For detailed definitions and additional diversity data, please visit the Appendix.",2021_boston_scientific_performance_report.pdf
"22 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Building capabilities with diverse talent In 2021 we broadened existing development programs and introduced new initiatives to increase opportunities for women and multicultural talent, strengthen retention efforts and offer additional pathways to leadership.",2021_boston_scientific_performance_report.pdf
GROW.,2021_boston_scientific_performance_report.pdf
"We expanded GROW — Give Real Opportunities for Valuable Work Experience — after talking with Black, Hispanic and Latinx employees who build our medical devices and are interested in furthering their careers in business roles at Boston Scientific.",2021_boston_scientific_performance_report.pdf
"The program, initially conceived in Cork, Ireland, enlists people leaders to mentor participants through a series of classroom and hands-on training sessions.",2021_boston_scientific_performance_report.pdf
"After piloting GROW in Maple Grove, Minnesota, we extended the opportunity to product builders based in Arden Hills, Minnesota and expect to expand the program to more sites in 2022.",2021_boston_scientific_performance_report.pdf
Accelerated Diverse Talent (ADT).,2021_boston_scientific_performance_report.pdf
Boston Scientific launched the ADT program to support the development of women and multicultural talent with the potential for advancing to more senior leadership roles.,2021_boston_scientific_performance_report.pdf
"Through coaching and mentoring, development assignments and executive sponsorships, the program is helping us build a robust and diverse leadership pipeline.",2021_boston_scientific_performance_report.pdf
"Out of nearly 80 employees who participated in ADT in 2021, more than half have moved to a different role or been promoted.",2021_boston_scientific_performance_report.pdf
Nearly 30% of those who were promoted moved up to vice president or director-level roles.Spanish-speaking manufacturing program.,2021_boston_scientific_performance_report.pdf
"In Spencer, Indiana, we collaborated with our Hispanic Organization for Leadership and Achievement (HOLA) employee resource group to introduce an all- Spanish language manufacturing shift to recruit product builders regardless of their proficiency in English.",2021_boston_scientific_performance_report.pdf
"The program grew to support multiple shifts and manufacturing areas, and helped mitigate pandemic-related unemployment and labor shortages in the area and the language obstacle faced by a growing Hispanic and Latinx community.",2021_boston_scientific_performance_report.pdf
"The company offers Spanish-speaking employees the opportunity to learn English at no cost, and it also offers their English-speaking colleagues comparable opportunities to learn Spanish.",2021_boston_scientific_performance_report.pdf
"“ We decided to invest in this project to attract employees who are going to be with our company for many, many years,” said project manager Marco Lopez, who pitched the idea for a Spanish- language work shift.",2021_boston_scientific_performance_report.pdf
Lopez worked for Boston Scientific in Costa Rica before transferring to our Indiana site in 2016.,2021_boston_scientific_performance_report.pdf
"In 2021, our Maple Grove, Minnesota site graduated its inaugural GROW class of participants.",2021_boston_scientific_performance_report.pdf
All seven graduates have since progressed in their careers.,2021_boston_scientific_performance_report.pdf
"23 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Mia Bischoff senior specialist, Quality Learning and Development, and 2021 global co-lead, Pacific East Asian Resources in Leadership (PEARL)“ I’m an Asian-American, and even though I was born in the U.S., I still felt like I was different from others.",2021_boston_scientific_performance_report.pdf
"With PEARL, I loved that I was surrounded by people with similar backgrounds and experiences.” Recruiting with purpose Boston Scientific collaborates with leading organizations that advocate for the advancement of individuals from underrepresented groups.",2021_boston_scientific_performance_report.pdf
"Since 2014, we have partnered with historically black college and university (HBCU) engineering schools to support scholarships, research and advisory board partnerships.",2021_boston_scientific_performance_report.pdf
"We also sponsor initiatives for Black and HBCU students, such as events organized by Advancement of Minority Interest in Engineering (AMIE), Career Communications Group (CCG), National Action Council for Minorities in Engineering (NACME) and the National Society of Black Engineers (NSBE).",2021_boston_scientific_performance_report.pdf
"In 2021, Boston Scientific was voted a “Top Supporter of HBCUs” by U.S. Black Engineer & Information Technology magazine for the second consecutive year.Elevating employee voices through employee resource groups (ERGs) Our voluntary, company-sponsored ERGs are essential to our inclusive culture.",2021_boston_scientific_performance_report.pdf
"While these groups are typically formed around a specific affinity such as gender, race, veteran status, sexual orientation or life stage, all employees are welcome and encouraged to join and participate in any ERG.",2021_boston_scientific_performance_report.pdf
"Each ERG has an executive sponsor and creates opportunities for members to network, develop career skills and contribute to our communities.",2021_boston_scientific_performance_report.pdf
Our Global Council for Inclusion (GCI) supports their efforts and meets quarterly to discuss ERG progress.,2021_boston_scientific_performance_report.pdf
"The GCI is co-chaired by our chief financial officer and executive vice president of Human Resources and also includes our chairman and CEO, the executive committee, DE&I team members and all nine global ERG leaders.",2021_boston_scientific_performance_report.pdf
"Global DE&I Summit speaks to inclusion through adversity More than 2,400 Boston Scientific leaders and employees participated in our second annual ERG summit.",2021_boston_scientific_performance_report.pdf
"The 20-hour virtual event featured two days of presentations and discussions on how to foster inclusion in times of adversity.ERGs foster collaboration 8,000+ employees across nine ERGs 115 chapters globally 44 chapters outside the U.S. 15 virtual chaptersLearn about how we are partnering to promote and support the development of talent from underrepresented groups.",2021_boston_scientific_performance_report.pdf
"24 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Attracting, developing and retaining talent Boston Scientific is a company where everyone’s ideas, ambitions and careers matter.",2021_boston_scientific_performance_report.pdf
"We want all employees to have work that means something to them, in roles where they have opportunities to learn and advance.",2021_boston_scientific_performance_report.pdf
This means ensuring that people at every level of the organization have access to continuous learning initiatives and tailored development programs.,2021_boston_scientific_performance_report.pdf
It also means providing advancement opportunities for women and multicultural talent.,2021_boston_scientific_performance_report.pdf
"Our 2021 investments reinforced our objectives for talent planning, manager development and engagement and retention.",2021_boston_scientific_performance_report.pdf
Hiring and developing talent to meet business needs Our talent planning approach relies on diverse representation and cultivating capabilities to address business needs.,2021_boston_scientific_performance_report.pdf
We do this by developing internal talent and recruiting top talent globally.,2021_boston_scientific_performance_report.pdf
"In 2021, remote work offered opportunities for us to recruit from new talent pools while preparing and promoting people within the business.",2021_boston_scientific_performance_report.pdf
"We also innovated with recruiting approaches, including a Medical Sales College scholarship program for students with high potential for becoming part of a salesforce that mirrors the diversity of our customers and their patients.",2021_boston_scientific_performance_report.pdf
We tracked workforce analytics and implemented ways to develop more skills internally.,2021_boston_scientific_performance_report.pdf
"In tandem with these efforts, leaders used digital dashboards to assess organizational trends and improve hiring, advancement and engagement practices.",2021_boston_scientific_performance_report.pdf
These insights helped us tailor our internal development efforts and refine our recruiting outreach.,2021_boston_scientific_performance_report.pdf
"As a result, Boston Scientific had more than 8,300 new hires and filled 22% of our open positions with internal candidates.",2021_boston_scientific_performance_report.pdf
"2021 recruitment and hiring 8,300+ new hires 69% of director level and above open positions hired from within“ I have been in the talent attraction space for more than 26 years and have never seen a workplace culture like ours.",2021_boston_scientific_performance_report.pdf
This is the first time in my career I can authentically be who I am at work and it has been a game changer for me.,2021_boston_scientific_performance_report.pdf
"The way Boston Scientific holistically cares about employees resonates with me and so many others.” Erica Henry director, Global Talent Acquisition 25 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Listening and learning Our best ideas come from our people.",2021_boston_scientific_performance_report.pdf
We devote resources to support ongoing feedback between employees and managers and communications channels for employees to share their valued perspectives.,2021_boston_scientific_performance_report.pdf
"Employee engagement survey We conducted a companywide engagement survey that provided valuable feedback from employees about their jobs, leadership, development opportunities and our work environment.",2021_boston_scientific_performance_report.pdf
Boston Scientific made tablets available at manufacturing facilities to increase employee access to the survey and encourage strong response rates.,2021_boston_scientific_performance_report.pdf
"With more than 31,000 employees participating, we recorded scores of 80% or higher for the key indices to the right.",2021_boston_scientific_performance_report.pdf
"We used engagement survey results to develop a multi‐year action plan focused on career pathways for all employees, supporting our teams through change and equity and inclusion initiatives for women and multicultural talent.",2021_boston_scientific_performance_report.pdf
"To make progress in 2021, we conducted focus groups and interviews with existing talent to help promote retention, expanded leadership training and retention resources, and provided tools for employees as they adjusted to new ways of working.",2021_boston_scientific_performance_report.pdf
Spark Survey.,2021_boston_scientific_performance_report.pdf
Our Spark Survey solicits feedback about our people leaders from their direct reports.,2021_boston_scientific_performance_report.pdf
The brief digital format asks employees to rate their managers on leadership attributes and is available in 14 languages.,2021_boston_scientific_performance_report.pdf
The survey is an important developmental tool for people managers and assists us with identifying enterprise people leadership strengths and opportunities.,2021_boston_scientific_performance_report.pdf
"In 2021, more than 21,000 employees were invited to evaluate approximately 5,000 leaders.",2021_boston_scientific_performance_report.pdf
"We had a response rate of 74%, and 95% of people leaders, as well as their supervisors, received a feedback report.Career growth and development initiatives Boston Scientific provides tools and training for continuous learning so every employee can envision greater possibilities no matter where they are in their careers.",2021_boston_scientific_performance_report.pdf
"We offer more than 150 professional and technical courses, including on-the-job training, skills- based education and programs for employees who have the potential to hold leadership positions.",2021_boston_scientific_performance_report.pdf
"In 2021, we launched a global Learning Leaders Council composed of cross-functional leaders who helped define and accelerate our vision for creating an agile, continuous learning organization.",2021_boston_scientific_performance_report.pdf
"They identified ways to further connect learning to our business strategy, embed it in the daily flow of work, and prioritize learning for leaders and their teams.",2021_boston_scientific_performance_report.pdf
"80% of employees report that they are actively engaged82% of employees feel enabled to do their jobs well80% of employees feel that our workplace culture is inclusiveEngagement IndexEnablement IndexInclusive Culture Index2021 employee engagement survey results 26 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Investing in our people leaders The skills needed to be a successful people leader are constantly changing.",2021_boston_scientific_performance_report.pdf
"We rolled out more resources to help managers develop as strategic leaders, create a work environment built on trust and help employees achieve their career goals.",2021_boston_scientific_performance_report.pdf
Our development work included these programs: • Manager Pathways.,2021_boston_scientific_performance_report.pdf
"This program focuses on building leadership skills among our people leaders, including how to be inclusive and coach with empathy.",2021_boston_scientific_performance_report.pdf
• People Leaders Experience (PLE).,2021_boston_scientific_performance_report.pdf
"This one-year opportunity for new people leaders addresses core leadership skills such as hiring, coaching and providing feedback.",2021_boston_scientific_performance_report.pdf
• Advanced Manager Experience.,2021_boston_scientific_performance_report.pdf
"This eight-month opportunity for succession-ready senior managers emphasizes capabilities such as business acumen, strategic thinking and inclusive leadership.",2021_boston_scientific_performance_report.pdf
• ExecOnline.,2021_boston_scientific_performance_report.pdf
These courses for leaders at or above the director level include content developed at top business schools and real-time projects that participants incorporate into their day-to-day jobs.,2021_boston_scientific_performance_report.pdf
"Virtual learning and development for our hybrid workforce We expanded our virtual learning offerings to include more topics and opportunities for all employees, including self-development courses, a coaching portal and self-directed mentoring programs.",2021_boston_scientific_performance_report.pdf
"In addition, we designed and hosted our first virtual leadership conference, a three-day event for people leaders.",2021_boston_scientific_performance_report.pdf
"• Virtual Learning Site employee views totaled 9,700+, including 4,500+ unique new views.",2021_boston_scientific_performance_report.pdf
"• Virtual Leadership Summit 2021: 3 days > 6,600 attendees > 50+ speakers > 4.5 (out of 5) average satisfaction score Talent review and succession planning Succession planning at Boston Scientific is a key component of our business processes.",2021_boston_scientific_performance_report.pdf
"Our Executive Committee annually conducts talent reviews to understand insights about our succession plans, identify areas of opportunity and ensure we are developing the necessary bench strength.",2021_boston_scientific_performance_report.pdf
The reviews result in a succession strategy for all executive and critical business roles.,2021_boston_scientific_performance_report.pdf
Succession plans for the CEO are reviewed annually by the company’s board of directors and its Nominating and Governance committee.,2021_boston_scientific_performance_report.pdf
Succession planning takes place for employees at every level when leaders gather annually to assess the performance of their teams and development plans.,2021_boston_scientific_performance_report.pdf
These review sessions help to ensure a strong pipeline of emerging leaders.,2021_boston_scientific_performance_report.pdf
"Throughout our talent review and succession planning processes, we continue to strengthen our commitment to advancing our diverse talent into leadership roles.",2021_boston_scientific_performance_report.pdf
In 2021 we evolved the annual review to include highlights on key diverse talent.,2021_boston_scientific_performance_report.pdf
This provided visibility and a commitment to actions to accelerate development and readiness for next roles.,2021_boston_scientific_performance_report.pdf
Key talent actions are monitored throughout the year.,2021_boston_scientific_performance_report.pdf
~700k total hours spent in on-demand virtual and classroom training1Continuous learning to build a workforce for the future 1 Inclusive of global indirect labor employees only.,2021_boston_scientific_performance_report.pdf
"27 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Employee well-being, rewards and safety At Boston Scientific, we prioritize the well-being, health and safety of our employees and their families.",2021_boston_scientific_performance_report.pdf
"We strive to be flexible about where and when employees perform their work and to offer benefits that are valued by our people, promote well-being and support life-work integration.",2021_boston_scientific_performance_report.pdf
"Adapting to new ways of working In the wake of the pandemic, the company reassessed its physical space and modified onsite protocols to support employees as they adopted new work modes.",2021_boston_scientific_performance_report.pdf
"This involved workplace modifications to meet health and safety guidelines, conference room upgrades, new ordering systems for home office equipment, and training to help employees succeed in hybrid, onsite and remote settings.",2021_boston_scientific_performance_report.pdf
"By the end of 202,1 as employees adapted to our culture of greater flexibility, 42% of our people worked onsite, 41% adopted hybrid work modes and 17% worked primarily from remote locations.",2021_boston_scientific_performance_report.pdf
"Our return-to-site resources included employee toolkits, onsite amenities, leader resources and safe onsite workspaces for collaboration.Benefits that meet employee needs Boston Scientific benefit programs support the well-being and health of our people while providing flexibility to meet their unique needs and expectations.",2021_boston_scientific_performance_report.pdf
Employee eligibility for benefits follows local regulations and practices.,2021_boston_scientific_performance_report.pdf
"In most countries, this means we offer benefits to full-time employees and part-time employees working more than a certain number of hours.",2021_boston_scientific_performance_report.pdf
We typically provide benefit programs that are above and beyond government requirements and offer a portfolio of additional benefits that support our diverse population and the individual needs of our employees.,2021_boston_scientific_performance_report.pdf
Embracing life-work needs Our Global Benefits to Fit Your Life program is designed to make life-work integration easier for all employees at any stage of life.,2021_boston_scientific_performance_report.pdf
"It provides the flexibility and benefits and services our employees want to be happy, productive and engaged in their roles.",2021_boston_scientific_performance_report.pdf
"In applicable countries, our life-work offerings include telehealth services, childcare and parental care benefits, college and financial planning, fertility and surrogacy benefits, a breast milk shipping service, domestic partner benefits, tuition support, a meal-planning service and sabbaticals for employees with more than seven years of service.",2021_boston_scientific_performance_report.pdf
"28 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix To learn more about our global benefit programs and services, visit BenefitsConnect.Our approach to compensation and pay equity We believe strongly in rewarding people for their contributions to our high performance.",2021_boston_scientific_performance_report.pdf
"Where it is relevant to an employee’s responsibilities and follows local and national labor standards, we strive to offer both a base and a variable component to employee pay.",2021_boston_scientific_performance_report.pdf
"Variable components include annual bonus programs, long-term incentive stock awards and performance rewards issued on a one-time basis, on-the-spot bonuses for highly successful projects and recognition awards for breakthrough performance.In 2021, we acknowledged the extraordinary efforts and resiliency of our teams during the pandemic with a one-time employee appreciation award for all employees.",2021_boston_scientific_performance_report.pdf
"In addition, we expanded eligibility for the Boston Scientific Annual Bonus Plan to include even more employees in 2022.",2021_boston_scientific_performance_report.pdf
Paying people equally for equal work is foundational to our inclusive culture.,2021_boston_scientific_performance_report.pdf
Our most recent assessment again reported 99% or greater pay equity for employees across gender globally and for multicultural talent in the United States and Puerto Rico.,2021_boston_scientific_performance_report.pdf
Our compensation experts regularly benchmark salaries and conduct companywide and external parity audits.,2021_boston_scientific_performance_report.pdf
We contract with an independent third party to assess pay equity for all positions using regression analysis.,2021_boston_scientific_performance_report.pdf
"This data-driven approach controls for variables that appropriately influence compensation such as job position, tenure, years of experience and location.",2021_boston_scientific_performance_report.pdf
We use the results to identify any potential pay disparities and address them accordingly.,2021_boston_scientific_performance_report.pdf
"99%+ pay equity for employees across gender globally and for multicultural talent in the U.S. and Puerto RicoMore mental health and well-being resources As ways of working changed for our people everywhere, we enhanced mental health and well-being resources to support employees in meeting their work and family commitments.",2021_boston_scientific_performance_report.pdf
• Webinars.,2021_boston_scientific_performance_report.pdf
We offered more than 50 health and well-being webinars led by caregiving specialists and licensed clinicians.,2021_boston_scientific_performance_report.pdf
• Employee network.,2021_boston_scientific_performance_report.pdf
We created a resource-rich virtual community that facilitates information sharing on topics such as parenting and well-being.,2021_boston_scientific_performance_report.pdf
• Virtual support.,2021_boston_scientific_performance_report.pdf
We expanded internal well-being circles to provide forums for employees to connect over shared circumstances and concerns.,2021_boston_scientific_performance_report.pdf
• Global Employee Assistance Program (EAP).,2021_boston_scientific_performance_report.pdf
We increased education on how to use our global network of well-being and mental health resources.,2021_boston_scientific_performance_report.pdf
• Access to care.,2021_boston_scientific_performance_report.pdf
"In the U.S., we increased telehealth mental health care options and waived all co-pays for mental health visits to ensure cost would not be a barrier to care.",2021_boston_scientific_performance_report.pdf
"Global pay equity 29 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Keeping our employees healthy and safe Boston Scientific takes a comprehensive approach to managing and monitoring employee health and safety at all offices and facilities globally.",2021_boston_scientific_performance_report.pdf
"In the United States in 2021, our occupational health nurse program and standards of practice earned national recognition from the American Board for Occupational Health Nurses (ABOHN).",2021_boston_scientific_performance_report.pdf
"Globally, we enhanced COVID-19 processes and protocols to keep employees safe.",2021_boston_scientific_performance_report.pdf
Employee safety initiatives we supported included: • Maximizing opportunities for people to work from home to reduce potential for disease transmission.,2021_boston_scientific_performance_report.pdf
• Providing advice and equipment for at-home testing.,2021_boston_scientific_performance_report.pdf
• Issuing personal protective equipment free of charge.,2021_boston_scientific_performance_report.pdf
• Offering an occupational health support call service.,2021_boston_scientific_performance_report.pdf
• Establishing a confidential employee vaccine register.,2021_boston_scientific_performance_report.pdf
We set health and safety goals called Total Recordable Incident Rate (TRIR) targets and have a 2030 goal of 0.25 TRIR per 100 employees.,2021_boston_scientific_performance_report.pdf
"Our global Employee Health and Safety (EHS) Operations Council reviews site TRIR performance monthly to discuss risks, trends and opportunities for improvement.",2021_boston_scientific_performance_report.pdf
"We expanded the employee coverage in our TRIR calculation to incorporate 98% of our employee population in 2021, up from 67% in 2020.",2021_boston_scientific_performance_report.pdf
"As a result, our TRIR performance now reflects incident rates for all global supply chain teams as well as the majority of commercial staff who work primarily in remote and office settings.In accordance with the Boston Scientific Environment, Health and Safety Policy , we integrate health and safety metrics across our global monitoring systems.",2021_boston_scientific_performance_report.pdf
Our workplace guidelines support this policy and set specific expectations for health- and safety-related programs.,2021_boston_scientific_performance_report.pdf
We have met International Organization for Standardization (ISO) requirements to achieve ISO 45001:2018 Occupational Health and Safety Management System certification at four company locations.,2021_boston_scientific_performance_report.pdf
"Our agile safety approach: 2021 COVID response team in India When a devastating COVID-19 surge struck India, we acted quickly to protect more than 550 employees and 140 contractors across the country.",2021_boston_scientific_performance_report.pdf
"Our team of cross-functional experts organized testing and medical services, financial assistance and vaccination drives and secured life-saving supplies such as oxygen concentrators.",2021_boston_scientific_performance_report.pdf
"With contingency processes in place, we prevented infection among employees, helped their families and avoided business disruption.",2021_boston_scientific_performance_report.pdf
Boston Scientific is a Great Place to Work-CertifiedTM organization in India and is recognized among India’s Great Mid-size Workplaces 2021.,2021_boston_scientific_performance_report.pdf
"Total Recordable Incident Rate (TRIR): 2021: 0.42 TRIR (0.42 injuries per 100 employees) 2030 Goal: 0.25 (0.25 injuries per 100 employees) 30 2021 Performance ReportIntroduction Transforming care Investing in our people Overview and 2021 highlights Our diverse, equitable and inclusive workplace Attracting, developing and retaining talent Employee well-being, rewards and safety Accelerating possibilities Protecting the environment Creating value responsibly Appendix Accelerating possibilities When we challenge inequities, we advance health care possibilities for people and communities.",2021_boston_scientific_performance_report.pdf
Our commitment to improving patient outcomes inspires us to address global health disparities.,2021_boston_scientific_performance_report.pdf
"We collaborate with partners outside the company to expand community education, increase health care provider outreach and break down barriers to care.",2021_boston_scientific_performance_report.pdf
"70 hospitals and providers acted to address inequities in specialty care through Close the Gap partnerships$75+ million in contributions for medical research, fellowships, education and charitable organizations globally 31 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix Overview and 2021 highlights In 2021, Boston Scientific collaborated with providers and nonprofit and local community organizations to confront persistent health care inequities in underrepresented populations.",2021_boston_scientific_performance_report.pdf
"Our teams worked to improve treatment access and increase diversity in medical research for women and individuals in Black, Hispanic and Latinx communities.",2021_boston_scientific_performance_report.pdf
"We also invested in initiatives to support our communities, including science, technology, engineering and math (STEM) education in underserved communities.",2021_boston_scientific_performance_report.pdf
"Improving health equity and access Social and economic factors — education, employment status, income level, zip code, gender and ethnicity — can have a significant impact on people’s ability to live long, healthy lives.",2021_boston_scientific_performance_report.pdf
"Because health care inequities are rooted in a broad range of injustices, our approach to mitigate those inequities is far-reaching.",2021_boston_scientific_performance_report.pdf
"Ralph Redd, MD vascular surgeon, Montgomery, Alabama“ Close the Gap’s disparity data helped us identify health needs within our local community — as a result, we set up a rural health clinic to evaluate patients for coronary artery and peripheral artery disease.",2021_boston_scientific_performance_report.pdf
This program is closing the treatment gap and helping patients receive the medical interventions they need.” 32 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix Our Close the Gap initiative to combat health inequities Close the Gap is our top initiative to address health care gaps in underserved communities in the United States.,2021_boston_scientific_performance_report.pdf
"Over the course of 18 years, we have expanded its reach to identify and address systemic and emerging treatment gaps.",2021_boston_scientific_performance_report.pdf
"Our vision is a world where all patients understand their medical conditions and have access to care.In 2021, as the COVID-19 pandemic continued to expose and worsen severe care disparities, we took the following measures to advance equitable care: • Educating providers.",2021_boston_scientific_performance_report.pdf
"We partnered with community providers to generate local disparity index data on disease prevalence and treatment inequities, identifying 72,000 women and people of color who were not receiving equitable specialty care.",2021_boston_scientific_performance_report.pdf
• Educating patients.,2021_boston_scientific_performance_report.pdf
"More than 10,000 patients visited KnowYourHealth.com for resources such as a personalized heart risk assessment and a find a doctor tool.",2021_boston_scientific_performance_report.pdf
"Approximately 2,100 patients attended virtual health summits organized by Close the Gap in 2021.",2021_boston_scientific_performance_report.pdf
"Close the Gap 2021: Empowering providers to act 72,000 women and people of color identified as missing equitable specialty care 70 of hospitals and providers acted to address inequities in specialty care 50+ health care providers participated in Black Health Matters events sponsored by Close the Gap Learn more about inequities in access to health care, and how our Close the Gap initiative was created to address these gaps on our website .",2021_boston_scientific_performance_report.pdf
We collaborate with health care providers to expand awareness of health inequities through community outreach and educational resources.,2021_boston_scientific_performance_report.pdf
Learn more by watching the full Close the Gap educational video .,2021_boston_scientific_performance_report.pdf
33 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix Increasing diversity in medical research Diversity in medical research is essential to ensuring everyone can benefit from treatments and therapies.,2021_boston_scientific_performance_report.pdf
We partner with providers and patient advocacy organizations to improve representation in clinical research.,2021_boston_scientific_performance_report.pdf
"For example, approximately 200 million people globally are affected by peripheral artery disease (PAD), a common circulatory problem that disproportionately affects Black men and women.",2021_boston_scientific_performance_report.pdf
"Yet, typically these groups are underrepresented in PAD clinical trials.",2021_boston_scientific_performance_report.pdf
"To expand the body of clinical evidence on the outcomes of patients diagnosed with PAD — particularly women and people of color — we launched ELEGANCE, a global patient registry and post-market study whose goal is to enroll no less than 40% women and 40% underrepresented minorities.",2021_boston_scientific_performance_report.pdf
"The registry is also groundbreaking for the diversity of its principal investigators, more than half of whom identify as women and/or people of color.",2021_boston_scientific_performance_report.pdf
“ Increasing diversity in medical research is a critical step to ensure that everyone can benefit from treatments and therapies.,2021_boston_scientific_performance_report.pdf
"Now is the time to eliminate disparities in health care — once and for all.” Michael R. Jaff, DO chief medical officer and vice president, Clinical Affairs, Technology & Intervention, Peripheral Interventions ELEGANCE breaks new ground in diversifying clinical studies 40% Objective: Enroll at least 40% women and 40% people of color 50% Principal investigator diversity: 50% women and people of color 34 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix Combating racism in the United States In the second year of our $3.5 million multiyear strategy to combat racism, we expanded our advocacy across five pillars of investment that we identified in collaboration with 28 national and local organizations, such as The New Commonwealth Racial Equity and Social Justice Fund in Massachusetts, Advancing Minorities' Interest in Engineering and Nexus Community Partners.",2021_boston_scientific_performance_report.pdf
More than 100 employees volunteered alongside company leaders with these organizations to launch initiatives primarily supporting the Black community.,2021_boston_scientific_performance_report.pdf
"Community Provided financial support for 200 Black, indigenous and people of color-owned businesses in Minnesota.",2021_boston_scientific_performance_report.pdf
Education Funded scholarships for more than 45 Historically Black Colleges and Universities students and graduate-level health care students of color.,2021_boston_scientific_performance_report.pdf
Health care Funded a mobile health clinic for The Family Van to provide free health screenings and coaching for underserved Boston-area communities.,2021_boston_scientific_performance_report.pdf
Economic empowerment Launched a mentorship program to increase the number of Black-owned businesses and train Black entrepreneurs to work with companies like Boston Scientific.,2021_boston_scientific_performance_report.pdf
Government / policies Sponsored a congressional Black Caucus Foundation fellowship.,2021_boston_scientific_performance_report.pdf
Confronting inequities We have a responsibility to uphold our values in all that we do.,2021_boston_scientific_performance_report.pdf
"In 2021, we continued to take decisive actions to confront racism and intolerance.",2021_boston_scientific_performance_report.pdf
"In the face of pandemic-fueled hate crimes targeting the Asian community, we spoke out against xenophobia and stood in solidarity with our colleagues.",2021_boston_scientific_performance_report.pdf
"We organized listening forums and offered resources to employees, including access to bystander intervention training and expanded leadership inclusion training.",2021_boston_scientific_performance_report.pdf
"In March 2021, we joined a coalition of organizations and allies who share support for Stop AAPI Hate by hosting virtual events and reporting on hate incidents using Stop AAPI Hate data.",2021_boston_scientific_performance_report.pdf
Our commitment to confronting discrimination and injustice compelled us to take additional action in 2021.,2021_boston_scientific_performance_report.pdf
"Boston Scientific introduced Anti-Racism & Cultural History (ARCH) training for U.S. employees to advance our collective understanding of race, culture and identity and its impact in the workplace and beyond.CEO action for racial equity Boston Scientific stepped up its commitment to CEO Action for Diversity & Inclusion with support for the CEO Action for Racial Equity Fellowship , an initiative to advance policy change at the federal, state and local levels.",2021_boston_scientific_performance_report.pdf
Boston Scientific CEO Mike Mahoney was among the first signatories of the CEO Action for Diversity & Inclusion Pledge shortly after its formation.,2021_boston_scientific_performance_report.pdf
"Iñaki Martin Cossio senior health equity consultant, Close the GapFor more on ARCH training, see the Investing in our people section of this report.Here are some examples of our contributions since 2020: "" Volunteering as part of our combating racism strategy has been an exciting and fulfilling project.",2021_boston_scientific_performance_report.pdf
"Boston Scientific has empowered me to make a difference in so many ways for Black communities across the United States.""",2021_boston_scientific_performance_report.pdf
"35 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix Supporting our communities Caring about human life is the basis for everything we do at Boston Scientific, including how we engage with the communities where we work and live.",2021_boston_scientific_performance_report.pdf
"Employees in more than 50 countries participated in STEM outreach to local students, helped raise awareness of chronic health conditions and contributed time and money to support those in need.",2021_boston_scientific_performance_report.pdf
"The company also donated more than $75 million to fund medical research, fellowships, education and charitable organizations globally.",2021_boston_scientific_performance_report.pdf
"And in the United States, the Boston Scientific Foundation awarded more than $1 million in grants and scholarships.",2021_boston_scientific_performance_report.pdf
"Our priorities for supporting communities are: 2021 contributions and engagement 50,000+ volunteer hours in 50+ countries where our employees contribute to their communities $75+ million in contributions for medical research, fellowships, education and charitable organizations globally 3,500+ nonprofits we support with donations, grant funding and in-kind contributions $1+ million in Boston Scientific Foundation contributionsAdvancing health We work to reduce health disparities and chronic disease risk in underserved populations by increasing access to screenings and qualified health care professionals.",2021_boston_scientific_performance_report.pdf
"In China, we collaborated to support a rural health clinic for children.",2021_boston_scientific_performance_report.pdf
Advancing community We empower our employees to improve life in their communities by donating their talent and resources through our matching gifts and volunteer programs.,2021_boston_scientific_performance_report.pdf
"In Malaysia, we donated care kits to children undergoing cancer treatment.",2021_boston_scientific_performance_report.pdf
Advancing education We support STEM programming for underserved students around the world to develop the next generation of health care innovators.,2021_boston_scientific_performance_report.pdf
"In Costa Rica, we mentored STEM students participating in a robotics program.",2021_boston_scientific_performance_report.pdf
36 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix Virtually assisted care in Colombia We partnered with local telecommunications companies to offer our Clinical Eye virtual tool to health professionals.,2021_boston_scientific_performance_report.pdf
"Providers in the region used the system’s assisted reality glasses to treat 746 remote and at-risk patients, including 336 in COVID isolation.Advancing health: Global Signature Health Grant Program The World Health Organization estimates a shortage of 18 million health care workers in low- and middle- income countries by 2030.",2021_boston_scientific_performance_report.pdf
We collaborate with nonprofit organizations to address this crisis by increasing the number of trained health care workers and improving the quality and availability of chronic disease screenings.,2021_boston_scientific_performance_report.pdf
"Since 2016, our Global Signature Health Grant Program has helped train nearly 5,000 community health workers in five countries and provided screenings for more than 23,000 individuals.",2021_boston_scientific_performance_report.pdf
"Training health care workers in vulnerable communities 5,000 community health workers trained in 5 countries 23,000+ health screenings provided since 2016 In Colombia, we partnered with Project Hope and local health departments, hospitals and universities to train more than 400 community health care workers to help treat nearly 700,000 patients with chronic diseases in small, rural clinics along the Venezuelan border.Colombia Since 2020 Learn about more of our digital solutions in the Transforming care section of this report.",2021_boston_scientific_performance_report.pdf
"37 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix In Ireland, Boston Scientific STEM teams sponsored the 2021 SciFest National Final, which featured nearly 600 projects by more than 1,000 students from 130 schools.In Costa Rica, we hosted a virtual open house where our employees showcased careers in health care for 200 students and guided them through STEM experiments.Advancing education: STEM outreach By supporting STEM programming for K-12 students, we are helping develop diverse talent who will contribute to health care innovations for generations to come.",2021_boston_scientific_performance_report.pdf
We launched partnerships with online platforms so our U.S.,2021_boston_scientific_performance_report.pdf
"STEM employee teams could make classroom presentations, provide one-on-one tutoring and teach students about careers in STEM and medical devices.",2021_boston_scientific_performance_report.pdf
"17 teams focused on STEM outreach globally 35,000+ students reached by our programs 340+ organizations supported through STEM outreach or donationsAdvancing community: Relief efforts and COVID-19 action When a natural disaster or other traumatic event strikes one of our communities, Boston Scientific has three priorities: keep employees and their families safe, assess the event’s impact and determine how to support relief efforts in the area.",2021_boston_scientific_performance_report.pdf
"In 2021, the company coordinated and encouraged employee donations to help people affected by COVID-19, the earthquake in Haiti and wildfires in the United States and Europe.",2021_boston_scientific_performance_report.pdf
Employees who donated to these efforts received a matching contribution from the company.,2021_boston_scientific_performance_report.pdf
"Vaccine availability led to stabilized COVID-19 rates in some parts of the world, while other areas with less access faced devastating surges.",2021_boston_scientific_performance_report.pdf
"Boston Scientific made additional financial contributions to assist with critical medical care, including vaccines and COVID-19 testing in India, Brazil and other countries where resources were needed.",2021_boston_scientific_performance_report.pdf
"We also took the following steps to support our employees, their families and communities: • Extended employee COVID-19 insurance support, financial assistance, vaccine reimbursement and telehealth services.",2021_boston_scientific_performance_report.pdf
"• Provided employees with supplies such as personal protective equipment, COVID-19 care kits and oxygen concentrators.",2021_boston_scientific_performance_report.pdf
"• Secured lodging for employees and family members with asymptomatic, mild or moderate COVID-19 so they could quarantine away from home.",2021_boston_scientific_performance_report.pdf
"For more information about our benefits and how we support employees globally during difficult times, see the Investing in our people section of this report.2021 STEM outreach 38 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Overview and 2021 highlights Improving health equity and access Confronting inequities Supporting our communities Protecting the environment Creating value responsibly Appendix Protecting the environment When we challenge our impact on the environment, we advance ways to protect it.",2021_boston_scientific_performance_report.pdf
Our commitment to improving the lives of patients calls for protecting the planet we all share.,2021_boston_scientific_performance_report.pdf
That means confronting climate change and challenging ourselves to meet ambitious environmental goals.,2021_boston_scientific_performance_report.pdf
"68% reduction in greenhouse gas emissions since 2009 (Scope 1 and 2)173% of electricity consumed generated from renewable sources, surpassing our interim goal of 50% by 20211, 2 1 Inclusive of all manufacturing and key distribution sites only.",2021_boston_scientific_performance_report.pdf
"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
"39 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Overview and 2021 highlights Boston Scientific took action for a healthier world by further reducing our environmental impact, addressing supply chain sustainability and working to mitigate material climate risks to the business.",2021_boston_scientific_performance_report.pdf
"We exceeded our target of 50% renewable electricity use by 2021, stayed on course for carbon neutrality in all of our manufacturing and key distribution sites by 2030 and committed to setting science-based targets and reaching net-zero carbon emissions across our entire value chain by 2050.",2021_boston_scientific_performance_report.pdf
Our teams also made progress monitoring the business risks associated with climate change and advancing product stewardship and waste management.,2021_boston_scientific_performance_report.pdf
"We recognize our responsibility to further respond to climate change, and are working towards implementing recommendations by the Task Force on Climate-Related Financial Disclosures (TCFD).Reducing our environmental impact We were one of the first medical device manufacturers to pledge to achieve carbon neutrality by 2030 in all manufacturing and key distribution sites, and we are on track to meet this goal.",2021_boston_scientific_performance_report.pdf
"In 2021, Boston Scientific expanded our climate action goals by joining the United Nations Race to Zero and Science Based Targets initiative (SBTi) Business Ambition for 1.5°C campaign.",2021_boston_scientific_performance_report.pdf
"By making this commitment, we build on our strong foundation and begin to establish ambitious science-based targets that will set us on a path toward net-zero carbon emissions across our entire value chain by 2050.",2021_boston_scientific_performance_report.pdf
"We will share our targets following the SBTi process and regularly report on our progress.2021 progress against our interim goals 73% of electricity consumed generated from renewable sources, surpassing our interim goal of 50% by 20211, 2 38% of all energy used at Boston Scientific facilities from renewable sources, on track to meet our interim goal of 90% by 20271 52% reduction in our carbon footprint since 2017 (Scope 1 and 2), while increasing the number of patients reached by 20%1Our path to net-zero3 1 Inclusive of all manufacturing and key distribution sites only.",2021_boston_scientific_performance_report.pdf
"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
"3 Trajectory to net-zero emissions defined by science-based targets.2024 2017 2021 2027 2030 2050100% Renewable electricity173% Renewable electricity, surpassing goal of 50%1,2One of the first medical device manufacturers to pledge to achieve carbon neutrality by 20301 90% Renewable energy (all sources)1 Carbon neutrality (Scope 1 and 2)1CO2 Net-zero emissions (Scope 1, 2 and 3) 40 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Key progress indicators definitions12017 2018 2019 2020 2021 Carbon footprint (MT CO2eq)Total amount of Scope 1 and Scope 2 greenhouse gas emissions emitted into the atmosphere from all manufacturing and key distribution sites.",2021_boston_scientific_performance_report.pdf
"Measured in metric tons of carbon equivalent.94,946 85,127 84,778 53,730 52,2842 Energy use (MWh)Total energy Boston Scientific consumes annually to manufacture our products.Total MWh 364k 355k 368k 381k 397k Normalized MWh/ million $ revenue40 36 34 38 33 Green real estate (% of total)Percentage of Boston Scientific real estate that is independently certified for energy efficiency by industry-leading bodies such as LEED for design and Energy Star or ISO 50001:2018 for building operations.32% 32% 41% 42% 46% Renewable energy (% of total)Percentage of total energy consumed, generated from renewable sources, with Boston Scientific owning the renewable attributes.Electricity percent — 5% 11% 71% 73%2 All sources percent — 3% 6% 35% 38%GEMS key performance indicators Using the Boston Scientific Global Energy Management System (GEMS), developed with the National University of Ireland Galway, we are making measurable strides toward carbon neutrality.",2021_boston_scientific_performance_report.pdf
"Our Global Facilities Utility Management (GFUM) Council benchmarks best practices, monitors all metrics and publicly reports results using four key performance indicators (KPIs) as indicated in the chart below.“ We share and learn best practices for energy management, adopting practices that make sense for Malaysia and align with our global sustainability goals.” Valluvan Shanmugam manager, Penang Facilities 2021 progress 68% reduction in greenhouse gas emissions since 2009 (Scope 1 and 2)1 CO2 1 Inclusive of all manufacturing and key distribution sites only.",2021_boston_scientific_performance_report.pdf
"2 Reflects adjustments to previously reported figure of 72% renewable electricity and 53.7k metric tons CO2 in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
"41 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Cutting energy use To ensure we’re investing in energy efficiency at all sites and developing new construction that meets the highest climate standards, we adhere to the Leadership in Energy and Environmental Design (LEED) framework and the International Organization for Standardization (ISO) 50001:2018 energy management standard.Minimizing our carbon footprint1 A central component of our approach to carbon neutrality is our C3 energy strategy: Cutting energy use through continual improvement in energy performance Converting to renewable energy sources instead of relying on fossil fuelsCompensating with carbon credits and offset projects for remaining unavoidable emissions“ Across our operations, we use science and innovation to create a sustainable and flexible footprint that accommodates change, supports productivity and protects the environment.” Paul Donhauser vice president, Global Real Estate, Facilities Operations, Environment, Health and SafetyConverting to renewable energy After investing in energy efficiency, converting to renewable energy is the next step in our C3 strategy.",2021_boston_scientific_performance_report.pdf
"We monitor the percentage of energy generated from renewable sources, whether produced onsite or purchased from outside suppliers.",2021_boston_scientific_performance_report.pdf
"In 2021, we achieved 73% renewable electricity, which exceeded our interim objective of 50% for 2021 and keeps us on track to source or generate 100% of our electricity from renewable sources by 2024.1, 2 We are targeting, by 2027, 90% of all energy used at Boston Scientific facilities be from renewable sources.1 Compensating with carbon offsets While our primary focus is cutting energy use and converting to clean energy sources, the third part of our C3 strategy is to offset unavoidable emissions for certified high quality carbon removals.",2021_boston_scientific_performance_report.pdf
We assess potential projects to ensure the results will balance our remaining emissions.,2021_boston_scientific_performance_report.pdf
1 Inclusive of all manufacturing and key distribution sites only.,2021_boston_scientific_performance_report.pdf
"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
"In 2021, Boston Scientific expanded operations in Galway.",2021_boston_scientific_performance_report.pdf
"The expansion includes more than 40,000 square feet of manufacturing space that will be powered by renewable energy.",2021_boston_scientific_performance_report.pdf
"42 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Transformation in Galway: carbon neutral clean room At our Galway, Ireland manufacturing campus, Boston Scientific teams re-engineered a computer manufacturing facility that the company purchased in 2016 into a carbon-neutral clean room.",2021_boston_scientific_performance_report.pdf
"The team converted the facility into an energy efficient space, powered by renewable electricity, with fresh air handling units, air- source heat pumps and piped heat energy recovery.",2021_boston_scientific_performance_report.pdf
"The facility, now certified ISO class 8, requires approximately one-third the energy of a conventional clean room of equivalent size.",2021_boston_scientific_performance_report.pdf
"Patrick van der Meer senior engineer, Kerkrade Facilities“ Energy efficiency is not a project, but a journey of continual improvement.",2021_boston_scientific_performance_report.pdf
"As the company grows and changes, our efforts to cut energy use and convert to renewable sources must work together to ensure progress.”16 buildings adhere to LEED and all newly constructed facilities are designed to the LEED rating system46% of Boston Scientific real estate is independently certified for energy efficiency by industry-leading bodies such as LEED for design and ISO 50001:2018 for building operations, representing 4+ million square feetOur green real estate expands 43 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Managing waste and water usage We use the ISO 14001:2015 environmental management system to measure and reduce waste and water usage at key manufacturing and distribution facilities.",2021_boston_scientific_performance_report.pdf
"As of 2021, we had 16 sites certified to this standard.",2021_boston_scientific_performance_report.pdf
"Managing non-hazardous waste To make progress toward our goal of diverting all waste from landfills and incineration by 2030, Boston Scientific is participating in the Total Resource Use and Efficiency (TRUE) certification program at our manufacturing and major distribution centers.",2021_boston_scientific_performance_report.pdf
This approach to resource use and facility operations is helping us take the additional steps necessary to achieve our zero-waste objective.,2021_boston_scientific_performance_report.pdf
"Conserving water While our operations are not water intensive, we are committed to minimizing usage and preparing for environmental challenges such as water scarcity.",2021_boston_scientific_performance_report.pdf
Water usage at our manufacturing and major distribution centers is predominantly associated with employees; 16% of consumption is associated with production processes.,2021_boston_scientific_performance_report.pdf
"2021 recycling and waste management1 55% of hazardous and regulated waste was recycled or recovered by the company’s operations and primary distribution sites 1,962 metric tons of solid waste were diverted from landfills for total landfill avoidance of 91% 8,673 metric tons – 74% of solid waste – recycled • Heredia and Coyol, Costa Rica: Using electricity predominantly from renewable sources, these manufacturing sites have been certified as carbon-neutral since 2016 — meeting the annual requirements for certification (INTE B5:2016, INTE/ ISO 14064-1:2006) from the Institute of Technical Standards of Costa Rica (INTECO).",2021_boston_scientific_performance_report.pdf
"• Clonmel, Cork and Galway, Ireland, and Kerkrade, the Netherlands: Our facilities source only 100% renewable electricity through our utility providers.",2021_boston_scientific_performance_report.pdf
"• Dorado, Puerto Rico: We completed solar installations in 2021 that generated approximately 1.5 million kWh for the site.",2021_boston_scientific_performance_report.pdf
"• Marlborough and Quincy, Massachusetts: Onsite solar installations at our Marlborough headquarters and Quincy distribution center generated approximately 29% of onsite electricity needs in 2021.Making progress toward environmental goals around the world Dorado, Puerto Rico solar installations were completed in 2021.",2021_boston_scientific_performance_report.pdf
1 Inclusive of all manufacturing and key distribution sites only.,2021_boston_scientific_performance_report.pdf
44 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Managing climate risk Climate change presents risks to the world around us and our business.,2021_boston_scientific_performance_report.pdf
"Natural disasters, extreme weather and other climate-related conditions could adversely affect our operations and supply chain, from the availability of materials to energy supply and transportation.",2021_boston_scientific_performance_report.pdf
"As we invest in protecting our business and customers from climate-related disruption, we incorporate climate risk into our modeling, planning and financial disclosures.",2021_boston_scientific_performance_report.pdf
"To help identify and monitor the impacts of climate change, we use risk management software to map our sites against climate risk indices such as wildfire hazard, drought hazard, heat stress and sea-level rise.",2021_boston_scientific_performance_report.pdf
"Our climate risk management approach Oversight The Boston Scientific Board of Directors oversees management of strategic, operational, financial, legal and compliance risks, including environmental and climate-related risks.",2021_boston_scientific_performance_report.pdf
Our Enterprise Risk Management (ERM) program supports the board in these activities.,2021_boston_scientific_performance_report.pdf
Risk assessment The ERM team analyzes climate risks so we can manage potential challenges to meeting our business objectives.,2021_boston_scientific_performance_report.pdf
They follow our climate- related controls and escalation procedures to report potential material impacts to the board.,2021_boston_scientific_performance_report.pdf
"Mitigation To mitigate climate risks, the company deploys and diverts resources as needed to secure our supply chain and limit operational disruption.",2021_boston_scientific_performance_report.pdf
"In response to severe weather events, we engage with potentially affected customers and external partners to maintain business continuity.",2021_boston_scientific_performance_report.pdf
"Measurement Using the CDP platform, we completed a comprehensive assessment of the company’s climate-related initiatives and received an A- score.",2021_boston_scientific_performance_report.pdf
"This result reflects strong progress toward our climate-related disclosures, including increased disclosures about our climate risks and environmental practices.",2021_boston_scientific_performance_report.pdf
"To learn more about business continuity and risk management, see Creating value responsibly .",2021_boston_scientific_performance_report.pdf
"45 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Advancing product stewardship Good product stewardship requires a concerted effort to minimize the health, safety, environmental and social impacts of our company’s products.",2021_boston_scientific_performance_report.pdf
"We take this seriously and are examining the environmental footprint of our devices — from design, sourcing, production and distribution to waste disposal or recycling.",2021_boston_scientific_performance_report.pdf
"We have made measurable progress with initiatives focused on packaging, labeling and device recycling and are focused on further reducing environmental impacts of our technologies throughout the entire product life cycle.",2021_boston_scientific_performance_report.pdf
"Reducing our footprint with improved packaging and labeling Boston Scientific packaging practices require the highest quality sterilization, distribution and storage of our medical devices.",2021_boston_scientific_performance_report.pdf
We develop packaging and labeling sustainability goals under the guidance of a global steering committee and use processes that meet international labeling regulations.,2021_boston_scientific_performance_report.pdf
"Our practices optimize design, reduce waste and limit emissions from shipping.",2021_boston_scientific_performance_report.pdf
"For example, we avoided more than 41 metric tons of paper waste in 2021 by hosting an eLabeling website where customers could download Instructions for Use (IFU) as needed in multiple languages.",2021_boston_scientific_performance_report.pdf
We continue to advocate for eLabeling expansion into the European Union through a MedTech Europe working group.Here are some examples of our 2021 packaging and labeling sustainability advances and other successful practices.,2021_boston_scientific_performance_report.pdf
• Men’s health move to eLabeling.,2021_boston_scientific_performance_report.pdf
We streamlined product literature and used eLabeling to reduce annual paper use by 3.9 metric tons and plastic waste by 854 kg.,2021_boston_scientific_performance_report.pdf
Minimizing the paper and plastic needed for shipping enabled us to cut carbon emissions by 16.8 metric tons.,2021_boston_scientific_performance_report.pdf
• Sustainable packaging solutions.,2021_boston_scientific_performance_report.pdf
"In our Quincy, Massachusetts and Kerkrade, the Netherlands distribution centers, we use integrated packaging machines for most of our orders.",2021_boston_scientific_performance_report.pdf
"These machines better fit products into custom-sized boxes, reduce empty space and require fewer cartons per order.",2021_boston_scientific_performance_report.pdf
"Since 2011, Boston Scientific has reduced packaging during shipping by 30% in Kerkrade.",2021_boston_scientific_performance_report.pdf
"In Quincy, we have reduced packaging during shipping by 27% since 2020.",2021_boston_scientific_performance_report.pdf
• Healthcare Plastics Recycling Council (HPRC).,2021_boston_scientific_performance_report.pdf
"As a member of HPRC, we collaborate with industry peers to increase the recycling of plastics in clinical settings.",2021_boston_scientific_performance_report.pdf
"For instance, we supported the HPRC’s work in 2021 to understand the guidelines for using advanced recycling technologies for medical recycling that break down plastic waste and require less sorting by facilities staff.2021 packaging sustainability snapshot 219 metric tons of packaging removed from waste stream 33,292 products diverted from landfill during development 103 pallet shipments avoided 46 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Collaborating to increase medical device recycling In the United States, we partner with industry leaders in medical recycling and waste management to offer sustainability solutions for select single-use devices, such as systems for recycling entire devices and converting product waste to energy.",2021_boston_scientific_performance_report.pdf
"For example, within participating customers, 65% of LithoVue™ systems and 39% of EXALT™ Model D systems were recycled in the United States in 2021.",2021_boston_scientific_performance_report.pdf
"We will continue to explore additional options in the future.A partnership to reduce environmental impact In 2021, we expanded our collaboration with the Liryc Electrophysiology and Heart Modeling Institute to focus on reducing the environmental impact of single-use electrophysiology (EP) catheters.",2021_boston_scientific_performance_report.pdf
Together we worked with a group of cross-functional experts to study catheter end-of-life practices such as recycling.,2021_boston_scientific_performance_report.pdf
"We also supported a survey conducted by Liryc, in partnership with the European Heart Rhythm Association (EHRA), to identify physician practices and opportunities to reduce the environmental impact of EP catheters.",2021_boston_scientific_performance_report.pdf
"47 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Overview and 2021 highlights Reducing our environmental impact Managing climate risk Advancing product stewardship Creating value responsibly Appendix Creating value responsibly When we challenge ourselves to innovate with integrity, we advance our contributions as global corporate citizens.",2021_boston_scientific_performance_report.pdf
"At Boston Scientific, our teams are guided by strong ethics, core values and respect for human life.",2021_boston_scientific_performance_report.pdf
We make products people trust and work together across our global supply chain to deliver solutions that change and save lives.,2021_boston_scientific_performance_report.pdf
"48 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Overview and 2021 highlights Good governance reflects our values Compliance, ethics and integrity Protecting human rights across our company and supply chain Keeping our supply chain resilient and reliable Risk management and global security Keeping our products and patient data secure Appendix ~35 million products delivered$865+ million spent on small and diverse suppliersOverview and 2021 highlights Meeting our responsibilities as a global company and corporate citizen called for new levels of innovation and resilience in 2021.",2021_boston_scientific_performance_report.pdf
"Boston Scientific teams addressed challenges and met our obligations to stakeholders amid geopolitical conflicts, climate concerns and the continuing COVID-19 pandemic.",2021_boston_scientific_performance_report.pdf
Risk and supply chain management were among our top priorities as we reinforced product and data security companywide.,2021_boston_scientific_performance_report.pdf
"Good governance reflects our values The Boston Scientific Board of Directors has adopted Corporate Governance Guidelines and charters for each of its standing committees (audit, executive compensation and human resources, nominating and governance, and risk).",2021_boston_scientific_performance_report.pdf
"Global tax strategy and compliance In keeping with our commitment to social responsibility, we comply with all applicable tax laws, regulations and related disclosure requirements in every jurisdiction where we operate.",2021_boston_scientific_performance_report.pdf
Our tax professionals are committed to the highest compliance standards and use processes based on standardization and automation to minimize tax risk.,2021_boston_scientific_performance_report.pdf
"In 2021, we published our global tax strategy outlining the Boston Scientific approach to taxation.",2021_boston_scientific_performance_report.pdf
"Political involvement for sound public policy Boston Scientific supports public policies that promote diversity, equity and inclusion and improve patient health, our employees’ lives as well as the livelihoods of the communities we serve.",2021_boston_scientific_performance_report.pdf
We advocate for policies that increase access to care and provide annual updates on political action committee (PAC) activity and other contributions.,2021_boston_scientific_performance_report.pdf
The Boston Scientific Corporation PAC facilitates voluntary political contributions by eligible employees and our board of directors to advance sound public policy in accordance with federal law.,2021_boston_scientific_performance_report.pdf
Public-private partnership to improve patient care and access Boston Scientific collaborates with trade associations and regulatory bodies to share our quality standards and stay informed about developments so we can be agile in our response to regulatory updates.,2021_boston_scientific_performance_report.pdf
"For example, we work closely with the U.S. Food and Drug Administration (FDA) through the Digital Health Software Precertification Program to expedite patient access to safe and effective software-based medical innovations.",2021_boston_scientific_performance_report.pdf
We are also part of the Medical Device Innovation Consortium working with the FDA to advance solutions that promote patient access to innovative medical technologies.,2021_boston_scientific_performance_report.pdf
"To learn more about our political involvement, visit our website .To learn more about expanding patient access to care, go to Transforming care .Learn more about the policies and standards we comply with in the Appendix.",2021_boston_scientific_performance_report.pdf
"49 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Overview and 2021 highlights Good governance reflects our values Compliance, ethics and integrity Protecting human rights across our company and supply chain Keeping our supply chain resilient and reliable Risk management and global security Keeping our products and patient data secure Appendix Compliance, ethics and integrity Ethics and integrity govern how we work every day including how we innovate, develop life-changing products and collaborate with one another and our partners.",2021_boston_scientific_performance_report.pdf
All Boston Scientific employees share a commitment to: • Act honestly and ethically in all company matters.,2021_boston_scientific_performance_report.pdf
"• Protect the privacy of patients, customers and employees.",2021_boston_scientific_performance_report.pdf
• Treat one another with respect and fairness.,2021_boston_scientific_performance_report.pdf
• Hold one another accountable for quality in everything we do.,2021_boston_scientific_performance_report.pdf
"Our Global Compliance team provides employees with the resources and training they need to conduct business responsibly, treat customers and suppliers fairly and report ethics concerns if they arise.",2021_boston_scientific_performance_report.pdf
"The team, led by our chief compliance officer, collaborates across the company to monitor our activities and compliance with applicable laws and company policies.",2021_boston_scientific_performance_report.pdf
The chief compliance officer reports to the Risk Committee of our board of directors on an annual basis and to the Audit Committee as needed.Marketing practices people can trust We promote our products honestly and accurately.,2021_boston_scientific_performance_report.pdf
"Our Code of Conduct and other policies emphasize the importance of fair and honest communications with patients, customers and the public.",2021_boston_scientific_performance_report.pdf
"All customer-facing employees receive training on fair and honest marketing practices, interactions with health care providers and public officials and respect for intellectual property.",2021_boston_scientific_performance_report.pdf
"The training also addresses how to navigate actual and perceived conflicts of interest, which includes guidance for managing off-label inquiries and focusing marketing discussions on approved, on-label use of our products.2021 sales and marketing training “Accelerating with Integrity” campaign We regularly sponsor campaigns to promote employee awareness of the Code of Conduct.",2021_boston_scientific_performance_report.pdf
"In 2021, our companywide Integrity Week featured video messages from senior leaders that emphasized the importance of working ethically and reporting ethics concerns.",2021_boston_scientific_performance_report.pdf
"10,000+ hours of compliance training for customer-facing employees Mandatory training All employees complete annual training on the Code of Conduct and take additional mandatory training courses that reinforce company policies, explain corruption- and compliance-related risks and provide resources for reporting concerns.",2021_boston_scientific_performance_report.pdf
Advice line All employees are responsible for immediately reporting any suspected violation of the Code of Conduct or other company policy.,2021_boston_scientific_performance_report.pdf
Ethics concerns may be confidentially reported at any time through the Boston Scientific advice line which is operated by a third party.,2021_boston_scientific_performance_report.pdf
"Non-retaliation policy The Boston Scientific Non-Retaliation Policy prohibits any form of retaliation, direct or indirect, against an individual who raises a concern in good faith.",2021_boston_scientific_performance_report.pdf
"This protection extends to anyone who assists with, or cooperates in, an investigation or report of misconduct.",2021_boston_scientific_performance_report.pdf
"Learn more about our policies and practices on our website .The Boston Scientific Code of Conduct Every Boston Scientific employee is required to read and understand the Boston Scientific Code of Conduct, the foundation for all of our business practices and relationships.",2021_boston_scientific_performance_report.pdf
"50 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Overview and 2021 highlights Good governance reflects our values Compliance, ethics and integrity Protecting human rights across our company and supply chain Keeping our supply chain resilient and reliable Risk management and global security Keeping our products and patient data secure Appendix Protecting human rights across our company and supply chain Businesses have a critical role to play in protecting human rights.",2021_boston_scientific_performance_report.pdf
"Boston Scientific respects and strictly adheres to all labor and human rights laws, including those related to modern slavery, child labor, human trafficking, bribery, discrimination, harassment and pay equity.",2021_boston_scientific_performance_report.pdf
"Our contractors, suppliers and business partners are required to conduct their businesses legally and ethically as well.",2021_boston_scientific_performance_report.pdf
"Please refer to the Boston Scientific Human Rights Policy to learn more about how we operate.Supporting transparency and accountability We conduct business in a way that respects human rights and the dignity of all people, and we require the same of our contractors, vendors and suppliers.",2021_boston_scientific_performance_report.pdf
"Our Human Resources and Compliance teams have processes for employees and external partners to discuss human rights concerns, report suspected failures and take necessary actions, up to termination.",2021_boston_scientific_performance_report.pdf
"• Enrolling contractors, suppliers and partners.",2021_boston_scientific_performance_report.pdf
Our business agreements with partners around the world require that they conduct their businesses legally and ethically.,2021_boston_scientific_performance_report.pdf
Our Supplier Guidebook mandates adherence to all human rights laws and labor standards and requires safe and healthy working conditions at all times.,2021_boston_scientific_performance_report.pdf
• Reporting concerns.,2021_boston_scientific_performance_report.pdf
"Our Global Compliance program provides resources for employees and people outside the company to ask questions, obtain guidance and report human rights or Code of Conduct concerns.",2021_boston_scientific_performance_report.pdf
"51 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Overview and 2021 highlights Good governance reflects our values Compliance, ethics and integrity Protecting human rights across our company and supply chain Keeping our supply chain resilient and reliable Risk management and global security Keeping our products and patient data secure Appendix Keeping our supply chain resilient and reliable The Boston Scientific Global Supply Chain team works tirelessly to lead our planning, sourcing, manufacturing and distribution efforts worldwide.",2021_boston_scientific_performance_report.pdf
"Our 18,000 team members partner with more than 10,000 active indirect and direct suppliers to deliver ~35 million products annually.",2021_boston_scientific_performance_report.pdf
"They perform this mission-critical work while meeting the highest benchmarks for quality, service, ethical conduct and regulatory compliance.",2021_boston_scientific_performance_report.pdf
We use a standardized supplier performance tool to assess the integrity of potential suppliers’ business practices to help ensure that we responsibly meet our commitments to our customers and their patients.,2021_boston_scientific_performance_report.pdf
"Our teams at our global manufacturing, distribution and customer care centers have worked with agility and persistence to serve customers throughout the pandemic.",2021_boston_scientific_performance_report.pdf
"As markets recovered, they stayed ahead of challenges, kept inventory stable and responded quickly.",2021_boston_scientific_performance_report.pdf
"In a year marked by global breakdowns in sourcing and supplies, Boston Scientific kept our end-to-end global supply chain operating and delivered products to the customers and patients who count on them for quality care and outcomes.Managing complexities around the clock ~35 million products delivered 18,000 team members across 16 principal manufacturing and distribution locations Brad Sorenson executive vice president, Global Operations“ Our Global Supply Chain team consistently manages uncertainty and disruption.",2021_boston_scientific_performance_report.pdf
"We were tested in new ways in 2021, and have delivered for the patients who count on our products around the world.” 52 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Overview and 2021 highlights Good governance reflects our values Compliance, ethics and integrity Protecting human rights across our company and supply chain Keeping our supply chain resilient and reliable Risk management and global security Keeping our products and patient data secure Appendix Risk management and global security The Boston Scientific enterprise risk management team analyzes strategic, operational, financial, legal and compliance risks so we can safely adapt to challenges, pursue opportunities and meet commitments to stakeholders.",2021_boston_scientific_performance_report.pdf
"Enterprise risk management is led by our vice president of global internal audit who reports any financial, operational or risk issues to the board of directors and its relevant committees.",2021_boston_scientific_performance_report.pdf
Our global security and resiliency team works closely with enterprise risk management to ensure we can sustain operations and secure our facilities in the event of a crisis.,2021_boston_scientific_performance_report.pdf
"Business resiliency Working closely with our global operations team, our global security and resiliency experts prepare for a range of potential threats, including meteorologic, geologic, geo-political and climate-related changes.",2021_boston_scientific_performance_report.pdf
They evaluate our entire value chain to enable comprehensive impact assessments in case of a disaster.,2021_boston_scientific_performance_report.pdf
"This includes identifying and mitigating high-risk dependencies in an effort to avoid events that could interfere with delivering our products to customers or jeopardize the safety of our people, suppliers and communities.",2021_boston_scientific_performance_report.pdf
"The team works closely with our information technology (IT) disaster recovery specialists to identify technology vulnerabilities so we can make investments that maintain the security of company operations.Protecting global assets Our global security and resiliency group protects our people, enterprise assets and operations.",2021_boston_scientific_performance_report.pdf
"The team uses industry-standard protocols to run a 24/7 global security operations center with support from a network of partners specializing in cybersecurity, environment, health and safety, supply chain, regulation and data privacy.",2021_boston_scientific_performance_report.pdf
"In 2021, we strengthened our operations by expanding the company’s digital infrastructure to include greater detail about suppliers, contractors and our small business partners.",2021_boston_scientific_performance_report.pdf
"In addition to maintaining operations without significant disruption, we built a scalable system that secures our capacity to do business responsibly as new risks emerge.",2021_boston_scientific_performance_report.pdf
"For more on our climate risk management work, see the Protecting the environment section of this report.",2021_boston_scientific_performance_report.pdf
"Supporting supplier diversity Our approach to supplier selection builds diversity, equity and inclusion throughout the Boston Scientific supplier network.",2021_boston_scientific_performance_report.pdf
"In the U.S., Boston Scientific prioritizes working with certified companies that share our dedication to improving customer and patient care, including businesses that are: Pamela Nelson president and chief executive officer, Bracane Company Inc. and Boston Scientific supplier“ By investing in programs that support Black-owned suppliers, Boston Scientific is doing its part to increase supplier diversity within the life sciences industry.”• Minority-owned • Women-owned • Small or disadvantaged• Service-disabled • Veteran-owned • LGBTQ-owned • Disability-owned 3,400 small and diverse suppliers engaged $865+ million spent on small and diverse suppliers 53 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Overview and 2021 highlights Good governance reflects our values Compliance, ethics and integrity Protecting human rights across our company and supply chain Keeping our supply chain resilient and reliable Risk management and global security Keeping our products and patient data secure Appendix Keeping our products and patient data secure Ensuring the safety and security of our products and the patients who rely on them is a top priority.",2021_boston_scientific_performance_report.pdf
Boston Scientific has global cybersecurity protocols that anticipate and address possible threats to product security and to patient information.,2021_boston_scientific_performance_report.pdf
"The company’s Remote Patient Management System that allows health care providers to remotely monitor Boston Scientific implantable cardiac medical devices is certified by the International Organization for Standardization ISO/ IEC 27001:2013 and ISO/IEC27018:2014, and we conduct business in compliance with applicable international laws and regulations governing product and data security.",2021_boston_scientific_performance_report.pdf
"As a member of the Health Information Sharing and Analysis Center (H-ISAC) community of private and public health organizations, we can access and share security best practices and threat intelligence across the health care and public health sectors.",2021_boston_scientific_performance_report.pdf
"Ensuring product security In 2021, we expanded our product security approach to include multiple layers of risk analysis for every hardware and software component, while using penetration testing — a form of security testing used to better understand potential weaknesses that could be exploited — to identify vulnerabilities.",2021_boston_scientific_performance_report.pdf
"Our product lifecycle security practices cover the design, sourcing, manufacturing and support of all devices according to our cybersecurity protocols that are incorporated into our global quality system.",2021_boston_scientific_performance_report.pdf
We also monitor various threat intelligence feeds for high profile vulnerabilities that may impact our products and post regular product vulnerability updates.,2021_boston_scientific_performance_report.pdf
"Here are some of the actions we take to ensure transparency: • Open communication: Our external Boston Scientific Product Security website communicates with customers, patients and caregivers about security findings.• Information sharing: We are an active member of the Health Information Sharing and Analysis Center (H-ISAC).",2021_boston_scientific_performance_report.pdf
We have a process in place for coordinated vulnerability disclosures to ensure that our customers and patients are notified of critical security vulnerabilities and mitigations as needed in coordination with researchers and the U.S. Department of Homeland Security’s Cybersecurity & Infrastructure Security Agency.,2021_boston_scientific_performance_report.pdf
Learn more about Boston Scientific product security on our website .,2021_boston_scientific_performance_report.pdf
Protecting data security Boston Scientific products may hold and transmit sensitive personal data.,2021_boston_scientific_performance_report.pdf
We protect this data with protocols that honor provider and patient privacy.,2021_boston_scientific_performance_report.pdf
Our teams uphold standards for data privacy with industry-leading data protection practices that protect confidential health care provider and patient information from unauthorized disclosures.,2021_boston_scientific_performance_report.pdf
The company has data security and incident response plans that address potential threats to information privacy across all product portfolios.,2021_boston_scientific_performance_report.pdf
"We regularly conduct awareness outreach with employees and external health providers to educate them about various types of data, privacy and security best practices and their role in protecting private information.",2021_boston_scientific_performance_report.pdf
"2021 regulatory and privacy objectives include: • Privacy impact assessments: We require all employees to submit impact assessments for any products, processes and initiatives that collect, use, manage or process personal data as part of the company’s culture of ensuring privacy by design and default.",2021_boston_scientific_performance_report.pdf
"In 2021, the Global Privacy team reviewed over 500 privacy impact assessments.",2021_boston_scientific_performance_report.pdf
• Protecting COVID data privacy: We introduced a COVID-19 vaccine tracking tool that complied with rapidly changing government regulations and enabled employees access to our sites and to customers.,2021_boston_scientific_performance_report.pdf
We protected employee and visitor privacy according to each jurisdiction and ensured that employees controlled their data for the purpose of contact tracing.,2021_boston_scientific_performance_report.pdf
"• Companywide data privacy training: We launched an employee training program with content tailored to different areas and functions, to make the training relevant to employees’ day-to-day work.",2021_boston_scientific_performance_report.pdf
Different training scenarios helped Boston Scientific employees who interact with customers to understand the types of data they may engage with and their responsibility to protect information and report privacy concerns.,2021_boston_scientific_performance_report.pdf
"54 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Overview and 2021 highlights Good governance reflects our values Compliance, ethics and integrity Protecting human rights across our company and supply chain Keeping our supply chain resilient and reliable Risk management and global security Keeping our products and patient data secure Appendix Appendix 55 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Stakeholder Engagement Customers • Clinical trial management • Post-market surveillance • Customer care • Training and medical education• Business continuity and resiliency planning • Close the Gap • Product and data security • Professional section of Bostonscientific.com • Performance Report Patients and patient advocacy groups• Clinical trials • Close the Gap • Product and data security• Customer service and complaint handling • Advocacy group engagement • Patients section of Bostonscientific.com Employees • Employee engagement surveys • Employee resource groups • Quarterly business updates • Business-specific town halls• Boston Scientific Intranet and Yammer • Weekly global newsletter and monthly CEO letter • Matching gift program and volunteering • Awards and recognition Individual shareholders and institutional investors• Annual shareholder meeting and quarterly earnings calls • Investor section of Bostonscientific.com • Bi-annual investor day • Investor calls and meetings• Annual report on Form 10-K and quarterly reports on Form 10-Q • Annual Proxy Statement • Performance Report Government regulators and policymakers • Government affairs team • Trade associations• Boston Scientific Corporation Political Action Committee • Policy & Advocacy Nongovernmental organizations and local communities• Boston Scientific Foundations • Grants, donations and exhibits • Employee volunteering• Scholarships and internships • Sponsorships, partnerships and collaborations Suppliers and distributors • Supplier diversity program • Global supplier guidebook and resource center• Supplier scorecards • Supplier quality and audit programsStakeholder engagement The following chart outlines our key stakeholders and describes the ways we regularly engage with them.",2021_boston_scientific_performance_report.pdf
"56 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Product quality and safety Unit 2018 2019 2020 2021 Class I recalls # 0 0 3 3 Value of Class I recalled products1USD millions 0 0 77.09 120.07 Class II recalls # 5 7 15 8 Value of Class II recalled products1USD millions 1.22 9.60 59.01 8.43 Regulatory inspections # 76 87 85 97 Form 483 observations # 7 0 0 5 Annual revenues from 483 affected facilities USD millions 107 0 0 0 Annual revenues impacted by production stoppages USD millions 0 0 0 0 FDA warning letters Yes/No No No No No Innovation Unit 2018 2019 2020 2021 Research & Development (R&D) spend USD millions 1,113 1,174 1,143 1,204 R&D spend as a percent of sales Percent 11.3 10.9 11.5 10.1 Number of R&D positions FTE 1,453 2,040 2,114 2,136Transforming careMetrics summary Our metrics summary provides key performance data organized under five pillars that align to leading Environmental, Social and Governance (ESG) ratings and inclusion within sustainability indices.",2021_boston_scientific_performance_report.pdf
"1 Of the recalls classified in the year, value is determined by recall quantity multiplied by cost to manufacture.",2021_boston_scientific_performance_report.pdf
"57 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 2021 Supervisors and managers1 Supervisors and managers — women2Percent 38.4 38.1 39.9 41.1 Supervisors and managers — multicultural talent3Percent 19.6 20.8 21.4 21.6 Total workforce (all levels) Share of total workforce — women Percent 46.5 47.0 47.4 48.3 Share of total workforce — multicultural talent Percent 31.7 33.2 34.0 35.7 Representation of women (globally) Board of directors — women Percent 30.0 30.0 30.0 30.0 Executive officers — women4Percent 18.8425.0425.0 18.8 Senior management — women5Percent 29.5 31.0 33.2 34.8 Supervisors and managers — women Percent 38.4 38.1 39.9 41.1 Share of total field sales management positions — women Percent 22.0 21.3 22.9 24.1Investing in our people 1 Supervisors and managers: includes all levels that are supervisor, manager I and manager II.",2021_boston_scientific_performance_report.pdf
2 Gender: includes all employees globally where gender is identified.,2021_boston_scientific_performance_report.pdf
"Excludes any employees where gender is ""undeclared"" and ""unknown.""",2021_boston_scientific_performance_report.pdf
"3 Multicultural talent: in the U.S. and Puerto Rico, defined as African American/Black, Asian, Hispanic/Latino, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander and two or more races.",2021_boston_scientific_performance_report.pdf
Excludes any employees who choose not to self-identify.,2021_boston_scientific_performance_report.pdf
4 Executive officers: includes all executive officers listed in the Annual Report.,2021_boston_scientific_performance_report.pdf
Figures for 2018-2019 have been restated to conform to this definition.,2021_boston_scientific_performance_report.pdf
"5 Senior management: includes all levels that are director, vice president, senior vice president, executive vice president and CEO.",2021_boston_scientific_performance_report.pdf
"58 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 2021 Representation of multicultural talent (U.S. and Puerto Rico)1 American Indian/Alaska Native Percent 0.3 0.3 0.3 0.3 Asian Percent 13.4 13.3 13.6 12.8 African American/Black Percent 6.5 7.2 7.9 9.2 Hispanic/Latino Percent 9.5 10.5 10.3 11.5 Two or more races Percent 1.6 1.6 1.7 1.7 Native Hawaiian/Other Pacific Islander Percent 0.3 0.3 0.3 0.2 Total Percent 31.6 33.2 34.1 35.7 Senior management Percent 13.1 13.6 14.4 16.5 Supervisors and managers Percent 19.6 20.8 21.4 21.6 Women by region United States and Puerto Rico Percent 44.3 45.0 45.3 46.8 Latin America Percent 57.7 56.1 55.7 55.6 Canada Percent 43.6 43.4 48.1 48.4 Europe, Middle East and Africa Percent 45.5 45.5 46.3 47.0 Asia Pacific Percent 43.3 46.4 46.9 46.5Investing in our people 1 Reflects Equal Employment Opportunity (EEO) race/ethnicity categories.Reflects Equal Employment Opportunity (EEO) race/ethnicity categories.",2021_boston_scientific_performance_report.pdf
59 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 2021 Expanding our pipeline (new hires) Multicultural talent Percent 46.2 43.5 42.5149.5 Women Percent 51.2 50.2 48.9151.7 Representation of employees by age group (U.S. and Puerto Rico) <30 Percent 11.1 14.0 16.1 18.9 30-50 Percent 58.3 57.8 57.6 56.1 >50 Percent 30.6 28.1 26.3 25.0 Representation of employees by age group (global) <30 Percent 14.6 18.3 21.5 24.2 30-50 Percent 63.0 61.1 59.8 58.0 >50 Percent 22.5 20.6 18.7 17.8Investing in our people 1 2020 figures restated.,2021_boston_scientific_performance_report.pdf
"60 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Career and culture Unit 2018 2019 2020 2021 Total new hires 7,298 8,417 6,494 8,303 Employee turnover rate Percent total employees 11.9 12.0 10.3 15.3 Employee voluntary turnover rate Percent total employees 9.5 9.5 7.1 11.4 Pay equity global (gender) Global BSC 99%+ 99%+Analysis not completed99%+1 Pay equity multicultural (U.S. and Puerto Rico) U.S. and Puerto Rico 99%+ 99%+Analysis not completed99%+1 Open positions filled by internal candidates Percent 20.1 17.5220.5 22.0 Period that long-term incentives for employees are paid out after Years 4 4 4343 Average learning hours/employee Hours — — 16.5418.64Investing in our people 1 We will be completing every other year.",2021_boston_scientific_performance_report.pdf
Next analysis scheduled for 2023.,2021_boston_scientific_performance_report.pdf
2 2019 number restated.,2021_boston_scientific_performance_report.pdf
3 Vesting for options and restricted units is four years (25% per year).,2021_boston_scientific_performance_report.pdf
Boston Scientific changed from 5-year to 4-year award vesting beginning with RSUs granted in FY 2019.,2021_boston_scientific_performance_report.pdf
Half of the value delivered to executives is through performance share units which have a three-year cliff vest.,2021_boston_scientific_performance_report.pdf
4 Inclusive of global indirect labor employees only.,2021_boston_scientific_performance_report.pdf
"61 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Employee health and safety Unit 2018 2019 2020 2021 Work-related fatalities — employees # 0.0 0.0 0.0 0.0 Work-related fatalities — contractors # 0.0 0.0 0.0 0.0 Total Recordable Incident Rate (TRIR) Injuries per 100 employees0.5 0.5 0.5 0.4 Total Recordable Injury Frequency Rate (TRIFR) Injuries per 1 million hours worked2.6 2.7 2.3 2.11 Lost Time Injury Frequency Rate (LTIFR) Lost time injuries per 1 million hours worked2.623.0 1.7 1.31 Occupational Lost Time Rate (OLTR) Lost time days per 100 employees5.235.9 4.7 4.51 TRIR, TRIFR, LTIFR and OLTR rate coverage Percent of employees 66.0 66.0 67.0 98.0Investing in our people 1 For 2021, Boston Scientific expanded the relevant headcount in scope for TRIR, TRIFR, LTIFR and OLTR reporting to include 98% of our population.",2021_boston_scientific_performance_report.pdf
2 OLTR figures include lost and restricted time injuries.,2021_boston_scientific_performance_report.pdf
3 LTIFR includes all injuries.,2021_boston_scientific_performance_report.pdf
"62 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Community engagement Unit 2018 2019 2020 2021 Monetary value of philanthropic cash contributions1 USD millions 8.90 8.14 9.04 7.21 Boston Scientific Foundation (U.S.) cash contributions USD millions 1.07 1.19 1.21 1.21 Employee volunteering hours Hours 43,000 41,000 23,000 51,000 Overhead costs for management of philanthropic activities USD millions 0.068 0.067 0.200¹ 0.2222 Environmental impact3Unit 2018 2019 2020 2021 Total municipal water consumed Million cubic meters 0.568 0.581 0.618 0.664 Total fresh water consumed Million cubic meters 0.121 0.109 0.119 0.185 Total process water discharged Million cubic meters 0.057 0.068 0.109 0.112 Total domestic water discharged Million cubic meters 0.412 0.430 0.511 0.590 Water intensity Cubic meters/ USD millions revenue70 64 74 71 Total non-hazardous and hazardous waste generated Metric tons 12,372 12,196 10,936 12,796 Total non-hazardous waste generated Metric tons 11,579 11,200 9,978 11,703Accelerating possibilities Protecting the environment 1 This includes donations to HCP and non-HCP charitable organizations and does not include any medical grant, research grant or fellowship funding.",2021_boston_scientific_performance_report.pdf
"2 2020 and 2021 data includes community engagement, sales charitable contributions committee costs and foundation consultant fees.",2021_boston_scientific_performance_report.pdf
"3 Environmental impact metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.",2021_boston_scientific_performance_report.pdf
"63 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Environmental impact1Unit 2018 2019 2020 2021 Total non-hazardous waste recycled Metric tons 9,667 8,943 7,843 8,673 Total non-hazardous waste energy recovered Metric tons 1,332 1,744 1,545 1,962 Total non-hazardous waste disposed to landfill Metric tons 581 514 591 1,067 Total hazardous waste generated Metric tons 792 996 958 1,093 Total hazardous waste recovered Metric tons 76 57 94 103 Total hazardous waste energy recovered Metric tons 310 362 376 468 Total hazardous waste treatment Metric tons 247 240 292 307 Total hazardous waste incinerated Metric tons 135 218 152 181 Total hazardous waste landfilled Metric tons 0 0 14 1 Total hazardous waste recycled Metric tons 24 119 29 33 Environmental notice of violation # 0 3 0 0Protecting the environment 1 Environmental impact metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.",2021_boston_scientific_performance_report.pdf
"64 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Climate change1Unit 2018 2019 2020 2021 Total direct greenhouse gas emissions (Scope 1) CO2 equivalent metric tons 31,257 34,168 35,908 35,395 Total indirect greenhouse gas emissions (Scope 2) CO2 equivalent metric tons 53,870 50,611 17,823 16,889 Non-renewable fuels consumed mWh 170,495 186,393 191,645 192,076 Total electricity purchased mWh 181,587 187,736 185,329 205,187 Total renewable electricity purchased mWh 9,149 22,508 131,8962149,617 Total energy use gWh 355 368 381 397 Green real estate3Percent 32 41 42 46 Number of LEED certified / registered buildings # 13 13 15 16 Number of ISO 50001:2018 certified sites # 2 5 6 9 Number of ISO 14001:2015 certified sites # 15 15 16 16 Carbon footprint (Scopes 1 and 2) Metric tons 85,127 84,778 53,730 52,2844 Renewable electricity purchased with renewable energy certificates Percent 5 11 71 734 Renewable energy (all sources) used with renewable energy certificates Percent 3 6 35 38 Energy intensity % MWh/ USD millions revenue36 34 38 33Protecting the environment 1 Climate change metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.",2021_boston_scientific_performance_report.pdf
2 2020 figure restated.,2021_boston_scientific_performance_report.pdf
"3 Green real estate: percentage of Boston Scientific real estate that is independently certified for energy efficiency by industry-leading bodies such as LEED for design and Energy Star or ISO 50001:2018 for building operations 4 Reflects adjustments to previously reported figure of 72% renewable electricity and 53.7k metric tons CO2 in our 2022 Annual Proxy Statement, based on subsequent internal audit.",2021_boston_scientific_performance_report.pdf
"65 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 2021 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,356 Percentage of suppliers identified as Tier 1 Percent 100 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 130 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.6 Supplier scorecard risk assessment — total number of Tier 1 suppliers assessed in last three years # 393 333 337 313 Supplier scorecard risk assessment — percentage of Tier 1 suppliers assessed in last three years Percent 26.3 20.2 22.6 23.1 Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.6 Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers in the last three yearsPercent 26.2 20.2 22.6 23.1 Compliance Unit 2018 2019 2020 2021 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,076 Reported taxes USD millions -249 -4,013 2 36 Reported tax rate Percent -17.5 -584.0 2.9 3.3 Cash taxes paid USD millions 1,037 242 207 302 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 66 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Governance Unit 2018 2019 2020 2021 Number of executive directors # 1 1 1 1 Number of independent directors # 9 9 9 9 Number of women executives # 3 3 4 3 Average tenure of independent board members (years) # 5 6 7 7 No.",2021_boston_scientific_performance_report.pdf
"of non-executive/independent directors who sit on four or less public company boards, including Boston Scientific# 9 9 8 9 No.",2021_boston_scientific_performance_report.pdf
"of public company boards outside of Boston Scientific on which non-executive/independent directors can sit¹# 3 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,712 Total annual CEO compensation USD millions 13.97 15.76 13.77 16.06 Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.9 Lobbying USD millions 1.68 1.68 1.52 1.52 Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.22 Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).",2021_boston_scientific_performance_report.pdf
"For more information, please review our Corporate Governance Guidelines.",2021_boston_scientific_performance_report.pdf
"67 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Indicator Description Response GRI 100 102-1 Name of the organization Boston Scientific Corporation 102-2 Activities, brands, products and services Form 10-K, Item 1. Business, Page 3 Performance Report, Boston Scientific: 2021 at a glance, Page 7 102-3 Location of headquarters 300 Boston Scientific Way, Marlborough, MA 01752-1234 102-4 Location of operations Form 10-K, Item 1. International Operations, Page 10 Form 10-K, Item 2.",2021_boston_scientific_performance_report.pdf
"Properties, Page 36 102-5 Ownership and legal form Boston Scientific Corporation, publicly traded on New York Stock Exchange as BSX 102-6 Markets served Form 10-K, Item 1.",2021_boston_scientific_performance_report.pdf
"Marketing and Sales, Page 10 102-7 Scale of the organization Performance Report, Boston Scientific: 2021 at a glance, Page 7 Form 10-K, Item 1. Business, Page 3 102-8 Information on employees and other workers Form 10-K, Item 1.",2021_boston_scientific_performance_report.pdf
"Human Capital, Page 14 Performance Report Appendix 102-9 Supply chain Form 10-K, Item 1.",2021_boston_scientific_performance_report.pdf
"Manufacturing and Raw Materials, Page 11 Performance Report, Creating value responsibly, Page 48 102-10 Significant changes to the organization and its supply chainForm 10-K, Item 7.",2021_boston_scientific_performance_report.pdf
"Management’s Discussion and Analysis of Financial Condition and Results of Operations, Page 40 102-11 Precautionary Principle or approach Form 10-K, Item 1. Business Strategy, Page 3 Performance Report, Our ESG strategy, Page 8Global Reporting Initiative (GRI) index The Global Reporting Initiative (GRI) Standards represent global best practices for reporting publicly on a range of ESG impacts.",2021_boston_scientific_performance_report.pdf
We continue to expand the scope of our ESG metrics and disclosures to topics material to our business and stakeholders.,2021_boston_scientific_performance_report.pdf
This report has been prepared in accordance with the GRI Standards: Core option.,2021_boston_scientific_performance_report.pdf
"The following table includes references to our 2021 performance report, 2021 Form 10-K, and other documents available on BostonScientific.com.",2021_boston_scientific_performance_report.pdf
"68 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Indicator Description Response 102-12 External initiatives Performance Report, Accelerating possibilities, Page 31 Performance Report, Protecting the environment, Page 39 Performance Report, Creating value responsibly, Page 48 Respecting Human Rights 102-13 Memberships of associations Trade Association Memberships 102-14 Statement from senior decision-maker Performance Report, A Message from our Chairman and Chief Executive Officer, Page 4 102-15 Key impacts, risks and opportunities Form 10-K, Item 1A.",2021_boston_scientific_performance_report.pdf
"Risk Factors, Page 22 102-16 Values, principles, standards and norms of behavior Performance Report, Our mission and values, Page 6 Code of Conduct 102-17 Mechanisms for advice and concerns about ethics Advice Line 102-18 Governance structure Proxy Statement Governance overview 102-19 Delegating authority Proxy Statement 102-20 Executive-level responsibility for economic, environmental and social topicsPerformance Report, Our ESG strategy, Page 8 Proxy Statement 102-21 Consulting stakeholders on economic, environmental and social topicsPerformance Report, Our ESG strategy, Page 8 Performance Report Appendix, Stakeholder engagement, Page 56 102-22 Composition of the highest governance body and its committeesProxy Statement 102-23 Chair of the highest governance body Proxy Statement 102-24 Nominating and selecting the highest governance body Proxy Statement 102-25 Conflicts of interest Code of Conduct 102-26 Role of highest governance body in setting purpose, values and strategyProxy Statement 102-27 Collective knowledge of highest governance body Proxy Statement 102-28 Evaluating the highest governance body’s performance Proxy Statement 69 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Indicator Description Response 102-29 Identifying and managing economic, environmental and social impactsForm 10-K, Item 1. Business, Page 3 Performance Report, Our ESG strategy, Page 8 102-30 Effectiveness of risk management processes Proxy Statement Performance Report, Risk management and global security, Page 53 102-31 Review of economic, environmental and social topics See 102-29 102-32 Highest governance body’s role in sustainability reporting Proxy Statement 102-33 Communicating critical concerns Proxy Statement 102-34 Nature and total number of critical concerns Form 10-K, Item 1A.",2021_boston_scientific_performance_report.pdf
"Risk Factors, Page 22 102-35 Remuneration policies Proxy Statement 102-36 Process for determining remuneration Proxy Statement 102-37 Stakeholders’ involvement in remuneration Proxy Statement 102-38 Annual total compensation ratio Proxy Statement 102-39 Percentage increase in annual total compensation ratio Proxy Statement 102-40 List of stakeholder groups See 102-21 102-41 Collective bargaining agreements Human Rights, Collective Bargaining 102-42 Identifying and selecting stakeholders See 102-21 102-43 Approach to stakeholder engagement See 102-21 102-44 Key topics and concerns raised Performance Report, Our ESG strategy, Page 8 102-45 Entities included in the consolidated financial statements Form 10-K, Exhibit 21 102-46 Defining report content and topic boundaries Performance Report, Table of contents, Page 3 102-47 List of material topics Performance Report, Our ESG strategy, Page 8 102-48 Restatements of information Throughout Performance Report and Performance Report Appendix 102-49 Changes in reporting Throughout Performance Report and Performance Report Appendix 102-50 Reporting period Data in the Performance Report covers the period between January 1, 2020, and December 31, 2020, unless otherwise indicated 70 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Indicator Description Response 102-51 Date of most recent report 4/15/2021 2020 Annual Performance Report 102-52 Reporting cycle Annual 102-53 Contact point for questions regarding the report Investor Relations 102-54 Claims of reporting in accordance with the GRI Standards Performance Report, Table of contents, Page 3 102-55 GRI content index Performance Report Appendix 102-56 External assurance This report has not been independently verified.",2021_boston_scientific_performance_report.pdf
"GRI 200 201-1 Direct economic value generated and distributed Form 10-K, Item 8.",2021_boston_scientific_performance_report.pdf
"Financial Statements & Supplementary Data, Page 70 Performance Report, Boston Scientific: 2021 at a glance, Page 7 201-2 Financial implications and other risks and opportunities due to climate changeForm 10-K, Item 1A.",2021_boston_scientific_performance_report.pdf
"Risk Factors, Page 35 Performance Report, Managing climate risk, Page 45 201-3 Defined benefit plan obligations and other retirement plansForm 10-K, Item 15.",2021_boston_scientific_performance_report.pdf
"Exhibits and Financial Statement Schedules Note S, Page 130 202-1 Ratios of standard entry level wage by gender compared to local minimum wageLabor and Human Rights, Commitment to Labor Initiatives or Standards 203-1 Infrastructure investments and services supported Form 10-K, Item 1.",2021_boston_scientific_performance_report.pdf
"Marketing and Sales, Page 10 203-2 Significant indirect economic impacts Performance Report, Transforming care, Page 13 Performance Report, Investing in our people, Page 20 Performance Report, Accelerating possibilities, Page 31 Performance Report, Protecting the environment, Page 39 Performance Report, Creating value responsibly, Page 48 204-1 Proportion of spending on local suppliers Performance Report, Keeping our supply chain resilient and reliable, Page 52 205-1 Operations assessed for risks related to corruption Anti-Corruption & Governance 205-2 Communication and training about anti-corruption policies and proceduresPerformance Report, Compliance, ethics and integrity, Page 50 206-1 Legal actions for anti-competitive behavior, anti-trust and monopoly practicesForm 10-K, Note K. Commitments and Contingencies, Page 113 71 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Indicator Description Response GRI 300 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41 Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41 Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41 Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products and servicesPerformance Report, GEMS KPIs, Page 41 Performance Report, Advancing product stewardship, Page 46 Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39 Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 2021 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using environmental criteriaPerformance Report, Creating value responsibly, Page 48 72 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Indicator Description Response GRI 400 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism and number of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition assistance programsPerformance Report, Investing in our people, Page 20 404-3 Percentage of employees receiving regular performance and career development reviewsPerformance Report, Investing in our people, Page 20 405-1 Diversity of governance bodies and employees Proxy Statement Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20 Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics 407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of indigenous peoplesHuman Rights 73 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact assessments and development programsPerformance Report, Supporting our communities, Page 36 Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48 415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product and service categoriesPerformance Report, Ensuring quality, health and safety, Page 17 416-2 Incidents of non-compliance concerning the health and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17 417-1 Requirements for product and service information and labelingPerformance Report, Ensuring quality, health and safety, Page 17 Performance Report, Advancing product stewardship, Page 46 419-1 Non-compliance with laws and regulations in the social and economic areaBoston Scientific adheres to all compliance requirements, see compliance references throughout the Performance Report and BostonScientific.com 74 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Topic Accounting metric Code Response Affordability and pricingRatio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-14 Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3 Class II recalls: 8 Total units recalled: 47,430 List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by typeHC-MS-250a.4 0 in 2021 Ethical marketing Total amount of monetary losses as a result of legal proceedings associated with false marketing claimsHC-MS-270a.1 $0 in 2021 Description of code of ethics governing promotion of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40; Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.",2021_boston_scientific_performance_report.pdf
"The following table summarizes how our existing reporting is guided by recommended disclosure topics and accounting metrics for the Medical Equipment and Supplies industry standard, and includes references to our 2021 Performance Report, 2021 Form 10-K and other documents available on BostonScientific.com.",2021_boston_scientific_performance_report.pdf
"75 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Topic Accounting metric Code Response Product design and lifecycle managementDiscussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable productsHC-MS-410a.1 Boston Scientific’s commitment to innovation and patient health extends beyond the surgical suite by managing the environmental and human health impact of chemicals in our products through design, manufacture and use.",2021_boston_scientific_performance_report.pdf
Our design and supplier management processes assess and manage relevant environmental and chemical requirements.,2021_boston_scientific_performance_report.pdf
"We work with our suppliers to ensure material compliance of all purchased goods and components, allowing us to make responsible material and chemical choices for the design and manufacture of our products.",2021_boston_scientific_performance_report.pdf
"Performance Report, Advancing product stewardship, Page 46 Total amount of products accepted for take-back and reused, recycled or donated, broken down by: (1) devices and equipment (2) suppliesHC-MS-410a.2 Within participating customers: • 65% of LithoVue™ systems recycled in the United States in 2021 • 39% of EXALT™ Model D systems recycled in the United States in 2021 Performance Report, Advancing product stewardship, Page 46 Supply chain managementPercentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product qualityHC-MS-430a.1 All Boston Scientific medical device manufacturing facilities are audited by external regulators or applicable authorities.",2021_boston_scientific_performance_report.pdf
"A majority of our direct suppliers are ISO certified (for example ISO 9001 or ISO 13485), as applicable, and demonstrate compliance and quality through certification audits.",2021_boston_scientific_performance_report.pdf
"Form 10-K, Quality Assurance, Page 13 Description of efforts to maintain traceability within the distribution chainHC-MS-430a.2 Boston Scientific maintains traceability within the manufacturing and distribution chain through either serial or batch control of finished products.",2021_boston_scientific_performance_report.pdf
"We: • Leverage product identification technologies, such as barcoding identification to track the information of products • Utilize enterprise resource planning (ERP) solutions to support identification and control of products once they leave manufacturing sites — including supporting specific patient tracking if required.",2021_boston_scientific_performance_report.pdf
"Our ERP solutions ensure compliance with regularity, quality and customs control requirements Description of the management of risks associated with the use of critical materialsHC-MS-430a.3 Form 10-K, Manufacturing and Raw Materials, page 11 Performance Report, Cr eating value responsibly, Page 48 Business ethics Total amount of monetary losses as a result of legal proceedings associated with bribery or corruptionHC-MS-510a.1 $0 in 2021 Description of code of ethics governing interactions with health care professionalsHC-MS-510a.2 Code of Conduct, Page 32 Performance Report, Creating value responsibly, Page 48 Activity metrics Code Response Number of units sold by product category HC-MS-000.A Not currently disclosed 76 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly United Nations Sustainable Development Goals (SDGs) The United Nations Sustainable Development Goals (SDGs) are a set of 17 global goals with the aim to end poverty, fight inequality and injustice and tackle climate change by 2030.",2021_boston_scientific_performance_report.pdf
The following table summarizes how our reporting aligns with the SDGs.,2021_boston_scientific_performance_report.pdf
More information on our priorities can also be found in Our ESG strategy .,2021_boston_scientific_performance_report.pdf
77 2021 Performance ReportIntroduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative (GRI) index Sustainability Accounting Standards Board (SASB) index United Nations Sustainable Development Goals (SDGs) Cautionary Statement Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.,2021_boston_scientific_performance_report.pdf
"Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “may,” “estimate,” “intend” and similar words.",2021_boston_scientific_performance_report.pdf
"These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.",2021_boston_scientific_performance_report.pdf
"These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the second quarter and full year 2022; our financial performance; our business and environmental, social and governance (ESG) plans, performance and goals; product performance; and the impact of the COVID-19 pandemic on the company’s results of operations.",2021_boston_scientific_performance_report.pdf
"If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.",2021_boston_scientific_performance_report.pdf
"These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this report.",2021_boston_scientific_performance_report.pdf
"As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.",2021_boston_scientific_performance_report.pdf
"Risks and uncertainties that may cause such differences include, among other things: the impact of the ongoing COVID-19 pandemic on our operations and financial results; future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors.",2021_boston_scientific_performance_report.pdf
"New risks and uncertainties may arise from time to time and are difficult to predict, including those that have emerged or have increased in significance or likelihood as a result of the COVID-19 pandemic.",2021_boston_scientific_performance_report.pdf
All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.,2021_boston_scientific_performance_report.pdf
"For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A — Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A — Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.",2021_boston_scientific_performance_report.pdf
"We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.",2021_boston_scientific_performance_report.pdf
This cautionary statement is applicable to all forward-looking statements contained in this report.,2021_boston_scientific_performance_report.pdf
All images are the property of Boston Scientific.,2021_boston_scientific_performance_report.pdf
All trademarks are the property of their respective owners.,2021_boston_scientific_performance_report.pdf
© 2022 Boston Scientific Corporation or its affiliates.,2021_boston_scientific_performance_report.pdf
All rights reserved.,2021_boston_scientific_performance_report.pdf
PR2021,2021_boston_scientific_performance_report.pdf
"2019 Boston Scientific Performance Report Foreword April 13, 2020 As we publish this report, the world is facing unprecedented challenges amid the COVID - 19 pandemic.",2019_Boston_Scientific_Performance_Report.pdf
"During this uncertain time, our priority is to protect and aid the health and safety of our employees, our physician customers and their patients.",2019_Boston_Scientific_Performance_Report.pdf
That has always meant ensuring that o ur life - changing devices and therapies would be available when needed.,2019_Boston_Scientific_Performance_Report.pdf
"Now, it also means finding new and creative ways to support the frontline healthcar e p roviders working tirelessly to address the COVID - 19 pandemic.",2019_Boston_Scientific_Performance_Report.pdf
We will continue to make decisions guided by our core values to support our global community.,2019_Boston_Scientific_Performance_Report.pdf
"To help meet the urgent needs of healthcare providers, we have contributed to COVID - 19 relief efforts globally through monetary and supply donations, and by providing engineering and manufacturing expertise and resources.",2019_Boston_Scientific_Performance_Report.pdf
This includes donations of personal protective equipment and me dical equipment to local hospitals and government agencies.,2019_Boston_Scientific_Performance_Report.pdf
"The company is also providing support to children, families and the most vulnerable through d irect financial contributions to community and global non - profit organizations including Project HOPE and International Federation of Red Cross and Red Crescent Societies .",2019_Boston_Scientific_Performance_Report.pdf
It will take time for nations and local communities to heal from the devastating and wide - ranging impact of this complex situati on.,2019_Boston_Scientific_Performance_Report.pdf
"At Boston Scientific, we have always found our purpose in working alongside healthcare providers to solve some of healthcare’s toughest challenges.",2019_Boston_Scientific_Performance_Report.pdf
"Ou r c ommitment is unwavering, regardless of the obstacles we face today, and we will emerge from this challenging time stronger, together.",2019_Boston_Scientific_Performance_Report.pdf
"To learn more about our actions in response to the COVID - 19 pandemic, visit our website .",2019_Boston_Scientific_Performance_Report.pdf
"Please note that the following report summarizes the company’s performance in 2019 and includes the letter to our stockholder s f rom our 2019 Annual Report, which was written before the COVID - 19 global pandemic.",2019_Boston_Scientific_Performance_Report.pdf
"2019 Performance ReportEvery day, Boston Scientific is... Bost on Scientific 2019 Performance Report 1 Throughout this document, unless otherwise noted, all revenue and other growth rates represent fiscal year 2019 compared to fiscal year 2018.",2019_Boston_Scientific_Performance_Report.pdf
"Letter from the company’s 2019 Annual Report, written before the COVID-19 global pandemic.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations achieving success through our people.transforming the lives of our patients.",2019_Boston_Scientific_Performance_Report.pdf
helping shape the future of our planet.,2019_Boston_Scientific_Performance_Report.pdf
committing to responsible practices.2 Feature Patient Highlight 3 A Message to Our Stockholders 9 Financial Highlights 10 Our Mis sion and Core Values 11 Boston Scientific at a Glance 12 Boston Scientific by the Numbers 13 Corporate Social Responsibility at Boston Scientific 16 Our Patients 22 Our People 44 Our Planet 51 Our Pr actices 65 Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 2 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Katharina Bauer: The Heart of a Champion The sport of pole vaulting is not for the faint of heart.,2019_Boston_Scientific_Performance_Report.pdf
"Competitors sprint down a track and launch themselves into the air, summoning enough speed to clear a crossbar high overhead.",2019_Boston_Scientific_Performance_Report.pdf
"For 29-year-old Katharina Bauer, pole vaulting is her life’s passion — or as she says, “her big love.” So it’s not surprising that Katharina’s goal is to take her passion all the way to the Olympics.",2019_Boston_Scientific_Performance_Report.pdf
"There was a time, however, when Katharina was unsure whether her heart was up to the challenge.",2019_Boston_Scientific_Performance_Report.pdf
"As a child, she was diagnosed with a condition that caused her heart to have a perilously high number of beats.",2019_Boston_Scientific_Performance_Report.pdf
"While a healthy human heart beats about 100,000 times a day, by the age of seven, Katharina experienced 6,000 extra beats daily.",2019_Boston_Scientific_Performance_Report.pdf
"In 2009, she underwent her first heart surgery.",2019_Boston_Scientific_Performance_Report.pdf
"Her condition eventually worsened to 18,000 extra beats per day, leading to a second heart surgery eight years later.",2019_Boston_Scientific_Performance_Report.pdf
"Despite these challenges, Katharina con- tinued to compete as a professional pole vaulter and captured a gold medal at the 2018 German Indoor Athletics Champion - ship.",2019_Boston_Scientific_Performance_Report.pdf
"At a regular health check after the event, her doctor detected another type of abnormal heartbeat — one Katharina learned can cause ventricular fibrillation and sudden cardiac death.",2019_Boston_Scientific_Performance_Report.pdf
"The next day, she made the decision to get a subcutaneous implantable cardioverter defibrillator (S-ICD).",2019_Boston_Scientific_Performance_Report.pdf
"In April 2018, she was implanted with the Boston Scientific EMBLEM™ MRI S-ICD System.",2019_Boston_Scientific_Performance_Report.pdf
"The S-ICD system, which includes a pulse generator and lead placed just under the skin, monitors Katharina’s heart and sends an electrical shock if it beats abnormally fast, protecting her from sudden cardiac arrest.",2019_Boston_Scientific_Performance_Report.pdf
"With continued medical supervision, Katharina returned to training, describing her defibrillator as a guardian angel.",2019_Boston_Scientific_Performance_Report.pdf
"Six weeks after the procedure, she cleared 4.20 meters at a competition.",2019_Boston_Scientific_Performance_Report.pdf
"Less than a year later, she returned to the Ger- man Indoor Athletics Championship and won a silver medal.",2019_Boston_Scientific_Performance_Report.pdf
"“I am grateful for every day, every jump and every training.",2019_Boston_Scientific_Performance_Report.pdf
"I love that I can follow my passion,” Katharina says.",2019_Boston_Scientific_Performance_Report.pdf
"As she trains to qualify for the next Summer Olympics and become the first Olympian with a defibrillator to compete, Katharina no longer fears for her heart.",2019_Boston_Scientific_Performance_Report.pdf
"“I turned it around,” she tells us.",2019_Boston_Scientific_Performance_Report.pdf
"“ There is no need for fear as long as you feel that fire inside.”” I am gr ateful for every day, every jump and every training.",2019_Boston_Scientific_Performance_Report.pdf
I love that I can follow my passion.,2019_Boston_Scientific_Performance_Report.pdf
"There is no need for fear as long as you feel that fire inside.” Katharina Bauer, Professional Pole Vaulter” I am gr ateful for every day, every jump and every training.",2019_Boston_Scientific_Performance_Report.pdf
I love that I can follow my passion.,2019_Boston_Scientific_Performance_Report.pdf
"There is no need for fear as long as you feel that fire inside.” Katharina Bauer, Professional Pole Vaulter Bost on Scientific 2019 Performance Report 3 We enter 2020 with a forty-year legacy of advancing science — and forty years guided by our mission to transform lives through medical solutions that improve the health of patients around the world.",2019_Boston_Scientific_Performance_Report.pdf
"Our company has achieved a great deal in its four decades, and those accomplishments put us on solid footing for the future.",2019_Boston_Scientific_Performance_Report.pdf
"As we move into the next decade, we face challenges from the growing burden of chronic conditions among an aging population, the demands of value-based care and new, disruptive competitors.",2019_Boston_Scientific_Performance_Report.pdf
"These trends also represent opportunities, and I am energized and inspired by the significant advancements we have made and will continue to make, and by the lives that have been extended or enhanced because of our products.",2019_Boston_Scientific_Performance_Report.pdf
"In the last year alone, we helped more than 30 million patients.Katharina Bauer, a pole vault competitor for the German National team, is one of those patients.",2019_Boston_Scientific_Performance_Report.pdf
"Since she was young, Katharina has had a heart condition that causes her heart to beat irregularly.",2019_Boston_Scientific_Performance_Report.pdf
"In April 2018, her doctors implanted our EMBLEM™ MRI subcutaneous implantable cardioverter defibrillator (S-ICD) system.",2019_Boston_Scientific_Performance_Report.pdf
"It monitors her heart and sends an electrical current to reset it, if necessary.",2019_Boston_Scientific_Performance_Report.pdf
"Six weeks after her device was implanted, Katharina started c ompeting again.",2019_Boston_Scientific_Performance_Report.pdf
"Within a year, she won a silver medal at the German Indoor Athletics Championship.",2019_Boston_Scientific_Performance_Report.pdf
Today she has ambitions to compete in the next summer Olympics.,2019_Boston_Scientific_Performance_Report.pdf
"For our 36,000 employees, our mission and stories like Katharina’s fuel our pursuit of innovation — for the sake of patients, society and our stockholders.",2019_Boston_Scientific_Performance_Report.pdf
"Despite multiple challenges in 2019, I’m proud of how strongly our global team performed across businesses, functions and regions.",2019_Boston_Scientific_Performance_Report.pdf
"While we strive to deliver high quality results each quarter, we are ever vigilant about what lies further ahead, and the ongoing need to adapt to the rapidly evolving healthcare environment.",2019_Boston_Scientific_Performance_Report.pdf
We must reduce the costs of improving outcomes and do more to benefit healthcare systems as a whole.,2019_Boston_Scientific_Performance_Report.pdf
This work requires a relentless sense of urgency.,2019_Boston_Scientific_Performance_Report.pdf
"We call it winning spirit, and it drives us to meet future challenges and to develop and deliver the highest quality and safest products and solutions.",2019_Boston_Scientific_Performance_Report.pdf
"2019 Business Results In 2019, Boston Scientific strengthened our portfolio and capabilities w hile d elivering strong revenue and adjusted earnings per share growth.1 These financials continue a more than five-year trend of excellent performance.",2019_Boston_Scientific_Performance_Report.pdf
"During this time, Boston 1 Adjusted operating margin, adjusted earnings per share and related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation-related net charges and credits, investment impairment charges, pension termination charges, EU MDR implementation charges, debt extinguishment net charges and credits, deferred tax expenses (benefits) and discrete tax items; see non-GAAP reconciliations on pages 65-67.",2019_Boston_Scientific_Performance_Report.pdf
2 Organic revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the first 12 months of sales from acquisitions in the periods for which there are no prior period related net sales.,2019_Boston_Scientific_Performance_Report.pdf
"Organic revenue growth also excludes the impact of the divestiture of our global embolic microspheres portfolio, a transaction entered into in connection with obtaining the antitrust clearances required to complete the acquisition of BTG plc (BTG); see non-GAAP reconciliations on pages 65-67.",2019_Boston_Scientific_Performance_Report.pdf
"3 Full year 2018 adjusted earnings per share was $1.47, which includes a $0.07 net tax benefit for the year.",2019_Boston_Scientific_Performance_Report.pdf
"Excluding this net tax benefit of $0.07, our 2018 adjusted earnings per share grew 11 percent.",2019_Boston_Scientific_Performance_Report.pdf
2019 adjusted EPS growth including the aforementioned 2018 net tax benefit is 8 percent and normalized for the 2018 net tax benefit is 13 percent.,2019_Boston_Scientific_Performance_Report.pdf
"Full year 2018 net tax benefit of $0.07 includes our second quarter $0.06 benefit from settling the IRS Stipulation of Settled Issues for the 2001 through 2010 tax years, offset by a fourth quarter $0.05 charge for our tax reinvestment strategy.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, the net benefit includes a $0.06 benefit in the fourth quarter for the settlement with the IRS of our 2011 through 2013 tax years.",2019_Boston_Scientific_Performance_Report.pdf
"Letter from the company’s 2019 Annual Report, written before the COVID-19 global pandemic.Dear Stockholders: Mike Mahoney, Chairman and CEO Helped ~30 million patients ~36,000 employees Full-year sales: $10.735 billion Organic sales growth: 7%2 5-Year total stockholder return: 241%Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Scientific has grown organic sales2 at an average rate of 7 percent.",2019_Boston_Scientific_Performance_Report.pdf
We’ve improved adjusted operating margin1 380 basis points and used that to drive an average 14 percent growth3 in adjusted earnings per share1 over the five-year period.,2019_Boston_Scientific_Performance_Report.pdf
"On 12/31/19, the closing price of our common stock represented a full-year return of 28 percent, in line with the total return of the S&P 500 index.",2019_Boston_Scientific_Performance_Report.pdf
"Our five- and three-year total stockholder returns of 241 percent and 109 percent, respectively, more than doubled the total returns of the S&P 500.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 42019 2017 2018 2016 2015 2014$350 $100 0350 1 Adjusted operating margin, adjusted earnings per share and related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation-related net charges and credits, investment impairment charges, pension termination charges, EU MDR implementation charges, debt extinguishment net charges and credits, deferred tax expenses (benefits) and discrete tax items; see non-GAAP reconciliations on pages 65-67.",2019_Boston_Scientific_Performance_Report.pdf
2 Organic revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the first 12 months of sales from acquisitions in the periods for which there are no prior period related net sales.,2019_Boston_Scientific_Performance_Report.pdf
"Organic revenue growth also excludes the impact of the divestiture of our global embolic microspheres portfolio, a transaction entered into in connection with obtaining the antitrust clearances required to complete the acquisition of BTG plc (BTG); see non-GAAP reconciliations on pages 65-67.",2019_Boston_Scientific_Performance_Report.pdf
"3 Full year 2018 adjusted earnings per share was $1.47, which includes a $0.07 net tax benefit for the year.",2019_Boston_Scientific_Performance_Report.pdf
"Excluding this net tax benefit of $0.07, our 2018 adjusted earnings per share grew 11 percent.",2019_Boston_Scientific_Performance_Report.pdf
2019 adjusted EPS growth including the aforementioned 2018 net tax benefit is 8 percent and normalized for the 2018 net tax benefit is 13 percent.,2019_Boston_Scientific_Performance_Report.pdf
"Full year 2018 net tax benefit of $0.07 includes our second quarter $0.06 benefit from settling the IRS Stipulation of Settled Issues for the 2001 through 2010 tax years, offset by a fourth quarter $0.05 charge for our tax reinvestment strategy.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, the net benefit includes a $0.06 benefit in the fourth quarter for the settlement with the IRS of our 2011 through 2013 tax years.",2019_Boston_Scientific_Performance_Report.pdf
4 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 65-67.,2019_Boston_Scientific_Performance_Report.pdf
"5 We have three reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices).",2019_Boston_Scientific_Performance_Report.pdf
We have included BTG’s Interventional Medicine business in our Peripheral Interventions operating segment’s 2019 revenues from the date of acquisition.,2019_Boston_Scientific_Performance_Report.pdf
6 Based on internal estimates.,2019_Boston_Scientific_Performance_Report.pdf
"7 We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.",2019_Boston_Scientific_Performance_Report.pdf
"Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries.",2019_Boston_Scientific_Performance_Report.pdf
We have revised prior year amounts to the current year’s presentation.,2019_Boston_Scientific_Performance_Report.pdf
The revision had an immaterial impact on prior year Emerging Markets sales.,2019_Boston_Scientific_Performance_Report.pdf
"8 As part of our acquisition of BTG, we acquired a specialty pharmaceuticals business (Specialty Pharmaceuticals).",2019_Boston_Scientific_Performance_Report.pdf
"Subsequent to acquisition, Specialty Pharmaceuticals is now a stand-alone operating segment presented alongside our Medical Device reportable segments.",2019_Boston_Scientific_Performance_Report.pdf
"9 Adjusted free cash flow is a non-GAAP measure that excludes from free cash flow the cash component of certain charges (credits) that are also excluded from adjusted net income as well as any cash tax benefits of such charges, as detailed below.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, we exclude payments or refunds that relate to resolving tax disputes related to prior periods.",2019_Boston_Scientific_Performance_Report.pdf
"Free cash flow is a non-GAAP measure that excludes net purchases of property, plant and equipment from cash provided by (used for) operating activities on a GAAP basis.",2019_Boston_Scientific_Performance_Report.pdf
The GAAP measure that is most directly comparable to adjusted free cash flow and free cash flow is cash provided by (used for) operating activities on a GAAP basis.,2019_Boston_Scientific_Performance_Report.pdf
See non-GAAP reconciliations on pages 65-67.,2019_Boston_Scientific_Performance_Report.pdf
"Letter from the company’s 2019 Annual Report, written before the COVID-19 global pandemic.Our full-year sales in 2019 were $10.735 billion.",2019_Boston_Scientific_Performance_Report.pdf
This represents 11.1 percent opera- tional revenue growth4 and 7.3 percent organic revenue growth2 compared to 2018.,2019_Boston_Scientific_Performance_Report.pdf
"Organic revenue growth was 8.8 percent in MedSurg,5 3.3 percent in Rhythm and Neuro5 and 9.3 percent in Cardiovas - cular.5 Our global performance was strong, with all regions delivering above-market growth.6 Total annual sales from Emerging Markets7 increased 19.5 percent on an operational basis compared to 2018.",2019_Boston_Scientific_Performance_Report.pdf
"Outside of our three reportable segments, Specialty Pharmaceuticals8 generated revenue of $81 million since the closing of the BTG acquisition in August 2019.",2019_Boston_Scientific_Performance_Report.pdf
This brings the full year pro-forma pharmaceutical sales to $250 million.,2019_Boston_Scientific_Performance_Report.pdf
"We also delivered a 60 basis-point improvement in adjusted operating margin1 and increased full-year adjusted earnings per share1 to $1.58, up 13 percent over the prior year (normalized for the 7 cent net tax benefit in 2018).3 We generated more than $2 billion of adjusted free cash flow9 while continuing to increase productivity, reduce costs, and redirect savings to high-growth technologies that strengthen our portfolio and capabilities for the future.",2019_Boston_Scientific_Performance_Report.pdf
Our strategy of category leadership in key markets and portfolio diversification into high growth adjacencies is working.,2019_Boston_Scientific_Performance_Report.pdf
We expect to continue to expand our presence in new markets and regions and to make our technologies accessible to more people in need.,2019_Boston_Scientific_Performance_Report.pdf
"Our goal is to continue to execute against our strategic plan objectives, further increase our organic growth profile, and deliver top-tier sales and adjusted earnings per share growth over the next five years.",2019_Boston_Scientific_Performance_Report.pdf
"We believe that the long-term combination of consistent, above-market revenue growth, adjusted operating margin expansion, targeted double-digit adjusted earnings per share growth, and the improved ability to generate — and strategically deploy — a strong free Comparison of 5-Year Cumulative Total Return * Boston Scientific Corporation S&P Health Care Equipment S&P 500 * $100 in vested on 12/31/14 in stock or index, including reinvestment of dividends.",2019_Boston_Scientific_Performance_Report.pdf
Fiscal year ending December 31.,2019_Boston_Scientific_Performance_Report.pdf
"© 2020 Standard & Poor’s, a division of S&P Global.",2019_Boston_Scientific_Performance_Report.pdf
All rights reserved.,2019_Boston_Scientific_Performance_Report.pdf
"2019 adjusted EPS growth: 14%1,3 85+ product launches EXALT ™ Model D is the world's first and only single-use duodenoscope to be cleared by the FDA.cash flow position Boston Scientific to continue to drive stockholder value.",2019_Boston_Scientific_Performance_Report.pdf
"Investing for Growth Our approach to innovation includes a mix of organic research programs, collaborations, and strategic investments and acquisitions that enrich the medical specialties we serve.",2019_Boston_Scientific_Performance_Report.pdf
"Our products are used to help diagnose or treat complex diseases and conditions across multiple fields: cardiovascular, respiratory, digestive, neurological, urological and pelvic health.",2019_Boston_Scientific_Performance_Report.pdf
"Our category leadership strategy to deepen our portfolio in these areas is helping us create value for patients, physicians and payers.",2019_Boston_Scientific_Performance_Report.pdf
"And it’s enabling us to grow faster than the markets in which we compete,6 and faster than most of our peers.",2019_Boston_Scientific_Performance_Report.pdf
"By 2022, we expect that our investments in technology development and acquisitions will allow us to introduce solutions for unmet clinical needs in adjacent markets that accelerate our served market growth rate to approximately 6 percent.6Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 5Innovative Technologies Solve Urgent Challenges Over the course of 2019, we executed more than 85 product launches and received several significant regulatory clearances, including in our Endoscopy, Neuromodulation and Interventional Cardiology businesses.",2019_Boston_Scientific_Performance_Report.pdf
"Our Endoscopy business introduced the EXALT™ Model D, the world’s first and only single-use duodenoscope to be cleared by the U.S. Food and Drug Administration (FDA).",2019_Boston_Scientific_Performance_Report.pdf
"Duodenoscopes, which are used during endoscopic procedures to examine the pancreatic and bile ducts, treat severe, often life-threatening, conditions.",2019_Boston_Scientific_Performance_Report.pdf
Scope cleaning and reprocessing are complex procedures that are vulnerable to manual error.,2019_Boston_Scientific_Performance_Report.pdf
"According to a study mandated by the FDA, one in twenty reusable duodenoscopes is contaminated with disease-causing pathogens.",2019_Boston_Scientific_Performance_Report.pdf
"The EXALT-D Duodenoscope was granted Breakthrough Device Designation by the FDA, a program that helps patients receive timely access to technologies that have the potential to more effectively diagnose or treat life- threatening or irreversibly debilitating diseases or conditions.",2019_Boston_Scientific_Performance_Report.pdf
10 1.5 Tesla MRI conditional when all conditions of use are met.,2019_Boston_Scientific_Performance_Report.pdf
11 ACURATE neo™ Aortic Valve System is CE Marked.,2019_Boston_Scientific_Performance_Report.pdf
"In the U.S., IDE device and not available for sale.",2019_Boston_Scientific_Performance_Report.pdf
"Letter from the company’s 2019 Annual Report, written before the COVID-19 global pandemic.Our Neuromodulation business launched the Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems with the Cartesia™ Directional Lead.",2019_Boston_Scientific_Performance_Report.pdf
The new systems treat the symptoms of Parkinson’s disease by delivering precisely targeted and personalized electrical stimulation in the brain and are designed to provide symptom relief and better control of unwanted side effects.,2019_Boston_Scientific_Performance_Report.pdf
"We also received FDA approval of ImageReady™ MRI labeling for the Vercise Gevia DBS System, which allows the device to be used in a full-body magnetic resonance imaging (MRI) environment.10 The approval of the LOTUS Edge™ Aortic Valve System added to our suite of Structural Heart product solutions.",2019_Boston_Scientific_Performance_Report.pdf
These now include the SENTINEL™ Cerebral Protection System and the WATCHMAN™ Left Atrial Appendage Closure Device as well as the ACURATE neo™ Aortic Valve System.11 The LOTUS Edge valve system is the only fully repositionable valve system on the market; it is approved for patients with severe aortic stenosis who are considered at high risk for surgical valve replacement through open heart surgery.,2019_Boston_Scientific_Performance_Report.pdf
The SENTINEL™ Cerebral Protection invasive device used to improve physical function and reduce pain in patients with moderate lumbar spinal stenosis.,2019_Boston_Scientific_Performance_Report.pdf
"This addition to our pain management portfolio — now composed of the Spectra WaveWriter™ Spinal Cord Stimulator System, the Vertiflex® procedure and radiofrequency ablation therapy — gives physicians another non-opioid pain management solution that can help improve quality of life for the growing number of patients suffering from chronic pain.",2019_Boston_Scientific_Performance_Report.pdf
"All of our evidence-based solutions are helping clinicians provide personalized treatments along the pain care continuum.System, the only device cleared by the FDA to protect patients against the risk of stroke during transcatheter aortic heart valve replacement (TAVR), is now used in an estimated 20 percent of all TAVR procedures in the United States.",2019_Boston_Scientific_Performance_Report.pdf
"Acquisitions to Strengthen Our Future In 2019, we made two strategic investments to support our category leadership strategy and presence in faster growing markets.",2019_Boston_Scientific_Performance_Report.pdf
"We acquired BTG plc., adding therapeutic technologies for patients with liver and kidney cancers to our interventional oncology portfolio.",2019_Boston_Scientific_Performance_Report.pdf
"The acquisition also gives us a vascular portfolio for the treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease.",2019_Boston_Scientific_Performance_Report.pdf
We are now able to support physicians who treat some of the most challenging diseases with a strengthened commercial infr astructure and offer our customers comprehensive technologies backed by clinical evidence.,2019_Boston_Scientific_Performance_Report.pdf
"In Neuromodulation, we completed the acquisition of Vertiflex, Inc., which developed the Superion® Indirect Decompression System, a minimally LOTUS Edge ™ is the only fully repositionable valve system on the market.",2019_Boston_Scientific_Performance_Report.pdf
"SENTINEL ™ Cerebral Protection System is used in 20% of all U.S. TAVR procedures.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations “ In 2019 , we invested more than $1 billion in research and development to fuel our pipeline; and nearly 5,000 patients participated in more than 100 global clinical trials with Boston Scientific devices.” Bost on Scientific 2019 Performance Report 6Collaborating to Advance Science Across our businesses, we invested more than $1 billion in research and development in 2019 to fuel our pipeline and create value for our customers and the patients whom we serve together.",2019_Boston_Scientific_Performance_Report.pdf
"To accelerate the pace of discoveries and bring new treatments to patients, collaboration is key.",2019_Boston_Scientific_Performance_Report.pdf
"At our global design centers in the United States, Costa Rica, Ireland, India, China, Puerto Rico and the United Kingdom, we take a collaborative approach to research and development.",2019_Boston_Scientific_Performance_Report.pdf
"Clinicians, researchers and industry work side by side, evaluating ideas, developing prototypes, and conducting feasibility studies.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, Mayo Clinic and Boston Scientific announced Motion Medical, a new joint innovation accelerator that aims to accelerate the development of minimally invasive technologies for interventional cardiology, heart rhythm management, endoscopy, neuromodulation and urology.",2019_Boston_Scientific_Performance_Report.pdf
"In doing so, our organizations will now share certain intellectual property and work together to rapidly develop medical devices to address unmet clinical needs.We also maintained a strong base of clinical research to support the safety and efficacy of our devices, with data gathered through bench testing, randomized controlled trials, and ongoing real-world evidence to support sustaining innovation as well as new product approvals.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, nearly 5,000 patients participated in more than 100 global clinical trials with Boston Scientific devices.",2019_Boston_Scientific_Performance_Report.pdf
"Trial highlights include: The RANGER II SFA trial and the IMPERIAL trials strengthen the growing body of evidence supporting the safety, efficacy and durability of our Ranger™ Drug- Coated Balloon (DCB) and Eluvia™ Drug-Eluting Vascular Stent (DES) for patients with peripheral artery disease.",2019_Boston_Scientific_Performance_Report.pdf
"$1+ billion invested in research and development The EMBLEM ™ S-ICD System has been implanted in nearly 75,000 patients worldwide.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations North America Maple Grove, USA St. Paul, USA Valencia, USAEuropeParis, FranceRatingen, Germany Milan, Italy Warsaw, PolandMadrid, SpainAsiaBeijing, China Chengdu, ChinaShanghai, China Gurgaon, India Miyazaki, Japan Tokyo, Japan Africa Johannesburg, South Africa “ At our global design c enters in the United States, Costa Rica, Ireland, India, China, Puerto Rico and the United Kingdom, we take a collaborative approach to research and development.",2019_Boston_Scientific_Performance_Report.pdf
"Clinicians, researchers and industry work side by side, evaluating ideas, developing prototypes, and conducting feasibility studies.”Expanding Our Footprint Through Medical Education Boston Scientific provides local training programs through our 15 Institutes for Advancing Science in the Americas, Africa, Asia and Europe.",2019_Boston_Scientific_Performance_Report.pdf
"Letter from the company’s 2019 Annual Report, written before the COVID-19 global pandemic.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 7 The UNTOUCHED study confirmed the value of our EMBLEM™ S-ICD System for a broad group of ICD-indicated patients, enabling them to avoid the long-term complications associated with trans- venous ICD leads.",2019_Boston_Scientific_Performance_Report.pdf
"The study evaluated the safety and efficacy of the EMBLEM™ S-ICD System, a device that has been implanted in nearly 75,000 patients worldwide.",2019_Boston_Scientific_Performance_Report.pdf
"The AF-FICIENT I study showed positive safety and efficacy data for the LUMINIZE™ RF Balloon Catheter, our single-shot ablation technology for the isolation of pulmonary veins (PV) when treating patients with atrial fibrillation (AF).",2019_Boston_Scientific_Performance_Report.pdf
"A randomized clinical trial with our Rezūm™ Water Vapor Therapy, a minimally invasive treatment for benign prostatic h yperplasia (BPH), demonstr ated that four years after treatment, the d evice provides durable results and preserves sexual f unction.",2019_Boston_Scientific_Performance_Report.pdf
"Mor e than 35,000 men have been successfully treated with the Rezūm System.",2019_Boston_Scientific_Performance_Report.pdf
"And we have worked with major insurance providers to extend coverage of the procedure, providing even more men with access to this transformative technology.",2019_Boston_Scientific_Performance_Report.pdf
The VIRTUS trial with 12-month data demonstrated that patients treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions exhibit a high rate of open target lesions.Medical education is also a vital component of safe procedure adoption and our collaboration with physicians.,2019_Boston_Scientific_Performance_Report.pdf
"We continue to provide local training programs through our 15 Institutes for Advancing Science in the Americas, Africa, Asia and Europe.",2019_Boston_Scientific_Performance_Report.pdf
"We recently completed the center in Chengdu, China that will expand our footprint and enable us to train thousands of doctors in Central and Western China.",2019_Boston_Scientific_Performance_Report.pdf
The EVOLVE Short DAPT (dual antiplatelet therapy) study with our SYNERGY™ Bio- absorbable Polymer Stent demonstrated a low rate of adverse events for patients at a high risk for bleeding who s top D APT at three months.,2019_Boston_Scientific_Performance_Report.pdf
The study evaluated abbreviated antipla telet therapy for patients at high risk for bleeding after undergoing percutaneous coronary intervention.,2019_Boston_Scientific_Performance_Report.pdf
The results expand the body of evidence supporting the excellent clinical outcomes of our SYNERGY BP Stent.,2019_Boston_Scientific_Performance_Report.pdf
We plan to submit these data to regulatory authorities to support an indication for use in patients who are at a high risk of experiencing a bleeding event.,2019_Boston_Scientific_Performance_Report.pdf
The OPTION trial has the potential to expand the number of patients with atrial fibrillation who can receive a left atrial appendage closure (LAAC) as an alternative to lifelong anticoagulants — and their potential side effects.,2019_Boston_Scientific_Performance_Report.pdf
The trial compares the safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure platform to first-line oral anticoagulants for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) who undergo a cardiac ablation procedure.,2019_Boston_Scientific_Performance_Report.pdf
"35,000+ men with BPH have been successfully treated with the Rezūm ™ System 15 Institutes for Advancing Science worldwideFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations "" As we move int o the next decade, we face challenges from the growing burden of chronic conditions among an aging population, the demands of value-based care and new, disruptive competitors.",2019_Boston_Scientific_Performance_Report.pdf
"These trends also represent opportunities, and I am energized and inspired by the significant advancements we have made and will continue to make, and by the lives that have been extended or enhanced because of our products.""",2019_Boston_Scientific_Performance_Report.pdf
"Letter from the company’s 2019 Annual Report, written before the COVID-19 global pandemic.",2019_Boston_Scientific_Performance_Report.pdf
Bost on Scientific 2019 Performance Report 8Fostering diversity and inclusion in the workplace requires a deliberate and consistent effort as well as a willingness to engage in difficult conversations and learn from them.,2019_Boston_Scientific_Performance_Report.pdf
"Our Global Council for Inclusion and more than 4,500 employees from nine Employee Resource Groups are at the heart of this work.",2019_Boston_Scientific_Performance_Report.pdf
"They provide forums for us to learn from one another, celebrate our diversity and develop inclusive leadership skills.",2019_Boston_Scientific_Performance_Report.pdf
Working in health care gives us the privilege to help advance science and improve patient outcomes.,2019_Boston_Scientific_Performance_Report.pdf
That privilege comes with a responsibility to work in a sustainable way that enriches our communities.,2019_Boston_Scientific_Performance_Report.pdf
We’ve set aggressive environmental goals to do our part.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we continued our push toward environmental impact.",2019_Boston_Scientific_Performance_Report.pdf
"By year end, we reduced our greenhouse gas emissions 47 percent and decreased water consumption 30 percent relative to our 2009 measurement baseline.",2019_Boston_Scientific_Performance_Report.pdf
"Our Heredia and Coyol, Costa Rica sites are already carbon-neutral, and we are on track with our longer-term goals of reaching 100 percent renewable energy usage by 2024 and being carbon neutral in all our manufacturing and key distribution sites by 2030.",2019_Boston_Scientific_Performance_Report.pdf
"During the past two years, we increased the number of patients we serve by 20 percent while at the same time reducing our carbon footprint by 11 percent at these sites.",2019_Boston_Scientific_Performance_Report.pdf
I’m proud of the progress we are making.,2019_Boston_Scientific_Performance_Report.pdf
"Our employees have made Boston Scientific an admired company with numerous recognitions, including being named among FORBES/ JUST Capital 100 Most JUST Companies, Newsweek’s America’s Most Responsible Companies, FORTUNE World’s Most Admired Companies, Glassdoor’s Employees’ Choice for Best Places to Work and a Derwent Top 100 Global Innovator.Looking Ahead Our team and technology pipeline have never been stronger, and I remain confident in our strategy and ability to address evolving customer needs in the markets in which we compete.",2019_Boston_Scientific_Performance_Report.pdf
We anticipate continued growth across most of our businesses and regions based on the strength and diversity of our portfolio and our talented and engaged employees.,2019_Boston_Scientific_Performance_Report.pdf
"On behalf of all of us at Boston Scientific, I want to thank our Board of Directors for their service.",2019_Boston_Scientific_Performance_Report.pdf
"I also thank you, our stockholders, for your continued support, and our employees for their unwavering commitment to our mission and values.",2019_Boston_Scientific_Performance_Report.pdf
I look forward to working together to make even greater contributions to advance science for life in the year and decade ahead.,2019_Boston_Scientific_Performance_Report.pdf
"Sincerely, Mike Mahoney Chairman, President and Chief Executive Officer March 10, 2020People and Citizenship Delivering high performance requires excellence across our operations, and we are a stronger and more innovative company when we cultivate a diverse and inclusive workplace that reflects the patients, customers and communities we serve.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we made strong progress toward our diversity and inclusion goals to increase the representation of women and multicultural talent12 in mid-manage - ment roles.",2019_Boston_Scientific_Performance_Report.pdf
"By 2023, our goal is to increase representation of these groups by three percentage points.",2019_Boston_Scientific_Performance_Report.pdf
Pay equity has also long been a focus.,2019_Boston_Scientific_Performance_Report.pdf
An independent analysis13 of employee pay equity showed that our global workforce had a less than 1 percent statistical difference in pay along gender lines.,2019_Boston_Scientific_Performance_Report.pdf
"During the past two years, we increased the number of patients we serve by 20% while at the same time reducing our carbon footprint by 11%.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations 12 In the U.S. and Puerto Rico, defined as African American/Black, Asian, Hispanic/Latino, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races.",2019_Boston_Scientific_Performance_Report.pdf
"Excludes any U.S. Puerto Rico employees where the ethnicity is “Unallocated.” 13 Independent pay equity analysis conducted by Resolution Economics, LLC.",2019_Boston_Scientific_Performance_Report.pdf
"Letter from the company’s 2019 Annual Report, written before the COVID-19 global pandemic.“ Delivering high per formance requires excellence across our operations, and we are a stronger and more innovative company when we cultivate a diverse and inclusive workplace that reflects the patients, customers and communities we serve.” Bost on Scientific 2019 Performance Report 911% 8% 8% 02 4 6 810 12 2019201820177% 7%7% P ercent of Reported Operational Consolidated 2019 Sales by Region (dollars in millions) Sales Growth4 N et Sales (%) U.S. $ 6,097 10.1% 56.8% EMEA (Europe, Middle East and Africa) 2,264 9.4% 21.1% APAC (Asia-Pacific) 1,898 12.3% 17.7% LACA (Latin America and Canada) 395 7.3% 3.7% Medical Devices5 10,654 10.2% 99.2% Specialty Pharmaceuticals8 81 n/a 0.8% Net Sales $10,735 11.",2019_Boston_Scientific_Performance_Report.pdf
"1% 100.0% P ercent of Reported Operational Consolidated 2019 Sales by Product Category (dollars in millions) Sales Growth4 N et Sales (%) MedSurg Endoscopy $ 1, 894 9.2% 17.6% Urology and Pelvic Health 1,413 14.7% 13.2% Rhythm and Neuro Car diac Rhythm Management 1 ,939 1 .2% 18.1% Electrophysiology 329 7.5% 3.1% Neuromodulation 873 13.1% 8.1% Cardiovascular Interventional Cardiology 2,816 11.0% 26.2% Peripheral Interventions 1,392 19.1% 13.0% Medical Devices5 10,654 10.2% 99.2% Specialty Pharmaceuticals8 81 n/a 0.8% Net Sales $10,735 11.",2019_Boston_Scientific_Performance_Report.pdf
"1% 100.0%1 Adjust ed operating margin, adjusted earnings per share and related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture- related net charges and credits, restructuring and restructuring-related net charges and credits, litigation-related net charges and credits, investment impairment charges, pension termination charges, EU MDR implementation charges, debt extinguishment net charges and credits, deferred tax expenses (benefits) and discrete tax items; see non-GAAP reconciliations on pages 65-67.",2019_Boston_Scientific_Performance_Report.pdf
2 Or ganic revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the first 12 months of sales from acquisitions in the periods for which there are no prior period related net sales.,2019_Boston_Scientific_Performance_Report.pdf
"Organic revenue growth also excludes the impact of the divestiture of our global embolic microspheres portfolio, a transaction entered into in connection with obtaining the antitrust clearances required to complete the acquisition of BTG plc (BTG); see non-GAAP reconciliations on pages 65-67.",2019_Boston_Scientific_Performance_Report.pdf
"3 F ull year 2018 adjusted earnings per share was $1.47, which includes a $0.07 net tax benefit for the year.",2019_Boston_Scientific_Performance_Report.pdf
"Excluding this net tax benefit of $0.07, our 2018 adjusted earnings per share grew 11 percent.",2019_Boston_Scientific_Performance_Report.pdf
2019 adjusted EPS growth including the aforementioned 2018 net tax benefit is 8 percent and normalized for the 2018 net tax benefit is 13 percent.,2019_Boston_Scientific_Performance_Report.pdf
"Full year 2018 net tax benefit of $0.07 includes our second quarter $0.06 benefit from settling the IRS Stipulation of Settled Issues for the 2001 through 2010 tax years, offset by a fourth quarter $0.05 charge for our tax reinvestment strategy.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, the net benefit includes a $0.06 benefit in the fourth quarter for the settlement with the IRS of our 2011 through 2013 tax years.",2019_Boston_Scientific_Performance_Report.pdf
4 Oper ational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 65-67.,2019_Boston_Scientific_Performance_Report.pdf
"5 W e have three reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices).",2019_Boston_Scientific_Performance_Report.pdf
We have included BTG’s Interventional Medicine business in our Peripheral Interventions operating segment’s 2019 revenues from the date of acquisition.,2019_Boston_Scientific_Performance_Report.pdf
"8 As par t of our acquisition of BTG, we acquired a specialty pharmaceu - ticals business (Specialty Pharmaceuticals).",2019_Boston_Scientific_Performance_Report.pdf
"Subsequent to acquisition, Specialty Pharmaceuticals is now a stand-alone operating segment presented alongside our Medical Device reportable segments.",2019_Boston_Scientific_Performance_Report.pdf
P ercentages are calculated using unrounded numbers and may not calculate precisely due to rounding.,2019_Boston_Scientific_Performance_Report.pdf
Amounts may not add due to rounding.,2019_Boston_Scientific_Performance_Report.pdf
"Financial HighlightsFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Operational Revenue Growth2,4 Operational revenue growth Organic revenue growth Adjusted earnings per share growth1 Adjusted earnings per share growth, excluding 2018 net tax benefit3Adjusted Operating Margin1Adjusted Earnings Per Share Growth1,3 020 2019 2018201713% 11%8% 17% 13% 0510 15 20 25 20192018201726.1% 25.5% 25% Bost on Scientific 2019 Performance Report 10 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Every day, Boston Scientific is... focusing on our mission.",2019_Boston_Scientific_Performance_Report.pdf
"We are dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.Our work is guided by core values that define Boston Scientific culture and empower our employees: Caring We act with integrity and compassion to support patients, customers, our communities and each other.",2019_Boston_Scientific_Performance_Report.pdf
"Diversity We embrace diversity and value unique talents, ideas and experiences of our employees.",2019_Boston_Scientific_Performance_Report.pdf
Global Collaboration We work collaboratively to pursue global opportunities that extend the reach of our medical solutions.,2019_Boston_Scientific_Performance_Report.pdf
"High Performance We strive for high performance to benefit our patients, clinicians and stockholders.",2019_Boston_Scientific_Performance_Report.pdf
"Meaningful Innovation We foster an environment of creativity to transform new ideas into breakthrough services and solutions that create value for patients, customers and employees.",2019_Boston_Scientific_Performance_Report.pdf
"Winning Spirit We adapt to change and act with speed, agility and accountability to further improve patient care.BostonScientific2019PerformanceReport 11BostonScientificataGlanceFeaturePatient HighlightAMessageto OurStockholdersFinancial HighlightsOurMissionand CoreValuesBostonScientific ataGlanceBostonScientific bytheNumbersCorporateSocial ResponsibilityOurPatients OurPeople OurPlanet OurPractices Non-GAAP Reconciliations BostonScientifictransformslivesthroughinnovativemedicalsolutionsthat improvethehealthofpatientsaroundtheworld.Asaglobalmedical technologyleaderfornearly40years,weadvancescienceforlifeby providingabroadrangeofhighperformancesolutionsthataddressunmet patientneedsandreducethecostofhealthcare.",2019_Boston_Scientific_Performance_Report.pdf
"Neuromoduatino:C Electronicimplantabletechnologiesthathelppatients managedebilitatingchronicpainandneurologicalconditions ctrdnthyMgiMmEt:tpeme:iC Technologiesthattreatirregularheartrhythms andheartfailureandhelpprotectagainstsuddencardiacarrest saehirovMgPnoaopgC Abroadrangeofmappingandtreatmenttechnologiesfor diagnosingandtreatingheartrhythmdisorders U:ierHe:ino:tactrdnoaopgC Minimallyinvasiveinnovationsthathelpimprovethe livesofpatientslivingwithheartandvascularconditions s:doPhovgC Minimallyinvasivedevicesfordiagnosingandtreatinggastrointestinal andpulmonaryconditions PernvMertaU:ierHe:ino:PC Devicesfordiagnosisandminimallyinvasivetreatmentsof peripheralvasculardiseaseandcancer Uroaopgt:dPeaHnhHetaiMC Solutionsforurological,urogynecologicaland gynecologicaldiseases AspartofouracquisitionofBTG,weacquiredtheSpecialtyPharmaceuticalsbusiness, whichisastand-aloneoperatingsegment.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 12 41,000 + employee volunteer hoursBoston Scientific by the Numbers* ~30 million patients servedTop 30 America’s Most JUST Companies** Reduced greenhouse gas emissions by 76,000 + tonnes***Recycled 8,900 + tonnes of solid waste ~36,000 employees in 100+ countriesFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations 99%+ gender pay equity Carbon neutrality in manufacturing and key distribution sites for all products by 2030$ 85 million + educational and charitable giving and medical research ~$1 billion invested in research and development$10.7 billion in full-year sales * All figures reflect 2019 results.",2019_Boston_Scientific_Performance_Report.pdf
"** Forbes and JUST Capital JUST 100 rankings *** Compared to 2009 baseline Bost on Scientific 2019 Performance Report 13Corporate Social Responsibility at Boston Scientific Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations At Boston Scientific, we are united by a deep caring for human life.",2019_Boston_Scientific_Performance_Report.pdf
Our work in health care comes with a profound responsibility to the people around us.,2019_Boston_Scientific_Performance_Report.pdf
"Guided by our core values, we are committed to shaping a better future for patients, customers, employees as well as the communities in which we live and work.",2019_Boston_Scientific_Performance_Report.pdf
Our teams are dedicated to transforming lives through innovative medical solutions that improve the health of patients around the globe — while also making measurable contributions to the world we all share.,2019_Boston_Scientific_Performance_Report.pdf
"Engaging with Stakeholders In keeping with our values, we act with integrity in our operational processes and all of our business relationships.",2019_Boston_Scientific_Performance_Report.pdf
"Throughout the company, we are focused on our obligations as a corporate citizen.",2019_Boston_Scientific_Performance_Report.pdf
"These responsibilities include continually working to better understand and anticipate the company’s environmental, social and economic impacts.",2019_Boston_Scientific_Performance_Report.pdf
A company-wide focus on Corporate Social Responsibility (CSR) is an essential aspect of our citizenship.,2019_Boston_Scientific_Performance_Report.pdf
"Our CSR strategy and practices are informed by conversations with diverse stakeholders inside and outside the company — locally, nationally and globally.",2019_Boston_Scientific_Performance_Report.pdf
"In our collaborations and other business relationships, we work with organizations who share our commitment to the people we serve.",2019_Boston_Scientific_Performance_Report.pdf
"Our Approach To ensure our efforts are aligned with the United Nations Sustainable Development Goals (SDGs), in 2017 we completed a baseline materiality assessment in accor- dance with the internationally accredited Global Reporting Initiative (GRI) guidelines.",2019_Boston_Scientific_Performance_Report.pdf
The assessment identified CSR issues of greatest importance to Boston Scientific and our stakeholders.,2019_Boston_Scientific_Performance_Report.pdf
We define these issues as material aspects.,2019_Boston_Scientific_Performance_Report.pdf
Our material aspects align with 10 of the 17 SDGs where we believe we can make a meaningful difference.,2019_Boston_Scientific_Performance_Report.pdf
Our teams track how our activities intersect with the SDGs and how we can most effectively join with others to contribute to these goals.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we increased the scope of our CSR metrics and disclosures, and we made it a priority to report at the GRI Comprehensive level by 2024, if not sooner.",2019_Boston_Scientific_Performance_Report.pdf
Boston Scientific employees participating in Volunteer Day in Minnesota.,2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 14As a global medical device manufacturer, our work is naturally focused on health and well-being.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, our portfolio of innovative products and solutions helped more than 30 million patients live better and longer lives.",2019_Boston_Scientific_Performance_Report.pdf
We continue to make investments in research and development and clinical trials to develop new technologies and breakthrough therapies.,2019_Boston_Scientific_Performance_Report.pdf
Our patient-centric focus supports expanded access to medical care for underserved populations around the world.,2019_Boston_Scientific_Performance_Report.pdf
"We invest significantly in the well-being of our employees and their families, and we support the communities where we work and live.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Boston Scientific Supports the SDGs To ensure we design, test, manufacture and distribute safe and effective devices, quality is integrated into every aspect and stage of our work.",2019_Boston_Scientific_Performance_Report.pdf
"We support initiatives to reduce waste through sustainable packaging, recycling, reuse and inventory management.",2019_Boston_Scientific_Performance_Report.pdf
"We also maintain strategic partnerships, many with small and diverse suppliers.",2019_Boston_Scientific_Performance_Report.pdf
"These partnerships help us deliver improved value to our customers, and they support economic development and sustainable production in the communities where we live and work.Our planet is facing significant challenges, and Boston Scientific is committed to identifying and mitigating risks to the climate and environment.",2019_Boston_Scientific_Performance_Report.pdf
"To do this, and contribute to SDGs 7 and 13, we have established aggressive targets, such as our goal to be carbon neutral by 2030 at all key manufacturing and distribution sites.",2019_Boston_Scientific_Performance_Report.pdf
We are also focused on moving to renewable energy sources and reducing our environmental impact.,2019_Boston_Scientific_Performance_Report.pdf
We monitor our progress through an established energy management system.,2019_Boston_Scientific_Performance_Report.pdf
"SDG 5 and SDG 10 relate directly to our core diversity value, which we define as inclusion, equity and opportunity for all.",2019_Boston_Scientific_Performance_Report.pdf
"By embracing unique backgrounds and perspectives, we create a more rewarding place to work.",2019_Boston_Scientific_Performance_Report.pdf
"Our Diversity and Inclusion (D&I) efforts focus on four strategic pillars: career, culture, commerce and community.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we made strong progress in achieving our “10/20/ 40 by 2020” objectives aimed at reshaping the company’s core mid-level employee base, and we continue to set higher goals.",2019_Boston_Scientific_Performance_Report.pdf
"We are an equal opportunity employer, committed to delivering fair and equitable compensation and benefits programs.",2019_Boston_Scientific_Performance_Report.pdf
"With our Close the Gap program, we are helping to address health inequities, increasing diverse patient enrollment in clinical trials and elevating the role of female physicians in health care.The Boston Scientific caring value guides how we engage with patients, work together as colleagues and invest in the well-being of our communities.",2019_Boston_Scientific_Performance_Report.pdf
Our EDUCARE program offers a variety of training programs to help healthcare providers deliver the best patient care possible.,2019_Boston_Scientific_Performance_Report.pdf
We also support future diverse talent with education and STEM programming for K-12 students around the world.,2019_Boston_Scientific_Performance_Report.pdf
The company invests in training and continuing education for our employees and ensures a positive work environment through global environmental health and safety policies.,2019_Boston_Scientific_Performance_Report.pdf
Our facilities reflect the priority we place on agile workspaces that offer flexibility.,2019_Boston_Scientific_Performance_Report.pdf
We are committed to SDG 16 and doing business with integrity and honesty.,2019_Boston_Scientific_Performance_Report.pdf
"Our teams responsibly research, develop, manufacture and deliver our products with a commitment to strong corporate governance, impeccable ethics and regulatory compliance.",2019_Boston_Scientific_Performance_Report.pdf
"The Boston Scientific Code of Conduct is the foundation for our policies and must be read, understood and followed by every employee.",2019_Boston_Scientific_Performance_Report.pdf
Our policies and practices reflect our belief in and support for all fundamental human rights.,2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 15 Owning and Managing CSR Our people in more than 100 countries work with an awareness of the world’s most pressing challenges, including inequality, economic disparity, climate change and environmental protection.",2019_Boston_Scientific_Performance_Report.pdf
"Their efforts to help address these issues are supported by our cross-functional CSR Council, Environmental Health and Safety (EH&S) policies and programs and a Global Council for Inclusion, along with local, regional and national employee and community programs.",2019_Boston_Scientific_Performance_Report.pdf
The CSR Council includes subject matter experts throughout the company who help define CSR strategy and ensure accountability.,2019_Boston_Scientific_Performance_Report.pdf
An executive steering committee oversees the Council and champions sustainable practices across the business.,2019_Boston_Scientific_Performance_Report.pdf
"Within this framework, everyone in the company contributes to our social responsibility.",2019_Boston_Scientific_Performance_Report.pdf
"Our CSR Performance We hold ourselves accountable for providing updates and data related to our CSR performance, and we share this information through several communications channels, including this report and www.bostonscientific.com.",2019_Boston_Scientific_Performance_Report.pdf
"Each year, we report the company’s impact on the environment as defined by the Carbon Disclosure Project, and we participate in several widely recognized environmental, social and governance rating surveys.",2019_Boston_Scientific_Performance_Report.pdf
This report has been prepared in accordance with the GRI guidelines.,2019_Boston_Scientific_Performance_Report.pdf
"Unless otherwise indicated, data in this report covers the period between January 1, 2019, and December 31, 2019.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Guided by our core values, we are committed to shaping a better future for patients, customers, employees as well as the communities in which we live and work.",2019_Boston_Scientific_Performance_Report.pdf
"Our teams are dedicated to transforming lives through innovative medical solutions that improve the health of patients around the globe — while also making measurable contributions to the world we all share.Mike Mahoney, Chairman and CEO, attending an event at the Berkshire Partners Blue Hill Boys & Girls Club, where Boston Scientific teamed up with the Boston Celtics to renovate a pre-teen room.",2019_Boston_Scientific_Performance_Report.pdf
Company Leadership and Corporate Social Responsibility The JUST 100: Forbes and JUST Capital ranked Boston Scientific in the top 30 of America's Most JUST Companies.,2019_Boston_Scientific_Performance_Report.pdf
America's Most Responsible Companies: Newsweek and Statista ranked Boston Scientific #48 in its first ranking of the most responsible companies in America.,2019_Boston_Scientific_Performance_Report.pdf
"World's Most Admired Companies: Boston Scientific was again named a FORTUNE World's Most Admired company, ranking #2 in the Medical Products and Equipment industry category.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 16 Every day, Boston Scientific is... transforming the lives of our patients.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Our Patients 17 Our P atients 21 Promoting Health Equity with Close the Gap The patient featured on the cover, German pole vaulter Katharina Bauer, strikes a yoga pose atop Lion's Head, a mountain overlooking Cape Town, South Africa.",2019_Boston_Scientific_Performance_Report.pdf
Bost on Scientific 2019 Performance Report 17 We are proud that in 2019 our devices and therapies helped more than 30 million patients live longer and better lives.,2019_Boston_Scientific_Performance_Report.pdf
Their stories inspire us to do more.,2019_Boston_Scientific_Performance_Report.pdf
"As we focus on solving the healthcare challenges that matter most, we are also expanding our efforts to increase healthcare access and help educate people on disease prevention.",2019_Boston_Scientific_Performance_Report.pdf
"Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Allen Brady (Pensacola, Florida, U.S.) When her husband, Allen, couldn’t finish a round of golf anymore, Dianne Brady knew that something was wrong.",2019_Boston_Scientific_Performance_Report.pdf
The 90-year-old decorated war veteran had no plans to slow down but was regularly getting out of breath.,2019_Boston_Scientific_Performance_Report.pdf
Allen later learned from his cardiologist that he was experiencing aortic stenosis and needed a valve change.,2019_Boston_Scientific_Performance_Report.pdf
He received the LOTUS Edge™ Aortic Valve System and was able to return to playing golf and enjoying time with Dianne.,2019_Boston_Scientific_Performance_Report.pdf
"Valentina Arango (Bogota, Colombia) For months, Valentina was feeling ill and the cause could not be determined.",2019_Boston_Scientific_Performance_Report.pdf
"Eventually, doctors discovered that she potentially had cancerous liver fibrosis and stones in her intrahepatic duct, which drains bile from the liver.",2019_Boston_Scientific_Performance_Report.pdf
Her doctors used SpyGlass™ DS Direct Visualization System in a procedure to destroy the stones and collect a biopsy to test for cancer — which was negative.,2019_Boston_Scientific_Performance_Report.pdf
"Valentina returned to her studies and normal life, feeling healthy and free of worry.Our Patients “ I haven’t f elt anything in my heart since that valve went in there, other than my body works better.",2019_Boston_Scientific_Performance_Report.pdf
"It’s like getting a new lease on life.”“ Living with f ear is difficult… Now I can live without fear of not having a future thanks to Boston Scientific.” Bost on Scientific 2019 Performance Report 18 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Gregory Gaddy (Memphis, Tennessee, U.S.) After falling from a ladder while working in his yard, Gregory was left with chronic pain from his injuries.",2019_Boston_Scientific_Performance_Report.pdf
"After more than 10 years of struggling with pain management, he chose to have a Boston Scientific spinal cord device implanted.",2019_Boston_Scientific_Performance_Report.pdf
"The SCS greatly reduced Gregory's pain and allowed him to return to tending his garden and achieving his goal of winning ""Yard of the Month"" in his community.",2019_Boston_Scientific_Performance_Report.pdf
"HeartLogic™ Heart Failure Diagnostic The HeartLogic™ Heart Failure Diagnostic is the first and only heart failure diagnostic tool proven to detect 70 percent of heart failure events several weeks in advance, potentially reducing further hospitalization for patients with heart failure.",2019_Boston_Scientific_Performance_Report.pdf
This diagnostic tool is featured in the Boston Scientific Resonate™ family of cardiac resynchronization therapy defibrillator (CRT-D) and implantable cardioverter defibrillator (ICD) devices.,2019_Boston_Scientific_Performance_Report.pdf
Symbols representing sensors from the Heartlogic heart failure diagnostic tool.,2019_Boston_Scientific_Performance_Report.pdf
"Kathryn Grosshans (Yorktown, Virginia, U.S.) In her early teenage years, Kathryn’s occasional leg pain was attributed to her heavy figure skating training schedule.",2019_Boston_Scientific_Performance_Report.pdf
"But by the time she was a senior in high school, Kathryn’s pain was so debilitating that she could barely walk.",2019_Boston_Scientific_Performance_Report.pdf
A vascular specialist diagnosed her with May-Thurner syndrome and recommended that she receive a stent to relieve a compressed vein.,2019_Boston_Scientific_Performance_Report.pdf
Kathryn was implanted with the VICI Venous Stent™ System in a same-day outpatient p rocedure and immediately experienced a difference.,2019_Boston_Scientific_Performance_Report.pdf
"A year later, she decided to train for her first marathon, which she completed free of pain.",2019_Boston_Scientific_Performance_Report.pdf
"“ Be cause of the stent, I can continue to do all of the things I want to do and accomplish dreams that I didn’t think I would be able to before.”“ SCS has given me my life back and I'm able to do things that I love.” Bost on Scientific 2019 Performance Report 19 Eluvia™ Drug-Eluting Vascular Stent System The Eluvia™ Drug-Eluting Vascular Stent System is a controlled drug delivery system designed and engineered to solve the unique challenge of restenosis in the superficial femoral artery (SFA), the main artery leading to the lower limbs.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations “ T om and I are both very excited to get our lives back.” Lisa Griener (Pittsburgh, Pennsylvania, U.S.) Meeting her husband, Tom, was an exciting new chapter in life — but 10 months after their wedding, Lisa was diagnosed with Parkinson’s disease.",2019_Boston_Scientific_Performance_Report.pdf
"To manage her Parkinson’s, Lisa took up to 13 pills a day, but her movements were so uncontrollable that it was difficult for her to work or socialize.",2019_Boston_Scientific_Performance_Report.pdf
"After receiving the Boston Scientific Vercise™ DBS System, Lisa’s tremors have minimized and she has regained control of her movements — allowing her to reduce her medications.",2019_Boston_Scientific_Performance_Report.pdf
"Most importantly, Lisa and Tom are enjoying their life together again and focusing on the years ahead.",2019_Boston_Scientific_Performance_Report.pdf
"Marjorie Giovannoni (Coupeville, Washington, U.S.) After a hemorrhagic stroke, Marjorie was paralyzed on her entire right side.",2019_Boston_Scientific_Performance_Report.pdf
"As time went on, she faced a difficult choice: go back on blood thinners to address her high risk of stroke or avoid them, because her condition made falls and bleeding more likely.",2019_Boston_Scientific_Performance_Report.pdf
"Marjorie elected to be implanted with a WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device as an alternative, which has given her peace of mind.",2019_Boston_Scientific_Performance_Report.pdf
"“ It is the best f eeling to know the WATCHMAN is in there and going to watch over me.” Bost on Scientific 2019 Performance Report 20 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Nicole Leon (Chicago, Illinois, U.S.) At 32, Nicole was diagnosed with a hepatocellular liver tumor.",2019_Boston_Scientific_Performance_Report.pdf
She was told that her tumor was inoperable and that she had six months to live.,2019_Boston_Scientific_Performance_Report.pdf
"A multi-disciplinary team at the University of Chicago Medicine’s Liver Tumor Program used the TheraSphere™ Y-90 Glass Microspheres to deliver a treatment called radiation embolization, which reduced the size of the tumor so it could be surgically removed.",2019_Boston_Scientific_Performance_Report.pdf
"Today, Nicole has nearly 100 percent of her liver volume back and normal liver function.",2019_Boston_Scientific_Performance_Report.pdf
"Nicole is now three years cancer-free, married and has a healthy baby boy whom she named after one of the doctors who helped save her life.",2019_Boston_Scientific_Performance_Report.pdf
"Alex Lamb (Smalley, Derbyshire, England) Not your typical 81-year-old, Alex has a regular regimen of karate, yoga and 5-kilometer daily runs.",2019_Boston_Scientific_Performance_Report.pdf
"When he was diagnosed with advanced prostate cancer, his doctor recommended radiation therapy, which is associated with unpleasant side effects such as rectal pain and diarrhea.",2019_Boston_Scientific_Performance_Report.pdf
"Alex’s d octors u sed o ur SpaceOAR™ Hydrogel , w hich p rotects or gans such as the rectum from radiation exposure during treatment and minimizes side effects.",2019_Boston_Scientific_Performance_Report.pdf
"The treatment was successful, and his Prostate-Specific Antigen (PSA) levels are now undetectable.",2019_Boston_Scientific_Performance_Report.pdf
Alex was running two days after his procedure and has now resumed his full workout routine.,2019_Boston_Scientific_Performance_Report.pdf
"EXALT™ Model D Duodenoscope In December 2019, the EXALT™ Model D, the world’s first and only single-use duodenoscope, was cleared by the U.S. FDA, eliminating the need for reprocessing and repairs.",2019_Boston_Scientific_Performance_Report.pdf
"The EXALT Model D supports physicians in their mission to deliver the highest quality patient care because they can now use a new, sterile device for every procedure.",2019_Boston_Scientific_Performance_Report.pdf
"“ I have a se cond chance at life — to get married and start a family and move on.” “ It w as vitally important for me to get running again because that really is my whole life.” Bost on Scientific 2019 Performance Report 21Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Massachusetts Conference for Women: Personal Brand, Heart Health and Exercise For the fifth consecutive year, Boston Scientific co-sponsored the annual Massachusetts Conference for Women in Boston, a program drawing more than 13,000 attendees.",2019_Boston_Scientific_Performance_Report.pdf
"Approximately 240 employees attended, and Boston Scientific women leaders served as panelists as well as guest speakers.",2019_Boston_Scientific_Performance_Report.pdf
"The Close the Gap team collaborated with WomenHeart, a patient advocacy group focused on heart disease in women, to engage conference participants in a dialogue about heart health and to experience on-site wellness activities, including mini-strength and stretching sessions.Promoting Health Equity with Close the Gap For more than a decade, the Boston Scientific Close the Gap health equity program has focused on eliminating care disparities and improving access to health services for under- served patient populations.",2019_Boston_Scientific_Performance_Report.pdf
"The company collaborates with healthcare providers, national patient advocacy groups and minority associations to advocate for broader representation of minorities in clinical trials and to support their access to quality care.",2019_Boston_Scientific_Performance_Report.pdf
We also partner with like-minded organizations to reach underserved patient populations with culturally relevant education and resources delivered through events and community programs.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, new data from the PLATINUM Diversity trial, one of the first clinical studies of its kind to identify the disparities experienced by women and minorities undergoing coronary stenting procedures as compared to white males, demonstrated that minority patients are more likely to stop their dual anti-platelet therapy after a coronary stenting procedure (when compared to white males), putting them at higher risk for potential adverse events.",2019_Boston_Scientific_Performance_Report.pdf
These findings can serve as a basis for action for healthcare providers and is leading investigators to look further into why this is happening.,2019_Boston_Scientific_Performance_Report.pdf
"57,000 people reached through Close the Gap awareness events.57 events held by Close the Gap in communities across the U.S.$750,000 grants awarded to organizations working to increase enrollment of underserved populations in clinical trials.180 Congressional Black and Hispanic Caucus members educated on inequities in health care and the impact of peripheral artery disease on African American men.",2019_Boston_Scientific_Performance_Report.pdf
"Boston Scientific employees participating in a Spirit of the Heart event in Georgia, U.S. Bost on Scientific 2019 Performance Report 22 Every day, Boston Scientific is... achieving success through our people.",2019_Boston_Scientific_Performance_Report.pdf
Our P eople 23 The People of Boston Scientific 24 Making Diversity and Inclusion a Priority 24 Leadership Commitment 26 Diversity and Inclusion Goals 29 Employee Resource Groups 32 List ening to Our People 33 Se tting the Bar Higher 34 Employe e Growth and Development 36 C ompensation and Benefits 40 Caring for Our CommunitiesFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 23The people of Boston Scientific are defined by: Global impact: Our employees make a difference for people around the world and around the corner.,2019_Boston_Scientific_Performance_Report.pdf
"Diversity: We are proud of the diversity of thought, background and perspective that leads to our greatest breakthroughs.",2019_Boston_Scientific_Performance_Report.pdf
Winning spirit: Our people take on the industry’s toughest challenges and never settle for the status quo.,2019_Boston_Scientific_Performance_Report.pdf
"Growth: We make learning, development and progression a priority.",2019_Boston_Scientific_Performance_Report.pdf
Talented and dedicated employees deserve opportunities to grow.,2019_Boston_Scientific_Performance_Report.pdf
"Engagement: In our collaborative work environment, people build lasting relationships with colleagues worldwide and advance our thought leadership in the industry.",2019_Boston_Scientific_Performance_Report.pdf
"Opportunity: We offer diverse and global career options, including international assignments and programs.The People of Boston Scientific In the last three years, we have made steady progress to increase the overall representation of women and multicultural1 talent, with an emphasis on supervisor and manager roles.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations By pushing the boundaries of what is possible, our approximately 36,000 employees across the globe collaborate every day to change and save lives.",2019_Boston_Scientific_Performance_Report.pdf
"As we develop innovative solutions to address unmet needs of patients, physicians and healthcare systems, their collective talent and shared sense of purpose give us our competitive edge.",2019_Boston_Scientific_Performance_Report.pdf
Innovation thrives in a culture of engage- ment and inclusion.,2019_Boston_Scientific_Performance_Report.pdf
People deserve to work in an environment where they can make significant contributions to the business while also pursuing their individual goals.,2019_Boston_Scientific_Performance_Report.pdf
"Our talent management practices support a workplace where people can create, explore and problem solve — and trust they will be recognized for their performance.Our People 1 In the United States and Puerto Rico, defined as African American/Black, Asian, Hispanic/Latino, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races.",2019_Boston_Scientific_Performance_Report.pdf
"Excludes any U.S. Puerto Rico employees where the ethnicity is “Unallocated.”“ W e do our best work to advance health care when we have a richness of perspectives and experience on our teams and when we can bring our whole selves to work.” — Wendy Carruthers, Senior Vice President, Boston Scientific Human Resources 2019 2018 201747.0%46.5% 45.5%Representation at All Levels 2019 2018 201733.2% 31.7% 30.7%Women (Global) Multicultural (U.S./Puerto Rico) Bost on Scientific 2019 Performance Report 24 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Making Diversity and Inclusion (D&I) a Priority Our diversity value stands for inclusion, equity and opportunity for all.",2019_Boston_Scientific_Performance_Report.pdf
"At Boston Scientific, D&I is instrumental to our thriving culture and our focus on innovation.",2019_Boston_Scientific_Performance_Report.pdf
We consider it an urgent issue and business imperative.,2019_Boston_Scientific_Performance_Report.pdf
"The society we live in and the customers and patients we serve are diverse in culture, gender identity and ability.",2019_Boston_Scientific_Performance_Report.pdf
"To remain innovative and competitive in the marketplace, we must reflect this truth through our people.",2019_Boston_Scientific_Performance_Report.pdf
"We recognize change is gradual, and we are committed to progress over time, not overnight.Leadership Commitment Our leading advocate for D&I is Boston Scientific Chairman and CEO Mike Mahoney.",2019_Boston_Scientific_Performance_Report.pdf
"He was among the first of more than 800 CEOs of leading companies to become a signatory of the CEO Action for Diversity & Inclusion Pledge, the largest CEO-driven business campaign in the United States to advance diversity and promote inclusive workplaces.",2019_Boston_Scientific_Performance_Report.pdf
"Consistent with our pledge commitments, we held a second annual Day of Under- standing to help employees embrace differences in our organizations and build a more inclusive culture inside and outside of work.",2019_Boston_Scientific_Performance_Report.pdf
"We welcomed the ”Check Your Blind Spots” mobile bus tour to our Marlborough, Massachusetts campus, where hundreds of employees boarded the bus to participate in virtual reality scenarios and learn new ways to understand and avoid unconscious bias.",2019_Boston_Scientific_Performance_Report.pdf
All participants signed an “I Act On” pledge affirming their personal commit- ment to a more inclusive workplace and community.,2019_Boston_Scientific_Performance_Report.pdf
We also collaborated with other CEO Action companies to share best practices for fostering a work environment where difficult conversations about diversity and inclusion can occur.,2019_Boston_Scientific_Performance_Report.pdf
"Boston Scientific employees welcomed the Check Your Blind Spots mobile bus to the Marlborough, Massachusetts campus.",2019_Boston_Scientific_Performance_Report.pdf
"They participated in a unique, technology- enabled multimedia experience focused on understanding and exploring ways to mitigate unconscious bias.",2019_Boston_Scientific_Performance_Report.pdf
D&I efforts throughout Boston Scientific align with four strategic pillars: CEO Action for Diversity and Inclusion Boston Scientific was among the first signatories of the CEO Action for Diversity & Inclusion Pledge when it launched in 2017.,2019_Boston_Scientific_Performance_Report.pdf
The coalition unites business leaders around four key commitments: 1.,2019_Boston_Scientific_Performance_Report.pdf
"W e will continue to make our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion.",2019_Boston_Scientific_Performance_Report.pdf
2.,2019_Boston_Scientific_Performance_Report.pdf
W e will implement and expand unconscious bias education.,2019_Boston_Scientific_Performance_Report.pdf
3.,2019_Boston_Scientific_Performance_Report.pdf
W e will share best — and unsuccessful — practices.,2019_Boston_Scientific_Performance_Report.pdf
4.,2019_Boston_Scientific_Performance_Report.pdf
"W e will create and share strategic inclusion and diversity plans with our Board of Directors.CAREER Attract, develop, advance and retain diverse employees COMMUNITY Promote diversity and inclusion awareness and encourage engagement company-wideCULTURE Build and sustain an inclusive environment that fosters innovation and high performanceDIVERSITY & INCLUSION VISION A diverse and inclusive culture that attracts, develops and retains the best team to deliver innovative medical solutionsCOMMERCE Facilitate diversity and inclusion outcomes to influence business opportunities Bost on Scientific 2019 Performance Report 25In 2019, we strengthened company-wide efforts to achieve our D&I goals for increasing representation of women and multicultural talent on regional and functional leadership teams across the organization.",2019_Boston_Scientific_Performance_Report.pdf
"Attracting diverse talent was a key area of focus and we continued our trend of hiring a greater percentage of multicultural talent and women than our current representation of these groups.Collaborating for Change We collaborate with leading organizations dedicated to promoting and supporting the rights and development of women, multicultural talent, people with disabilities and lesbian, gay, bisexual, transgender and queer/questioning (LGBTQ+) talent.",2019_Boston_Scientific_Performance_Report.pdf
"In the United States, our partnerships include Advancing Minorities’ Interest in Engineering (AMIE), American Indian Science and Engineering Society (AISES), Disability:IN, Hiring Our Heroes, the Hispanic Promise, the Human Rights Campaign (HRC), the National Society of Black Engineers (NSBE), National Action Council for Minorities in Engineering (NACME), reacHIRE, the Society of Hispanic Professional Engineers (SHPE) and the Society of Women Engineers (SWE).",2019_Boston_Scientific_Performance_Report.pdf
"Boston Scientific is a founding member of Disability:IN’s Inclusion Works Program (formerly Going for the Gold), and in 2019 we were premier sponsors of the “IN for Inclusion” annual conference.",2019_Boston_Scientific_Performance_Report.pdf
"The event offered a forum for 1,500 participants from more than 10 countries, including 200 NextGen Leaders with disabilities, to engage with industry peers about disability inclusion.",2019_Boston_Scientific_Performance_Report.pdf
"The conference featured sessions on topics ranging from workplace and supply chain to technology, and it celebrated leaders in disability equality.Targeted Development & Retention Programs Over the last two years, we broadened the scope of EXCELerate, a multi-year program first designed to foster female talent from manufacturing, supply chain, quality and new product development teams to now include participants from information technology, global business systems and security.",2019_Boston_Scientific_Performance_Report.pdf
We also launched an effort to begin offering the program to all multicultural talent.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, employees from four countries were matched with Boston Scientific executives who serve as advisors, mentors and career advocates.",2019_Boston_Scientific_Performance_Report.pdf
Our MARC (Men Activating Real Change) Leaders Program supports men as allies and promotes a more level playing field for all.,2019_Boston_Scientific_Performance_Report.pdf
Its curriculum examines assump- tions and mindsets to help leaders better understand how dominant busines s cultur e and unconscious bias affect partnerships between men and women.,2019_Boston_Scientific_Performance_Report.pdf
"The program features an immersive day-and-a-half workshop and facilitated dialogue, including ongoing engagement through MARC alumni networks.",2019_Boston_Scientific_Performance_Report.pdf
"Following a successful pilot in 2018, we offered the program to executive teams in 2019 and will offer new MARC opportunities to all employees going forward.Our Women’s Network (WN) Employee Resource Group chapters continued to expand in 2019 with four new chapters, resulting in representation in each of the company’s four global regions.",2019_Boston_Scientific_Performance_Report.pdf
"The WN chapters hold programs that help participants develop their leader ship skills, set and pursue career goals and expand their networks.",2019_Boston_Scientific_Performance_Report.pdf
"Examples of these offerings include the WN Twin Cities, Minnesota Professional Development Series, the WN “Lessons from LeadHers” in our Europe, Middle East and Africa region, and various chapter mentoring initiatives such as Mentoring Circles and Male Ally Network (MAN) mentor matching program.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations 2019 2018 201750.2%51.2% 50.5%New Hires 2019 2018 201743.5% 42.6% 40.7%Women (Global) Multicultural (U.S./Puerto Rico) Bost on Scientific 2019 Performance Report 26 Diversity and Inclusion Goals We transparently measure and report our progress in building a diverse workforce that fully reflects our core values and the customers and patients we serve.",2019_Boston_Scientific_Performance_Report.pdf
"While traditional diversity recruiting efforts have targeted entry- level positions or relied on top-down change, our “10/20/ 40” by 2020 initiative shifted our focus to reshaping the company’s core mid-level employee base.",2019_Boston_Scientific_Performance_Report.pdf
"Our recent D&I progress was driven by these 10/20/40 by 2020 goals: 10: Be recognized as a top 10 leader for workplace inclusion; 20: Increase representation of multicultural talent to 20 percent at the supervisor and manager levels in the United States, including Puerto Rico; and 40: Increase representation of women globally to 40 percent at the supervisor and manager levels.We gained D&I momentum in 2019, achieving our ""10"" objective with numerous Top 10 recognitions, as a Diversity Best Practices Top 10 Percent Inclusion Index Company, among them.",2019_Boston_Scientific_Performance_Report.pdf
"We also exceeded our ""20"" goal with 20.8 percent multicultural representation at the supervisor and manager levels.",2019_Boston_Scientific_Performance_Report.pdf
"We made significant progress toward our ""40"" goal with 38.1 percent representation of women in supervisor and manager roles.",2019_Boston_Scientific_Performance_Report.pdf
"At all levels of the organization, representation of women increased.",2019_Boston_Scientific_Performance_Report.pdf
"The results reinforce the importance of making progress over time, not overnight.",2019_Boston_Scientific_Performance_Report.pdf
"To that end, we have set new ambitious D&I goals to reach by 2023.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations We were proud to be recognized as a Top 10% Inclusion Index Company by Diversity Best Practices.",2019_Boston_Scientific_Performance_Report.pdf
"See more awards .We reported 20.8% representation of multi- cultural talent at the supervisor and manager levels, meeting our goal.",2019_Boston_Scientific_Performance_Report.pdf
*We reported 38.1% representation of women at supervisor and manager levels.,2019_Boston_Scientific_Performance_Report.pdf
"*D&I 10/20/40 by 2020 Results *Results include 2019 acquisitions.10TOP 20%40% Bost on Scientific 2019 Performance Report 27Continue to be a top 10% globally recognized leader for workplace inclusion , because we know that diversity and inclusion benefits us allIncrease our goal for representation of multi- cultural talent at the supervisor and manager levels by 3 percentage points or more, to at least 23%Setting New Goals Our “3Up by 2023” goals are growth focused and ensure we continue to build on our measurable goals while also challenging ourselves to achieve them in shorter time frames.",2019_Boston_Scientific_Performance_Report.pdf
"By December 31, 2022, we aim to achieve a 3 percentage point increase from our 10/20/40 by 2020 representation goals: Increase our goal for representation of women at the supervisor and manager level by 3 percentage points or more, for a total of at least 43 percent.",2019_Boston_Scientific_Performance_Report.pdf
"Increase our goal for representation of multicultural talent at the supervisor and manager level by 3 percentage points or more, for a total of at least 23 percent.",2019_Boston_Scientific_Performance_Report.pdf
"Continue to be a Top 10 percent globally recognized leader for workplace inclusion, because we know that diversity benefits us all.Achieving these goals will require continued change in three key areas of the management-level employee experience: Attraction: Hiring diverse managerial talent allows us to cultivate a rich pool of perspectives and backgrounds that will help us innovate beyond our current capabilities.",2019_Boston_Scientific_Performance_Report.pdf
Development: Recognizing and providing opportunities to diverse talent already within our workforce helps to ensure employees at all levels experience meaningful career journeys.,2019_Boston_Scientific_Performance_Report.pdf
Retention: Paying attention to who leaves our team matters just as much as who joins it.,2019_Boston_Scientific_Performance_Report.pdf
"By supporting, engaging and retaining diverse talent, we can stem attrition to maintain our diverse and innovative culture.We believe sharing our workforce demographic data is an important step in holding ourselves accountable to measurable progress.",2019_Boston_Scientific_Performance_Report.pdf
"To learn more about our progress, visit our D&I website .",2019_Boston_Scientific_Performance_Report.pdf
"Increase our goal for representation of women at the supervisor and manager levels by 3 percentage points or more, to at least 43% Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations ” D&I is a busines s imperative and success requires the engagement of our entire company.” — Camille Chang Gilmore, Vice President, Boston Scientific Human Resources and Global Chief Diversity Officer 3Up by 2023 Goals Bost on Scientific 2019 Performance Report 28D&I Initiatives Boston Scientific is committed to creating equal opportunities for growth across the company.",2019_Boston_Scientific_Performance_Report.pdf
"We believe that meeting this objective requires: Communicating with transparency about our strategy, actions and results Promoting diversity awareness and inclusion competency skills for employees worldwide Driving accountability to promote measurable D&I progress With a heightened focus on attraction, development and retention, we accelerated our D&I efforts with new resources and programs in 2019.",2019_Boston_Scientific_Performance_Report.pdf
"Diverse Leaders of Tomorrow: We launched Diverse Leaders of Tomorrow, a program to help diverse talent manage their personal and professional develop- ment and career progression.",2019_Boston_Scientific_Performance_Report.pdf
"The two-day experience for high-potential leaders and their managers focuses on equipping participants for future leadership oppor - tunities through skill building, strategic planning and network expansion.Recruiting Diverse Talent: Boston Scientific stepped up efforts to recruit emerging talent by deepening our relationships with institutions such as Historically Black Colleges and Universities (HBCUs).",2019_Boston_Scientific_Performance_Report.pdf
"In the summer of 2019, we hired more than 170 diverse interns from colleges and universities across the United States after making 105 on-the-spot offers to students at campus diversity recruiting conferences.",2019_Boston_Scientific_Performance_Report.pdf
Talent Management Bias Audit: We conducted a third-party review of our global talent management processes to identify potential unconscious bias.,2019_Boston_Scientific_Performance_Report.pdf
"Using four key checkpoints — clear structures and standards, difference awareness, skill building and data accountability — the evaluation offered insights for how we can further refine management practices to achieve greater inclusion.",2019_Boston_Scientific_Performance_Report.pdf
Inclusion Toolkit: We launched a new online Inclusion Toolkit that offers all employees on-demand D&I tools and information.,2019_Boston_Scientific_Performance_Report.pdf
The content was developed in response to feedback from 2018 focus groups with 350 employees.,2019_Boston_Scientific_Performance_Report.pdf
"The toolkit’s resources include an Inclusive Behaviors self-assessment that encourages people to know and increase their Inclusion Intelligence Quotient (IIQ).Unconscious Bias Training: We expanded our Unconscious Bias training to all employees, making it available in 18 languages.",2019_Boston_Scientific_Performance_Report.pdf
"The 15-minute online course walks employees through questions and scenarios that help them recognize blind spots or unconscious biases that can negatively influence their work relationships and decision making.D&I Dashboard: This new internal analytics tool provides leaders a dashboard to review and analyze their organization’s representation and trends, as well as metrics for hiring, promotion and attrition.",2019_Boston_Scientific_Performance_Report.pdf
A summary is regularly provided to the Executive Committee.,2019_Boston_Scientific_Performance_Report.pdf
"Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 29 More than 4,500 Boston Scientific employees are active across nine ERGs with 96 chapters globally, including 10 virtual chapters and 30 chapters outside the United States.",2019_Boston_Scientific_Performance_Report.pdf
"BRIDGE: Developing a Community of Black Leaders HOLA: Hispanic Organization for Leadership and Achievement LEAD: Leadership, Education and Allies for Disabilities PEARL: Pacific East Asian Resources in Leadership PRIDE: Promoting Respect, Inclusion, Diversity and Equality SAIL: South Asians in Leadership VETS: Veterans & Employees Together in Service WN: Women’s Network YPN: Young Professionals NetworkEmployee Resource Groups Employee Resource Groups (ERGs) are at the foundation of our D&I strategy.",2019_Boston_Scientific_Performance_Report.pdf
"ERGs are voluntary, company-sponsored employee groups that foster and celebrate our diverse work environment.",2019_Boston_Scientific_Performance_Report.pdf
"While ERGs are typically formed around a specific diversity dimension such as gender, race, veteran status, sexual orientation or life stage, all employees are welcome and encouraged to join any ERG.",2019_Boston_Scientific_Performance_Report.pdf
"Our ERG chapters around the world collaborate across the business at all levels and are considered powerful voices for change in the company.Boston Scientific supports each ERG with resources, global and local executive sponsors and step-by-step information on how to structure and lead these organizations.",2019_Boston_Scientific_Performance_Report.pdf
"Our Employee Resource Group Handbook addresses all aspects of launching and operating an ERG, from mentorship and sponsorship to expense policies and communications guidelines.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we piloted ERG Insights, a new software management platform that connects employee groups in all regions of the world.",2019_Boston_Scientific_Performance_Report.pdf
"It offers online tools for sharing information and managing group responsibilities, including event planning, budgeting and member communications.",2019_Boston_Scientific_Performance_Report.pdf
"Following a successful soft launch with ERG leads, we will soon offer all employees access to ERG Insights in 2020.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations The number of ERGs at Boston Scientific has more than doubled over the past five years.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019 alone, 11 new ERG chapters were launched.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 30 Serving the Underserved with Health Camps Boston Scientific employees in our SAIL ERG collaborate across our Marlborough, Massachusetts and Gurgaon, India offices to offer health camps for children.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, SAIL teamed up with the Health Care Services organization in India to organize local school visits by medical professionals.",2019_Boston_Scientific_Performance_Report.pdf
Approximately 800 students in three locations had the opportunity to receive healthcare screenings and follow-up vaccines as well as dental and eye care.,2019_Boston_Scientific_Performance_Report.pdf
"Students also received backpacks with dental kits and other supplies, and participated in STEM activities led by our volunteers.",2019_Boston_Scientific_Performance_Report.pdf
"Workplace Accessibility In September, our LEAD ERG chapters in 10 locations participated in Make Way Day, a global event dedicated to identifying ways to improve accessibility at Boston Scientific sites.",2019_Boston_Scientific_Performance_Report.pdf
"From furniture and equipment to collaboration areas and digital accessibility, employees in the United States, Ireland, Puerto Rico and Costa Rica worked together to generate new ideas for improving facilities.",2019_Boston_Scientific_Performance_Report.pdf
Their work continues in 2020 with the objective of developing a company-wide accessibility strategy.Inclusive Restroom Signage Our PRIDE ERG played a lead role in a 2019 effort to create more inclusive restroom signage at Boston Scientific office locations.,2019_Boston_Scientific_Performance_Report.pdf
PRIDE representatives collaborated with Human Resources and Global Facilities team members to review and consider proposals for signage and restroom design updates.,2019_Boston_Scientific_Performance_Report.pdf
"As a result, two updates to our Global Design Guidelines were approved and are now being implemented.",2019_Boston_Scientific_Performance_Report.pdf
ERG HighlightsFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 31 Global Council for Inclusion The Boston Scientific Global Council for Inclusion oversees the implementation of the company’s D&I strategies.,2019_Boston_Scientific_Performance_Report.pdf
"Chief Financial Officer Daniel Brennan chairs the council and its members include Chairman and CEO Mike Mahoney, the Executive Committee, our global D&I team and all global ERG leaders.",2019_Boston_Scientific_Performance_Report.pdf
The council meets quarterly to evaluate D&I progress and consider challenges that may arise for our employee groups in all locations.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, this work included the development of action items to ensure that ERGs and all leaders have the support they need to foster an inclusive environment.",2019_Boston_Scientific_Performance_Report.pdf
The council also welcomed nominations for our first-ever D&I Impact Awards and selected winners in four categories.,2019_Boston_Scientific_Performance_Report.pdf
Inaugural D&I Impact Awards The Diversity and Inclusion Impact Awards were established to recognize employees whose efforts help create a workplace where people can bring their authentic selves to work every day.,2019_Boston_Scientific_Performance_Report.pdf
"The company honored winners in the categories of Business Impact, Valued Ally, Workplace Culture and ERG Leader of the Year.Equal Employment Opportunity Policy Boston Scientific has been, and will continue to be, an equal opportunity employer.",2019_Boston_Scientific_Performance_Report.pdf
"To ensure full implementation of the company’s equal employment policy, we continue to ensure that recruitment, hiring, assignment, promotion, compensation and all other personnel decisions are made and administered without regard to race, religion, ethnicity, national origin, citizenship, sex, sexual orientation, gender identity, gender expression, veteran’s status, age, mental or physical disability, genetic information or any other protected class.",2019_Boston_Scientific_Performance_Report.pdf
We draw strength from the unique talents inherent in a diverse workforce and we believe the best and most innovative products come from an inclusive workplace where varied viewpoints are welcomed and encouraged.,2019_Boston_Scientific_Performance_Report.pdf
"We also have a strict policy against harassment that is reinforced through training and multiple communications channels.LGBTQ+ Equality In 2019, we: Sponsored the Equality Act legislation to establish protections against discrimination based on sexual orientation or gender identity, and we signed onto an Amicus Brief filed with the U.S. Supreme Court to support upholding inclusive federal non-discrimination policies.",2019_Boston_Scientific_Performance_Report.pdf
"Equalized paid benefits for bonding leave in the United States for the birth parent, non-birth parent, adoptive parent or parent who has a child through a surrogate, and expanded transgender coverage for both voice and communication therapy and gender reassignment surgery.",2019_Boston_Scientific_Performance_Report.pdf
"Created more inclusive restroom signage at Boston Scientific office locations, including a n ew “ All G ender” r estroom sign design (formally “Gender Neutral”) as well as single-occupancy restroom locator signs outside of gender-specific restrooms.",2019_Boston_Scientific_Performance_Report.pdf
Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 32Listening to Our People Our best ideas come from our people.,2019_Boston_Scientific_Performance_Report.pdf
We listen to them as we continuously improve our work environments and strive to attract and retain top talent.,2019_Boston_Scientific_Performance_Report.pdf
"In addition to encouraging ongoing communication and feedback between employees and their managers, we devote resources to ensuring that all employees have the opportunity to share their ideas and insights.",2019_Boston_Scientific_Performance_Report.pdf
"Expanding Engagement We revamped our Employee Engagement Survey in 2019 to make it a more dynamic, real-time assessment tool.",2019_Boston_Scientific_Performance_Report.pdf
"The new format will launch in 2020 with employee pulse surveys to facilitate continuous engagement, which will be followed by a Global Census Survey.",2019_Boston_Scientific_Performance_Report.pdf
The surveys and results dashboards will be available on mobile devic es to offer easy access for participation and review.,2019_Boston_Scientific_Performance_Report.pdf
This all-electronic approach now enables us to evaluate and share employee feedback with reduced turnaround time.,2019_Boston_Scientific_Performance_Report.pdf
Assessing People Leadership Skills Our outreach to provide people leaders with feedback includes employee input on annual performance reviews and 360-degree surveys.,2019_Boston_Scientific_Performance_Report.pdf
We also offer the SPARK survey that lets employees rate their manager’s performance against a defined set of leadership behaviors.,2019_Boston_Scientific_Performance_Report.pdf
"More than 23,000 employees were invited to offer feedback on 3,380 people leaders in 2019, with a response rate of 77 percent.",2019_Boston_Scientific_Performance_Report.pdf
"Of the participating managers, 87 percent (those with three or more direct reports responding) received a personalized feedback report.",2019_Boston_Scientific_Performance_Report.pdf
Evaluating our Communications Boston Scientific conducts a bi-annual all-employee survey about our communications content and channels.,2019_Boston_Scientific_Performance_Report.pdf
"The 2019 survey generated responses from nearly 10,000 employees in all regions, an increase from 8,200 in 2017.",2019_Boston_Scientific_Performance_Report.pdf
"Of those respondents, 77 percent were non-management employees, 20 percent were supervisors and managers and 3 percent were leaders at the director level and above.",2019_Boston_Scientific_Performance_Report.pdf
"The results showed an increase of 7 percent in overall satisfaction with company communications and provided insights that are informing ongoing efforts to engage our workforce.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 33 D&I Awards Bloomberg Gender-Equality Index: Boston Scientific was one of 230 companies globally to be included in the Index, which tracks the performance of public companies most committed to supporting gender equality.",2019_Boston_Scientific_Performance_Report.pdf
"Best Place to Work for Disability Inclusion: For the fourth consecutive year, we have been recognized as a Best Place to Work for Disability Inclusion, receiving a 100% on the Disability Equality Index in 2019.",2019_Boston_Scientific_Performance_Report.pdf
Forbes Best Employers for Diversity: Forbes recognized Boston Scientific on its America's Best Employers for Diversity list for the second year in a row.,2019_Boston_Scientific_Performance_Report.pdf
"Best Place to Work for LGBTQ Equality: For the fifth consecutive year, we earned a 100% score on the Human Rights Campaign's Corporate Equality Index, earning the designation as a Best Place to Work for LGBTQ Equality.",2019_Boston_Scientific_Performance_Report.pdf
"Hispanic Association on Corporate Responsibility (HACR) Corporate Inclusion Index (CII): In our first year participating, we were named a 5-Star Company for Employment based on HACR’s ac countability survey that assesses inclusion of Hispanics in Corporate America.",2019_Boston_Scientific_Performance_Report.pdf
Diversity Best Practices: Boston Scientific was one of only 14 companies to be named a Top 10% Inclusion Index Company in 2019.,2019_Boston_Scientific_Performance_Report.pdf
"Beyond the Yellow Ribbon Company: We were honored as a Yellow Ribbon company for supporting service members, military families and veterans as they transition to employment.",2019_Boston_Scientific_Performance_Report.pdf
"Best Companies for Multicultural Women: Working Mother Magazine recognized Boston Scientific for its policies, programs and practices that support career advancement for multicultural women.",2019_Boston_Scientific_Performance_Report.pdf
"Best Companies for Moms & Dads: Working Mother Magazine selected Boston Scientific for its annual 100 Best Companies and Best Company for Dads lists, based on maternal and paternal leave policies, flexible work schedules and inclusive benefits.",2019_Boston_Scientific_Performance_Report.pdf
Workplace Awards America’s Best Large Employers: Forbes ranked Boston Scientific #1 in the Health Care Equipment and Services industry.,2019_Boston_Scientific_Performance_Report.pdf
"Family Friendly Certified Company, Korea: Boston Scientific Korea was certified as a Family Friendly Organization by the Korean Government Ministry of Gender Equality and Family, a designation acknowledging our inclusive and family-friendly culture.",2019_Boston_Scientific_Performance_Report.pdf
"Best Companies to Work for in Asia: Our Taiwan and Hong Kong sites were both recognized as top places to work, based on our workplace culture and high levels of employee engagement.",2019_Boston_Scientific_Performance_Report.pdf
"Great Place to Work Certified, India: The Great Place to Work Institute honored Boston Scientific with this award for our high-trust, high-performance culture in India.",2019_Boston_Scientific_Performance_Report.pdf
"Top 50 Workplaces of the Fortune 500: We were recognized as a top-rated workplace by Indeed, which includes companies on the Fortune 500 Index with at least 100 employee reviews.",2019_Boston_Scientific_Performance_Report.pdf
"2019 Glassdoor Best Places to Work: Our employees contributed valuable, candid feedback about working at Boston Scientific, earning us this honor based entirely on their reviews.",2019_Boston_Scientific_Performance_Report.pdf
"Top 50 STEM Workplaces: We were honored for the third consecutive year by AISES (American Indian Science and Engineer Society), a U.S. non-profit focused on substantially increasing representation of Native peoples in STEM studies and careers.Setting the Bar Higher Boston Scientific is fully committed to promoting an inclusive culture and being an employer of choice for globally diverse talent.",2019_Boston_Scientific_Performance_Report.pdf
"In the spirit of transparency, we participate in external benchmark index surveys that candidly assess our progress and ensure we are doing all we can to achieve our D&I goals.",2019_Boston_Scientific_Performance_Report.pdf
We are proud to have been recognized by the following organizations in 2019.,2019_Boston_Scientific_Performance_Report.pdf
Please visit our website for a complete listing of Boston Scientific awards and recognitions.,2019_Boston_Scientific_Performance_Report.pdf
2019 People AwardsFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 34 Employee Growth and Development Developing our people professionally is one of the most important things we do.,2019_Boston_Scientific_Performance_Report.pdf
"At every level of the company, employees have access to programs, training and tools they can use to advance their skills and expertise and cr eate gr eater pos sibilities f or their careers.",2019_Boston_Scientific_Performance_Report.pdf
Developing Talent We invest in building and sustaining an environment where coaching and develop- ment are a priority.,2019_Boston_Scientific_Performance_Report.pdf
"To ensure the success and growth of our leaders, we offer tools and training to support their continuous development as well as their accountability.",2019_Boston_Scientific_Performance_Report.pdf
"With the pace of business moving faster than ever, we are becoming more agile in the ways we meet the needs of our multigenerational workforce.",2019_Boston_Scientific_Performance_Report.pdf
The company introduced and expanded development programs for all levels with easy-access tools tha t allow employe es t o manage their own growth and careers.,2019_Boston_Scientific_Performance_Report.pdf
"Boston Scientific offers more than 150 professional and technical courses each year, including on-the-job training, skills-based learning and programs for talent who have the potential to hold future leadership positions.Accelerated Leadership Development Program (ALDP) expedites the readiness of high potential leaders and key successors t o take on more complex roles.",2019_Boston_Scientific_Performance_Report.pdf
"Senior leaders act as facilitators for a series of one-week Team Acceleration is a customized, interactive workshop that helps employees build and sustain high- performing teams.",2019_Boston_Scientific_Performance_Report.pdf
"The two-day curriculum offers tools that use customer insights to help teams gain clarity about their goals, roles, processes and strategies in order to accelerate and succeed.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, more than 60 participants in the U.S. completed this pilot program.",2019_Boston_Scientific_Performance_Report.pdf
"Insights Discovery is a methodology that uses a four-color model and evaluator to help people become more self-aware about their style and strengths, guiding them to better understand how they interact and perform as team members.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, more than 1,800 employees participated in this training.",2019_Boston_Scientific_Performance_Report.pdf
"Mastering Emotional Intelligence is a training module that helps employees increase their emotional quotient (EQ) skills, including how they communicate, make decisions, respond to change and handle stress or conflict.",2019_Boston_Scientific_Performance_Report.pdf
"More than 300 people at Boston Scientific completed the on-demand, voluntary training in 2019.2019 Highlightsclassroom sessions featuring business simulations, coaching, case studies and networking with peers and Executive Committee members.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, the ALDP graduated 27 leaders from 11 countries.",2019_Boston_Scientific_Performance_Report.pdf
Leadership Development Program (LDP) is designed for director-level and above employees who are nominated to prepare for their next level of growth.,2019_Boston_Scientific_Performance_Report.pdf
The curriculum enhances their personal and leadership skills through interactive sessions and gives them opportunities to network with global peers and senior leaders.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, 39 par- ticipants from 10 countries completed the program.",2019_Boston_Scientific_Performance_Report.pdf
More than 500 Boston Scientific leaders have graduated from the LDP.,2019_Boston_Scientific_Performance_Report.pdf
"In 2020, the curriculum and participants will shift to focus on preparing senior managers for director-level roles.",2019_Boston_Scientific_Performance_Report.pdf
Management Development Program (MDP) features resources and coaching tools for new leaders.,2019_Boston_Scientific_Performance_Report.pdf
"The mandatory 18-month program covers hiring practices, talent and performance management, unconscious bias, situational leadership and coaching skills.",2019_Boston_Scientific_Performance_Report.pdf
"More than 2,200 managers worldwide completed over 5,000 MDP sessions in 2019.",2019_Boston_Scientific_Performance_Report.pdf
"Based on the success of the MDP, we are launching the People Leader Experience in 2020, a 12-month program for new leaders that includes onboarding activities, development experiences and guidance for enhancing partnerships with supervisors.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations 568,000 hours spent by non- manufacturing employees in virtual and classroom training in 2019 Bost on Scientific 2019 Performance Report 35Leadership Development Across Cultures Boston Scientific offers targeted leadership development programs to complement corporate programs and support talent throughout the organization.",2019_Boston_Scientific_Performance_Report.pdf
"Some examples of our regional development programs include the following: Our Key Talent Program in the Europe, Middle East and Africa (EMEA) region provides high-potential senior managers and directors the opportunity to advance their development.",2019_Boston_Scientific_Performance_Report.pdf
"The initiative aims to deepen the region’s leadership talent through a combination of growth experiences, coaching and interactions with senior leadership.",2019_Boston_Scientific_Performance_Report.pdf
The Asia Pacific Leadership Development Program is an accelerated development program for talented and diverse leaders to build our talent pipeline for future commercial leaders in the Asia Pacific region.,2019_Boston_Scientific_Performance_Report.pdf
"The curriculum includes business projects and career-building international work experiences, and it is customized to meet each talent’s unique developmental needs.",2019_Boston_Scientific_Performance_Report.pdf
"Senior leaders and program alumni facilitate our leadership development program in La tin Americ a, which suppor ts building capabilities to address the region’s emerging market challenges and unique health ecosystem.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, 60 participants from five countries completed the 10-session curriculum.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, nearly 200 emerging leaders participated in country-level development programs in Colombia (above left), Brazil, Argentina, Puerto Rico and Mexico (above right).",2019_Boston_Scientific_Performance_Report.pdf
"The bi-annual Asia Pacific Women's Leadership Summit , held in Bangkok, Thailand, included female leaders, male advocates and senior executives from 10 countries (left).",2019_Boston_Scientific_Performance_Report.pdf
"With the theme “Behind every strong woman leader is a network supporting her,” the summit provided a platform for leaders to sharpen their skills and build a network for sharing best practices and promoting women’s career advancement.",2019_Boston_Scientific_Performance_Report.pdf
"Cross-Cultural Learning As a global company, we offer employees the opportunity to routinely interact with peers, customers and patients from a variety of cultures and countries.",2019_Boston_Scientific_Performance_Report.pdf
We have developed a comprehensive portfolio of on-demand training and resources to support cross-cultural learning and awareness among all employees.,2019_Boston_Scientific_Performance_Report.pdf
Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 36Compensation and Benefits Boston Scientific compensation and benefit programs support the well-being and health of our people while also providing flexibility to meet their needs and expectations.,2019_Boston_Scientific_Performance_Report.pdf
"Our teams continually evaluate these programs to reach beyond best practices with offerings that are the best fit for our employees in our multigenerational, multicultural workforce.",2019_Boston_Scientific_Performance_Report.pdf
Compensation We believe strongly in pay for performance.,2019_Boston_Scientific_Performance_Report.pdf
"Where it is relevant to an employee’s responsibilities and is in compliance with local and national labor standards, we strive to offer both a base and a variable component to employee pay, including annual bonus programs, long-term incentive stock awards and performance rewards issued on a one-time basis, including on-the-spot bonuses for highly successful projects, and recognition awards for breakthrough performance.",2019_Boston_Scientific_Performance_Report.pdf
Sustaining equal pay for equal work requires constant measurement and attention.,2019_Boston_Scientific_Performance_Report.pdf
"Our pay practices support the company’s high-performance culture, including regular company-wide bench- marking of salaries, internal parity audits and reviews of pay recommendations across the business.",2019_Boston_Scientific_Performance_Report.pdf
We continue to assess and fine-tune our practices to Equal Pay for Equal Work: Pay Equity Global compensation practices at Boston Scientific are rooted in our values and the high priority we place on paying people equally for equal work.,2019_Boston_Scientific_Performance_Report.pdf
"We regularly bench- mark salaries, conduct annual internal and external parity audits and review pay recommendations company wide.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, we contract with an indepen- dent, third party2 to annually assess pay equity across all positions using regression analysis.",2019_Boston_Scientific_Performance_Report.pdf
"This data analytics approach controls for variables that influence compensation such as job position, tenure, years of experience and location.",2019_Boston_Scientific_Performance_Report.pdf
We use the results to identify any potential pay disparities that should be addressed.,2019_Boston_Scientific_Performance_Report.pdf
"In this process, we look closely at both pay equity and pay parity.",2019_Boston_Scientific_Performance_Report.pdf
"We place more weight on pay equity to advance inclusion, equality and opportunity for all.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we continued to see pay equity results that reflect our practices and the commitment of our leaders to ensure equal pay: 99+ percent pay equity for gender globally and 99+ percent pay equity for multicultural talent in the United States and Puerto Rico.",2019_Boston_Scientific_Performance_Report.pdf
In the few instances where we identified a gender disparity — which occurred in positions involving both men and women — we examined the circumstances and acted to increase pay where appropriate.,2019_Boston_Scientific_Performance_Report.pdf
"improve on our results, maintain trans- parency and educate leaders on our pay equity practices.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, our compensation experts also held face-to-face meetings and teleconferences at major worksites globally to address employee questions.",2019_Boston_Scientific_Performance_Report.pdf
"2 Resolution Economics LLCHourly 2019 2018 Sales 2019 2018 Salaried 2019 2018 99.3% 99.5%99.4% 100%99.2% 99.9% 99.3% 99.3%100% 100%99.4% 100% Salaried 2019 2018 Sales 2019 2018 Hourly 2019 2018 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations 99%+pay equity for gender globally, and for multicultural talent in the U.S. and Puerto Rico Pay Equity Gender (Global) Multicultural Talent (U.S./Puerto Rico) Bost on Scientific 2019 Performance Report 37Benefits We understand that good health, well-being, financial health and security are essential for a productive and thriving workforce.",2019_Boston_Scientific_Performance_Report.pdf
One of the important ways we support a culture of health for our people is by providing them with comprehensive benefits.,2019_Boston_Scientific_Performance_Report.pdf
"Our benefits plans are based on these principles: Enable high-performing talent: As part of a broader rewards portfolio, we offer market competitive benefits that are flexible and affordable to meet the individual needs of our increasingly diverse talent base.",2019_Boston_Scientific_Performance_Report.pdf
"Support life-work integration: We strive to offer programs that acknowledge, respect and support an individual’s life and work choices.",2019_Boston_Scientific_Performance_Report.pdf
"Promote well-being: Our programs are holistic in approach and designed to support physical, emotional, social and financial well-being.",2019_Boston_Scientific_Performance_Report.pdf
"Value and cultural fit: We strive to offer benefits that our employees value, differentiate our culture and support an inclusive work environment.",2019_Boston_Scientific_Performance_Report.pdf
"Communication and tools: We aim to communicate in a manner that makes our plans easy to use and enables employees to take action to achieve well-being.In 2019, we addressed the increasingly varied needs for support and flexibility in our workforce, which is more multigenerational than ever before.",2019_Boston_Scientific_Performance_Report.pdf
"In Japan, we developed a handbook and new managerial practices to support women returning to work after childbirth or other career break.",2019_Boston_Scientific_Performance_Report.pdf
"We a lso c ompleted a Workflex pilot program in t he U nited States aimed at improving life-work satisfaction and expanded financial wellness benefits to address the needs of employees, from those starting their careers and building financial profiles to those investing for retirement.",2019_Boston_Scientific_Performance_Report.pdf
We took further action to acknowledge that “f amily” has become a broadly defined and inclusive term.,2019_Boston_Scientific_Performance_Report.pdf
The following benefits became effective in 2019 or in January of 2020.,2019_Boston_Scientific_Performance_Report.pdf
"EMEA paid parental leave: In the EMEA region, we significantly expanded parental leave for employees.",2019_Boston_Scientific_Performance_Report.pdf
All new parents working at Boston Scientific sites in the region are now eligible for a minimum of 18 weeks of fully paid leave during the first year of their child’s birth or adoption.,2019_Boston_Scientific_Performance_Report.pdf
"Women’s and family health: In the United States, we partnered with the virtual clinic Maven to expand our offerings for employees and their partners who are pregnant, up to six Global Employee Assistance Programs The company’s Global Employee Assistance Programs maintain a network of support and resources that encourage overall well-being, including help with finances, family life, elder/childcare and mental health.",2019_Boston_Scientific_Performance_Report.pdf
We continued to broaden the availability of these programs to include all countries where our company has a concentration of employees.,2019_Boston_Scientific_Performance_Report.pdf
"Embracing Life-Work Needs Our Global Benefits to Fit Your Life program is a package of solutions designed to make life-work integration easier for all employees, regardless of their stage of life.",2019_Boston_Scientific_Performance_Report.pdf
"It provides the benefits and services our employees want in order to be happy, productive and engaged in their roles.",2019_Boston_Scientific_Performance_Report.pdf
"Our life-work offerings include telehealth services, childcare and parental care benefits, college and financial planning, a breast milk shipping service, tuition support, a meal-planning service and sabbaticals for employees with more than seven years of service.months postpartum or pursuing fertility treatment.",2019_Boston_Scientific_Performance_Report.pdf
"No-cost benefits available through Maven include support through egg freezing, fertility, pregnancy, postpartum, adoption, surrogacy, early pediatrics and returning to work.",2019_Boston_Scientific_Performance_Report.pdf
"U.S. paid parental leave: Benefits are available to all employees who are new parents — birth parents, non-birth parents, adoptive parents and now for parents who have a child through surrogacy.",2019_Boston_Scientific_Performance_Report.pdf
"In 2020, we also expanded non-birth paid parental bonding leave to eight weeks.",2019_Boston_Scientific_Performance_Report.pdf
Surrogacy benefits: We introduced a surrogacy expense reimbursement program so U.S. employees who have a child through surrogacy now have benefits similar to those we offer employees who adopt children.,2019_Boston_Scientific_Performance_Report.pdf
"Expanded fertility benefit: We enhanced our employee fertility benefit for U.S. employees to cover treatments without any diagnosis requirements, making it easier for employees to receive assisted reproductive technology, including those who are single or in same-sex relationships.",2019_Boston_Scientific_Performance_Report.pdf
"To learn more about our benefit programs and services, visit BenefitsConnect.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 38 Employee Health and Safety Boston Scientific takes a global approach to prioritizing, executing and monitoring efforts to ensure employee safety and foster a safety-oriented culture in all of our offices and facilities.",2019_Boston_Scientific_Performance_Report.pdf
We set health and safety goals called Total Recordable Incident Rate (TRIR) targets for every Boston Scientific operations site.,2019_Boston_Scientific_Performance_Report.pdf
"To measure the number of injuries per 100 employees, our EHS Operations Council reviews performance monthly to discuss trends and risks, as well as opportunities for improvement.Occupational Health and Well-being The people of Boston Scientific are our most valuable resource, and a comprehensive occupational health and well-being program is an integral part of our employee support system.",2019_Boston_Scientific_Performance_Report.pdf
"Our Occupation Health Council expands the reach of our health and wellness programs with offerings including employee nutrition, healthy minds, healthy bodies, weight management support, yoga, mindfulness meditation, smoking cessation support and group sporting events.",2019_Boston_Scientific_Performance_Report.pdf
"We also broadened our focus on mental health awareness and developed more ways to offer help, resources and referrals to care providers.During the year we expanded the TRIR goal to include our global organization and set a goal of 0.25 by 2030, cutting our incident rate by 50 percent across the company.",2019_Boston_Scientific_Performance_Report.pdf
"This new 2030 TRIR goal will be a key performance indicator incorporated into our company-wide performance tracking for safety, quality, service and cost.",2019_Boston_Scientific_Performance_Report.pdf
"We integrate multiple health and safety metrics in our Environment, Health and Safety monitoring systems at both the local and global level in accordance with the Boston Scientific EHS policy .",2019_Boston_Scientific_Performance_Report.pdf
"Our performance against these metrics is reviewed daily by local site groups, weekly in management meetings and monthly with global leadership to identify and respond to any adverse trends or incidents.In 2019, we promoted the benefits of volunteering through community litter pickups, blood donations, group mountain climbs and our LEAD ERG’s support for a “Run 1 Mile” event.",2019_Boston_Scientific_Performance_Report.pdf
We also released the EHS Essentials handbook for employees with EHS responsibilities throughout the organization.,2019_Boston_Scientific_Performance_Report.pdf
"The handbook details our company-wide EHS strategy and policy, and establishes the expectations and responsibilities for all Boston Scientific sites.",2019_Boston_Scientific_Performance_Report.pdf
"Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Total Recordable Incident Rate (TRIR) Goals In 2019, we met our 10-year target of 0.5 TRIR 2030 Goal: 0.25 TRIR Achieve a company-wide safety goal of 0.25 injuries per 100 employeesAn employee enjoying her workout in the fitness center at our global headquarters in Marlborough, Massachusetts.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 39Buenos Aires, Argentina Our Buenos Aires team moved into a newly renovated office that offers collaborative spaces and plenty of natural light.",2019_Boston_Scientific_Performance_Report.pdf
"Clonmel, Ireland The new open-space building on our Clonmel, Ireland campus is designed to encourage employee mobility.Shanghai, China Our Shanghai headquarters features a renovated Institute for Advancing Science and office space.",2019_Boston_Scientific_Performance_Report.pdf
"Pursuit of Excellence in our Global Facilities Madrid, Spain Our Madrid team moved into a new office that features an Institute for Advancing Science as well as ample collaboration spaces.",2019_Boston_Scientific_Performance_Report.pdf
Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations We maintain facilities at the highest standards to ensure the company’s workspaces promote optimal physical health and overall well-being.,2019_Boston_Scientific_Performance_Report.pdf
"Our scientific environments are designed to foster creativity, communication and innovation.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, our facilities teams increased the use of natural light at a number of campuses and added collaborative work areas that offer employees greater flexibility, more networking opportunities and the agility to do their best work.Chengdu, China In Chengdu, China we opened an Institute for Advancing Science, a 17,000 square-foot facility with state-of-the-art labs and classrooms for healthcare professionals to learn about Boston Scientific products and procedures.",2019_Boston_Scientific_Performance_Report.pdf
Bost on Scientific 2019 Performance Report 40Caring for Our Communities Our employees are the driving force behind the way we live our caring value in the communities where we work.,2019_Boston_Scientific_Performance_Report.pdf
They have a prominent voice in how we invest in the well-being of communities and volunteer to make the world a better place.,2019_Boston_Scientific_Performance_Report.pdf
Our community outreach focuses on three key areas: Health: We aim to decrease health disparities for the underserved by providing access to quality care.,2019_Boston_Scientific_Performance_Report.pdf
"This work is grounded in prevention through education and awareness, providing access to care by increasing the number of qualified healthcare workers and preparing kids at risk for, or diagnosed with, a chronic disease for their journey into adulthood.",2019_Boston_Scientific_Performance_Report.pdf
"Community: Through engagement and recognition programs, we are empowering our employees to advance possibilities in their local communities by donating their time and resources to help those most in need.",2019_Boston_Scientific_Performance_Report.pdf
"Education: As a longtime advocate for education and STEM (Science, Technology, Engineering and Math) programming for K-12 students, we are developing diverse future talent that will enable us to create health solutions for generations to come.In 2016, Boston Scientific partnered with the health and humanitarian relief orga- nization Project HOPE to fund the United Dialogue and Action Against Non-Com - municable Disorders (UDAAN) program.",2019_Boston_Scientific_Performance_Report.pdf
"We entered into this collaboration to h elp stem the significant rise in premature mortality in India, where chronic diseases are estimated to account for 60 percent of all deaths.",2019_Boston_Scientific_Performance_Report.pdf
"Over the last three years, we worked with the Project HOPE team to implement the program in the Ranchi district of Jharkhand State.",2019_Boston_Scientific_Performance_Report.pdf
"The initiative focused on working collab- oratively with the State Government of Rajasthan to deliver services, care and support for health practices that can help prevent chronic disease.",2019_Boston_Scientific_Performance_Report.pdf
It also built capacity into health systems to identify and manage chronic disease in theHEALTH: Fostering Healthy Communities We embrace the profound responsibility that comes with our work in health care.,2019_Boston_Scientific_Performance_Report.pdf
"Because preventing illness is as important as treating it, our health awareness programs offer education and resources to help people live better, healthier lives.",2019_Boston_Scientific_Performance_Report.pdf
"In regions where people lack adequate access to information and basic care, we collaborate with charities and other non-governmental organizations to make strides in reducing chronic disease risk and health disparities in these underserved populations.",2019_Boston_Scientific_Performance_Report.pdf
"In an effort to contribute to improved health for as many patients as possible, we share our products, expertise, time and resources globally.",2019_Boston_Scientific_Performance_Report.pdf
"Our partnerships with Project HOPE, Children’s HeartLink and Partners in Health have helped to increase the number of healthcare workers focused on chronic disease worldwide.",2019_Boston_Scientific_Performance_Report.pdf
"Since 2016, these collaborations have provided training for more than 2,800 healthcare professionals and chronic disease screening, education or care for more than 23,000 people in India, South Africa, Malaysia and Mexico.community and strengthen the necessary referrals to chronic disease clinics, Accredited Social Health Activist (ASHA) and Anganwadi Workers (AWW) for home follow-up care.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, the UDAAN program’s education efforts emphasized the importance of healthy lifestyles through interpersonal counseling and community mobilization.",2019_Boston_Scientific_Performance_Report.pdf
"Because of the commitment of Boston Scientific, Project HOPE: Screened 13,534 adults between the ages of 30 and 70 for non-communicable diseases (NCDs) Trained 1,321 community health workers and medical officers on NCD protocols Reached 220,000 people from 200 villages Project HOPE in IndiaFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 41COMMUNITY: Giving Back In 2019, more than 10,000 Boston Scientific employee volunteers contributed more than 41,000 hours of their time in 38 countries, and they supported more than 600 community events.",2019_Boston_Scientific_Performance_Report.pdf
"Our annual awards program, which recognizes and rewards employee community service efforts, received more than 140 nominations.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, Boston Scientific contributed more than $85 million to support medical research, education and charitable organizations.",2019_Boston_Scientific_Performance_Report.pdf
"We provided $77 million in funding for research, education and fellowships addressing a broad spectrum of health conditions and diseases.",2019_Boston_Scientific_Performance_Report.pdf
Our charitable donations to support communities around the globe totaled more than $8.1 million.,2019_Boston_Scientific_Performance_Report.pdf
"In addition, as a result of employee participation in the Boston Scientific Employee Matching Gifts Program, we made $1.2 million in contributions.",2019_Boston_Scientific_Performance_Report.pdf
Possibility Grants Boston Scientific employees from our Massachusetts and Minnesota facilities have the opportunity to nominate local non-profits for Possibility Grants that help meet a significant community need.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we awarded $15,000 in Possibility Grants to 10 non-profit groups.",2019_Boston_Scientific_Performance_Report.pdf
"Community efforts and improvements supported by these grant recipients include: A local school’s new program to offer students first-time access to robots Repairs for a farm that provides enrichment programs for individuals with and without disabilities New shelving for a food pantry to provide access for all clients regardless of mobility restrictions STEM experiences for students from homeless families who are placed in transitional housing facilities Week of Caring In the second annual Boston Scientific Week of Caring, employees in over 15 countries demonstrated the positive difference we can make together through an impressive range of community projects.",2019_Boston_Scientific_Performance_Report.pdf
"Our contributions included book drives for hospital libraries in Greece, a fitness challenge in Galway, Ireland and disaster relief supply campaign in Singapore.",2019_Boston_Scientific_Performance_Report.pdf
"In Latin America, employees mobilized to commemorate World Environment Day with tree plantings and other green initiatives.",2019_Boston_Scientific_Performance_Report.pdf
"In Malaysia, we hosted a blood donation campaign and worked with local charities to expand their outreach.",2019_Boston_Scientific_Performance_Report.pdf
"Closer t o our global headquar ters in Massachusetts, we sponsored volunteer awareness events and deployed teams to staff 28 community projects in the Boston area.10,000 + employee volunteers 41,000 + hours 38 countries 600+ community events 140+ award nominations $162+ million in contributions for medical research, education and charitable organizationsFeature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 42 China Caring Team Employees in China volunteered alongside the China Mayor's Association and the Bethune Foundation to help with local patient health screenings.",2019_Boston_Scientific_Performance_Report.pdf
"The first event of this initiative was held in Panzhihua, Sichuan Province.",2019_Boston_Scientific_Performance_Report.pdf
"With the assistance of the local government and the Panzhihua Chinese-Western Hospital, more than 300 patients received blood pressure screenings and education materials on various medical conditions.Colon Cancer Awareness Events The Southern California Endoscopy Sales Team joined their local customers to host colon cancer awareness events led by California hospitals and communities.",2019_Boston_Scientific_Performance_Report.pdf
The purpose of the events was to reach at-risk individuals in the community and provide them with information as well as access to colon cancer screenings.,2019_Boston_Scientific_Performance_Report.pdf
Volunteer Recognition Awards The Boston Scientific Global Community Engagement team announced the three winners of our second annual Volunteer Recognition Awards.,2019_Boston_Scientific_Performance_Report.pdf
Nearly 100 employees from 24 countries were nominated for their commitments to improving their local and global communities.,2019_Boston_Scientific_Performance_Report.pdf
"Our honorees’ contributions included grassroots volunteer campaigns, advocacy for disabled athletes, and leadership that resulted in medical and humanitarian missions.STEM and Family in Seoul Employees and their children gathered in Seoul for our South Korea STEM and Family Event.",2019_Boston_Scientific_Performance_Report.pdf
"Using a bring-your-child-to- work approach, the program offered an opportunity for kids to develop an interest in STEM as they learned about Boston Scientific, our products and what their parents do at work.",2019_Boston_Scientific_Performance_Report.pdf
Participants were also trained in CPR and how to help in a life-threatening situation.,2019_Boston_Scientific_Performance_Report.pdf
Rhythm Management Product Donation Program We support U.S. physicians with resources for their humanitarian missions.,2019_Boston_Scientific_Performance_Report.pdf
Our Cardiac Rhythm Management and Electrophysiology Grant Committee reviews and approves applications from doctors for indigent care and humanitarian product donations.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, the committee approved $180,000 in funding for missions to Egypt, India, Honduras, Bolivia, Lebanon and Dominican Republic.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations 2019 Highlights: Caring for Customers, Communities and Patients “ In nearly 30 years of working a t Boston Scientific, I’ve never been prouder of how our teams embrace so many significant ways of caring.” — Marilee Grant, Director, Boston Scientific Global Community Engagement Bost on Scientific 2019 Performance Report 43 EDUCATION: Inspiring the Next Generation of STEM Innovators Our employee volunteers bring their energy and expertise to introduce K-12 youth to STEM experiences and careers.",2019_Boston_Scientific_Performance_Report.pdf
"In our work to inspire a diverse generation of STEM innovators, Boston Scientific brings customized STEM activities and interactive experiences to the young people in the communities we serve.",2019_Boston_Scientific_Performance_Report.pdf
Our teams are especially interested in introducing students from under- represented populations to the possibilities STEM learning can provide.,2019_Boston_Scientific_Performance_Report.pdf
"They consult with educators to better understand students’ needs and conduct STEM outreach through a combination of mentoring, sharing career experiences and leading participants through hands-on experiments and onsite tours.",2019_Boston_Scientific_Performance_Report.pdf
Boston Scientific has dedicated volunteer teams focused on STEM programming at 13 sites.,2019_Boston_Scientific_Performance_Report.pdf
"Their work to help grow a future pipeline of diverse talent includes finding creative ways to share their passion for their work, from career cards and videos to events that introduce students to a variety of STEM roles.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, our people contributed: 12,000+ STEM volunteer hours 1,500+ STEM volunteers 160+ STEM eventsSTEM Camp in Puerto Rico The Boston Scientific Dorado manufacturing plant hosted 19 public school students for an intensive one-week summer technology camp.",2019_Boston_Scientific_Performance_Report.pdf
"The program, designed and led by our local STEM team, focused on how to put new concepts for innovation into practice.",2019_Boston_Scientific_Performance_Report.pdf
Students participated in problem-solving activities and took on challenges such as applying Newton’s Laws and constructing a robot.,2019_Boston_Scientific_Performance_Report.pdf
Technical Training in India Employees in Gurgaon partnered with the Kiki Centre for Technology to offer a new pathway for youth to apply skills they learn in the classroom to real-world experiences.,2019_Boston_Scientific_Performance_Report.pdf
Students enrolled in the three-year technical training course received classroom instruction and industry training with local businesses.,2019_Boston_Scientific_Performance_Report.pdf
Three students selected for Boston Scientific internships completed their first year of training in 2019.,2019_Boston_Scientific_Performance_Report.pdf
"Future Med-Tech in China At Boston Scientific Shanghai, we welcomed 30 sixth graders for a day of STEM activities that included a site tour, a 3D-surgery tutorial and simulated surgical operations.",2019_Boston_Scientific_Performance_Report.pdf
"A highlight of the event was the launch of Design Thinking with Future Med-Tech, a new interactive program developed with the help of JA China.",2019_Boston_Scientific_Performance_Report.pdf
"The curriculum was designed to inspire innovation and show students how new ways of thinking can lead to healthcare solutions.Our Commitment to STEM Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 44 Every day, Boston Scientific is... helping shape the future of our planet.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Our Plane t 46 GEMS Key Performance Indicators 47 Climate Change 48 Environmental Impact 50 Green Team Environmental Sustainability Initiatives Boston Scientific employees participating in a tree planting event in Colombia in September 2019.",2019_Boston_Scientific_Performance_Report.pdf
Bost on Scientific 2019 Performance Report 45Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations A critical challenge for us as a global medical device manufacturer is to deliver on our promise to customers and patients while caring for the planet.,2019_Boston_Scientific_Performance_Report.pdf
"The way we do our jobs each day contributes to reducing our environmental impacts, achieving carbon neutrality and improving supply chain sustainability.",2019_Boston_Scientific_Performance_Report.pdf
"We are making measurable progress toward shaping a better future for our planet by proactively addressing energy consumption, carbon emissions, waste management and water use.",2019_Boston_Scientific_Performance_Report.pdf
"The Boston Scientific Environment, Health and Safety (EHS) Policy outlines our high environmental standards and is central to the work of our newly established EHS Center of Excellence.",2019_Boston_Scientific_Performance_Report.pdf
"We rigorously measure, assess and report progress toward our EHS goals globally.",2019_Boston_Scientific_Performance_Report.pdf
"Across all operations and key distribution locations, we strive to meet and exceed International Organiza - tion for Standardization (ISO) standards for environmental management systems.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, our newest manufacturing location in Penang, Malaysia achieved ISO 14001:2015 certification.",2019_Boston_Scientific_Performance_Report.pdf
"Of the 16 Boston Scientific sites that have earned this certification, 13 facilities achieved zero non-conformances during the 2019 audit cycle.Our Global Energy Management System (GEMS) helps ensure that we meet ambitious energy reduction and greenhouse gas (GHG) reduction targets using the C3 strategy (Cut, Convert, Compensate).",2019_Boston_Scientific_Performance_Report.pdf
"Developed in collaboration with the National University of Ireland, Galway (NUI Galway), GEMS focuses on cutting energy use, converting to renewable energy resources instead of fossil fuels and compensating with carbon offset projects where needed.",2019_Boston_Scientific_Performance_Report.pdf
"Our advances through GEMS earned Boston Scientific and NUI Galway recognition as finalists for the 2019 US-Ireland Research Innovation Awards, a joint initiative of the Royal Irish Academy and the American Chamber of Commerce, Ireland.",2019_Boston_Scientific_Performance_Report.pdf
"We are continually monitoring progress through GEMS and our teams are working to meet or exceed the following targets with the overall goal of achieving carbon neutrality by 2030: 50 percent renewable electricity by 2021 100 percent renewable electricity by 2024 90 percent renewable energy (all sources) by 2027Our Planet “ W orking in the healthcare space, we have the privilege to help advance science and improve patient health, but we also have the responsibility to do this work in a sustainable manner that enriches communities.",2019_Boston_Scientific_Performance_Report.pdf
"We’ve set aggressive environmental goals to do our part to help shape a better future for our planet, and we’re holding ourselves accountable.” — Brad Sorenson, Senior Vice President, Boston Scientific Manufacturing and Supply Chain Our targets to achieve carbon neutrality by 2030: 50% renewable electricity by 2021 100% renewable electricity by 2024 90% renewable energy (all sources) by 2027 Bost on Scientific 2019 Performance Report 46The GEMS methodology is implemented through our global energy team, including representatives from each Boston Scientific manufacturing and main distribution sites.",2019_Boston_Scientific_Performance_Report.pdf
"We measure our performance through these GEMS key performance indicators (KPIs): 20 15 20 16 20 17 20 18 20 19 Carbon F ootprint Total amount of Scope 1 and Scope 2 GHG emissions emitted into the 118,327 108,694 94,946 85,127 84,778 (MT CO2eq) atmosphere from manufacturing and distribution sites.",2019_Boston_Scientific_Performance_Report.pdf
Measured in metric tons of carbon equivalent.,2019_Boston_Scientific_Performance_Report.pdf
Ener gy Use (kWh) Total energy Boston Scientific consumes annually to manufacture 3 70M 367M 364M 352M 368M our products.,2019_Boston_Scientific_Performance_Report.pdf
Ener gy Use kWh/$K Total normalized energy Boston Scientific consumes annually to 4 9 44 40 36 34 Revenue manufacture our products.,2019_Boston_Scientific_Performance_Report.pdf
EM3 An energy management maturity model to establish where in the 2.7 3.2 3.6 3.7 3.9 “energy journey” each manufacturing site resides on a scale from 1 to 5 (Minimal > Emerging > Developing > Advancing > Leading).,2019_Boston_Scientific_Performance_Report.pdf
Gr een Real Estate Percentage of Boston Scientific real estate that is independently 27% 28% 32% 37% 45% (% of total) certified for energy efficiency by industry-leading programs such as LEED for design and Energy Star or ISO50001 for building operations.,2019_Boston_Scientific_Performance_Report.pdf
"R enewable Energy Percentage of total energy consumed, generated from renewable – – – 5% 11% (% of total) energy sources, with Boston Scientific owning the renewable attributes.",2019_Boston_Scientific_Performance_Report.pdf
"Cleaner Ener gy Energy produced from fossil fuels, but based on high-efficiency 6% 7% 9% 9% 11% (% of total) technologies such as combined heat and power (CHP) in comparison to conventional power generation.",2019_Boston_Scientific_Performance_Report.pdf
"Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 47Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Climate Change By addressing the company’s energy consumption, carbon emissions and environmental design, we are reducing our climate impacts.",2019_Boston_Scientific_Performance_Report.pdf
Striving for Carbon Neutrality Boston Scientific is committed to achieving carbon neutrality across our manufacturing and key distribution sites by 2030.,2019_Boston_Scientific_Performance_Report.pdf
Carbon neutrality means achieving net zero carbon emissions associated with manufacturing operations and energy use by balancing the amount of carbon released with an equal amount removed or compensated.,2019_Boston_Scientific_Performance_Report.pdf
"Increased levels of carbon dioxide and other GHG emissions in the atmosphere are closely tied to climate change, and achieving carbon neutrality will significantly reduce our contribution to this pressing issue.",2019_Boston_Scientific_Performance_Report.pdf
Leading in Energy Certification Sustainability is a critical objective for our global facilities' teams as we focus on improving existing sites and developing new construction in an environmentally responsible manner.,2019_Boston_Scientific_Performance_Report.pdf
Leadership in Energy and Environmental Design (LEED) is an internationally recognized certification program for the environmental performance and sustainable design of buildings.,2019_Boston_Scientific_Performance_Report.pdf
"Boston Scientific now has 14 LEED-certified buildings on campuses in the United States, Central America, Europe and Asia, including our San Jose Baytech site in California, which achieved LEED certification in 2019.",2019_Boston_Scientific_Performance_Report.pdf
"In Sweden, our Helsingborg Office achieved ""Miljöbyggnad” Silver certification from the Sweden Green Building Council, Sweden's largest organization for sustainable community building.",2019_Boston_Scientific_Performance_Report.pdf
Continual improvement in the energy performance of our manufacturing operations has earned ISO certification for five of our manufacturing locations.,2019_Boston_Scientific_Performance_Report.pdf
The company’s two Costa Rica manufacturing sites in Coyol and Heredia have been carbon-neutral since 2016 and received ISO 50001:2011 certification the following year.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, Boston Scientific facilities in Clonmel, Cork and Galway, Ireland achieved ISO 50001:2018 certification.",2019_Boston_Scientific_Performance_Report.pdf
"Our distribution center in Kerkrade, Netherlands maintained its 3rd Lean & Green Star certification, first awarded in 2018 by Europe’s leading program for sustainable logistics.",2019_Boston_Scientific_Performance_Report.pdf
We are one of only nine companies in Europe to receive this award for carbon emissions reduction.,2019_Boston_Scientific_Performance_Report.pdf
"In total, Boston Scientific operates 4.3 million square feet of independently certified green real estate that supports our energy performance and sustainability goals, representing 45 percent of our footprint worldwide.",2019_Boston_Scientific_Performance_Report.pdf
We have committed to achieving carbon neutrality in all of our manufacturing and key distribution sites by 2030.,2019_Boston_Scientific_Performance_Report.pdf
"LEEDing Locations 45% of our global footprint worldwide is green real estate United States San Jose Baytech, California LEED Silver Maple Grove, Minnesota LEED Silver / LEED Certified Marlborough, Massachusetts LEED Gold / LEED Certified Quincy, Massachusetts LEED Silver / LEED Certified Central America Coyol, Costa Rica LEED Silver / ISO 50001:2011 Heredia, Costa Rica ISO 50001:2011 Europe Clonmel, Ireland ISO 50001:2018 Cork, Ireland ISO 50001:2018 Galway, Ireland ISO 50001:2018 Kerkrade, Netherlands LEED Silver / Lean and Green Helsingborg, Sweden Miljöbyggnad Silver Asia Beijing, China LEED Silver / LEED Certified Shanghai, China LEED Silver Penang, Malaysia LEED Silver Singapor e LEED Silver Bost on Scientific 2019 Performance Report 48Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Investing in Renewable Energy Our work to reduce GHG emissions includes investing in renewable energy.",2019_Boston_Scientific_Performance_Report.pdf
"At two of the company's locations in Massachusetts, we have onsite solar installations that generated a combined total of 3.1 million kilowatt-hours of renewable electricity in 2019, resulting in savings of nearly 1,000 metric tons of GHG emissions.",2019_Boston_Scientific_Performance_Report.pdf
"At our Marlborough headquarters and Quincy distribution center, solar energy was responsible for 46 percent and 45 percent of the electricity required to operate, respectively.",2019_Boston_Scientific_Performance_Report.pdf
"Also in Massachusetts, Boston Scientific became the anchor business customer for a new 12.9-megawatt community solar development, a project involving large and small businesses and residential households that will increase access to clean energy across the state.We continue to make progress toward our goal of purchasing 100 percent renewable electricity by 2024.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, our three manufacturing sites in Ireland marked their first full year of operating with certified 100 percent renewable electricity.",2019_Boston_Scientific_Performance_Report.pdf
"Over the course of the year, renewable energy accounted for 11 percent of our energy purchased.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, we executed a virtual power purchase agreement for 100 percent renewable electricity for our U.S. energy needs.",2019_Boston_Scientific_Performance_Report.pdf
"Environmental Impact As a company with a global footprint and global impact, we have a responsibility to carefully manage the materials in our products and packaging, the resources used to manufacture and transport them and what happens to any waste generated.",2019_Boston_Scientific_Performance_Report.pdf
We measure waste generation and water use at our major manufacturing and distribution facilities through the implementation of ISO 14001:2015.,2019_Boston_Scientific_Performance_Report.pdf
"The Boston Scientific plant in Malaysia achieved ISO 14001:2015 certification in 2019, and we now have 16 sites certified to this standard.",2019_Boston_Scientific_Performance_Report.pdf
Waste Management Sustainable waste management continues to be a significant priority for Boston Scientific.,2019_Boston_Scientific_Performance_Report.pdf
We have adopted international best practices and research-based protocols as our teams work to continually make greater progress.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we recycled 80 percent — 8,943 metric tons — of total solid waste.",2019_Boston_Scientific_Performance_Report.pdf
The company’s operations and primary distribution sites recycled or recovered 54 percent of hazardous and regulated waste generated.,2019_Boston_Scientific_Performance_Report.pdf
We also diverted 95 percent of solid waste from landfills.,2019_Boston_Scientific_Performance_Report.pdf
"In addition, we almost met our 10-year environmental goal of an 81 percent recycling rate.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we evaluated our efforts and committed to a 2030 goal of achieving TRUE Zero Waste Certification for our operations and key distribution sites.",2019_Boston_Scientific_Performance_Report.pdf
This certification will create a framework for minimizing non-hazardous solid wastes and maximizing efficiency in the company’s use of resources.,2019_Boston_Scientific_Performance_Report.pdf
"Solar installment at Boston Scientific global headquarters in Marlborough, MassachusettsClearway Energy Group community solar project in Massachusetts Bost on Scientific 2019 Performance Report 49 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Conserving Water We understand the importance of water as a shared resource.",2019_Boston_Scientific_Performance_Report.pdf
"While Boston Scientific operations are not water-intensive, we are committed to minimizing consumption and being prepared for environmental challenges such as water scarcity.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we conducted an assessment of water- related risks and opportunities at all manufacturing and central distribution sites based on local water stress and intensity of water use.",2019_Boston_Scientific_Performance_Report.pdf
"Using the World Resources Institute Aqueduct — a global water risk-mapping tool — we determined that 11 locations are at low overall water-related risk, and six facilities are in the low-to-medium water-related risk category.",2019_Boston_Scientific_Performance_Report.pdf
This effort will expand in 2020 to include the company’s significant commercial operations.,2019_Boston_Scientific_Performance_Report.pdf
Water usage at our manufacturing and major distribution centers is predominantly associated with headcount; only 25 percent of our consumption is associated with production processes.,2019_Boston_Scientific_Performance_Report.pdf
"Even with a 12.5 percent increase in headcount in 2019, we consumed marginally less water than in 2018.",2019_Boston_Scientific_Performance_Report.pdf
"Over the past 10 years, we have reduced water consumption by 30 percent.Recognitions for Sustainability Leadership FTSE4Good Constituent: Boston Scientific earned 2019 certification in the FTSE4Good Corporate Social Responsibility Index, which measures the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.",2019_Boston_Scientific_Performance_Report.pdf
"Chelsea Santucci Greenovation Awards: Boston Scientific sites in Dorado and Maple Grove were honored for their environmental performance and sustainability efforts by Kimberly-Clark Professional.Double Wins: Greenovation Award Our teams in Dorado, Puerto Rico and Maple Grove, Minnesota received 2019 Chelsea Santucci Greenovation Awards for results they achieved as participants in RightCycle, the first large-scale recycling program for non-hazardous laboratory and industrial waste.",2019_Boston_Scientific_Performance_Report.pdf
"Through an intensive effort to collect previously hard-to-recycle nitrile gloves, the Boston Scientific team in Dorado diverted 12,385 pounds of gloves from local landfills and won Greenovation honors for the second year in a row.",2019_Boston_Scientific_Performance_Report.pdf
"In Maple Grove, our employees collected enough nontraditional waste — gloves as well as single-use garments, hoods and boot covers — to divert 35,500 pounds of waste from landfills, winning Greenovation recognition for the fifth consecutive year.",2019_Boston_Scientific_Performance_Report.pdf
"The Greenovation awards were established in 2013 and renamed in 2015 in honor of Chelsea Santucci, a former Kimberly-Clark Professional employee who was instrumental in creating the RightCycle program before dying of cancer at age 26.",2019_Boston_Scientific_Performance_Report.pdf
"Ariel Gonzalez, Boston Scientific EHS manager in Dorado, Puerto Rico, receiving the Greenovation Award from Daniel Perez, Kimberly-Clark representative.30% decrease in water consumption* 80% of total solid waste recycled 95% of solid waste diverted from landfills *Compared to 2009 baseline Bost on Scientific 2019 Performance Report 50 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Green Team Environmental Sustainability Initiatives Boston Scientific Green Team initiatives are inspired and led by employees across the globe.",2019_Boston_Scientific_Performance_Report.pdf
"Every year, they organize and implement projects focused on reducing the company’s environmental footprint and improving the communities where our people live and work.",2019_Boston_Scientific_Performance_Report.pdf
Their efforts help to strengthen our business practices while raising environmental awareness and supporting local partners dedicated to caring for our planet.,2019_Boston_Scientific_Performance_Report.pdf
Our Green Teams continued to embrace sustainability in 2019.,2019_Boston_Scientific_Performance_Report.pdf
"In Kerkrade, Netherlands , employees collected plastic lids and donated the recycling refunds to the Royal Dutch Guide Dog Foundation (KNGF Geleidehonden).",2019_Boston_Scientific_Performance_Report.pdf
"Milan, Italy employees organized an initiative to eliminate complimentary water bottles from workplace common areas.",2019_Boston_Scientific_Performance_Report.pdf
"Similarly, we eliminated water bottles in meeting rooms and kitchens in all of our Latin America sales offices.",2019_Boston_Scientific_Performance_Report.pdf
"The Warsaw, Poland Green Team led an effort to install water dispensers for employees and organized a World Environment Day that included a cleanup day at a local park.",2019_Boston_Scientific_Performance_Report.pdf
"Environmental Wins in Minnesota A newly organized Green Team in Minnetonka, Minnesota made its mark with a series of projects.",2019_Boston_Scientific_Performance_Report.pdf
"They started an onsite volunteer garden, successfully implemented a campaign to eliminate onsite disposable cup use and held a first annual “Ec olympics” to educate employees about the environment.",2019_Boston_Scientific_Performance_Report.pdf
"In May, the team completed a utility-funded energy audit that resulted in an initial 5 percent reduction in electricity use and 17 percent decrease in natural gas use.",2019_Boston_Scientific_Performance_Report.pdf
"The Minnesota Safety Council recognized the team’s efforts with a Meritorious Achievement Award.Cork Green Team Takes to the Shores With the 2019 motto “Our Planet, Our Waters,” the Cork, Ireland Green Team members focused on making local shorelines cleaner and safer.",2019_Boston_Scientific_Performance_Report.pdf
"The team partnered with the Cork Water Harbour Keepers to offer an employee education program about the environmental impact of single-use plastics, then organized volunteers for two local cleanup events.",2019_Boston_Scientific_Performance_Report.pdf
"At the Blackrock Shoreline Clean in June, they picked up litter along a stretch of shore especially popular with walkers and runners.",2019_Boston_Scientific_Performance_Report.pdf
"In August, at Carrigrenan beach in Little Island — where water pollution can make swimming unsafe — they turned out with family and friends to clear the high volume of waste washed ashore.Clean and Green in Valencia The Boston Scientific Green Team in Valencia, California devoted their time to support two ambitious ecosystem initiatives.",2019_Boston_Scientific_Performance_Report.pdf
"In Santa Clarita, they joined the volunteer ranks of the 10th annual Earth Arbor Day tree-planting crews, taking shovels to the ground at the city’s Central Park to plant 10 eight-foot trees.",2019_Boston_Scientific_Performance_Report.pdf
"In Santa Monica, the Valencia Green Team worked alongside more than 13,500 volunteers for the 35th annual Coastal Cleanup Day, an effort that diverted 30,165 pounds of waste from the aquatic ecosystems of oceans and waterways.",2019_Boston_Scientific_Performance_Report.pdf
"Keeping Our Planet Clean In 2019, Boston Scientific employees volunteered their time to support efforts to preserve beaches and habitats and protect local ecosystems.",2019_Boston_Scientific_Performance_Report.pdf
Green Teams also developed environmental education campaigns and introduced additional green practices within the company.,2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 51 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Our P ractices 52 Compliance, Ethics and Integrity 55 Developing Innov ative Products 57 Innov ation Initiatives 58 Quality and Safety 61 Sustainable Supply Chain 62 Responsible Marketing 62 Customer Relationship Management 63 Packaging and Labeling 64 Supporting Small Business and Supplier Diversity Boston Scientific employees help inspire the next generation of innovators through the Little Doctors program in Guangzhou, China.Every day, Boston Scientific is... committing to responsible practices.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 52Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Our business practices support and ensure our company’s worldwide focus on quality, safety and sustainability as we deliver meaningful innovations that make a difference in patients' lives.",2019_Boston_Scientific_Performance_Report.pdf
We operate with a culture of integrity; we believe in strong corporate governance; and we insist on impeccable ethics and regulatory compliance.,2019_Boston_Scientific_Performance_Report.pdf
"Compliance, Ethics and Integrity Boston Scientific employees have a shared commitment to: Act honestly and ethically in all company matters Protect the privacy of patients, customers and employees Treat one another with respect and fairness Hold one another accountable to ensure quality in all that we do Our Global Compliance team provides employees with the resources and training they need to do business with integrity, treat customers and suppliers fairly, and report ethics concerns when they arise.",2019_Boston_Scientific_Performance_Report.pdf
"Led by our Chief Compliance Officer, the team collaborates across the company to monitor our activities and performance.",2019_Boston_Scientific_Performance_Report.pdf
"The Chief Compliance Officer reports quarterly to the Audit Committee of our Board of Directors and more frequently as needed.Code of Conduct for Employees and Channel Partners Every Boston Scientific employee is required to read and understand our Code of Conduct, which is the foundation for all of our business practices and relationships.",2019_Boston_Scientific_Performance_Report.pdf
Employees also complete multiple mandatory training curriculums that explain company policies and corruption- and compliance-related risks and point them to resources where they can report concerns.,2019_Boston_Scientific_Performance_Report.pdf
Our training offers scenario-based content to help prepare people to respond ethically to issues that may arise in their daily work.,2019_Boston_Scientific_Performance_Report.pdf
"The global marketplace in which we compete is advancing rapidly, and our workforces in many countries are continually adapting to new developments in technology, public policies and the environment.",2019_Boston_Scientific_Performance_Report.pdf
"In a world of c onstant change , it’s increasingly important that we provide our people with clear guidance about how to handle ethical challenges.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we completed a year-long effort to update the Boston Scientific Code of Conduct.",2019_Boston_Scientific_Performance_Report.pdf
Changes range from additional language about our Corporate Social Responsibility (CSR) commitment to expanded provisions on conflicts of interest and patient and data privacy.,2019_Boston_Scientific_Performance_Report.pdf
"The updated Code of Conduct went into effect on January 1, 2020.",2019_Boston_Scientific_Performance_Report.pdf
It is available online in 21 languages.,2019_Boston_Scientific_Performance_Report.pdf
"Code of Conduct Changes The 2020 update of our Code of Conduct includes: New language about CSR — what it means for us at Boston Scientific and our responsibility as a global citizen Greater specificity about respecting patient, customer and employee privacy and additional explanations about ethical and legal requirements New language about the importance of maintaining a safe and healthy work environment and what that means in practice Additional emphasis on data privacy and protecting confidential company information Expanded information on conflicts of interest and potential conflicts that must be disclosed Our compliance training is comprehensive.",2019_Boston_Scientific_Performance_Report.pdf
"It includes customer interactions training to provide guidance on the laws, policies and processes for working with licensed healthcare professionals in the U.S.",2019_Boston_Scientific_Performance_Report.pdf
"The curriculum also includes anti-corruption training that explains compliance require- ments for interacting with healthcare professionals, public officials and other third parties, including channel partners (e.g., distributors, dealers and agents) outside the U.S.Additional global ethics initiatives include sexual harassment training for all our salesforce managers as well as training for our Human Resources team on local and national laws that govern employment compensation, sexual harassment and discrimination.Our Practices Bost on Scientific 2019 Performance Report 53 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations The Boston Scientific Channel Partner Code of Conduct details our expectations for channel partners doing business on our behalf.",2019_Boston_Scientific_Performance_Report.pdf
All channel partners complete mandatory onboarding training as well as annual ethics training in which they pledge to adhere to our Code of Conduct.,2019_Boston_Scientific_Performance_Report.pdf
"They are also required to abide by national anti-bribery and anti-corruption laws, such as the U.S. Foreign Corrupt Practices Act and the U.K.",2019_Boston_Scientific_Performance_Report.pdf
Bribery Act.,2019_Boston_Scientific_Performance_Report.pdf
Our third-party program to monitor and support channel partners includes onsite auditing and other procedures that verify their compliance with our requirements.Compliance Program Strong alignment with the Boston Scientific Code of Conduct requires a shared sense of integrity among employees throughout the company.,2019_Boston_Scientific_Performance_Report.pdf
"We have a comprehensive compliance program to prevent, detect and respond to any conduct or situation that does not fully conform with the Code of Conduct.",2019_Boston_Scientific_Performance_Report.pdf
"Advice Line As stated in the Boston Scientific Code of Conduct, all employees are responsible for imme diately reporting any suspected violation of the code or company policy.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we expanded efforts to promote our Advice Line through an internal campaign (see side bar).",2019_Boston_Scientific_Performance_Report.pdf
"T he t oll-free service is operated by a third party and is available 24 hours a day, seven days a week, in multiple languages.",2019_Boston_Scientific_Performance_Report.pdf
Our Non-Retaliation Policy is an essential component of our Compliance Program.,2019_Boston_Scientific_Performance_Report.pdf
"It prohibits any form of retaliation, direct or indirect, against an individual who raises a concern in good faith.",2019_Boston_Scientific_Performance_Report.pdf
"This protection extends to anyone who assists with, or cooperates in, an investigation or report of misconduct.",2019_Boston_Scientific_Performance_Report.pdf
Governance The Boston Scientific Board of Directors and Executive Committee oversee all aspects of our role as a corporate citizen.,2019_Boston_Scientific_Performance_Report.pdf
"These leaders and directors play a critical part in implementing guidelines to ensure we act ethically in our business practices, comply with all tax and business laws and regulations, and remain transparent in our reporting.",2019_Boston_Scientific_Performance_Report.pdf
"The Board maintains charters for its governing committees, which meet regularly to discuss their respective areas of focus.",2019_Boston_Scientific_Performance_Report.pdf
"The Board’s committees in 2019 were the Audit Committee, Executive Compensation and Human Resources Committee, Finance Committee, and Nominating and Governance Committee.",2019_Boston_Scientific_Performance_Report.pdf
“ Our c aring value reminds us to uphold the Boston Scientific mission in a way that is fair and considerate to everyone.,2019_Boston_Scientific_Performance_Report.pdf
"This includes treating our customers, colleagues and competitors with respect.",2019_Boston_Scientific_Performance_Report.pdf
"It also means always acting with integrity and ensuring our business decisions and relationships embody that integrity.” — Desiree Ralls-Morrison, Boston Scientific Senior Vice President, General Counsel and Corporate Secretary New Communications Initiatives We launched new global employee communications initiatives in 2019 to increase transparency and expand aware- ness of our compliance activities and resources.",2019_Boston_Scientific_Performance_Report.pdf
"Our global Boston Scientific newsletter includes an “Int egrity Corner” segment that features real-world examples of ethical challenges, describes what happens when an ethics concern is reported and an overview of compliance activity.",2019_Boston_Scientific_Performance_Report.pdf
We also introduced an “Open Doors” campaign to help managers handle ethics issues raised by their direct reports.,2019_Boston_Scientific_Performance_Report.pdf
"In addition, we conducted an all-employee ethics survey to gauge employees’ understanding of — and confidence in — how the company deals with ethical concerns.",2019_Boston_Scientific_Performance_Report.pdf
The results were reported across the company and will inform future compliance efforts.,2019_Boston_Scientific_Performance_Report.pdf
"Boston Scientific Chairman and CEO, Mike Mahoney, participating in an integrity awareness event at the Marlborough, Massachusetts global headquarters in 2019.",2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 54In 2019, our Board and stockholders approved and adopted two by-law provisions that reflect best practices and input from stockholder engagement.",2019_Boston_Scientific_Performance_Report.pdf
"Majority Vote Standard in Uncontested Elections: Under this standard, director nominees must receive a majority of votes to be elected.",2019_Boston_Scientific_Performance_Report.pdf
"An increasing number of S&P 500 companies have adopted this corporate governance best practice, and our Board believes it will enhance accountability to stockholders.",2019_Boston_Scientific_Performance_Report.pdf
Proxy Access: This new by-law permits stockholders who meet certain ownership requirements to include a nominee for director election in the company’s annual proxy statement.,2019_Boston_Scientific_Performance_Report.pdf
The Board expects the change will enhance stockholder rights and increase the company’s accountability to stockholders.,2019_Boston_Scientific_Performance_Report.pdf
"Enterprise Risk Management Under the oversight of our Board of Directors, the company’s Enterprise Risk Management (ERM) team supports company leadership with background and guidance on issues that could affect the achievement of performance objectives.",2019_Boston_Scientific_Performance_Report.pdf
"ERM team members analyze strategic, operational, financial, legal and compliance risks to ensure we can adapt to challenges, seize opportunities to help patients and deliver on our commitments to stockholders.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations As warranted, the ERM team, led by our Chief Audit Officer, communicates with the Board and management to discuss enterprise-level issues that present potential obstacles to preserving and growing stockholder value.",2019_Boston_Scientific_Performance_Report.pdf
"According to the company’s escalation framework, any matter that presents a potential risk to the company’s financial results, operations or reputation is reported by management to one or more members of the Board.",2019_Boston_Scientific_Performance_Report.pdf
"Global Security Our Global Security and Resilience team provides solutions that promote enterprise resiliency while protecting our people, profitability and operations.",2019_Boston_Scientific_Performance_Report.pdf
"The team uses a combination of industry-standard protocols and global situational awareness to manage our security posture and maintain a Global Security Operations Center 24 hours a day, seven days a week.",2019_Boston_Scientific_Performance_Report.pdf
"Efforts to continuously protect and enhance physical security and cybersecurity are supported by a network of partners who specialize in facilities, IT security, environment, health and safety, global regulation and data privacy.",2019_Boston_Scientific_Performance_Report.pdf
The company’s global security and resilience experts also lead a business continuity program and resiliency working group.,2019_Boston_Scientific_Performance_Report.pdf
"To maximize operational resiliency across global operations, our facilities are prepared to address emergency response, enterprise business continuity and crisis management.Political Involvement and Contributions Boston Scientific supports public policies that promote diversity and inclusion and improve our employees’ lives, the patients we serve and the communities where we live.",2019_Boston_Scientific_Performance_Report.pdf
We advocate responsibly and transparently for inclusive policies that focus on increasing patient access to life-changing and life-saving technologies.,2019_Boston_Scientific_Performance_Report.pdf
"The company shares annual updates on contributions t o politic al action c ommittees, corporate contributions to state officials, and memberships in associations that engage in public policy advocacy.",2019_Boston_Scientific_Performance_Report.pdf
"To promote the advancement of sound public policy, the Boston Scientific Corporation Political Action Committee (PAC) facilitates voluntary political contributions by eligible employees and our Board of Directors in accordance with federal law.",2019_Boston_Scientific_Performance_Report.pdf
"While the PAC supports our company values, it accepts no corporate contributions.",2019_Boston_Scientific_Performance_Report.pdf
The PAC is run by a governing board of senior employees who represent our primary businesses and functions.,2019_Boston_Scientific_Performance_Report.pdf
"The Nominating and Governance Committee of our Board of Directors annually reviews political contributions made by our company and the PAC.In partnership with our global Employee Resource Groups (ERGs), in 2019 we developed new measures for assessing PAC contributions to candidates and efforts that support our core values.",2019_Boston_Scientific_Performance_Report.pdf
"As part of this work, we updated selection criteria to include a candidate’s character and integrity.",2019_Boston_Scientific_Performance_Report.pdf
"All donations also now include a letter that emphasizes our company’s core values, including the importance of diversity and inclusion.",2019_Boston_Scientific_Performance_Report.pdf
"Boston Scientific PAC contributions are bipartisan and based on the following criteria: Candidate sits on a congressional committee with jurisdiction over issues affecting our business Candidate serves in elected leadership within Congress or in a position that shapes public policy Candidate represents a district or state with a Boston Scientific facility Candidate’s voting record supports key issues affecting Boston Scientific Candidate’s character and integrity, including his or her statements and positions, do not conflict with the company’s core values Bost on Scientific 2019 Performance Report 55 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Human Rights At Boston Scientific, we believe that corporations have a responsibility to respect and protect human rights.",2019_Boston_Scientific_Performance_Report.pdf
We support the United Nations (UN) International Bill of Rights and its founding principles.,2019_Boston_Scientific_Performance_Report.pdf
"The International Bill of Human Rights consists of: the Universal Declaration of Human Rights, the International Covenant on Economic, Social and Cultural Rights, the International Covenant on Civil and Political Rights and its two Optional Protocols.",2019_Boston_Scientific_Performance_Report.pdf
"We adhere to all applicable labor and human rights laws, including those related to slavery, child labor, human trafficking, bribery, discrimination, harassment and pay equity.",2019_Boston_Scientific_Performance_Report.pdf
We require that our third-party partners do as well.,2019_Boston_Scientific_Performance_Report.pdf
"Our company’s efforts to uphold and protect human rights include support for the rights of children to have access to education, health care and protection from criminal behavior.",2019_Boston_Scientific_Performance_Report.pdf
We take the necessary steps to ensure that forced labor and human trafficking do not take place in our business or supply chains.,2019_Boston_Scientific_Performance_Report.pdf
"In addition, we adhere to local and national human rights laws and regulations, including disclosure requirements under the California Supply Chain Transparency Act and the U.K. Modern Slavery Act.Developing Innovative Products Boston Scientific maintains a steadfast focus on delivering services and solutions to address the healthcare challenges that matter most to patients and customers.",2019_Boston_Scientific_Performance_Report.pdf
We foster creativity and collaboration so our people can continually pursue and develop life-changing innovations.,2019_Boston_Scientific_Performance_Report.pdf
Our teams collaborate inside and outside the c ompany to design and champion solutions that will make patients’ lives better.,2019_Boston_Scientific_Performance_Report.pdf
Approach Our new product development teams follow the Product Life Cycle Process methodology.,2019_Boston_Scientific_Performance_Report.pdf
"This global pr ocess int egrates business, technical and quality-system tasks to support a uniform and transparent development approach company wide.",2019_Boston_Scientific_Performance_Report.pdf
"The result is a robust capacity for driving breakthrough ideas from concept through commercialization to product end-of-life.We have research and development (R&D) sites in the U.S., Puerto Rico, European Union, Costa Rica, India and China.",2019_Boston_Scientific_Performance_Report.pdf
"Some of these sites also serve as R&D Centers of Excellence with specific focus, expertise and capabilities that are shared across our global development network.",2019_Boston_Scientific_Performance_Report.pdf
Pre-Clinical Sciences Boston Scientific conducts extensive pre-clinical research into the safety and efficacy of our medical devices before progressing to human clinical trials.,2019_Boston_Scientific_Performance_Report.pdf
"Our pre-clinical research and science policies set stringent standards that govern our training practices, product testing and regulatory compliance.Biocompatibility and toxicology play a pivotal role in medical device development.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we expanded our Global Biocom- patibility and Toxicology group to advance our product development expertise, streamline capabilities and improve our agility in responding to regulatory changes.",2019_Boston_Scientific_Performance_Report.pdf
This expansion will continue in 2020 to reflect ongoing innovations in the company’s product development pipeline.,2019_Boston_Scientific_Performance_Report.pdf
Ensuring that we meet the highest safety standards in all new products and therapies sometimes calls for animal testing in our R&D efforts.,2019_Boston_Scientific_Performance_Report.pdf
"When we use new materials in medical devices, the U.S. Food and Drug Administration (FDA) may require evidence of pre-clinical animal testing before starting human clinical trials.",2019_Boston_Scientific_Performance_Report.pdf
Boston Scientific is committed to the humane care and treatment of laboratory animals.,2019_Boston_Scientific_Performance_Report.pdf
"We use alternative testing when- ever such methods are feasible, scientifically valid and appropriate.",2019_Boston_Scientific_Performance_Report.pdf
"Our pre-clinical research personnel are highly trained professionals with multiple certifications, and our facilities meet or exceed applicable laws and regulatory requirements, guide- lines and standards.",2019_Boston_Scientific_Performance_Report.pdf
"We are routinely audited by internal experts and relevant government agencies, including the FDA, U.S. Department of Agriculture (USDA) and the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).Our practices reflect the basic tenet of the International Bill of Human Rights: “ All human beings ar e born free and equal in dignity and rights.",2019_Boston_Scientific_Performance_Report.pdf
They are endowed with reason and conscience and should act towards one another in a spirit of brotherhood.” UN International Bill of Rights Bost on Scientific 2019 Performance Report 56 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Clinical Trials Scientifically rigorous clinical trials and the data they generate are essential to document the safe and effective use of our products.,2019_Boston_Scientific_Performance_Report.pdf
An internal Clinical Data Task Force led a 2019 effort to strengthen our advanced analytics capabilities by adopting unified trial data definitions.,2019_Boston_Scientific_Performance_Report.pdf
We also expanded the information technology infrastructure that supports all clinical trials.,2019_Boston_Scientific_Performance_Report.pdf
"With a significant investment in new research tools, we implemented our strategy to meet and exceed European Union Medical Device Regulation (EU MDR) standards.",2019_Boston_Scientific_Performance_Report.pdf
We also made operational enhancements to support EU General Data Protection Regulation (GDPR) compliance and International Organization for Standardization (ISO) excellence.,2019_Boston_Scientific_Performance_Report.pdf
"Also in 2019, we piloted an initiative, called the start-up Center of Excellence (COE), to identify practices used in the earliest stages of successful clinical trials and apply them seamlessly across all trials.",2019_Boston_Scientific_Performance_Report.pdf
The new framework will support future trial start-ups through a centralized COE team of start-up experts and proven best practices.,2019_Boston_Scientific_Performance_Report.pdf
"We conducted 115 active trials in 2019, enrolling nearly 5,000 patients globally.“ Mor e than 40 years of experience in developing medical devices has shown us that the path to innovation is complex.",2019_Boston_Scientific_Performance_Report.pdf
"The collaboration between Mayo Clinic and Boston Scientific supports our shared goal of advancing patient-centered innovation.” — Mike Mahoney, Boston Scientific Chairman and CEO Accelerating Innovation Through Meaningful Collaboration To solve the toughest healthcare challenges, we rely on our ability to iterate quickly, collaborate and take informed risks while ensuring that quality and patient safety are our primary focus.",2019_Boston_Scientific_Performance_Report.pdf
"For nearly a decade, engineering and clinical teams from Boston Scientific and the Mayo Clinic have worked side-by-side to discover and develop new life-changing solutions.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, the Mayo Clinic and Boston Scientific announced a new joint innovation accelerator called Motion Medical.",2019_Boston_Scientific_Performance_Report.pdf
"Located in Rochester, Minnesota, Motion Medical focuses on developing minimally invasive treatments for conditions that impede quality and longevity of life.",2019_Boston_Scientific_Performance_Report.pdf
"This includes early-stage medical technologies for interventional cardiology, heath rhythm management, endoscopy, neuromodulation and urology.",2019_Boston_Scientific_Performance_Report.pdf
"Gianrico Farrugia, MD, president and CEO of Mayo Clinic, and Mike Mahoney, chairman and CEO, Boston Scientific, at the Motion Medical ribbon cutting ceremony.",2019_Boston_Scientific_Performance_Report.pdf
Bost on Scientific 2019 Performance Report 57Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Breakthrough Ideas Innovation can come from anyone and anywhere in the company.,2019_Boston_Scientific_Performance_Report.pdf
The annual Boston Scientific ImagineIF program takes a venture-style approach to funding bold ideas from our employees.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, the company funded seven new projects through this program, including Artificial Intelligence (AI)-driven algorithms to improve diagnostic processes and a machine-learning model to analyze manufacturing and testing patterns.",2019_Boston_Scientific_Performance_Report.pdf
"Since 2014, ImagineIF has resulted in 52 funded projects and more than 20 patent filings, all above and beyond the ongoing work of our research and development teams and planned product pipeline projects.",2019_Boston_Scientific_Performance_Report.pdf
"Recognize Success At the 12th annual Boston Scientific Recognize Success event , we celebrated the collective work of thousands of our employees.",2019_Boston_Scientific_Performance_Report.pdf
"More than 50 leaders and their teams were honored for their roles in improving quality, patient care and value for the business.",2019_Boston_Scientific_Performance_Report.pdf
"Develop Excellence Every year, our Recognize Development Excellence program identifies and rewards Boston Scientific cross-functional teams who work together to develop meaningful medical innovations for customers and patients.",2019_Boston_Scientific_Performance_Report.pdf
Idea Portal We invite original ideas from customers and innovators outside of the company.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, our external Idea Portal received more than 80 submissions from physicians and academic institutions worldwide.",2019_Boston_Scientific_Performance_Report.pdf
Two innovators were selected to enter medical device exploratory programs.,2019_Boston_Scientific_Performance_Report.pdf
“ The C onnected Patient Challenge fosters dialogue and strengthens relationships in the digital health community that will accelerate the pace of change.,2019_Boston_Scientific_Performance_Report.pdf
"The energy of the exchanges will fuel our continued commitment to enhance patient care — that is the most satisfying outcome of all.” — Jodi Euerle Eddy, Boston Scientific Senior Vice President and CIODigital Health In September 2019, Boston Scientific, in partnership with Google, launched the fifth Connected Patient Challenge.",2019_Boston_Scientific_Performance_Report.pdf
This external innovation competition focused on future digital health solutions that can manage chronic health conditions.,2019_Boston_Scientific_Performance_Report.pdf
"Inventors and entrepreneurs uploaded their proposals, with a record number of entrants submitting new product ideas.",2019_Boston_Scientific_Performance_Report.pdf
The Nutrimedy telenutrition platform won the challenge.,2019_Boston_Scientific_Performance_Report.pdf
"BreathResearch received runner-up honors for its mobile technology to detect the early signs of respiratory attacks.Innovation Initiatives Bost on Scientific 2019 Performance Report 58 Digital Health Advances made by our Digital Health teams allow us to secure, connect and use data in new ways to benefit patients and customers through predictive analytics and tools for care coordination.",2019_Boston_Scientific_Performance_Report.pdf
One example of this work is the AI behind our HeartLogic™ Heart Failure Diagnostic.,2019_Boston_Scientific_Performance_Report.pdf
"The first and only diagnostic of its kind, HeartLogic can predict worsening heart failure events weeks before they happen, giving physicians critical time to act.",2019_Boston_Scientific_Performance_Report.pdf
"We also made new progress in pain management through our partnership with IBM Research, using patient data to develop an objective measure for pain that we hope will lead to highly personalized therapies.",2019_Boston_Scientific_Performance_Report.pdf
Our digital health offerings also include safe and secure methodologies for smarter management of patient data.,2019_Boston_Scientific_Performance_Report.pdf
We developed the Boston Scientific MyLATITUDE™ app so patients with subcutaneous implantable defibrillators (S-ICD) can easily monitor their heart data on personal mobile devices.,2019_Boston_Scientific_Performance_Report.pdf
We have also equipped healthcare providers with tools and applications to help them optimize their care processes by quickly and securely integrating their data.,2019_Boston_Scientific_Performance_Report.pdf
"Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations “ This is the true pr omise of digital health: a future in which connected smart devices, the Internet of Things and predictive digital diagnostics come together to drive better, faster actions for providers and patients alike.",2019_Boston_Scientific_Performance_Report.pdf
"Stay tuned… the future is nearer than you think.” — David Feygin, Boston Scientific Chief Digital Health Officer 2019 Innovation and Product Awards Edison Awards: The Boston Scientific LithoVue Empower™ Retrieval Deployment Device won silver, and the AXIOS™ Stent and Electrocautery Enhanced Delivery System earned bronze for Best New Products in the Medical Field category.",2019_Boston_Scientific_Performance_Report.pdf
"Shingo Prize: Our Coyol, Costa Rica facility received the 2019 Shingo Prize for operational excellence and demonstrating a c ommitment t o continuous improvement.",2019_Boston_Scientific_Performance_Report.pdf
Top 100 Global Innovator: Boston Scientific was honored by Derwent as a Top 100 Global Innovator for the third consecutive year.,2019_Boston_Scientific_Performance_Report.pdf
"MDEA (Medical Design Excellence Awards): Our LithoVue Empower™ Retrieval Deployment Device won silver for Gastrointestinal and Genitourinary Devices; the Eluvia™ Drug-Eluting Vascular Stent earned bronze in the Drug-Delivery and Combination Products category.Quality and Safety Innovative, high-quality and safe products that break new ground can make all the difference in patient outcomes.",2019_Boston_Scientific_Performance_Report.pdf
"We continually strive to exceed expectations with customer-centric, quality solutions that transform patient lives.",2019_Boston_Scientific_Performance_Report.pdf
"Our global quality and safety efforts are supported by: Quality Systems training for all employees A Quality master plan that prioritizes quality improvement projects, leading to higher quality products and better patient outcomes Our global Quality system that integrates customer feedback and regulatory requirements into our processes The Boston Scientific Best4 strategy (see next page) for delivering industry- leading performance Our commitment to quality begins with the one-line Quality Policy that is highly visible in our facilities: “ I impr ove the quality of patient care and all things Boston Scientific.” Bost on Scientific 2019 Performance Report 59Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Best4 Strategy The quality materials we use are vital to our manufacturing decisions as we develop safe and effective products.",2019_Boston_Scientific_Performance_Report.pdf
"Teams across the company carefully assess component and device materials and consider a range of factors, from efficiency and availability to worldwide medical and environmental requirements and regulations.",2019_Boston_Scientific_Performance_Report.pdf
"Strategic Quality Process (SQP) Our manufacturing process requirements reflect the Boston Scientific Corporation Quality Policy and our SQP, which evolves year-over-year, and encompasses:Best4 underpins every Boston Scientific process, including product development.",2019_Boston_Scientific_Performance_Report.pdf
"Our teams rely on a global design controls process, risk assessment and usability engineering to create safe and effective solutions from new technologies.",2019_Boston_Scientific_Performance_Report.pdf
"At every stage of development, we are focused on the unmet needs of patients who will benefit from our products.",2019_Boston_Scientific_Performance_Report.pdf
"For example, employees are encouraged to spend time in the field, observing procedures and talking with patients and healthcare providers.",2019_Boston_Scientific_Performance_Report.pdf
Operational strategy How we execute our work Our pursuit of continuous improvement How we measure performance Recognition and engagement Every manufacturing site across the business develops its own customized SQP to support the facility’s focus and performance objectives.,2019_Boston_Scientific_Performance_Report.pdf
"The cohesion of quality within our culture is reinforced by consistent, direct linkages between individual site SQPs and our overarching corporate SQP.“ Our Best4 Strategy ensures patient safety is always our top priority.” — Roz Burke, Boston Scientific Senior Vice President, Global Quality and Regulatory Best Culture: Together, we sustain a culture that makes the Quality Policy real for every employee.",2019_Boston_Scientific_Performance_Report.pdf
"We reinforce the importance of everyone’s role in improving patient lives, and we sustain a diverse, winning quality team that lives our core values.",2019_Boston_Scientific_Performance_Report.pdf
"Best Agility: We add value by reducing complexity, removing obstacles and adapting to changing business needs.",2019_Boston_Scientific_Performance_Report.pdf
This means having intentional simplicity in our systems as well as lean practices and the right technology for process efficiency.,2019_Boston_Scientific_Performance_Report.pdf
"Best Performance: For our teams, best performance means developing and making the best products, services and solutions for patients and customers.",2019_Boston_Scientific_Performance_Report.pdf
Quality by Design and Continuous Improvement are core foundations of this work.,2019_Boston_Scientific_Performance_Report.pdf
Best Compliance: We follow and comply with global laws and regulations with one global Quality System.,2019_Boston_Scientific_Performance_Report.pdf
This work includes ongoing risk mitigation and an effective transition to the EU MDR.,2019_Boston_Scientific_Performance_Report.pdf
"Our Quality Policy is complemented by our Quality Mission , which states: “ W e exceed expectations with customer-centric quality solutions that transform patient lives.” Bost on Scientific 2019 Performance Report 60Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Our Latest Quality Initiatives We take on targeted quality and compliance projects every year with a focus on continuous improvement.",2019_Boston_Scientific_Performance_Report.pdf
"Highlights of our 2019 accomplishments include: Implementing a global usability, risk management and design-controls process to harmonize best practices for product design and performance Completing work to prepare our Quality System for meeting new EU MDR requirements Further supporting acquisition integration activities with the launch of an online Quality and Operations Acquisition Integration Roadmap Strengthening our medical device cybersecurity protocols in accordance with FDA guidance Investing in additional improvements in Post-Market Quality Assurance that further enhance our Post-Market Surveillance capabilitiesCultivating Quality in Our Culture with Everyone Makes an Impact Events Our annual Everyone Makes an Impact events take place at Boston Scientific sites around the world.",2019_Boston_Scientific_Performance_Report.pdf
These onsite employee gatherings bring our quality policy to life through the stories and experiences of patients who have benefited from our devices.,2019_Boston_Scientific_Performance_Report.pdf
"Indira Quirós: In Heredia, Costa Rica, Indira talked with our team about how she suffered from Wolff-Parkinson-White syndrome,1 a rare congenital heart disorder involving an extra electrical pathway that results in abnormal heartbeat, with symptoms including tachyarrhythmia that could result in sudden death.",2019_Boston_Scientific_Performance_Report.pdf
She underwent a procedure that used three devices made by our Heredia team.,2019_Boston_Scientific_Performance_Report.pdf
"Indira’s heart surgeons used the Dynamic XT™ and VIKING™ catheters to diagnose her condition, then implanted the BLAZER™ II catheter to treat her cardiac ablation.",2019_Boston_Scientific_Performance_Report.pdf
She traveled from Nic aragua t o me et the 14 0 employe es who work ed t ogether on the devices that dramatically improved her prognosis and quality of life.,2019_Boston_Scientific_Performance_Report.pdf
"Indira has resumed her regular activities and is enjoying a healthy, active life with her two children.",2019_Boston_Scientific_Performance_Report.pdf
"Indira posing with the 140 Boston Scientific employees who worked on the devices used in her diagnosis and treatment.Meho Temim: After being diagnosed with Sick sinus syndrome,2 a group of heart rhythm problems in which the heart’s natural pacemaker does not work properly, Meho was implanted with a Boston Scientific Accolade™ MRI EL pacemaker.",2019_Boston_Scientific_Performance_Report.pdf
"F or t his d edicated member of our Electrophysiology development te am i n A rden H ills, Minnesota, the successful treatment hit close to home.",2019_Boston_Scientific_Performance_Report.pdf
"“It’ s a nice feeling to know you have a device that you can count on,” he told his colleagues at our 2019 event in Minnesota.",2019_Boston_Scientific_Performance_Report.pdf
"“My coworkers and I built my pacemaker with the highest quality standards in the world, and I’m proud of that.” Meho being interviewed at the Arden Hills, Minnesota Everyone Makes an Impact event by David Thompson, Boston Scientific Vice President, Clinical Solutions, Cardiac Rhythm Management.",2019_Boston_Scientific_Performance_Report.pdf
"1 ""Wolff Parkinson White Syndrome.""",2019_Boston_Scientific_Performance_Report.pdf
Rare Disease Database.,2019_Boston_Scientific_Performance_Report.pdf
"https://rarediseases.org/rare-disease/wolff-parkinson-white-syndrome/2 ""Sick sinus syndrome.""",2019_Boston_Scientific_Performance_Report.pdf
Mayo Clinic.,2019_Boston_Scientific_Performance_Report.pdf
"https://www.mayoclinic.org/diseases-conditions/sick-sinus-syndrome/symptoms-cause/syc-20377554 Bost on Scientific 2019 Performance Report 61 Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Sustainable Supply Chain Our manufacturing and supply chain teams lead the company’s efforts t o p lan, source, m anufacture and distribute more than 15,000 products with the potential to improve or save lives.",2019_Boston_Scientific_Performance_Report.pdf
"In this work, we collaborate with leading suppliers to provide a reliable supply of high-quality products to customers and patients in all regions globally.",2019_Boston_Scientific_Performance_Report.pdf
"We use a strategic quality process to prioritize, execute and monitor our manufacturing and supply chain.To maintain the highest-quality component supply, we take a rigorous risk manage - ment approach as we select supply chain partners.",2019_Boston_Scientific_Performance_Report.pdf
Our sourcing team assesses risk to ensure that long-term suppliers share our quality standards and customer focus as well as our values.,2019_Boston_Scientific_Performance_Report.pdf
The logistics experts on our supply chain team facilitate planning across divisions and regions as they monitor progress and adapt to meet evolving customer and patient needs.,2019_Boston_Scientific_Performance_Report.pdf
Setting Industry Standards Boston Scientific collaborates with trade associations and regulatory bodies around the world to set new standards in quality and remain informed and agile about new and changing regulatory requirements.,2019_Boston_Scientific_Performance_Report.pdf
We make it a priority to help influence industry and regulatory approaches to quality as we share the best practices behind our patient-focused systems.,2019_Boston_Scientific_Performance_Report.pdf
"FDA Digital Health: Through the FDA Digital Health Precertification Program, Boston Scientific completed a 2019 assessment that confirmed the high quality of our Digital Health product development process.",2019_Boston_Scientific_Performance_Report.pdf
"As a result, we now have access to program benefits such as expedited regulatory approval pathways for new and innovative devices.",2019_Boston_Scientific_Performance_Report.pdf
"Industry Leadership: In 2019, we continued to identify and prioritize opportunities to expand the leadership and influence of Boston Scientific in priority areas.",2019_Boston_Scientific_Performance_Report.pdf
"These include medical device user fee negotiations, regulatory submission initiatives such as the FDA Safer Technologies Program (STeP), and collaborative efforts such as the National Evaluation System for health Technology (NEST).",2019_Boston_Scientific_Performance_Report.pdf
"FDA Case for Quality: As a participant in the FDA Case for Quality Voluntary Improvement Program (VIP), five Boston Scientific manufacturing sites have undergone quality system maturity appraisals to drive continuous improve- ment and organizational excellence.",2019_Boston_Scientific_Performance_Report.pdf
Significant benefits of the program include expedited manufacturing change approvals and a streamlined FDA inspection schedule.,2019_Boston_Scientific_Performance_Report.pdf
Measuring and Monitoring Quality and Compliance Effectiveness We regularly conduct internal audits to verify that our Global Quality System conforms to internal and external require- ments and is effectively implemented and maintained.,2019_Boston_Scientific_Performance_Report.pdf
"As we plan and execute our internal audits, we conduct follow-up activities, including re-auditing prior observations and verifying actions taken.",2019_Boston_Scientific_Performance_Report.pdf
"External regulatory agencies also review our performance to ensure quality and compliance, with the following results in 2019: External regulatory inspections* 87 Percent external regulatory inspections resulting in no findings* 79% Average findings per external regulatory Inspection* 0 .35 Average findings per FDA inspection 0 * Includes Notified Body, Competent Authority, FDA Bost on Scientific 2019 Performance Report 62Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Product Performance Boston Scientific reviews customer feedback and monitors their experiences with our devices.",2019_Boston_Scientific_Performance_Report.pdf
This information provides valuable inputs for our Quality system as well as future product iterations and innovations.,2019_Boston_Scientific_Performance_Report.pdf
We follow our Corrective and Preventative Action process to collect and analyze data that can help identify root causes for potential quality and compliance issues.,2019_Boston_Scientific_Performance_Report.pdf
Our teams are then able to address potential problems and prevent future issues or recurrences.,2019_Boston_Scientific_Performance_Report.pdf
"We initiate field actions (product advisories, product advisory updates, product retrievals), including follow-up and closure, to ensure that regulatory or field safety issues are resolved quickly and effectively.",2019_Boston_Scientific_Performance_Report.pdf
"In 2019, Boston Scientific had zero Class I recalls and zero open FDA warning letters.Responsible Marketing Our company has a firm commitment to ethical and responsible marketing and promotion throughout the business.",2019_Boston_Scientific_Performance_Report.pdf
Our Code of Conduct and all other related employee policies emphasize the impor- tance of fair and honest communications with patients and customers.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we spent nearly $1 million on company-wide programs that provided almost 13,000 hours of training for customer-facing employees on a range of integrity topics.",2019_Boston_Scientific_Performance_Report.pdf
"The curriculum for these sessions included identifying and avoiding conflicts of interest, respecting intellectual property, fair and honest marketing practices and appropriate interactions with physicians and government officials.",2019_Boston_Scientific_Performance_Report.pdf
Customer Relationship Management Our achievements are rooted in a deep commitment to helping healthcare providers meet patient needs.,2019_Boston_Scientific_Performance_Report.pdf
The Boston Scientific Customer Relationship Management (CRM) team takes the lead in our work to monitor and learn from customer satisfaction feedback.,2019_Boston_Scientific_Performance_Report.pdf
Metrics from our customer surveys provide crucial information on what we are doing well and where we need to make improvements to better serve our customers.,2019_Boston_Scientific_Performance_Report.pdf
"Our industry- leading CRM practices in the United States are now expanding to other regions across the globe.In March 2019, the Boston Scientific Customer Service organization was honored with the Customer Relationship Management Institute LLC (CRMI) NorthFace ScoreBoard Award (NFSB) for achieving excellence in customer service in the “Over all” and “Cust omer Service” categories.",2019_Boston_Scientific_Performance_Report.pdf
"BostonScientific2019PerformanceReport 63FeaturePatient HighlightAMessageto OurStockholdersFinancial HighlightsOurMissionand CoreValuesBostonScientific ataGlanceBostonScientific bytheNumbersCorporateSocial ResponsibilityOurPatients OurPeople OurPlanet OurPractices Non-GAAP Reconciliations PackagingandLabeling PackagingpracticesatBostonScientific reflectourobligationtoprotectmedical devicesduringsterilization,distribution, storageanduse.Wecollaboratewith ourcustomersandconductusability assessmentstoensurewearemeeting theirneedsandrequirements.",2019_Boston_Scientific_Performance_Report.pdf
"Asthebusinessmakesadvanceswith sustainability,aglobalSustainability PackagingandLabelingSteering CommitteeconferswiththeBoston ScientificCSRCounciltodevelopour packagingstrategyandgoals.Our packagingandsupplychainpractices includeoptimizingdesign,reducing wasteandlimitingemissionsfrom shipping.Inaddition,ourpackaging teamsusecasestudiestocommunicate keypackagingobjectivesandfurther engageourpeopleastheydocument andsharesuccessfulpractices.In 2019,weexpandedthecompany’s sustainabilitycasestudyportfolioby morethan50percentfrom2018.Wecontinuallyassessourlabeling processesfornewwaystomeet customerneedswhilealsoreducingour environmentalfootprint.Inparallelwith afocusonsustainability,Boston Scientifichascontrolsinplacetoverify thatourproductlabelingmeetsglobal labelingregulationsandcomprehensive internalqualitystandards.",2019_Boston_Scientific_Performance_Report.pdf
"In2019,BostonScientificwasproudto jointheHealthcarePlasticsRecycling Council(HPRC),aconsortiumofindustry leadersdedicatedtoboostingplastics recyclingeffortsinclinicalsettings.Asa memberoftheHPRC,BostonScientific sharesinnovationsandcollaborateswith peercompaniestosupportincreased useofrecycledmaterial,removebarriers towastereductionandeducatethe marketaboutsustainability.",2019_Boston_Scientific_Performance_Report.pdf
"2019SnashotM Approximately140tonsofpackaging wastedivertedfromlandfills 3,560palletshipmentsavoided 14,500acresofforestprojectedtobe savedfromCO2emissions 750productsrepurposedduring development“Wearedelightedtohave BostonScientificjoinour efforts.Asanindustry leader,BostonScientific hasapassionforsolving thechallengesthatmatter most.Thecompanyis motivatedbyadeepcaring forhumanlifeandastrong senseofcorporateand environmental responsibility.” — Peylina Chu, Director of the Healthcare Plastics Recycling Council (HPRC)eaMrlRadurcEvMRtnanc wnvRltnmrnMadSMrwalchoRs OneofthelargestBostonScientific distributioncentersachievedsignificant winsinmaterialreductionandenviron- mentalstewardshipin2019.Theteam inQuincy,Massachusettsconducted areviewofinternalprocessesand identifiedavoidableproductwaste associatedwithcustomer-applied labels.Byimplementingmorespecific instructionsandvisualaids,thefacility prevented11.18tonsofpackaging wastefromreachinglandfills.",2019_Boston_Scientific_Performance_Report.pdf
Bost on Scientific 2019 Performance Report 64Supporting Small Business and Supplier Diversity Meeting the needs of more than 30 million patients each year requires a wide variety of perspectives.,2019_Boston_Scientific_Performance_Report.pdf
Diverse vendors and suppliers bring new and innovative ideas to our business.,2019_Boston_Scientific_Performance_Report.pdf
"These professionals allow us to approach challenges from different angles, collaborate more constructively and better serve customers and their patients.",2019_Boston_Scientific_Performance_Report.pdf
This focus on diversity and inclusion extends throughout our supply chain.,2019_Boston_Scientific_Performance_Report.pdf
"In 2019, we worked with more than 4,600 diverse suppliers in the United States, including businesses that are: Minority-owned Women-owned Small or disadvantaged Veteran-owned Service-disabled, veteran-owned LGBTQ-owned Disability-ownedIn 2019, we spent $755 million with diverse suppliers, an 18% increase from 2018.",2019_Boston_Scientific_Performance_Report.pdf
"In 2020, we are aiming to increase this spend by 7 percent.",2019_Boston_Scientific_Performance_Report.pdf
We also conducted more than 200 capability assessments with diverse vendors.Our Responsible Supplier Standards Quality is the most important aspect of our supplier relationships.,2019_Boston_Scientific_Performance_Report.pdf
"Our more than 27,000 suppliers throughout the world meet a robust set of standards.",2019_Boston_Scientific_Performance_Report.pdf
"The company actively seeks supply chain partners who will consistently deliver industry-leading quality, reliability and value.",2019_Boston_Scientific_Performance_Report.pdf
All direct materials suppliers for Boston Scientific are required to comply with strict quality requirements.,2019_Boston_Scientific_Performance_Report.pdf
We agree to partnerships only with companies that share our commitment to ethical conduct and that are in full compliance with all applicable laws and regulations.,2019_Boston_Scientific_Performance_Report.pdf
"To identify these businesses, we use a standardized supplier performance assessment tool with criteria ranging from CSR practices to strategic business processes.",2019_Boston_Scientific_Performance_Report.pdf
"Our mandatory evaluation protocol allows us to build relationships with responsible and high-performing suppliers that make significant contributions to our work.“ I w as born and raised in South Africa, and the importance of diversity has always been apparent to me in every facet of my life.",2019_Boston_Scientific_Performance_Report.pdf
Watching the devastating effects of discrimination has left me with a passion to obliterate this injustice in any way within my power and influence.,2019_Boston_Scientific_Performance_Report.pdf
"Every person should be aware of the direct impact they can make by choosing to support small and diverse vendors in their personal and professional lives.” — Saken Khokhar, Manager, Boston Scientific Supplier Diversity From sourcing manufacturing materials to managing the distribution of Boston Scientific products to more than 120 countries, these partners work with us to ensure that our products are in the right place at the right time to improve patient lives.",2019_Boston_Scientific_Performance_Report.pdf
"We use an inclusive procurement process that involves close collaboration with our Diversity and Inclusion team, input from our CSR Council and input from employee resource groups.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Bost on Scientific 2019 Performance Report 65This Performance Report contains forward-looking statements within the meaning of the federal securities laws.",2019_Boston_Scientific_Performance_Report.pdf
"See the discussion under “Saf e Harbor for Forward-Looking Statements” in the Annual Report on Form 10-K for the year ended December 31, 2019, for matters to be considered in this regard.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, please see our Annual Report on Form 10-K for a description of our Non-GAAP adjustments and the reasons for excluding each item.",2019_Boston_Scientific_Performance_Report.pdf
"Year Ended December 31, Total BSC Revenue Growth 2019 20 18 20 17 20 16 20 15 5- Year Average Percentage change in net sales, as reported 9 .3 % 8 .6 % 7 .9 % 12 % 1 % 8 % Less: Impact of foreign currency fluctuations (1.8)% 0.6 % 0.1 % —% (7)% (1)% Percentage change in net sales, operational 11.",2019_Boston_Scientific_Performance_Report.pdf
"1 % 8 .0 % 7 .8 % 12 % 8 % 9 % Less: Impact of certain acquisitions and divestitures 3.8 % 0.8 % 1.2 % 2 % 3 % 2 % Percentage change in net sales, organic 7 .3 % 7 .2 % 6 .6 % 10 % 5 % 7 % Year Ended December 31, 2019 Rhythm Percentage Change in Net Sales of Reportable Segments MedSur g and N euro Car diovascular Percentage change in net sales, reported 10.0 % 3.3 % 11.4 % Less: Impact of foreign currency fluctuations (1.5)% (1.6)% (2.1)% Percentage change in net sales, operational 11.5 % 4.9 % 13.5 % Less: Impact of certain acquisitions and divestitures 2.7 % 1.6 % 4.2 % Percentage change in net sales, organic 8.8 % 3.3 % 9.3 % Year Ended December 31, Operating Margin 2019 2018 20 17 20 16 20 15 Operating margin, reported 14.1 % 15.3 % 14.2 % 5.3 % (3.8)% Less: Non-GAAP adjustments (12.0)% (10.2)% (10.8)% (18.8)% (26.1)% Operating margin, adjusted 26.1 % 25.5 % 25.0 % 24.1 % 22.3 % Basis Point Improvement from 2018 60 Basis Point Improvement from 2015 380Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Percentages are calculated using unrounded numbers and may not calculate precisely due to rounding.",2019_Boston_Scientific_Performance_Report.pdf
Amounts may not add due to rounding.,2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 66 Year Ended December 31, 2019 Less: Impact Less: Im pact of of R ecent R eported F oreign Currency Operational A cquisitions/ Or ganic Percentage Change in Net Sales of Reportable Segments Basis Fluctuations Basis Div estitures Basis Endoscopy 7.5 % (1.7)% 9.2% 0.0% 9.2% Urology and Pelvic Health 13 .4 % (1.3)% 14.7% 6.3% 8.4% MedSurg 10 .0 % (1.5)% 11.5% 2.",2019_Boston_Scientific_Performance_Report.pdf
7% 8 .8% Cardiac Rhythm Management (0 .6)% (1.8)% 1.2% 0.0% 1.2% Electrophysiology 5.5 % (2.0)% 7.5% 0.0% 7.5% Neuromodulation 12.0 % (1.1)% 13.1% 6.3% 6.8% Rhythm and Neuro 3 .3 % (1.,2019_Boston_Scientific_Performance_Report.pdf
6)% 4.,2019_Boston_Scientific_Performance_Report.pdf
9% 1.,2019_Boston_Scientific_Performance_Report.pdf
6% 3 .3% Interventional Cardiology 8 .7 % (2.3)% 11.0% 1.0% 10.0% Peripheral Interventions 17 .3 % (1.8)% 19.1% 11.3% 7.8% Cardiovascular 11.4 % (2.,2019_Boston_Scientific_Performance_Report.pdf
"1)% 13 .5% 4.2% 9 .3% Year Ended December 31, 2019 Less: Impact of R eported F oreign Currency Oper ational Percentage Change in Net Sales by Region Basis Fluctuations Basis U.S. 10.1% — % 10 .1% EMEA (Europe, Middle East and Africa) 4.0% (5.4)% 9.4% APAC (Asia-Pacific) 9 .9% (2.4)% 12.3% LACA (Latin America and Canada) 3 .3% (4.0)% 7.3% Medical Devices5 8 .5% (1.",2019_Boston_Scientific_Performance_Report.pdf
7)% 10 .2% Specialty Pharmaceuticals8 n/a n/a n/a Net Sales 9 .3% (1.,2019_Boston_Scientific_Performance_Report.pdf
8)% 11.,2019_Boston_Scientific_Performance_Report.pdf
"1% Emerging Markets7 14.1% (5.4)% 19.5% 5 We have three reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices).",2019_Boston_Scientific_Performance_Report.pdf
We have included BTG’s Interventional Medicine business in our Peripheral Interventions operating segment’s 2019 revenues from the date of acquisition.,2019_Boston_Scientific_Performance_Report.pdf
"7 We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.",2019_Boston_Scientific_Performance_Report.pdf
"Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerg - ing Market countries.",2019_Boston_Scientific_Performance_Report.pdf
We have revised prior year amounts to the current year’s presentation.,2019_Boston_Scientific_Performance_Report.pdf
The revision had an immaterial impact on prior year Emerging Markets sales.,2019_Boston_Scientific_Performance_Report.pdf
"8 As part of our acquisition of BTG, we acquired a specialty pharmaceuticals business (Specialty Pharmaceuticals).",2019_Boston_Scientific_Performance_Report.pdf
"Subsequent to acquisition, Specialty Pharmaceuticals is now a stand-alone operating segment presented alongside our Medical Device reportable segments.Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Percentages are calculated using unrounded numbers and may not calculate precisely due to rounding.",2019_Boston_Scientific_Performance_Report.pdf
Amounts may not add due to rounding.,2019_Boston_Scientific_Performance_Report.pdf
"Bost on Scientific 2019 Performance Report 67 Year Ended December 31, Earnings Per Share 2019 2018 20 17 20 16 20 15 20 14 GAAP net income (loss) per share $ 3.33 $ 1.19 $0 .08 $0 .25 $(0 .18) $(0 .09) Amortization expense 0 .44 0.37 0.35 0.35 0.33a 0.29b Intangible asset impairment charges 0 .07 0.02 — 0.01 0.01a 0.12b Acquisition/divestiture-related net charges (credits) 0 .48 — 0.01 0.09 0.17a (0.03)b Restructuring and restructuring-related net charges 0 .05 0.05 0.05 0.04 0.05a 0.07b Litigation-related net charges (credits) 0 .05 0.06 0.12 0.37 0.52a 0.49b Investment impairment charges — — 0 .03 — — — EU MDR implementation charges — — — — — — Debt extinguishment net charges (credits) 0 .05 — — — 0.02a — Deferred tax expenses (benefits) (2.",2019_Boston_Scientific_Performance_Report.pdf
"91) — — — — — Discrete tax items 0 .01 (0.23) 0.62 — (0.01)a (0.01)b Pension termination charges — — — — 0 .02a — Adjusted net income (loss) per share $ 1.58 $ 1.47 $ 1.26 $ 1.11 $ 0.93 $ 0.84 Less: Impact of 2018 net tax benefit3 — 0.07 — Adjusted net income (loss) per share, excluding 2018 net tax benefit $ 1.58 $ 1.40 $ 1.26 Adjusted EPS growth from prior year 8% 17% 13% 20% 11% 15% Adjusted EPS growth from prior year, excluding 2018 net tax benefit 13% 11% 5-Year Average Adjusted EPS growth 14% Adjusted Free Cash Flow (in millions) 20 19 20 18 Operating cash flow, reported $ 1,836 $ 310 Less: Purchases of property, plant and equipment 461 316 Add: Proceeds on disposals of property, plant and equipment 7 14 Free Cash Flow 1,382 8 Plus: Restructuring and restructuring-related payments 66 89 Plus: Acquisition-related payments 266 205 Plus: EU medical device regulation payments 4 — Plus: Special Tax Payments (Refunds/Credits) (42) 977 Plus: Litigation-related Settlements 330 791 Adjusted free cash flow $2, 007 $ 2,070 YoY Growth (3)% Feature Patient HighlightA Message to Our StockholdersFinancial HighlightsOur Mission and Core ValuesBoston Scientific at a GlanceBoston Scientific by the NumbersCorporate Social ResponsibilityOur Patients Our People Our Planet Our Practices Non-GAAP Reconciliations Percentages are calculated using unrounded numbers and may not calculate precisely due to rounding.",2019_Boston_Scientific_Performance_Report.pdf
"Amounts may not add due to rounding.a Assumes dilution of 21.5 million shares for the year ended December 31, 2015. b Assumes dilution of 23.7 million shares for the year ended December 31, 2014.",2019_Boston_Scientific_Performance_Report.pdf
"3 Full year 2018 adjusted earnings per share was $1.47, which includes a $0.07 net tax benefit for the year.",2019_Boston_Scientific_Performance_Report.pdf
"Excluding this net tax benefit of $0.07, our 2018 adjusted earnings per share grew 11 percent.",2019_Boston_Scientific_Performance_Report.pdf
2019 adjusted EPS growth including the aforementioned 2018 net tax benefit is 8 percent and normalized for the 2018 net tax benefit is 13 percent.,2019_Boston_Scientific_Performance_Report.pdf
"Full year 2018 net tax benefit of $0.07 includes our second quarter $0.06 benefit from settling the IRS Stipulation of Settled Issues for the 2001 through 2010 tax years, offset by a fourth quarter $0.05 charge for our tax reinvestment strategy.",2019_Boston_Scientific_Performance_Report.pdf
"In addition, the net benefit includes a $0.06 benefit in the fourth quarter for the settlement with the IRS of our 2011 through 2013 tax years.Boston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-1234 bostonscientific.com© 2020 Boston Scientific Corporation or its affiliates.",2019_Boston_Scientific_Performance_Report.pdf
All rights reserved.,2019_Boston_Scientific_Performance_Report.pdf
PR2019,2019_Boston_Scientific_Performance_Report.pdf
"TRANSFORMING LIVES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT12 Boston Scientific by the Numbers 13 Meaningful Innovation 15 Corporate Social Responsibility at Boston Scientific 53 Non-GAAP Reconciliations03 Our Mission and Core Values 04 A Message from Our Chairman and CEO 10 Financial Highlights 11 Boston Scientific at a Glance Throughout this document, unless otherwise noted, all revenue and other growth rates represent fiscal year 2018 compared to fiscal year 2017.",Boston_Scientific_Performance_Report_2018.pdf
"TABLE OF CONTENTS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.2 17 OUR PLANET Climate Change Environmental Impact Recognitions for Sustainability Leadership Green Team Environmental Sustainability Initiatives24 OUR PEOPLE Accelerating Diversity and Inclusion Attracting and Engaging Diverse Talent Leadership Commitment Listening to Support an Inclusive Culture Employee Resource Groups Setting the Bar Higher Employee Growth and Development Compensation and Benefits Embracing New Life-Work Needs Promoting Health Equity Inspiring the Next Generation of Leaders Giving Back to Our Communities42 OUR PRACTICES Working Responsibly Governance Compliance, Ethics and Integrity Developing Innovative Products Quality and Safety Sustainable Supply Chain Packaging and Labeling Supporting Small Business and Supplier Diversity BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.3 OUR MISSION AND CORE VALUES Boston Scientific provides health grants to organizations such as the Dimock Center in Boston, Massachusetts, which is committed to providing the local community with equitable access to comprehensive healthcare and education.Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.",Boston_Scientific_Performance_Report_2018.pdf
Our work is guided by core values that define Boston Scientific culture and empower our employees.,Boston_Scientific_Performance_Report_2018.pdf
"CARING: We act with integrity and compassion to support patients, customers, our communities and each other.",Boston_Scientific_Performance_Report_2018.pdf
"DIVERSITY: We embrace diversity and value unique talents, ideas and experiences of our employees.",Boston_Scientific_Performance_Report_2018.pdf
GLOBAL COLLABORATION: We work collaboratively to pursue global opportunities that extend the reach of our medical solutions.,Boston_Scientific_Performance_Report_2018.pdf
"HIGH PERFORMANCE: We strive for high performance to benefit our patients, clinicians and shareholders.",Boston_Scientific_Performance_Report_2018.pdf
"MEANINGFUL INNOVATION: We foster an environment of creativity to transform new ideas intro breakthrough services and solutions that create value for patients, customers and employees.",Boston_Scientific_Performance_Report_2018.pdf
"WINNING SPIRIT: We adapt to change and act with speed, agility and accountability to further improve patient care.In our early days as a company, Boston Scientific established a mission to transform lives through innovative medical solutions that improve the health of patients around the world.",Boston_Scientific_Performance_Report_2018.pdf
"Throughout our history, our leaders and innovators played a significant role in advancing science through more accessible, lower cost and lower trauma medical innovations.",Boston_Scientific_Performance_Report_2018.pdf
"This year will mark the company’s 40th anniversary, and our mission continues to hold true and inspire our work today.",Boston_Scientific_Performance_Report_2018.pdf
"It challenges us to do more for our customers and the patients we serve together, while driving sustainable and inclusive business practices.",Boston_Scientific_Performance_Report_2018.pdf
"I am extremely proud that our global team of dedicated employees demonstrated high performance across all businesses, functions and regions in 2018.",Boston_Scientific_Performance_Report_2018.pdf
"We delivered on our financial commitments to shareholders while investing for durable, long-term growth and most importantly, we worked together to help improve the lives of approximately 30 million patients – more people than at any time in our history.",Boston_Scientific_Performance_Report_2018.pdf
We held ourselves to the highest standards of quality and safety and fueled our pipeline by investing approximately $1 billion in research and development.,Boston_Scientific_Performance_Report_2018.pdf
We also announced 10 strategic acquisitions in support of our category leadership strategy and continued expansion into high growth markets.,Boston_Scientific_Performance_Report_2018.pdf
I also know that we can’t be satisfied with the status quo.,Boston_Scientific_Performance_Report_2018.pdf
"The healthcare industry continues to undergo transformation, with external forces presenting wide-ranging challenges and opportunities, including a growing burden of chronic conditions, an aging population, increasing consumerism, industry consolidation, and technology companies moving into healthcare.",Boston_Scientific_Performance_Report_2018.pdf
"Addressing these changes will require agility, responsiveness and bold new thinking.",Boston_Scientific_Performance_Report_2018.pdf
Our mission and values will continue to guide us as we rise to meet future needs.,Boston_Scientific_Performance_Report_2018.pdf
2018 BUSINESS RESULTS 2018 was yet another strong year for Boston Scientific with results that extend our track record of excellent performance over the five-year 2014 to 2018 period.,Boston_Scientific_Performance_Report_2018.pdf
"During this time, Boston Scientific has grown operational sales at an average rate of 8 percent and organic sales at an average rate of 7 percent.1,2 We’ve improved adjusted operating margin 530 basis points and leveraged that to drive an average 14 percent growth in adjusted earnings per share over the five-year period, excluding the $0.07 net tax benefit in 2018.1 Our common stock returned 43 percent, and our five- and three-year total shareholder returns have consistently outpaced the S&P 500 index, growing 194 percent and 92 percent, respectively.",Boston_Scientific_Performance_Report_2018.pdf
"Our full-year sales in 2018 were $9.823 billion, representing 8.0 percent operational revenue growth and 7.2 percent organic revenue growth, which excludes 80 basis points of growth from certain recent acquisitions.2,3 Organic sales growth was 8.2 percent in MedSurg†, 7.6 percent in Rhythm and Neuro† and 6 percent in Cardiovascular.3 In addition to our strong revenue growth, we delivered a 50 basis point improvement in adjusted operating margin and full-year adjusted earnings per share growth of 17 percent to $1.47, which includes a $0.07 net tax benefit for the year.1 Excluding this net tax benefit of $0.07, our adjusted earnings per share Mike Mahoney, Chairman and Chief Executive Officer † Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments.",Boston_Scientific_Performance_Report_2018.pdf
"The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment, which includes Cardiac Rhythm Management (CRM), Electrophysiology and Neuromodulation.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, we reclassified the Middle East and Africa (MEA) regions from the former AMEA region with Europe to create the new EMEA region.",Boston_Scientific_Performance_Report_2018.pdf
The new Asia-Pacific (APAC) region was also previously part of the former AMEA region.,Boston_Scientific_Performance_Report_2018.pdf
Prior year balances and year over year growth rates (denoted with †) have been revised accordingly.,Boston_Scientific_Performance_Report_2018.pdf
"1 Adjusted operating margin, adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation related net charges and credits, pension termination charges, certain debt extinguishment charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.",Boston_Scientific_Performance_Report_2018.pdf
2 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 55-57.,Boston_Scientific_Performance_Report_2018.pdf
3 Organic revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the first twelve months of sales from the acquisitions of the electrophysiology business of C.R.,Boston_Scientific_Performance_Report_2018.pdf
"Bard Inc., the Interventional Division of Bayer AG, the American Medical Systems male urology portfolio, EndoChoice Holdings, Inc., Symetis SA, NxThera, Inc., Claret Medical, Inc. and Augmenix, Inc., since there are no prior period related net sales; see non-GAAP reconciliations on pages 55-57.",Boston_Scientific_Performance_Report_2018.pdf
"DEAR SHAREHOLDERS: A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.4075150225300 12/18 12/17 12/16 12/15 12/14 12/13$100 075150225300 grew 11 percent.1 Through increased productivity and reduced costs, we were able to redirect savings to high-growth technologies that strengthen our portfolio and capabilities for the future.",Boston_Scientific_Performance_Report_2018.pdf
"These results also generated more than $2 billion of adjusted free cash flow, representing 20 percent growth over the prior year.4 We were able to invest a significant portion of these funds to augment future growth via multiple exciting acquisitions.",Boston_Scientific_Performance_Report_2018.pdf
"In global markets, we continued expanding our business with broad-based growth across regions.",Boston_Scientific_Performance_Report_2018.pdf
"Total annual sales from Emerging Markets increased 21.4 percent operational compared to 2017.2,5 We expect to continue to grow our presence in new markets and regions and to make our technologies accessible to more people in need.Our strategy of category leadership in key markets and portfolio diversification into high growth adjacencies is working.",Boston_Scientific_Performance_Report_2018.pdf
Our goal is to continue to execute against our strategic plan objectives and deliver top-tier sales and adjusted earnings per share growth over the next five years.,Boston_Scientific_Performance_Report_2018.pdf
"We believe that the combination of long-term, consistent, above market revenue growth, adjusted operating margin expansion, targeted double-digit earnings per share growth, and the improved ability to deploy our strong free cash flow uniquely position Boston Scientific to continue to drive shareholder value.",Boston_Scientific_Performance_Report_2018.pdf
"SOLUTIONS THAT MATTER MOST Our work at Boston Scientific is driven by our commitment to better understand unmet health needs and collaborate with diverse healthcare stakeholders to solve them, from patient education resources and technology breakthroughs to strategic investments that deepen our expertise and impact.",Boston_Scientific_Performance_Report_2018.pdf
"Our approach to innovation includes a mix of organic programs, collaborations and strategic acquisitions that are focused on enriching our capabilities in the medical specialties that we serve.",Boston_Scientific_Performance_Report_2018.pdf
"We believe that this clinical depth and category leadership strategy are helping us create value for patients, physicians and payers and enabling us to grow faster than our underlying markets and most peers.",Boston_Scientific_Performance_Report_2018.pdf
Expansion into New Markets The investments we’ve made and platform technologies we have built enable greater agility to reach additional patient populations with critical unmet needs.,Boston_Scientific_Performance_Report_2018.pdf
We will continue to expand our business in exciting growth areas and expect that our technology development efforts and acquisitions have positioned us to enter new adjacencies that will represent approximately $20 billion in addressable market opportunity by 2022.,Boston_Scientific_Performance_Report_2018.pdf
"The Boston Scientific Interventional Cardiology business is leading the way on this front as we continue the global expansion of our WATCHMAN™ Left Atrial Appendage Closure (LAAC) Technology, with more than 70,000 patients implanted.",Boston_Scientific_Performance_Report_2018.pdf
The WATCHMAN Device is designed to reduce the risk of stroke for patients with non-valvular atrial fibrillation (AF) and is now recognized in medical society guidelines as a therapeutic option for patients who need an alternative to long-term oral anticoagulant therapy.,Boston_Scientific_Performance_Report_2018.pdf
"We further expanded our structural heart portfolio and strengthened our commitment to improving transcatheter aortic valve replacement (TAVR) patient outcomes through the addition of the Sentinel™ Cerebral Protection System, which is the only device cleared by the U.S. Food and Drug Administration (FDA) to protect patients against the risk of stroke during TAVR and has been used in nearly 10,000 procedures.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, we continue to develop our A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.5 COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN* Boston Scientific Corporation S&P Health Care Equipment S&P 500 * $100 invested on 12/31/13 in stock or index, including reinvestment of dividends.",Boston_Scientific_Performance_Report_2018.pdf
Fiscal year ending December 31.,Boston_Scientific_Performance_Report_2018.pdf
"© 2019 Standard & Poor’s, a division of S&P Global.",Boston_Scientific_Performance_Report_2018.pdf
All rights reserved.,Boston_Scientific_Performance_Report_2018.pdf
"1 Adjusted operating margin, adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation related net charges and credits, pension termination charges, certain debt extinguishment charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.",Boston_Scientific_Performance_Report_2018.pdf
2 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 55-57.,Boston_Scientific_Performance_Report_2018.pdf
4 Adjusted free cash flow and its related growth rate are non-GAAP measures that exclude the cash component of certain charges (credits) that are also excluded from adjusted net income as well as any cash tax benefits of such charges.,Boston_Scientific_Performance_Report_2018.pdf
"In addition, we exclude tax settlements payments that relate to prior periods.",Boston_Scientific_Performance_Report_2018.pdf
The GAAP measure that is most directly comparable to adjusted free cash flow is free cash flow on a GAAP basis.,Boston_Scientific_Performance_Report_2018.pdf
"Free cash flow on a GAAP basis is calculated by subtracting net purchases of property, plant and equipment from cash provided by operating activities; see non-GAAP reconciliations on pages 55-57.",Boston_Scientific_Performance_Report_2018.pdf
"5 We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors, and our global capabilities.",Boston_Scientific_Performance_Report_2018.pdf
"Currently, we include 20 countries in our definition of Emerging Markets.dual-valve TAVR strategy with the ACURATE neo™ valve6 — the fastest growing valve in Europe — and the LOTUS Edge™ Aortic Valve System7, which upon FDA approval will provide customers with the only fully repositionable valve system on the market.",Boston_Scientific_Performance_Report_2018.pdf
"In endoluminal surgery, our goal is to transform gastrointestinal cancer resections by developing a comprehensive portfolio that allows the procedures to be performed endoscopically.",Boston_Scientific_Performance_Report_2018.pdf
"Worldwide, 2.8 million people suffer from gastrointestinal cancers.8 There is a tremendous opportunity for a less invasive endoscopic alternative to surgical resection of cancer or pre-cancer to enhance patient recovery, while also reducing length of stay, adverse events and cost of care.",Boston_Scientific_Performance_Report_2018.pdf
Strategic Acquisitions An important part of our story in 2018 involved strategic investments across business units.,Boston_Scientific_Performance_Report_2018.pdf
"We announced an agreement to acquire BTG plc, a leader in minimally invasive therapies targeting cancer and vascular diseases.",Boston_Scientific_Performance_Report_2018.pdf
"Our Urology and Pelvic Health business expanded our women’s health portfolio with the addition of nVision Medical, offering a platform for potential earlier diagnosis of ovarian cancer — a condition for which there are currently no recommended early screening tests.",Boston_Scientific_Performance_Report_2018.pdf
"We also invested in novel therapies for men’s health with Augmenix, including the SpaceOAR™ Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy, and NxThera, the developer of the Rezūm™ System, a minimally invasive treatment option for patients with benign prostatic hyperplasia.",Boston_Scientific_Performance_Report_2018.pdf
"Adding to our Interventional Cardiology business, we acquired Claret Medical, and its Sentinel™ Cerebral Protection System, providing a new layer of safety and peace of mind for physicians and their patients undergoing TAVR procedures.",Boston_Scientific_Performance_Report_2018.pdf
"With the acquisition of Cryterion Medical, our Electrophysiology business added to our portfolio a single-shot cryoablation platform for atrial fibrillation treatment, making Boston Scientific the first to offer physicians both cryothermal and radiofrequency (RF) single-shot, balloon-based ablation therapies.",Boston_Scientific_Performance_Report_2018.pdf
PURSUIT OF EXCELLENCE We constantly strive to improve our offerings to patients and healthcare systems with technology advancements that are supported with a strong body of clinical evidence.,Boston_Scientific_Performance_Report_2018.pdf
Our teams work with a sense of urgency and purpose to bring forward new solutions with quality and safety as the top priority.,Boston_Scientific_Performance_Report_2018.pdf
"A disciplined portfolio management strategy guides our investment in clinical trials and research and development, and as we support our customers and champion their transition to value-based care, we are gaining new perspectives that help us innovate and improve patient outcomes.""",Boston_Scientific_Performance_Report_2018.pdf
"Our approach to innovation includes a mix of organic programs, collaborations and strategic acquisitions that are focused on enriching our capabilities in the medical specialties that we serve.",Boston_Scientific_Performance_Report_2018.pdf
"We believe that this clinical depth and category leadership strategy are helping us create value for patients, physicians and payers and enabling us to grow faster than our underlying markets and most peers.""",Boston_Scientific_Performance_Report_2018.pdf
— Mike Mahoney A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.6 6 Caution: ACURATE neo is an investigational device in the U.S. Not available for sale.,Boston_Scientific_Performance_Report_2018.pdf
CE Marked.,Boston_Scientific_Performance_Report_2018.pdf
7 Caution: LOTUS Edge Aortic Valve System is an investigational device in the U.S. and not available for sale.,Boston_Scientific_Performance_Report_2018.pdf
CE Marked.,Boston_Scientific_Performance_Report_2018.pdf
8 https://www.who.int/news-room/fact-sheets/detail/cancer.,Boston_Scientific_Performance_Report_2018.pdf
"In men’s health we are addressing benign prostatic hyperplasia (BPH) treatment with Rezūm™ Water Vapor Therapy, a minimally invasive treatment we acquired via NxThera.",Boston_Scientific_Performance_Report_2018.pdf
"BPH is an enlargement of the prostate that affects 110 million men worldwide and can cause problems with urinary and sexual function.13,14 A four-year randomized clinical trial recently demonstrated that patients treated with Rezūm Therapy experienced significant and sustained improvement in their symptoms and quality of life.",Boston_Scientific_Performance_Report_2018.pdf
"Supporting Value-Based Care In addition to providing technologies that improve patient outcomes, we are focused on diagnostics, digital health and services that can take cost out of the healthcare system and improve how hospitals operate.",Boston_Scientific_Performance_Report_2018.pdf
Understanding the broader challenges healthcare systems face allows us to make decisions on new technologies and shift our portfolio mix to deliver technologies that will help customers meet their outcome and economic objectives.,Boston_Scientific_Performance_Report_2018.pdf
"An example is our RESONATE™ family of devices, which includes our HeartLogic™ Heart Failure Diagnostic.",Boston_Scientific_Performance_Report_2018.pdf
"Annually, heart failure accounts for more than 1.1 million hospitalizations15 with 25 percent of heart failure patients re-admitted within 30 days of initial hospital- ization.16,17 The HeartLogic diagnostic tool tracks key physiological trends related to heart failure and was validated to predict heart failure events more than Firsts in Vascular Interventional Technology Our Peripheral Interventions business launched the Eluvia™ Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease (PAD).",Boston_Scientific_Performance_Report_2018.pdf
The Eluvia System is the first peripheral vascular interventional technology approved in the U.S. to offer sustained release of an antiproliferative drug to treat patients with PAD.,Boston_Scientific_Performance_Report_2018.pdf
"Approximately 8.5 million people in the U.S. are affected by PAD, which occurs when fatty or calcified atherosclerotic material builds up on the walls of the arteries of the legs.9 Eleven percent of patients with PAD develop critical limb ischemia (CLI), a chronic lack of blood supply to the lower legs.10,11 Research has shown that within one year of being diagnosed with CLI, 30 percent of patients will have undergone amputation.",Boston_Scientific_Performance_Report_2018.pdf
"To address this clinical need, we began enrollment in the SAVAL Trial, studying the SAVAL™ Below the Knee (BTK) Drug-Eluting Stent System, the first stent designed to treat CLI.",Boston_Scientific_Performance_Report_2018.pdf
"Due to the absence of effective treatment options for patients suffering from CLI, the FDA granted the Expedited Access Pathway (EAP) designation to the SAVAL BTK Stent System, the first CLI device to receive this designation.",Boston_Scientific_Performance_Report_2018.pdf
Helping Physicians Tailor Therapy in Neuromodulation Our Neuromodulation business recently launched the Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems with the Cartesia™ Directional Lead.,Boston_Scientific_Performance_Report_2018.pdf
"The new systems feature technology designed to allow physicians to control the range, shape, position and direction of electrical stimulation to treat the symptoms of Parkinson's disease (PD) through highly-personalized therapy.",Boston_Scientific_Performance_Report_2018.pdf
"More than 10 million people are living with PD,12 and the progression of the disease requires a therapy that can evolve with the patient over time.",Boston_Scientific_Performance_Report_2018.pdf
The INTREPID study further documented the safety and effectiveness of the Vercise DBS System as an important treatment option for patients living with this debilitating condition.,Boston_Scientific_Performance_Report_2018.pdf
"We also invested in research and expanded treat - ment options for chronic pain with the Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System, a potential non-opioid solution for the millions of people suffering from debilitating lower limb and back pain.",Boston_Scientific_Performance_Report_2018.pdf
Positive results from the WHISPER study and WaveWriter real-world outcomes study provided further evidence of the value of providing patients with multiple waveform therapies for the relief of chronic pain.,Boston_Scientific_Performance_Report_2018.pdf
Innovation in Flexible Ureteroscopy and Men’s Health The Boston Scientific Urology and Pelvic Health business launched the LithoVue Empower™ Retrieval Deployment Device.,Boston_Scientific_Performance_Report_2018.pdf
"One in eleven people are affected by kidney stones, and the LithoVue Empower Device is designed to enable this procedure to be performed more efficiently by one clinician and is an example of how we are adapting our technology to meet clinical needs.",Boston_Scientific_Performance_Report_2018.pdf
"A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.7 9 Centers for Disease Control: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_pad.htm Accessed February 2019 10 Mozaffarian D, Benjamin EJ, Go AS, et al.",Boston_Scientific_Performance_Report_2018.pdf
Heart disease and stroke statistics—2015 update: a report from the American Heart Association.,Boston_Scientific_Performance_Report_2018.pdf
Circulation .,Boston_Scientific_Performance_Report_2018.pdf
2015 Jan 27;131(4):e29-322.,Boston_Scientific_Performance_Report_2018.pdf
"Cited in Clarivate Analytics, Incidence and Prevalence Database.",Boston_Scientific_Performance_Report_2018.pdf
"11 Nehler MR, Duval S, Diao L, et al.",Boston_Scientific_Performance_Report_2018.pdf
Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population.,Boston_Scientific_Performance_Report_2018.pdf
J Vasc Surg .,Boston_Scientific_Performance_Report_2018.pdf
2014 Sep;60(3):686-95.e2.,Boston_Scientific_Performance_Report_2018.pdf
"12 http://parkinson.org/Understanding-Parkinsons/Causes-and-Statistics/ Statistics 13 https://www.healthline.com/health/enlarged-prostate#symptoms 14 https://www.physiciansweekly.com/tag/benign-prostatic-hyperplasia/ 15 Boehmer JP, Hariharan R, Devecchi FG, et al.",Boston_Scientific_Performance_Report_2018.pdf
A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study.,Boston_Scientific_Performance_Report_2018.pdf
JACC Heart Fail .,Boston_Scientific_Performance_Report_2018.pdf
"2017 Mar;5(3):216-25 16 Fonarow GC, Abraham WT, Albert NM, et al.",Boston_Scientific_Performance_Report_2018.pdf
Association between performance measures and clinical outcomes for patients hospitalized with heart failure.,Boston_Scientific_Performance_Report_2018.pdf
JAMA .,Boston_Scientific_Performance_Report_2018.pdf
2007 Jan 3;297(1):61-70.,Boston_Scientific_Performance_Report_2018.pdf
"17 O’Connor CM, Abraham WT, Albert NM, et al.",Boston_Scientific_Performance_Report_2018.pdf
Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).,Boston_Scientific_Performance_Report_2018.pdf
Am Heart J .,Boston_Scientific_Performance_Report_2018.pdf
"2008 Oct;156(4):662-73. faced barriers accessing quality healthcare, our Close the Gap teams shared data with healthcare providers to help them develop action plans and track progress in eliminating inequities among high-risk patients.",Boston_Scientific_Performance_Report_2018.pdf
"Our health equity efforts also included community education and outreach to populations most affected by disparities in heart disease treatment, assistance with continuing healthcare professional education and advocacy for adherence to clinical guidelines to help ensure equitable care.",Boston_Scientific_Performance_Report_2018.pdf
"In addition to advancing science and improving pa- tient health and access to care, we have the privilege and responsibility to use our resources to enrich communities.",Boston_Scientific_Performance_Report_2018.pdf
Boston Scientific employees around the world continue to invest thousands of hours each year to support environmental restoration projects and programs to improve local schools and commu- nities.,Boston_Scientific_Performance_Report_2018.pdf
"Many of these programs are fueling the next generation of life science professionals by encour - aging students to achieve in Science, Technology, Engineering and Math (STEM).",Boston_Scientific_Performance_Report_2018.pdf
We also recognize the need to ensure that the manufacturing of our products does not have a negative impact on the environment and are reducing our global environ- mental footprint through increased use of renewable and cleaner energy sources.,Boston_Scientific_Performance_Report_2018.pdf
In 2018 we reduced our greenhouse gas emissions 47 percent and decreased water consumption 30 percent relative to our 2009 measurement baseline.,Boston_Scientific_Performance_Report_2018.pdf
"Our commitment to sustain- ability and making a positive environmental impact is an important part of how we live by our values.four weeks in advance,15 allowing earlier intervention with patients and avoiding hospitalizations by shifting reactive treatment to proactive care.",Boston_Scientific_Performance_Report_2018.pdf
Another area of focus is the work underway with our Endoscopy business to build a comprehensive product portfolio designed to help customers meet or exceed guidelines for infection prevention.,Boston_Scientific_Performance_Report_2018.pdf
"The Exalt™ Single-Use Duodenoscope18 has the potential to reduce cross-contamination risk, minimize capital investment and reduce reprocessing issues and is targeted to launch by the end of 2019.",Boston_Scientific_Performance_Report_2018.pdf
"We are also helping customers achieve and sustain cost, quality and growth targets with our ADVANTICS™ Innovative Healthcare Solutions portfolio.",Boston_Scientific_Performance_Report_2018.pdf
"Examples include standardizing care for patients with chronic cardiovascular diseases and performance optimiza- tion solutions focused on patient flow.DEEPEST COLLABORATION Significant unmet needs for patient-centered innovation remain, and the biggest advances are made through collaboration between clinicians, researchers, care providers, patients, regulators and industry.",Boston_Scientific_Performance_Report_2018.pdf
"We maintain a strong base of clinical evidence to support the safety and efficacy of our devices, with data gathered from bench testing, randomized controlled trials and ongoing real-world evidence.",Boston_Scientific_Performance_Report_2018.pdf
"To meet needs for localized training and innovation, we have established 14 Institutes for Advancing Science located in the Americas, Africa, Asia and Europe.",Boston_Scientific_Performance_Report_2018.pdf
"We also take a global approach to research and development at our four research and development design centers, with work underway to expand capabilities in India, Costa Rica and China.",Boston_Scientific_Performance_Report_2018.pdf
Health Equity & Enriching Our Communities In 2018 we prioritized efforts to promote health equity and make a sustainable impact through our Close the Gap initiative.,Boston_Scientific_Performance_Report_2018.pdf
Our primary focus in this work was cardiovascular disease and treatment disparities among women and minority populations.,Boston_Scientific_Performance_Report_2018.pdf
"In communities across the U.S. that have traditionally A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.8 "" In all that we accomplished over the course of the year, there is one common denominator that gave us a distinct edge: the winning spirit of our people.",Boston_Scientific_Performance_Report_2018.pdf
"Our employees are the talented and dedicated force behind every Boston Scientific milestone.""",Boston_Scientific_Performance_Report_2018.pdf
"— Mike Mahoney 15 Boehmer JP, Hariharan R, Devecchi FG, et al.",Boston_Scientific_Performance_Report_2018.pdf
A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study.,Boston_Scientific_Performance_Report_2018.pdf
JACC Heart Fail .,Boston_Scientific_Performance_Report_2018.pdf
2017 Mar;5(3):216-25 18 Device under development.,Boston_Scientific_Performance_Report_2018.pdf
"Not available for sale or use worldwide.""",Boston_Scientific_Performance_Report_2018.pdf
I think perhaps one of the most important metrics in a company beyond the financials is employee engagement.,Boston_Scientific_Performance_Report_2018.pdf
"I’m very proud of the high engagement levels we have across the business, the extra effort our employees make, and the teamwork they demonstrate to deliver for patients who really need our solutions.""",Boston_Scientific_Performance_Report_2018.pdf
"— Mike Mahoney levels we have across the business, the extra effort our employees make, and the teamwork they demonstrate to deliver for patients who really need our solutions.",Boston_Scientific_Performance_Report_2018.pdf
All of us at Boston Scientific understand that we need to continuously push ourselves to make a greater contribution to patients around the world.,Boston_Scientific_Performance_Report_2018.pdf
"Looking ahead, I know that the community and culture we have built will equip us to adapt to the needs of the rapidly evolving healthcare landscape.",Boston_Scientific_Performance_Report_2018.pdf
"Even after a year of so many accomplishments, I can say with confidence that our most meaningful and exciting work is yet to come.",Boston_Scientific_Performance_Report_2018.pdf
I commend our employees for the passion they bring to our mission every day.,Boston_Scientific_Performance_Report_2018.pdf
"On behalf of all of us, I want to thank our Board of Directors for their commitment and service to Boston Scientific.",Boston_Scientific_Performance_Report_2018.pdf
"And I extend our sincere gratitude to you, our shareholders, for your continued support.",Boston_Scientific_Performance_Report_2018.pdf
I am fortunate to lead this incredible company and I look forward to all that we will accomplish in the year ahead.,Boston_Scientific_Performance_Report_2018.pdf
"Sincerely, Mike Mahoney Chairman and Chief Executive Officer March 15, 2019Our People In all that we accomplished over the course of the year, there is one common denominator that gave us a distinct edge: the winning spirit of our people.",Boston_Scientific_Performance_Report_2018.pdf
Our employees are the talented and dedicated force behind every Boston Scientific milestone.,Boston_Scientific_Performance_Report_2018.pdf
"Our top industry awards and rankings include FORTUNE World’s Most Admired Companies, Forbes’ Best Large Employer, Newsweek Green Rankings, the Human Rights Campaign’s Corporate Equality Index, Working Mother 100 Best Companies, NAFE Top Companies for Executive Women, and the Diversity Best Practices Inclusion Index.",Boston_Scientific_Performance_Report_2018.pdf
"As a global company, it is important to have diverse perspectives and people who reflect the patients, customers and markets we serve.",Boston_Scientific_Performance_Report_2018.pdf
"In addition to driving growth, this leads to greater diversity of thought, which fuels innovation, creates a more rewarding place to work and helps us attract and retain top talent.",Boston_Scientific_Performance_Report_2018.pdf
"We announced an 18-month initiative to strengthen the core of our organization by 2020 through diversity and inclusion, including a goal of increasing global representation of women and people of color in supervisor and manager roles.",Boston_Scientific_Performance_Report_2018.pdf
We also launched initiatives to help us better understand the needs of our employees in different parts of the world and tailor benefits accordingly.,Boston_Scientific_Performance_Report_2018.pdf
Our Benefits to Fit Your Life program launched globally in 2018 as a comprehensive package designed to meet employees at various stages of work and life.,Boston_Scientific_Performance_Report_2018.pdf
"Examples of offerings in the U.S. include expanded infertility treatment support, maternal and paternal leave, a breast milk shipping service, adult and child back-up care, and enhanced planning programs for college assistance as well as employees with aging parents.",Boston_Scientific_Performance_Report_2018.pdf
LOOKING AHEAD I think perhaps one of the most important metrics in a company beyond the financials is employee engagement.,Boston_Scientific_Performance_Report_2018.pdf
"I’m very proud of the high engagement A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.9 2018 SALES BY REGION Reported Operational (DOLLARS IN MILLIONS) Sales Growth1 U.S. $ 5,538 7.3% Europe, Middle East and Africa (EMEA)† 2,176 9.0% Asia-Pacific (APAC)† 1,727 7.5% Latin America and Canada (LACA) 383 15.8% $9,823 8.0% 2018 SALES BY PRODUCT CATEGORY Reported Operational (DOLLARS IN MILLIONS) Sales Growth1 MedSurg Endoscopy $ 1,762 8.3% Urology and Pelvic Health 1,245 10.6% Rhythm and Neuro Cardiac Rhythm Management 1,951 2.1% Electrophysiology 311 10.9% Neuromodulation 779 22.5% Cardiovascular Interventional Cardiology 2,590 6.6% Peripheral Interventions 1,187 9.2% $9,823 8.0% † Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments.",Boston_Scientific_Performance_Report_2018.pdf
"The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment, which includes Cardiac Rhythm Management (CRM), Electrophysiology and Neuromodulation.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, we reclassified the Middle East and Africa (MEA) regions from the former AMEA region with Europe to create the new EMEA region.",Boston_Scientific_Performance_Report_2018.pdf
The new Asia-Pacific (APAC) region was also previously part of the former AMEA region.,Boston_Scientific_Performance_Report_2018.pdf
Prior year balances and year over year growth rates (denoted with “†”) have been revised accordingly.,Boston_Scientific_Performance_Report_2018.pdf
1 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 55-57.,Boston_Scientific_Performance_Report_2018.pdf
2 Organic revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the first twelve months of sales from the acquisitions of the electrophysiology business of C.R.,Boston_Scientific_Performance_Report_2018.pdf
"Bard Inc., the Interventional Division of Bayer AG, the American Medical Systems male urology portfolio, EndoChoice Holdings, Inc., Symetis SA, NxThera, Inc., Claret Medical, Inc. and Augmenix, Inc., since there are no prior period related net sales; see non-GAAP reconciliations on pages 55-57.",Boston_Scientific_Performance_Report_2018.pdf
"3 Adjusted operating margin, adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation related net charges and credits, pension termination charges, certain debt extinguishment charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.",Boston_Scientific_Performance_Report_2018.pdf
"BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.10 FINANCIAL HIGHLIGHTS OPERATIONAL REVENUE GROWTH1,2 2018: 8% 7% 2017: 8% 7% 2016: 12% 10% Operational revenue growth Organic revenue growthADJUSTED EARNINGS PER SHARE GROWTH3 2018: 17% 2017: 13% 2016: 20% Adjusted EPS growth from prior year includes $0.07 net tax benefit in 2018.",Boston_Scientific_Performance_Report_2018.pdf
"Adjusted EPS growth from prior year, excluding $0.07 net tax benefit in 2018, increased 11% in 2018 as compared to the prior year.ADJUSTED OPERATING MARGIN3 2018: 25.5% 2017: 25.0% 2016: 24.1% 024681012 16 17 180510152025 16 17 1805101520 16 17 18 BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.11 BOSTON SCIENTIFIC AT A GLANCE Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.",Boston_Scientific_Performance_Report_2018.pdf
"As a global medical technology leader for nearly 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.",Boston_Scientific_Performance_Report_2018.pdf
"ENDOSCOPY Industry leader in minimally invasive devices for diagnosing and treating gastrointestinal and pulmonary conditions UROLOGY AND Industry-leading solutions for urological, urogynecological and gynecological PELVIC HEALTH conditions CARDIAC RHYTHM Groundbreaking technologies that treat irregular heart rhythms and heart MANAGEMENT failure and help protect against sudden cardiac arrest ELECTROPHYSIOLOGY A broad range of mapping and treatment technologies for diagnosing and treating heart rhythm disorders NEUROMODULATION Electronic implantable technologies that help patients manage debilitating chronic pain and neurological conditions INTERVENTIONAL Minimally invasive innovations that help improve the lives of patients living CARDIOLOGY with heart and vascular conditions PERIPHERAL Minimally-invasive treatments of peripheral vascular disease and cancer INTERVENTIONS Committed to carbon neutrality in manufacturing and key distribution sites for all products by 2030 BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.12 BOSTON SCIENTIFIC BY THE NUMBERS 200+ STEM events 32,000+ employees worldwide$9.8+ billion in salesHelped improve approximately 30 million patient livesApproximately $1 billion invested in research and developmentRecycled 9,600+ tonnes of solid waste$81 million+ provided for medical research, educational and charitable giving Named to the Forbes' list of The World’s Most Innovative CompaniesLaunched approximately 100 new product innovations globally Reduced greenhouse gas emissions* by 75,000+ tonnes *Compared to 2009 baseline.43,000+ employee volunteer hours BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.13 MEANINGFUL INNOVATION SpyGlass™ DS Direct Visualization System The first minimally invasive, single-use, single-operator digital scope used for cholangiopancreatoscopy procedures designed to target biopsies and stone fragments in the bile, hepatic and pancreatic ducts.ACURATE neo™ Aortic Valve System* and LOTUS Edge™ Valve System** Complementary transcatheter aortic valve replacement (TAVR) devices that are designed to enable implanting physicians to treat the broadest range of patients and aortic valve anatomies.Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System Designed to provide personalized, long-lasting pain relief through combination therapy, novel sub-perception algorithms and waveform automation.Eluvia™ Drug-Eluting Vascular Stent System The first peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease.",Boston_Scientific_Performance_Report_2018.pdf
*The ACURATE device is an investigational device and is not available for sale in the U.S. ACURATE CE Marked.,Boston_Scientific_Performance_Report_2018.pdf
**The LOTUS device is an investigational device and is not available for sale.,Boston_Scientific_Performance_Report_2018.pdf
"CE Marked.ACURATE neo™ Aortic Valve System* LOTUS Edge™ Valve System** Rezu–m™ Water Vapor Therapy A minimally invasive treatment for benign prostatic hyperplasia (BPH) that is typically performed in a physician’s office to remove excess prostate tissue and reduce BPH-related symptoms, such as pain and a frequent need to urinate.",Boston_Scientific_Performance_Report_2018.pdf
"SpaceOAR™ Hydrogel System An absorbable gel that is injected prior to radiation therapy for prostate cancer treatment, which temporarily increases the space between the rectum and prostate, thereby reducing rectal radiation dose and associated side effects.WATCHMAN Left Atrial Appendage Closure Device The first and only FDA-approved one-time heart implant proven to reduce stroke risk in patients with non- valvular atrial fibrillation who need an alternative to long-term blood thinners.MEANINGFUL INNOVATION MEANINGFUL INNOVATION BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.14 15.Boehmer JP, Hariharan R, Devecchi FG, et al.",Boston_Scientific_Performance_Report_2018.pdf
A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study.,Boston_Scientific_Performance_Report_2018.pdf
JACC Heart Fail .,Boston_Scientific_Performance_Report_2018.pdf
"2017 Mar;5(3):216-25.HeartLogic™ Heart Failure Diagnostic The first and only heart failure diagnostic tool proven to detect 70 percent of heart failure events several weeks in advance, potentially reducing further hospital- ization for patients with heart failure.15 Featured in the Boston Scientific Resonate™ family of cardiac resynchronization therapy defibrillator (CRT-D) and implantable cardioverter defibrillator (ICD) devices.",Boston_Scientific_Performance_Report_2018.pdf
Symbols representing sensors from the HeartLogic diagnostic tool.,Boston_Scientific_Performance_Report_2018.pdf
"A Boston Scientific employee participating in volunteer day near our Marlborough, Massachusetts headquarters.CORPORATE SOCIAL RESPONSIBILITY AT BOSTON SCIENTIFIC MANAGING CORPORATE SOCIAL RESPONSIBILITY Our CSR Council is composed of subject matter experts from across the company and charged with defining our strategy and driving accountability across the organization by setting clear targets and measuring progress.",Boston_Scientific_Performance_Report_2018.pdf
An Executive Steering Committee sponsors the priorities and goals set by the Council and supports efforts to further embed responsible practices into the business.,Boston_Scientific_Performance_Report_2018.pdf
"OUR APPROACH: MATERIALITY To focus our CSR efforts where we can have the greatest impact, we must understand the changing healthcare landscape, what matters to our stakeholders and what most affects our business across key markets.",Boston_Scientific_Performance_Report_2018.pdf
"In 2017, we completed a materiality assessment to identify the CSR issues of greatest importance to Boston Scientific and our stakeholders, including employees, customers, investors and communities where we live and work.",Boston_Scientific_Performance_Report_2018.pdf
The assessment was performed in accordance with the internationally accredited Global Reporting Initiative (GRI) guidelines and evaluated topics related to our business strategy and stakeholder interests.,Boston_Scientific_Performance_Report_2018.pdf
"The assessment identified our material aspects, the highest priority issues to our stakeholders for social, economic and environmental impact.The actions we take today can shape a better future for our patients, customers, employees, communities and the world we share.",Boston_Scientific_Performance_Report_2018.pdf
"Our approach to corporate social responsibility (CSR) is based on assessments of social, environmental and governance issues that guide our policies and day-to-day practices.",Boston_Scientific_Performance_Report_2018.pdf
"This work is supported by our cross-functional CSR Council, Environmental Health and Safety (EH&S) policies and programs, a Global Council for Inclusion as well as employee and community programs.",Boston_Scientific_Performance_Report_2018.pdf
"ENGAGING WITH STAKEHOLDERS At Boston Scientific, we engage with stakeholder groups at the global, national and local levels to inform our corporate responsibility strategy.",Boston_Scientific_Performance_Report_2018.pdf
"This engagement occurs at all levels of the organization, from employees at our manufacturing sites and research facilities to senior management in our divisions and Executive Committee leaders.",Boston_Scientific_Performance_Report_2018.pdf
"We value the opportunity to learn about the concerns and priorities of the communities and stakeholder groups we serve as we work to anticipate and better understand emerging environmental, social and governance topics.",Boston_Scientific_Performance_Report_2018.pdf
"CORPORATE SOCIAL RESPONSIBILITY AT BOSTON SCIENTIFIC BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.15In 2018, we aligned the outcomes of this assessment to the United Nations Sustainable Development Goals (SDGs), which address key global challenges to create a better and more sustainable future for everyone.",Boston_Scientific_Performance_Report_2018.pdf
"Though the United Nation’s 17 SDGs are interconnected, our material aspects align to 10 goals where we believe we can make the most meaningful contributions to critical issues.",Boston_Scientific_Performance_Report_2018.pdf
A focus on positively influencing these goals will continue to guide our CSR programs in 2019 and beyond.,Boston_Scientific_Performance_Report_2018.pdf
"OUR CSR PERFORMANCE We hold ourselves accountable for providing updates and data related to our corporate social responsibility performance, and we share this information through several communication channels, including this report.",Boston_Scientific_Performance_Report_2018.pdf
"Each year, we report the company’s impact on the environment as defined by the Carbon Disclosure Project (CDP), and we actively participate in several important environment, social and governance rating surveys.",Boston_Scientific_Performance_Report_2018.pdf
This report has been prepared by referencing the Global Reporting Initiative (GRI) guidelines.,Boston_Scientific_Performance_Report_2018.pdf
"Data in this report covers the period between January 1, 2018 and December 31, 2018, unless otherwise indicated.Boston Scientific Supports the SDGs Our Planet Climate Change Environmental ImpactOur People Diversity and Inclusion Culture and Career Community Stakeholder EngagementOur Practices Innovative Products Governance and Ethics Compliance Sustainable Supply ChainOf the seventeen United Nations Sustainable Development Goals (SDGs), our material aspects align with ten, which will continue to guide our corporate social responsibility programs in 2019 and beyond.",Boston_Scientific_Performance_Report_2018.pdf
"CORPORATE SOCIAL RESPONSIBILITY AT BOSTON SCIENTIFIC BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.16 BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.17 OUR PLANET OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.18 In all established operations and distribution locations, we proactively pursue environmental standards that deliver exceptional ISO14001:2015 performance.",Boston_Scientific_Performance_Report_2018.pdf
"During the 2018 audit cycle, we achieved zero non-conformances globally.",Boston_Scientific_Performance_Report_2018.pdf
We also received zero regulatory environmental noncompliance notices or fines.,Boston_Scientific_Performance_Report_2018.pdf
"Our Global Energy Management System (GEMS), developed in collaboration with the National University of Ireland, Galway, helps ensure that we meet our energy reduction commitment globally.",Boston_Scientific_Performance_Report_2018.pdf
"Using the C3 strategy (Cut, Convert, Compensate), GEMS focuses on cutting energy use, converting to renewable energy sources instead of fossil fuels and compensating with carbon offset projects where needed.",Boston_Scientific_Performance_Report_2018.pdf
"Across our global manufacturing and distribution locations, we have established the following targets and are continually monitoring progress through GEMS: 50% renewable electricity by 2021 100% renewable electricity by 2024 90% renewable energy (all sources) by 2027 Carbon neutral by 2030 As a global medical device manufacturer, we understand that our planet is facing challenges that affect the well-being of patients, customers, employees, communities and investors.",Boston_Scientific_Performance_Report_2018.pdf
"By proactively addressing energy consumption, carbon output, waste management and water use, we are making measurable progress toward shaping a better future for our planet.",Boston_Scientific_Performance_Report_2018.pdf
"Our Environment, Health and Safety (EHS) Policy outlines our high standards as we pursue environmental excellence.",Boston_Scientific_Performance_Report_2018.pdf
"We take a global approach to prioritizing, executing and monitoring efforts to achieve EHS goals and measure progress to deliver sustainable development.",Boston_Scientific_Performance_Report_2018.pdf
"The newest Boston Scientific manufacturing site in Penang, Malaysia, was granted LEED Silver certification in 2018.CARING FOR OUR PLANET Boston Scientific has 13 LEED-certified buildings around the globe.",Boston_Scientific_Performance_Report_2018.pdf
OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.19 KPI DEFINITION Carbon Total amount of Scope 1 and Scope 2 greenhouse Footprint gas emissions emitted into the atmosphere from (MT CO2eq) manufacturing and distribution sites.,Boston_Scientific_Performance_Report_2018.pdf
Measured in tonnes of carbon equivalent.,Boston_Scientific_Performance_Report_2018.pdf
Energy Use Total energy Boston Scientific consumes annually (kWh) to manufacture our products.,Boston_Scientific_Performance_Report_2018.pdf
EM3 An energy management maturity model to establish (% change where in the “energy journey” each manufacturing in score) site resides on a scale from 1 to 5 (Minimal > Emerging > Developing > Advancing > Leading) Green Real Percentage of Boston Scientific real estate that is Estate independently certified for energy efficiency by (% of total) industry-leading programs such as LEED for design and Energy Star or ISO50001 for building operations.,Boston_Scientific_Performance_Report_2018.pdf
"Renewable Percentage of total energy consumed, generated Energy from renewable energy sources, with Boston Scientific (% of total) owning the renewable attributes.",Boston_Scientific_Performance_Report_2018.pdf
"Cleaner Energy Energy produced from fossil fuels, but based on (% of total) high-efficiency technologies such as combined heat and power (CHP) in comparison to conventional power generation.",Boston_Scientific_Performance_Report_2018.pdf
"The GEMS methodology is implemented through our global energy team, including representatives from each of our manufacturing and key distribution sites.",Boston_Scientific_Performance_Report_2018.pdf
"Our performance is continually measured through our GEMS key performance indicators (KPIs): 2015 118,327 370,083,323 2.7 27% — 6%2016 108,694 367,102,517 3.2 28% — 7%2017 94,946 363,684,542* 3.6 32% — 9%*2018 85,127 352M 3.7 37% 5% 9% *2017 kilowatt hour figures corrected due to conversion factor error for diesel fuel use.CLIMATE CHANGE Striving for Carbon Neutrality As a medical device manufacturer with facilities and employees around the world, we recognize we have an important role in addressing climate change.",Boston_Scientific_Performance_Report_2018.pdf
Our commitment is to achieve carbon neutrality across Boston Scientific manufacturing and key distribution sites by 2030.,Boston_Scientific_Performance_Report_2018.pdf
Carbon neutrality means achieving net zero carbon emissions associated with manufac - turing operations and energy use by balancing the amount of carbon released with an equal amount removed or compensated.,Boston_Scientific_Performance_Report_2018.pdf
"As increased levels of carbon dioxide and other greenhouse gases in our atmosphere are closely tied to climate change, achieving carbon neutrality will greatly reduce our contribution to this pressing global issue.",Boston_Scientific_Performance_Report_2018.pdf
Leading in Energy Certification A critical part of our sustainability effort includes ongoing improvement of existing facilities and development of new construction in an environmentally responsible manner.,Boston_Scientific_Performance_Report_2018.pdf
Leadership in Energy and Environmental Design (LEED) is an internationally recognized certification program for the environmental performance and sustainable design of buildings.,Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific now has 13 LEED-certified buildings around the globe (37 percent of total) – including our newest manufacturing site in Penang, Malaysia, which was granted LEED Silver certification in March 2018.",Boston_Scientific_Performance_Report_2018.pdf
"Our two sites in Costa Rica, Coyol and Heredia, have both received ISO 50001:2011 Energy Management System certification.",Boston_Scientific_Performance_Report_2018.pdf
"ISO 50001 is an energy management system standard that provides a framework for all aspects of energy, including procurement and use.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, our distribution center in Kerkrade, Netherlands, received a third star from Lean and Green, Europe’s leading program for sustainable logistics.",Boston_Scientific_Performance_Report_2018.pdf
We are one of only six companies in Europe to receive this highest-level award for carbon output reduction.,Boston_Scientific_Performance_Report_2018.pdf
"In total, Boston Scientific operates nearly 3.3 million square feet of independently certified Green Real Estate that supports our energy efficiency and sustainability goals, representing 37 percent of our global footprint.",Boston_Scientific_Performance_Report_2018.pdf
OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.20 We have committed to achieving carbon neutrality in all of our manufacturing and key distribution sites by 2030.,Boston_Scientific_Performance_Report_2018.pdf
"LEEDing Locations United States: A Maple Grove, Minnesota LEED Silver LEED Certified B Marlborough, Massachusetts LEED Gold LEED Certified C Quincy, Massachusetts LEED Silver LEED Certified Central America: D Coyol, Costa Rica LEED Silver ISO 50001 E Heredia, Costa Rica ISO 50001 Europe: F Kerkrade, Netherlands LEED Silver Lean and Green Asia: G Penang, Malaysia LEED Silver H Singapore LEED Silver I Beijing, China LEED Silver LEED Certified J Shanghai, China LEED SilverA BC DEF G HI JInvesting in Energy Efficiency Increased use of renewable energy is another way that we are reducing GHG emissions.",Boston_Scientific_Performance_Report_2018.pdf
"Two Boston Scientific locations in Massachusetts each have solar installments: our Marlborough headquarters site generates 31 percent of its required electricity and the Quincy distribution center generates 26 percent of its required electricity, resulting in cumulative savings of about 1,000 tonnes of GHG emissions.",Boston_Scientific_Performance_Report_2018.pdf
"In June 2018, our facility in Dorado, Puerto Rico, joined a Power Purchase Agreement (PPA) to purchase electricity generated from solar panels to be installed on-site.",Boston_Scientific_Performance_Report_2018.pdf
"We are making progress toward our goal of purchasing 100 percent renewable energy by 2024 by purchasing only renewable electricity for our three sites in Ireland, installing on-site solar at certain facilities and pursuing a virtual power purchase agreement for renewable electricity for our U.S. energy needs.",Boston_Scientific_Performance_Report_2018.pdf
We will continue to implement a combination of on-site and off-site projects to achieve our renewable energy goals.,Boston_Scientific_Performance_Report_2018.pdf
Renewable electricity accounted for 5 percent of our energy purchased globally in 2018.,Boston_Scientific_Performance_Report_2018.pdf
"ENVIRONMENTAL IMPACT As a company with a global footprint and global impact, we have a responsibility to manage how we consume resources and reduce waste.",Boston_Scientific_Performance_Report_2018.pdf
"We carefully measure waste generation and water use at our major manufacturing and distribution facilities using ISO 14001:2015, a globally recognized standard CorkIRELANDfor environmental management systems (EMS).",Boston_Scientific_Performance_Report_2018.pdf
"The system ensures that throughout our operations we respond to changing environmental conditions, meet compliance obligations, enhance environmental performance and deliver sustainable development.",Boston_Scientific_Performance_Report_2018.pdf
"As of 2018, 15 of our sites achieved third-party certifications to this standard.",Boston_Scientific_Performance_Report_2018.pdf
"Reducing Waste We approach waste-reduction systematically, through the adoption of international best practices and research-backed protocols.",Boston_Scientific_Performance_Report_2018.pdf
"In 2017, we met our ambitious goal to achieve a recycling index of 81 percent for solid waste generated by our major manufacturing and distribution facilities.",Boston_Scientific_Performance_Report_2018.pdf
"Striving to do even better, we further improved our recycling index and achieved 83 percent in 2018.",Boston_Scientific_Performance_Report_2018.pdf
"Of the remaining non-recycled solid waste, we divert the majority away from landfills.",Boston_Scientific_Performance_Report_2018.pdf
"OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.21 Sustainability at our Ireland Facilities Beginning in October of 2018, the three Boston Scientific manufacturing sites in Ireland, located in Galway, Cork and Clonmel, began purchasing certified 100 percent renewable electricity.",Boston_Scientific_Performance_Report_2018.pdf
This represents 12 percent of our total purchased electricity and delivers a 9 percent overall reduction in carbon emissions.,Boston_Scientific_Performance_Report_2018.pdf
"In November 2018, Boston Scientific joined other businesses in Ireland and signed the Business in The Community (BITC) Low Carbon Pledge.",Boston_Scientific_Performance_Report_2018.pdf
These companies pledge to reduce scope 1 and scope 2 greenhouse gas (GHG) emission intensity 50 percent by 2030.,Boston_Scientific_Performance_Report_2018.pdf
"Scope 1 GHGs are those produced by Boston Scientific facilities directly, and scope 2 GHGs are those generated by the purchased electricity we consume.",Boston_Scientific_Performance_Report_2018.pdf
We plan to surpass this goal with our carbon neutrality pledge.GOAL SET IN 2009: 35% reduction in greenhouse gas (GHG) emissions* by 2019.,Boston_Scientific_Performance_Report_2018.pdf
"2018 RESULT: 47% reduction (75,711 tonnes)** *Using market-based emissions calculations.",Boston_Scientific_Performance_Report_2018.pdf
"**Compared to the 2009 manufacturing operations baseline.Galway ClonmelConserving Water While Boston Scientific operations are not water- intensive, we understand the importance of water as a shared resource.",Boston_Scientific_Performance_Report_2018.pdf
We strive to minimize our consumption and plan for environmental challenges such as water scarcity.,Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we further decreased water usage by 5 percent, representing a total reduction of more than 30 percent since 2009.",Boston_Scientific_Performance_Report_2018.pdf
"RECOGNITIONS FOR SUSTAINABILITY LEADERSHIP Received a Third Star for our facility in Kerkrade, Netherlands, from Lean & Green, Europe’s leading program for sustainable logistics Confirmed a FTSE4Good Index Series constituent, designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices Awarded the Ecological Blue Flag Award with five stars by the Costa Rican government, the highest ranking in the climate change category OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.22 Recognition for Solid Waste Reduction Achievement In April 2018, the Boston Scientific site in Maple Grove, Minnesota, received the Chelsea Santucci Greenovation Award from Kimberly-Clark Professional for diverting 39,920 pounds of waste from landfills.",Boston_Scientific_Performance_Report_2018.pdf
"We participate in The RightCycle Program, the first large-scale recycling program for non-hazardous lab, cleanroom and industrial waste.",Boston_Scientific_Performance_Report_2018.pdf
"RightCycle is designed to help pharmaceutical companies, research laboratories and manufacturing facilities reduce solid waste streams by recycling nontraditional waste such as garments, gloves, hoods, boot covers, masks and safety eyewear.",Boston_Scientific_Performance_Report_2018.pdf
Participants in the program have diverted more than 600 tons of waste from landfills since 2011.,Boston_Scientific_Performance_Report_2018.pdf
"Above: Boston Scientific employees in Maple Grove, Minnesota, commemorate Earth Day 2018 with their award.2018 ACHIEVEMENTS: 83% increase* in solid waste recycle index, or 9,660+ tonnes.",Boston_Scientific_Performance_Report_2018.pdf
"30% water use reduction*...equal to 301,571 cubic meters.",Boston_Scientific_Performance_Report_2018.pdf
"1,332 tonnes of non-recycled solid waste was diverted away from landfills, achieving 95% avoidance.",Boston_Scientific_Performance_Report_2018.pdf
*Compared to 2009 baseline.,Boston_Scientific_Performance_Report_2018.pdf
"The blue flag at the Coyol, Costa Rica office symbolizes our commitment to sustainability.",Boston_Scientific_Performance_Report_2018.pdf
"OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.23 Beach Clean-up in Costa Rica In Coyol, Costa Rica, more than 100 Boston Scientific employees, and their families and friends, gathered at Guacalillo Beach for a clean-up initiative in April 2018.",Boston_Scientific_Performance_Report_2018.pdf
"The event was organized in conjunction with the local community, government, Red Cross organization and local foundations, Operation Rich Coast and Algo por la Tierra.",Boston_Scientific_Performance_Report_2018.pdf
"This effort resulted in the collection of approximately one ton of waste and litter, including more than 70 used car tires.",Boston_Scientific_Performance_Report_2018.pdf
"This demonstration in caring for our planet is an important reminder of why we strive to meet ambitious waste reduction and recycling goals.River Stewardship in California In Valencia, California, Boston Scientific employee volunteers partnered with the Community Hiking Club, the California Wilderness Coalition and outdoor retail co-op REI to clean along Piru Creek, a part of the protected National Wild & Scenic Rivers System.",Boston_Scientific_Performance_Report_2018.pdf
"During October 2018, volunteers worked to help preserve the habitat by removing impediments to endangered migrating fish and collecting more than 500 pounds of trash.GREEN TEAM ENVIRONMENTAL SUSTAINABILITY INITIATIVES Our employee-led Green Teams present new ideas and implement projects that reduce the company’s environmental footprint globally, improve the communities in which we do business and strengthen our business practices.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we worked with many community partners to make a positive impact and raise environmental awareness.",Boston_Scientific_Performance_Report_2018.pdf
"Keeping our Planet Clean Beyond maintaining our facilities, our employees around the globe participated in efforts to preserve beaches and habitats in surrounding communities, helping to ensure that local ecosystems remain intact as wildlife habitats and for future generations to enjoy.BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.24 OUR PEOPLE OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.25 At Boston Scientific, our work has purpose – it results in lives changed, and lives saved.",Boston_Scientific_Performance_Report_2018.pdf
"Together, our employees strive to solve healthcare challenges that matter most, with an unwavering focus on the needs of patients, physicians and healthcare systems.",Boston_Scientific_Performance_Report_2018.pdf
"Our team of more than 32,000 employees around the globe are collaborators, explorers and problem- solvers, united by a focus on advancing science for life.",Boston_Scientific_Performance_Report_2018.pdf
"We understand that choosing the right place to work is an important decision, and that people join companies to find meaningful purpose and a place to grow.",Boston_Scientific_Performance_Report_2018.pdf
We recognize that the aspirations and goals of each employee are personal.,Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific global talent management practices support a workplace where individuals can: Build a career with global impact — truly make a difference to people both around the world and around the corner Be empowered with opportunities to grow — thrive in a culture that prioritizes learning, development and progression Meaningfully contribute in a collaborative environment — build lasting relationships with colleagues and global thought leaders Embrace a culture with “winning spirit” — be part of a culture that takes measured risks and challenges the status quo Be rewarded — enjoy a workplace that recognizes success and rewards individual and team performance Choose from diverse career options — explore careers that suit varying backgrounds and ambitions Experience mobility with global opportunities — expand personal reach and contribute to business imperatives through international assignments and programs The talent of our teams and individuals creates a competitive advantage for the company.",Boston_Scientific_Performance_Report_2018.pdf
"That’s why we work hard to attract diverse talent, enable a culture of engagement and inclusion and enhance our organizational capabilities to build the workforce of the future.",Boston_Scientific_Performance_Report_2018.pdf
"The Boston Scientific Women’s Network worked with the Girls on the Run organization to help young girls develop essential skills to establish a lifetime of health and fitness.OUR PEOPLE OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.26 ACCELERATING DIVERSITY AND INCLUSION At Boston Scientific, our diversity value stands for inclusion, equality and opportunity for all, and guides our work to advance science and improve patient health.",Boston_Scientific_Performance_Report_2018.pdf
"By embracing unique backgrounds and perspectives, we create a more rewarding place to work that better reflects the patients, customers and communities we serve.",Boston_Scientific_Performance_Report_2018.pdf
"Our Diversity and Inclusion efforts are focused on four strategic pillars: Career Culture Commerce Community ATTRACTING AND ENGAGING DIVERSE TALENT In 2018, we launched “10/20/40 by 2020” goals to accelerate our diversity and inclusion efforts.",Boston_Scientific_Performance_Report_2018.pdf
These goals are aimed at reshaping the company’s core mid-level employee base to move beyond traditional diversity recruiting efforts that tend to target the entry-level pipeline or focus on top-down change.,Boston_Scientific_Performance_Report_2018.pdf
Transparent reporting is an important part of how we hold ourselves accountable.,Boston_Scientific_Performance_Report_2018.pdf
"By the end of 2018, we achieved the following progress toward our goals: By 2020, our goals are to: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.27 Women Global46.5% 45.5 %2017 |2018 People of Color U.S./Puerto Rico31.7% 30.7 %2017 |2018All Levels 38.4% 37.4% Supervisors & Managers429.5% 27.3% Senior Management318.8 % 12.5 % Executive Officers230.0 % 30.0 % Board of Directors2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level44.3%43.6 % 56.2% 50.5% 45.5% 40.6 %57.7% 43.6 % 45.5% 43.3%US/PR Latin America Canada Europe, Middle East & Africa Asia Pacific2017 |2018By region American Indian / Alaskan Asian Black / African American Hispanic / Latino Multiracial Native Hawaiian / Other Pacific Islander13.7% 13.4% 5.1% 10.1% 9.5% 1.2% 0.3%1.6% 0.3%6.5%0.3% 0.3%2017 |2018By ethnic groupRepresentation of Women Around the Globe1 Representation of People of Color in the U.S. and Puerto Rico5 *Based on individuals' voluntary self-identification 1 Gender: Gender information is collected uniformly for global reporting purposes.",Boston_Scientific_Performance_Report_2018.pdf
2 Executive Officers includes all executive committee members listed in the company's Annual Report.,Boston_Scientific_Performance_Report_2018.pdf
"3 Senior Management includes all levels that are director, vice president, senior vice president, executive vice president and CEO 4 Supervisors and Managers includes all levels that are supervisor, manager I and manager II.",Boston_Scientific_Performance_Report_2018.pdf
5 People of Color (PoC): Each country has specific requirements and legal considerations regarding how PoC data can be used and reported.,Boston_Scientific_Performance_Report_2018.pdf
"Our reporting focuses on our US/PR PoC populations as it is uniform in definition, reporting and use.THE PEOPLE OF BOSTON SCIENTIFIC* OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.28 LEADERSHIP COMMITMENT Fostering a more inclusive environment starts at the top.",Boston_Scientific_Performance_Report_2018.pdf
"Chairman and CEO Mike Mahoney, along with chief executives of the world’s leading companies, are part of the CEO Action for Diversity and Inclusion Pledge , the largest CEO-driven business commitment to advance workplace diversity and inclusion.",Boston_Scientific_Performance_Report_2018.pdf
"Since signing the pledge in 2017, Boston Scientific and other participating companies have shared best practices for creating a work environment where complex and sometimes difficult conversations about diversity and inclusion can occur, including holding a Day of Understanding to provide a forum for employees to engage in meaningful dialogue on inclusion barriers.",Boston_Scientific_Performance_Report_2018.pdf
"To achieve our 10/20/40 goals, each business, regional and functional leadership team has established plans to increase representation of women, people of color and globalization within their organizations.",Boston_Scientific_Performance_Report_2018.pdf
"Examples of plan initiatives include mandatory consideration of a diverse slate of qualified candidates for all manager and above roles, required unconscious bias training for all those who manage people and programs that promote diversity awareness and inclusive competency skills.",Boston_Scientific_Performance_Report_2018.pdf
"Additionally, we audit key talent management practices such as interview questions and high-potential leadership program requirements to ensure support of an inclusive culture.",Boston_Scientific_Performance_Report_2018.pdf
"Collaborating for Change We proudly partner with leading organizations that promote and support the development of women, people of color, people with disabilities and LGBTQ talent.",Boston_Scientific_Performance_Report_2018.pdf
"In the United States, these partnerships include Advancing Minorities’ Interests in Engineering, Disability:IN, Hiring Our Heroes, the Human Rights Campaign, the National Society of Black Engineers, National Action Council for Minorities in Engineering, reacHIRE, the Society of Hispanic Professional Engineers and the Society of Women Engineers, among others.",Boston_Scientific_Performance_Report_2018.pdf
We are building similar collaborations in other parts of the world.,Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we hosted 100 members of the Japan Women’s Innovative Network (J-Win) organization at our corporate headquarters as part of the organization’s Annual Overseas Study Tour.",Boston_Scientific_Performance_Report_2018.pdf
"During their visit, J-WIN members learned more about the medical device industry and participated in an interactive career experience session with Boston Scientific leaders.",Boston_Scientific_Performance_Report_2018.pdf
"As a founding member of Disability:IN’s Inclusion Works Program (formerly Going for the Gold), we are advancing programs to support the hiring and inclusion of people with disabilities.",Boston_Scientific_Performance_Report_2018.pdf
"Through this collaboration, we conducted disability awareness training globally, increased understanding and adoption of the reasonable accommodations process and expanded the availability of on-site resources.",Boston_Scientific_Performance_Report_2018.pdf
"Also in 2018, our fulfillment center in Quincy, Massachusetts, launched a program to assist people with disabilities seeking customer service and distribution center employment.",Boston_Scientific_Performance_Report_2018.pdf
Boston Scientific has been recognized for three consecutive years as a Disability Equality Index® (DEI) Best Place to Work.,Boston_Scientific_Performance_Report_2018.pdf
"In 2018, our Europe, Middle East and Africa region established a regional D&I Council that includes D&I champions who set regional goals and address the needs of employees located across 35 countries and three continents.51.2 % 50.5% Women Global2017 |2018 42.6% 40.7% People of Color U.S./Puerto Rico2017 |2018Boston Scientific New Hires OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.29 Targeted development/retention programs We continue to increase focus on developing women and people of color through specific development initiatives that include executive sponsorship, deliberate job movement and leadership development programs.",Boston_Scientific_Performance_Report_2018.pdf
"One example of this work is the Boston Scientific EXCELerate program, a multi-year sponsorship focused on the career development of female talent in a range of technical fields, including R&D, manufacturing, supply chain, clinical, quality, information technology, global business systems and security.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, 93 women from seven countries participated in the program and were matched with Boston Scientific executive sponsors who serve as advisors, mentors and career advocates.In addition, our Women’s Network Employee Resource Group chapters across local markets support the personal and professional development of women through formal mentoring programs.",Boston_Scientific_Performance_Report_2018.pdf
"These programs are designed to help participants develop leadership skills, set realistic career goals and plans to achieve them, while expanding their network within Boston Scientific.",Boston_Scientific_Performance_Report_2018.pdf
"For instance, our Women’s Network chapter in Japan held its annual PRISM congress in 2018 with all female employees and their managers.",Boston_Scientific_Performance_Report_2018.pdf
The event focused on the state of diversity and inclusion in Japan and how to further address cultural barriers that impact the representa- tion of women in sales and leadership positions.,Boston_Scientific_Performance_Report_2018.pdf
"LISTENING TO SUPPORT AN INCLUSIVE CULTURE Our best ideas come from our people, including how to continuously improve our workplace and culture to attract and retain top talent.",Boston_Scientific_Performance_Report_2018.pdf
Employee Surveys We regularly conduct a global Employee Engagement survey to better understand our cultural and organizational strengths and areas for improvement.,Boston_Scientific_Performance_Report_2018.pdf
"Results from the latest global survey include an overall engagement score of 79 percent, positioning Boston Scientific eight points above the global benchmark for high performing companies across industries.",Boston_Scientific_Performance_Report_2018.pdf
"* The company also exceeded the global high performing norm in four out of the five benchmarked categories (engagement, * Source: Corporate Executive Boardimmediate manager, senior leadership, talent and performance management and total rewards).",Boston_Scientific_Performance_Report_2018.pdf
"Leaders, working with employees, reviewed these results to create measurable multi-year action plans to refine and improve on results at the corporate and local level.",Boston_Scientific_Performance_Report_2018.pdf
We also conducted a 2018 qualitative study with a global cross-representation of employees to better understand engagement differences in employee perceptions of career development opportunities.,Boston_Scientific_Performance_Report_2018.pdf
"As a result of this effort, as well as best-practice benchmarking, we expanded manager skill-building programs and drove greater transparency of our diversity data, initiatives and goals.",Boston_Scientific_Performance_Report_2018.pdf
Several of these initiatives were launched in 2018 and will continue into the next year and beyond.,Boston_Scientific_Performance_Report_2018.pdf
"Self-ID Survey As a U.S. federal contractor doing business with the U.S. government, Boston Scientific is required to regularly survey employees about their disability status.",Boston_Scientific_Performance_Report_2018.pdf
"In response to employee feedback, our 2018 survey included questions related to self- identification in the categories of military, gender, LGBTQ and ethnicity/race.",Boston_Scientific_Performance_Report_2018.pdf
Nearly 30 percent of the company’s U.S. and Puerto Rico employee population completed the questionnaire.,Boston_Scientific_Performance_Report_2018.pdf
"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.30 Our Employee Resource Groups (ERGs) help create thriving communities for our diverse employees to connect and succeed, while impacting communities around the world.",Boston_Scientific_Performance_Report_2018.pdf
"Here are a few examples of their achievements in 2018: Bridge to the Future The Valencia, California, BRIDGE chapter hosts an annual Bridge to the Future program that helps introduce students of color to STEM education.",Boston_Scientific_Performance_Report_2018.pdf
"The nine-month experience for 10th through 12th graders includes sessions such as this one focused on programming, coding and robotics and professional skills.",Boston_Scientific_Performance_Report_2018.pdf
"In April 2018, BRIDGE hosted their seventh graduation, celebrating the growth and development of 27 students.New ERGs in Ireland Our Clonmel, Cork and Galway sites in Ireland coordinated the launch of three new LEAD chapters in 2018, while also coordinating site-specific disability inclusion training.",Boston_Scientific_Performance_Report_2018.pdf
"The sites collaborated to develop programs dedicated to supporting people with disabilities in the workplace.Operation Gratitude In 2018, our VETS chapters collaborated with Operation Gratitude to collect more than 700 pounds of requested supplies across Boston Scientific locations.",Boston_Scientific_Performance_Report_2018.pdf
Operation Gratitude supports U.S. troops and their families by sending care packages to all who bravely serve and delivering items needed by their families at home.,Boston_Scientific_Performance_Report_2018.pdf
"EMPLOYEE RESOURCE GROUPS Our ERGs are at the heart of our culture of diversity, collaborating across the business at all levels to promote awareness in a wide range of areas.",Boston_Scientific_Performance_Report_2018.pdf
"When people join and contribute to these groups, they take on valuable new experiences and opportunities to handle new responsibilities.",Boston_Scientific_Performance_Report_2018.pdf
"More than 4,400 Boston Scientific employees are active in 9 ERGs with 85 chapters around the world: BRIDGE: Developing a Community of Black Leaders HOLA: Hispanic Organization for Leadership and Achievement LEAD: Leadership, Education and Allies for Disabilities PACE: People Accepting and Celebrating Equality PEARL: Pacific East Asian Resources in Leadership SAIL: South Asians in Leadership VETS: Veterans & Employees Together in Service (Military) Women’s Network: Promoting Professional Development of Women YPN: Young Professionals Network OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.31 Global Council for Inclusion Our leaders are important role models for driving change.",Boston_Scientific_Performance_Report_2018.pdf
The Boston Scientific Global Council for Inclusion guides the implementation of our D&I strategies.,Boston_Scientific_Performance_Report_2018.pdf
"The council is chaired by Chief Financial Officer Dan Brennan and its members include Chairman and CEO Mike Mahoney, the Executive Committee, our global D&I team and all global ERG leaders.",Boston_Scientific_Performance_Report_2018.pdf
The council meets quarterly to assess diversity and inclusion progress and engage in candid conversations on issues that our employee groups may be facing.,Boston_Scientific_Performance_Report_2018.pdf
Each of our nine ERGs are also sponsored by an Executive Committee member.,Boston_Scientific_Performance_Report_2018.pdf
"Recognizing that our businesses, functions and regions experience D&I challenges differently, we have also established local inclusion councils to support these unique opportunities.",Boston_Scientific_Performance_Report_2018.pdf
SETTING THE BAR HIGHER Boston Scientific participates in several external benchmark index surveys that enable us to compare and assess our progress and practices for continued improvement.,Boston_Scientific_Performance_Report_2018.pdf
"With a D&I goal focused on achieving Top 10 workplace inclusion leadership in key focus areas (women, people of color, disabilities and LGBTQ), we are committed to driving practices that promote an inclusive culture and enable us to be an employer of choice for globally diverse talent.",Boston_Scientific_Performance_Report_2018.pdf
"We are proud to have been recognized by the following organizations in 2018 for our work:2018 Awards LATINA Style’s 50 Best Companies for Latinas (2015-2018) Disability Equality Index (DEI) (2016 - 2018) Fatherly Top 50 Places to Work for New Dads (2018) Forbes list of Best Employers for Women (2018) Forbes list of Best Employers for Diversity (2018) Glassdoor Employees' Choice Best Places to Work (2018) Historically Black Colleges and Universities (HBCU) Top Supporter (2016-2018) Human Rights Campaign’s Corporate Equality Index (2015–2018) Leading Diversity Best Practices Inclusion Index Organization (2018) National Association for Female Executives Top Companies for Executive Women (2018) Working Mother ""100 Best Companies"" (2017-2018)Equal Employment Opportunity Policy Boston Scientific has been, and will continue to be, an equal opportunity employer.",Boston_Scientific_Performance_Report_2018.pdf
"To ensure full implementation of the company’s equal employment policy, we continue to work to ensure that recruitment, hiring, assignment, promotion, compensation and all other personnel decisions are made and administered without regard to race, religion, color, national origin, citizenship, sex, sexual orientation, gender identity, gender expression, veteran’s status, age, mental or physical disability, genetic information or any other protected class.",Boston_Scientific_Performance_Report_2018.pdf
We draw strength from the unique talents and abilities inherent in a diverse workforce and we believe that the best and most innovative products come from an inclusive workplace where varied viewpoints are welcomed and encouraged.,Boston_Scientific_Performance_Report_2018.pdf
We also have a strict policy against harassment that is reinforced through training and other ongoing communication.,Boston_Scientific_Performance_Report_2018.pdf
OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.32 EMPLOYEE GROWTH AND DEVELOPMENT Growing and developing our people is essential to growing our company.,Boston_Scientific_Performance_Report_2018.pdf
"Employees at every level have access to a variety of programs, training and tools to advance their skills and career so they can meaningfully contribute to our mission of transforming lives.",Boston_Scientific_Performance_Report_2018.pdf
Coaching and Development Creating an environment where coaching and development are valued and prioritized will accelerate our company performance.,Boston_Scientific_Performance_Report_2018.pdf
"To ensure the growth and success of our leaders as coaches, we have invested in tools and training to support their continued development and expand measures for accountability, including: Management Development Program (MDP): The MDP features tools and coaching for our employees who manage people.",Boston_Scientific_Performance_Report_2018.pdf
"The mandatory 18-month curriculum focuses on enhancing skills ranging from hiring talent to managing performance, unconscious bias training and situational leadership.",Boston_Scientific_Performance_Report_2018.pdf
"Upon completion, leaders are provided with several tools and resources that help put this training into practice.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, more than 2,000 managers globally completed more than 6,000 MDP sessions.",Boston_Scientific_Performance_Report_2018.pdf
Employee feedback: To provide leaders valuable feedback on their coaching performance from those who interact with them most in this role — their employees — we provide a number of tools to help initiate dialogue and inform our leaders’ individual development plans.,Boston_Scientific_Performance_Report_2018.pdf
"These tools include employee input on annual performance reviews, 360-degree surveys and an employee leadership assessment survey – SPARK – that gives employees an opportunity to rate their manager’s performance against the behaviors that define a people leader at Boston Scientific.",Boston_Scientific_Performance_Report_2018.pdf
Empowering Leaders of Today and Tomorrow Boston Scientific offers learning and development programs that help employees achieve their unique career goals and aspirations.,Boston_Scientific_Performance_Report_2018.pdf
These programs range from on-the-job training and skills-based learning to focused leadership programs aimed at accelerating the growth and development of our talent who have the potential to hold leadership roles in our business in the future.,Boston_Scientific_Performance_Report_2018.pdf
"In addition to offering more than 150 professional and technical skills courses to all global employees each year, we also offer several specific leadership development programs: Building Managerial Potential (BMP): The BMP is for employees who nominate themselves to build the skills they need to prepare for management roles.",Boston_Scientific_Performance_Report_2018.pdf
"Since its launch in 2016, approximately 500 employees have graduated from the program, including more than 200 in 2018.",Boston_Scientific_Performance_Report_2018.pdf
"Advanced Manager Development Program (AMDP): The AMDP helps middle managers with several years of experience strengthen key compe- tencies such as strategic thinking, communication and managing across cultures.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, 91 managers participated in the program; more than 500 have completed the course since 2016.",Boston_Scientific_Performance_Report_2018.pdf
"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.33 Leadership Development Program (LDP): Director- level and above employees are nominated to participate in LDP to prepare for their next level of growth by enhancing skills in personal and team leadership through interactive sessions and busi- ness simulation, while providing opportunities for networking and interaction with global peers and senior leaders.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, the LDP had 62 participants from 13 countries.",Boston_Scientific_Performance_Report_2018.pdf
More than 490 leaders have participated since the first offering in 2013.,Boston_Scientific_Performance_Report_2018.pdf
"Accelerated Leadership Development Program (ALDP): Senior leaders act as facilitators for ALDP, which is designed to accelerate the readiness of high potentials and key successors to take on more complex roles in the organization.",Boston_Scientific_Performance_Report_2018.pdf
"A series of one-week classroom sessions provides simula- tions, case studies and networking opportunities with peers across the company and members of the Executive Committee.",Boston_Scientific_Performance_Report_2018.pdf
"During the sessions, each participant is assigned a coach to support continued feedback and development.",Boston_Scientific_Performance_Report_2018.pdf
"Nearly 330 leaders have completed the program since its inception in 2010, with 27 participants in 2018.",Boston_Scientific_Performance_Report_2018.pdf
Leadership Development Within Regions and Across Cultures Boston Scientific has also created targeted leadership development programs to complement corporate programs and support the development of talent across the organization.,Boston_Scientific_Performance_Report_2018.pdf
"Some examples of regional development programs include: Through a combination of challenging interna- tional work experiences and business projects, the Asia Pacific Global Leadership Development Program (GLDP) is a tailored program that aims to systematically develop talented, diverse and global leaders who are capable of leading the organization into the future.",Boston_Scientific_Performance_Report_2018.pdf
"In Latin America, regional leadership development programs are facilitated by senior leaders and program alumni to support the development of competencies and capabilities that address the region’s unique health ecosystem and emerging market challenges.",Boston_Scientific_Performance_Report_2018.pdf
"The Europe, Middle East and Africa region’s Key Talent Program provides high potential senior managers and directors with opportunities, experiences and leadership exposure to accelerate their development and deepen the region’s leadership pipeline.",Boston_Scientific_Performance_Report_2018.pdf
"Cross Cultural Learning As a global company operating around the world, employees have an opportunity to interact routinely with peers, customers and patients from a variety of cultures and countries.",Boston_Scientific_Performance_Report_2018.pdf
"To support cross-cultural learning and awareness among all employees, the company offers a portfolio of on-demand training and resources.COMPENSATION AND BENEFITS We are committed to delivering compensation and benefit programs that support overall well-being and health, while providing flexibility to meet our employees’ unique needs and expectations.",Boston_Scientific_Performance_Report_2018.pdf
"We embrace our multigenerational workforce, with programs that go beyond best-practice and focus on best-fit.",Boston_Scientific_Performance_Report_2018.pdf
Equal Pay for Equal Work Paying our employees equally for equal work is consistent with our values and is at the heart of our global compensation practices.,Boston_Scientific_Performance_Report_2018.pdf
"Our approach to monitoring and maintaining pay equity includes regularly benchmarking global salaries, conducting rigorous internal and external parity audits and reviewing pay recommendations across the company as part of our annual compensation process.",Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific works with an independent, third party to annually assess pay equity across global salaried and sales populations.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we expanded our focus to include hourly employees.",Boston_Scientific_Performance_Report_2018.pdf
"We check for pay equality using regression analysis — an approach to analyzing data that controls for variables that appropriately influence pay such as job, tenure, years of experience and location.",Boston_Scientific_Performance_Report_2018.pdf
"We then look for differences in pay between genders and, in the U.S. and Puerto Rico, individuals of different races/ ethnicities.More than 2,000 people leaders around the globe completed over 6,000 MDP sessions.2018 ACHIEVEMENT: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.34 Consistent with our previously published findings, our 2018 analyses found less than a 1 percent statistical difference in pay along gender lines for our global salaried, hourly and sales employees.",Boston_Scientific_Performance_Report_2018.pdf
"For hourly employees, we identified less than a 1.1 percent statistical difference for race/ethnicity in the U.S. and Puerto Rico*, and no disparities for salaried and sales employees.",Boston_Scientific_Performance_Report_2018.pdf
In the few instances where we identified a gender disparity — which occurred in positions involving both men and women — we examined the circumstances and acted to increase pay where appropriate.,Boston_Scientific_Performance_Report_2018.pdf
We will continue to evolve our practices to maintain and improve on our results.,Boston_Scientific_Performance_Report_2018.pdf
"For example, to further reduce potential for biases in our hiring practices, in 2018, we prohibited the request of salary history from all U.S. job applicants.",Boston_Scientific_Performance_Report_2018.pdf
"The range of our jobs are based on the skill set, experience required and what the market demands, not on what candidates have earned before.",Boston_Scientific_Performance_Report_2018.pdf
We are evaluating similar hiring practices for global locations in concert with local laws and regulations.,Boston_Scientific_Performance_Report_2018.pdf
Analysis and reporting of pay equity results are completed annually.,Boston_Scientific_Performance_Report_2018.pdf
"Benefits Good health, financial wellness and security are critical to a productive workforce.",Boston_Scientific_Performance_Report_2018.pdf
We support a culture of health by providing comprehensive benefits to our employees.,Boston_Scientific_Performance_Report_2018.pdf
"The following principles govern our benefit plans on a global basis: Enable High Performing Talent — As part of a broader rewards portfolio, we offer market competitive benefits that are flexible and affordable to meet the individual needs of our increasingly diverse talent base Support Life/Work Integration — We strive to offer programs that acknowledge, respect and support an individual’s life and work choices Sales100 % Hourly99.5% Salaried99.9%2018 Gender Globally Sales100 % 100 % Hourly98.9 % Salaried 2018 Race / Ethnicity: U.S. / Puerto Rico Promote Well-being — Our holistic programs are intended to support and encourage physical, emotional, financial and social well-being.",Boston_Scientific_Performance_Report_2018.pdf
"Empowering employee well-being leads to improved performance for the individual and the organization Value and Cultural Fit — We strive to offer benefits that are valued by our employees, differentiated by our culture when appropriate, and supportive of an inclusive work environment Communication and Tools — We aim to communicate in a manner that makes our plans easy to understand and use, and enables employees to take action to achieve well-being.",Boston_Scientific_Performance_Report_2018.pdf
"For a comprehensive look at Boston Scientific benefits package, please visit: https://secure.",Boston_Scientific_Performance_Report_2018.pdf
"bscbenefitsconnect.com/home/index.html Global Sabbaticals Policy In 2018, Boston Scientific began offering sabbaticals to employees with more than seven years of service to recognize their tenure and enable a planned time of renewal for development or enrichment.",Boston_Scientific_Performance_Report_2018.pdf
"For those countries where national laws mandate that companies allow employees to apply for a sabbatical leave with less than seven years of service, the local tenure threshold is used.",Boston_Scientific_Performance_Report_2018.pdf
"We believe employees return from time away revitalized, with new perspectives that enable them to be more productive and engaged.",Boston_Scientific_Performance_Report_2018.pdf
Sabbaticals also represent interim opportunities for others within the organization to build skills and capabilities.,Boston_Scientific_Performance_Report_2018.pdf
*Each country has specific requirements and legal considerations regarding how race/ethnicity data can be used and reported.,Boston_Scientific_Performance_Report_2018.pdf
"Our reporting focuses on our US/PR populations as it is uniform in definition, reporting and use.Equal Pay For Equal Work Percentage of employees who showed no statistically significant pay disparity: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.35 Global Employee Assistance Program Global Employee Assistance programs provide a network of support and valuable resources that encourages overall well-being, including help with finances, family life, elder/child care and mental health.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we expanded the availability of the programs to include coverage in all countries where Boston Scientific has a concentration of employees.",Boston_Scientific_Performance_Report_2018.pdf
"EMBRACING NEW LIFE-WORK NEEDS Our Benefits to Fit Your Life program provides a range of benefits and services for different stages of life that reflect what our employees want and need to be happy, productive and engaged in their roles.",Boston_Scientific_Performance_Report_2018.pdf
"In the U.S., the program includes enhanced infertility treatment support and expanded maternal and paternal leave, as well as breast milk shipping service and increased assistance for working parents to find and pay for child care.",Boston_Scientific_Performance_Report_2018.pdf
"We also added telehealth services and a new meal planning service, while expanding programs for college planning and caring for aging parents.",Boston_Scientific_Performance_Report_2018.pdf
"We will continue to evolve these programs with a focus on paid time off, employee needs resulting from the impact of delaying a family for a career, fertility in all family units, and tuition and educational support that includes remote learning and non-degree education.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we expanded the Benefits to Fit Your Life program globally with programs developed in direct response to regional employee input.",Boston_Scientific_Performance_Report_2018.pdf
"Examples of our new offerings include: Ireland – Alignment of maternity and paternity pay and job-sharing for direct labor employees as well as career staff Japan – Programs to expand flexibility and family support options for employees, including improved work-from-home policies Hong Kong – Flexible fitness, engagement, personal development, child care and dental benefits China – New family-friendly options for working parents such as flexible hours on the first day of the school term India and Korea – Child care subsidies for working parents as well as new education support options Employee Health and Safety A commitment to employee health and safety is a prerequisite to our pursuit of patient care.",Boston_Scientific_Performance_Report_2018.pdf
A shared culture of ensuring the safety of our employees enables meaningful innovation and business success.,Boston_Scientific_Performance_Report_2018.pdf
"Our strong health and safety performance contributes to competitive strength and benefits for not only our employees, but also our customers, communities and shareholders.",Boston_Scientific_Performance_Report_2018.pdf
"To deliver on our goals in accordance with the Boston Scientific Environmental, Health and Safety (EHS) policy, we integrate safety metrics in our overall monitoring systems at the local and global levels.",Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific teams review these metrics daily in local groups, weekly in management meetings and monthly with global leadership, with a focus on adverse trends or significant incidents to ensure effective responses.",Boston_Scientific_Performance_Report_2018.pdf
"We set measurable safety goals called Total Recordable Incident Rate (TRIR) targets for every Boston Scientific site, with lower targets at our less complex locations.",Boston_Scientific_Performance_Report_2018.pdf
"Our EHS Operations Council assesses performance monthly to discuss trending and improvement opportunities, including global company leadership reviews.2018 ACHIEVEMENT: 0.5/100 We maintained our target safety goal of 0.5 injuries per 100 employees, which we achieved in 2017... two years ahead of our 2019 target.",Boston_Scientific_Performance_Report_2018.pdf
*Safety goal specific to Boston Scientific major manufacturing and distribution facilities.,Boston_Scientific_Performance_Report_2018.pdf
"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.36 2018 renovations in our Galway, Ireland, facility focused around biophilic design, an emerging field with the goal of connecting people more closely to nature.",Boston_Scientific_Performance_Report_2018.pdf
"2018 was the first full year of operations in our expanded Heredia, Costa Rica, facility, featuring bright and open collaboration spaces and new amenities.Our new Hong Kong office, which opened in February 2018, offers modern, collaborative equipment and plenty of natural light in a location convenient to public transportation.Renovations to our San Jose – Baytech, California, facility included adding more than 20,000 square feet of state- of-the-art R&D lab and open office space, as well as a new on-site fitness center.The Arden Hills, Minnesota, office was renovated in 2018 to include a state-of-the-art employee café and multi-use space.Boston Scientific WorkspacesOccupational Health and Well-being Our employees are our most important resource and a comprehensive employee well-being program is an integral part of our employee support system.",Boston_Scientific_Performance_Report_2018.pdf
"To ensure stronger and more focused programs, we launched a new Occupation Health Council in 2017 and saw promising results from its first full year of work in 2018.Health and wellness programs provided in 2018 included employee nutrition, yoga, weight management support, smoking cessation, mindfulness and organized team sports events.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, we maintain global facilities at a high standard to ensure our physical workspaces promote optimal physical health and overall well-being.",Boston_Scientific_Performance_Report_2018.pdf
"We continue to invest in Boston Scientific workspaces worldwide to provide energy-filled, creative environments that allow innovation to thrive and employees to feel included, valued and engaged.",Boston_Scientific_Performance_Report_2018.pdf
"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.37 CARING FOR OUR COMMUNITIES Boston Scientific employees volunteer at a variety of organizations in communities where we operate, including this event during our annual Week of Caring to support a homeless shelter in California.",Boston_Scientific_Performance_Report_2018.pdf
"Our caring value guides us in how we engage with patients, how we work together as colleagues and how we invest in the well-being of communities.",Boston_Scientific_Performance_Report_2018.pdf
"Around the world, our employees participate in and influence the way we care for people in local communities.",Boston_Scientific_Performance_Report_2018.pdf
"We focus our community engagement efforts on three key areas: Health We aim to decrease health disparities for the underserved by providing access to quality care, supporting prevention and awareness programs and helping to prepare children for a healthy journey into adulthood.Education By supporting education and STEM (Science, Technology, Engineering and Math) programming for K-12 students around the globe, we are helping to develop the diverse future talent that will enable us to create health solutions for generations to come.Community Through engagement and recognition programs, we are empowering our employees to Advance Possibilities in their local communities by donating their time and resources to help those most in need.",Boston_Scientific_Performance_Report_2018.pdf
OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.38 PROMOTING HEALTH EQUITY Fostering Healthy Communities Our work in healthcare comes with a profound responsibility to those around us.,Boston_Scientific_Performance_Report_2018.pdf
"As the industry landscape evolves, we know that preventing illness is just as important as treating it.",Boston_Scientific_Performance_Report_2018.pdf
Our health awareness programs provide education and resources to help people around the world live better and healthier lives.,Boston_Scientific_Performance_Report_2018.pdf
"Additionally, we work with global organizations to bring new resources to regions where people lack access, information and basic care.",Boston_Scientific_Performance_Report_2018.pdf
We are also focused on reducing risk and decreasing health disparities in chronic disease for underserved populations.,Boston_Scientific_Performance_Report_2018.pdf
"We strive to help as many patients as possible improve their health by sharing our products, expertise, time and resources.",Boston_Scientific_Performance_Report_2018.pdf
"Our global collaborations with Project Hope, Partners in Health and Children’s HeartLink have helped to increase the investment in, and number of, global healthcare workers focused on chronic disease.",Boston_Scientific_Performance_Report_2018.pdf
"Since 2016, the combined impact of these partnerships has included training for 2,255 healthcare workers and chronic disease screening, education or care for 20,147 people in India, South Africa, Malaysia and Mexico.",Boston_Scientific_Performance_Report_2018.pdf
"Project HOPE in South Africa Boston Scientific collaborated with Project HOPE, a U.S.-based global health and humanitarian relief organization, to implement new health screening protocols in South Africa, a priority set by South Africa’s Ministry of Health.",Boston_Scientific_Performance_Report_2018.pdf
The project focused on creating standards for screening and on increasing the skills of local community health workers to reduce occurrence of noncommunicable diseases.,Boston_Scientific_Performance_Report_2018.pdf
"Project HOPE teams have completed training of more than 350 community health workers on effective health screening of diabetes and hypertension, as well as nearly 50 nurses.",Boston_Scientific_Performance_Report_2018.pdf
"As a result of Boston Scientific funding and employee volunteers, Project HOPE expects to reach 60,000 people who will receive screening and health services from newly trained community health workers in South Africa.",Boston_Scientific_Performance_Report_2018.pdf
"Health Camp in India Boston Scientific teams in India and Marlborough, Massachusetts, joined forces with HCS Wellness, a firm in India that helps workplaces build wellness programs, to provide a healthcare camp for children at an underprivileged school in Gurgaon, India.",Boston_Scientific_Performance_Report_2018.pdf
"More than 200 children were given health tutorials and medical, dental and eye screenings to determine their need for eyeglasses, vaccines and additional dental procedures.",Boston_Scientific_Performance_Report_2018.pdf
"The teams also handed out school supplies, dental care items and fleece blankets.",Boston_Scientific_Performance_Report_2018.pdf
"25,000+ People reached in 2018 by Close the Gap health equity activities and initiatives100+ U.S. Congress members educated on the impact of critical limb ischemia and lower extremity amputations among African Americans17 States with high cardio- vascular disease mortality and/or significant health disparity* benefited from education and awareness activities 433,000+ Impressions from the Close the Gap Twitter account in 201873% Positive response to all tweets and campaigns OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.39 Close the Gap Health Equity Initiative Boston Scientific is leading efforts to promote health equity through our Close the Gap initiative , which aims to eliminate care disparities and improve patients’ access to health services regardless of age, gender, race, ethnicity or primary language.",Boston_Scientific_Performance_Report_2018.pdf
"The company collaborates with diverse stakeholders to advocate for broader minority representation in clinical trials, to support patient advocacy efforts, and to reach underserved patient populations with culturally relevant education and resources delivered through events, programs and social media dialogue.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, nearly 60 Close the Gap events took place in communities across the United States.",Boston_Scientific_Performance_Report_2018.pdf
*Measured by the Agency for Healthcare Research and Quality.Close the Gap By the NumbersTaking Action to Close the Gap Collaborating at Pride The Close the Gap team collaborates closely with the PACE (People Accepting and Celebrating Equality) ERG to create relevant LGBTQ+ educational materials focused on health disparities in the community.,Boston_Scientific_Performance_Report_2018.pdf
"At the June 2018 Twin Cities Pride Festival in Minneapolis, Minnesota, volunteer physicians from the Minneapolis Heart Institute Foundation answered questions from participants about heart disease while volunteer nurses performed more than 100 blood pressure screenings and provided education on existing health disparities in the LGBTQ+ community.",Boston_Scientific_Performance_Report_2018.pdf
"This outreach will serve as a model for us at future Pride events in the U.S. OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.40 INSPIRING THE NEXT GENERATION OF LEADERS To inspire a global and diverse generation of future science, technology, engineering and math (STEM) innovators, Boston Scientific provides challenging and fun opportunities to expose children to STEM experiences and future careers.",Boston_Scientific_Performance_Report_2018.pdf
"Our volunteers bring STEM experiences to students in the communities where we operate, collaborating with educators to understand their students' needs and shape a customized approach.",Boston_Scientific_Performance_Report_2018.pdf
"From mentoring and sharing career experiences to hands-on experiments and tours of Boston Scientific facilities, we work to introduce students from underrepresented populations to the possibilities STEM learning can provide and maintain dedicated STEM teams at 13 Boston Scientific sites.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, our teams achieved: 10,500+ STEM volunteer hours 1,300+ STEM volunteers 200+ STEM events Our STEM programming is intended to help grow a future pipeline of diverse talent.",Boston_Scientific_Performance_Report_2018.pdf
An important part of our STEM outreach efforts has been finding creative and interactive ways for Boston Scientific employees to share their passion for their work with young learners.,Boston_Scientific_Performance_Report_2018.pdf
"We’ve created career cards, videos and other tools to introduce students to employees in a variety of STEM roles.",Boston_Scientific_Performance_Report_2018.pdf
"Left: Each year, the Boston Scientific Arden Hills, Minnesota, STEM team hosts an annual Girl Scout Patch Day with the Society of Women Engineers.",Boston_Scientific_Performance_Report_2018.pdf
"Junior Girl Scouts participate in activities to learn about engineering, science and package design.",Boston_Scientific_Performance_Report_2018.pdf
"Left: In 2018, Boston Scientific introduced students to a new friend, Procedure Pal.",Boston_Scientific_Performance_Report_2018.pdf
"Designed to help demonstrate how some Boston Scientific devices are used, Procedure Pal is an interactive table-top model that helps kids see real examples of where devices are placed within the body and how each works.",Boston_Scientific_Performance_Report_2018.pdf
Our volunteers can explain medical procedures such as deep brain stimulation for the treatment of Parkinson’s disease symptoms and the implantation of cardiac pacemakers to help the heart beat more regularly.,Boston_Scientific_Performance_Report_2018.pdf
"Created by Boston Scientific volunteers from Minnesota and Massachusetts, Procedure Pal models have been featured in demonstrations globally, including here in our Galway, Ireland facility.Right: Through the “Little Doctors” program in China, Boston Scientific employees share practical and fun lessons on first aid, CPR and trauma dressing with local students.",Boston_Scientific_Performance_Report_2018.pdf
STEM Spotlight: Nurturing Talent for the Future S.T.E.M.,Boston_Scientific_Performance_Report_2018.pdf
OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.41 states.,Boston_Scientific_Performance_Report_2018.pdf
We also managed an Employee Disaster Relief Fund to support individuals and families impacted by large natural weather events and disasters.,Boston_Scientific_Performance_Report_2018.pdf
"Many people who were impacted by Hurricane Maria in September 2017 continued to benefit from this fund in 2018, with Boston Scientific employees and the company donating $810,000 in 2018, adding to the more than $4 million given in 2017.",Boston_Scientific_Performance_Report_2018.pdf
"Possibility Grants In 2018, Boston Scientific offered Massachusetts and Minnesota employees the opportunity to nominate local non-profits for Possibility Grants intended to help solve a significant problem in a local community.",Boston_Scientific_Performance_Report_2018.pdf
"Ten award winners received a total of nearly $14,000 to support projects and programs including a new indoor arena for a therapeutic horseback riding program for young adults with special needs, a middle school garden and compost program, and new computers for a teen crisis center.",Boston_Scientific_Performance_Report_2018.pdf
"GIVING BACK TO OUR COMMUNITIES In 2018, our global network of Boston Scientific employee volunteers raised awareness through more than 600 community engagement events in 33 countries.",Boston_Scientific_Performance_Report_2018.pdf
We have an awards program to recognize outstanding employee volunteers and received more than 250 nominations highlighting the work of employees who are making a difference through culturally and locally relevant community service.,Boston_Scientific_Performance_Report_2018.pdf
We also help communities in need through the Boston Scientific Employee Matching Gifts Program and the Employee Disaster Relief Fund.,Boston_Scientific_Performance_Report_2018.pdf
"Through our Employee Matching Gifts Program, employees can contribute to a cause they care about with Boston Scientific matching their gift.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we provided $8.9 million in charitable contributions to support communities around the world, targeted mostly to health and education efforts.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, we provided over $72 million in funding for research and education efforts across a wide category of health and disease Living Our Caring Value: 43,000+ hours volunteering in our communities 8,500+ employee volunteers around the world 600+ employee volunteering events worldwide Boston Scientific volunteers in Maple Grove, Minnesota, participated in an event called Free Bikes for Kids to benefit local children.",Boston_Scientific_Performance_Report_2018.pdf
"BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.42 OUR PRACTICES OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.43 As we work together to advance science for life, the quality and safety of our products and services is our top priority.",Boston_Scientific_Performance_Report_2018.pdf
"We are committed to applying safe, ethical and sustainable business practices in all that we do to make a meaningful difference in the lives of patients and their families.",Boston_Scientific_Performance_Report_2018.pdf
"WORKING RESPONSIBLY We work responsibly to research, develop, man- ufacture and deliver our innovative products with our commitment to strong corporate governance, impeccable ethics and compliance with industry regulations.",Boston_Scientific_Performance_Report_2018.pdf
GOVERNANCE Boston Scientific is committed to doing business with integrity and honesty.,Boston_Scientific_Performance_Report_2018.pdf
"An ethical workplace and governing structure begins with our Board of OUR PRACTICES Directors and executive leadership, who oversee the implementation of guidelines to ensure we act ethically in our business practices, comply with local tax and business laws and regulations, and remain transparent in our reporting.",Boston_Scientific_Performance_Report_2018.pdf
"All of our employees are responsible for applying these guidelines to interactions with customers, suppliers and investors, and in the communities in which we operate.",Boston_Scientific_Performance_Report_2018.pdf
Our Board maintains charters for governing its committees.,Boston_Scientific_Performance_Report_2018.pdf
"The current committees of the Board are the Audit Committee, Executive Compensation and Human Resources Committee, Finance Committee, and Nominating and Governance Committee.",Boston_Scientific_Performance_Report_2018.pdf
A nominating and governance committee reviews our Board composition and committee membership annually to ensure it reflects the needs of our diverse stakeholders.,Boston_Scientific_Performance_Report_2018.pdf
Risk management is essential to our governance.,Boston_Scientific_Performance_Report_2018.pdf
"Our Board oversees an Enterprise Risk Management program, which identifies strategic, operational, financial, legal and compliance risks so we can anticipate and adapt to potential challenges.",Boston_Scientific_Performance_Report_2018.pdf
"We continually evaluate our corporate governance guidelines, committee charters and Code of Conduct, taking into consideration relevant laws, regulations and listing requirements, as well as best practices suggested by recognized governance authorities.",Boston_Scientific_Performance_Report_2018.pdf
"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.44 COMPLIANCE, ETHICS AND INTEGRITY Our company values underpin our commitment to ethical and honest business practices in everything we do.",Boston_Scientific_Performance_Report_2018.pdf
"Our employees are expected to: Act honestly and ethically in all company matters Protect the privacy of patients, customers and employees Treat each other with respect and fairness Hold each other accountable to ensure quality in all that we do The Global Compliance team, led by our chief compliance officer, supports the company’s world- wide culture of compliance and ethics through partnerships and collaboration with commercial team members and other key stakeholders.",Boston_Scientific_Performance_Report_2018.pdf
The chief compliance officer reports quarterly to the audit committee of the Board of Directors.,Boston_Scientific_Performance_Report_2018.pdf
"Code of Conduct for Employees and Channel Partners Boston Scientific strives to comply with applicable laws in every relationship, every day.",Boston_Scientific_Performance_Report_2018.pdf
Our Code of Conduct is the foundation for our existing policies and must be read and fully understood by every employee.,Boston_Scientific_Performance_Report_2018.pdf
"Additionally, we have multiple training curriculums which are required for all employees.",Boston_Scientific_Performance_Report_2018.pdf
"Our Code of Conduct training curriculum provides ongoing education to employees on our policies, corruption and compliance-related risks, and resources for asking questions and reporting concerns.",Boston_Scientific_Performance_Report_2018.pdf
"It also features real-life, scenario-based content.Our U.S.",Boston_Scientific_Performance_Report_2018.pdf
"Customer Interactions training provides guidance on the laws, policies, principles and processes for interacting with healthcare professionals licensed to practice in the U. S. Our anti-corruption training course reviews the compliance requirements for interacting with healthcare professionals, public officials and other third parties, such as our channel partners (e.g., distributors, dealers and agents) outside of the U.S. Our Channel Partner Code of Conduct sets forth expectations for our channel partners (i.e., distributors, dealers and agents) doing business on our behalf.",Boston_Scientific_Performance_Report_2018.pdf
All channel partners annually certify adherence to the Boston Scientific and Channel Partner Codes of Conduct as part of on-boarding or renewal procedures as well as complete mandatory training.,Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific requires channel partners to abide by anti-bribery and anti-corruption laws, such as the U.S. Foreign Corrupt Practices Act, the U.K.",Boston_Scientific_Performance_Report_2018.pdf
Bribery Act and other national laws.,Boston_Scientific_Performance_Report_2018.pdf
"We monitor and support our channel partners through our Third Party Program, which includes on-site auditing and other procedures that validate channel partners’ compliance with our requirements.",Boston_Scientific_Performance_Report_2018.pdf
"Compliance Program We have a comprehensive compliance program to prevent, detect and respond, if needed, to conduct that does not align to our Code of Conduct.",Boston_Scientific_Performance_Report_2018.pdf
"Our program also includes periodic assessments of our compliance program’s effectiveness and an annual risk assessment, using internal and external inputs, to determine strategic focus areas across all elements of our compliance program.",Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific Advice Line We encourage employees to ask questions and report concerns, including anything that conflicts with our Code of Conduct, through our advice line, which is operated by a third party and available 24 hours a day in multiple languages.",Boston_Scientific_Performance_Report_2018.pdf
"Our Non-Retaliation Policy prohibits any form of retaliation, direct or indirect, against an individual who raises a concern in good faith.",Boston_Scientific_Performance_Report_2018.pdf
"This policy extends to anyone who assists with, or cooperates in, an investigation or report of misconduct.EMPLOYEE EXPECTATIONS: Act honestly and ethically.",Boston_Scientific_Performance_Report_2018.pdf
"Protect privacy of patients, customers and employees.",Boston_Scientific_Performance_Report_2018.pdf
Be respectful and fair.,Boston_Scientific_Performance_Report_2018.pdf
"Hold each other accountable, to ensure quality in all we do.",Boston_Scientific_Performance_Report_2018.pdf
OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.45 DEVELOPING INNOVATIVE PRODUCTS It takes an unwavering focus to deliver life-changing treatments.,Boston_Scientific_Performance_Report_2018.pdf
"We foster an environment of creativity to transform new ideas into breakthrough services and solutions that create value for patients, customers and employees.",Boston_Scientific_Performance_Report_2018.pdf
"Our teams collaborate internally and externally to solve the challenges that matter most, always with a focus on patients.",Boston_Scientific_Performance_Report_2018.pdf
"Our Global Approach to Innovation Boston Scientific new product development teams follow the Product Life Cycle Process (PLCP), a global process that integrates business, technical and quality system tasks to drive innovative product ideas from strategy through commercialization to product end-of-life.",Boston_Scientific_Performance_Report_2018.pdf
"This methodology helps us share experience and knowledge across the company and ensures a consistent, quality-focused approach to new products and services.",Boston_Scientific_Performance_Report_2018.pdf
"To better meet the needs of patients and customers in global markets, we have research and development sites in the United States, European Union, Costa Rica, India and China.",Boston_Scientific_Performance_Report_2018.pdf
These sites help us closely align our R&D teams designing products with our manufacturing teams building products.,Boston_Scientific_Performance_Report_2018.pdf
"In addition, our R&D Centers of Excellence help us share expertise and capabilities across our global product development network.",Boston_Scientific_Performance_Report_2018.pdf
Pre-Clinical Sciences Boston Scientific conducts pre-clinical research to investigate and demonstrate the safety and efficacy of our medical device products prior to human clinical trials and use.,Boston_Scientific_Performance_Report_2018.pdf
"To ensure excellence in our pre-clinical research and science, our policies set standards to be certain that we are consistently pursuing product efficacy, fulfilling regulatory requirements and engaging in essential training.",Boston_Scientific_Performance_Report_2018.pdf
"At times, to ensure we meet our obligations of safety in new products and therapies, animal testing is utilized and serves as an important component of our research and development efforts.",Boston_Scientific_Performance_Report_2018.pdf
The FDA may require evidence from pre-clinical testing prior to commencing human clinical trials.,Boston_Scientific_Performance_Report_2018.pdf
"We are committed to the humane care and treatment of laboratory animals, and use alternative testing whenever such methods are feasible, scientifically valid and appropriate.",Boston_Scientific_Performance_Report_2018.pdf
"Our pre-clinical research personnel are highly trained with multiple certifications and our facilities meet or exceed applicable laws and regulatory authority requirements, guidelines and standards.",Boston_Scientific_Performance_Report_2018.pdf
"Finally, we are routinely audited by our own internal experts and relevant government agencies including FDA, USDA and AAALAC.",Boston_Scientific_Performance_Report_2018.pdf
Clinical Trials Advancing our product pipeline to include new and expanded indications requires a commitment to leading transformative and innovative science.,Boston_Scientific_Performance_Report_2018.pdf
Clinical trials are critical to our assurance that the products we offer are of the highest quality and safety.,Boston_Scientific_Performance_Report_2018.pdf
"We conduct trials in accordance with international and national regulatory requirements with dedication to our quality systems, which are designed for legal and regulatory compliance, as well as for enhancing delivery of global trial operations.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we invested in operational enhancements that will prepare our trials for compliance with the General Data Protection Regulation, E.U.",Boston_Scientific_Performance_Report_2018.pdf
Medical Device Regulation and Risk-Based Monitoring as well as additional enhancements to drive ISO (International Standards Organization) and operational excellence.,Boston_Scientific_Performance_Report_2018.pdf
"CLINICAL STUDIES AT A GLANCE: There were 150 active clinical studies in 2018, including more than 55,000 patients globally.Recognize Development Excellence is an annual Boston Scientific program that recognizes and rewards cross-functional teams who develop meaningful innovations for patients, customers and company.Now in its fourth year, the Boston Scientific Connected Patient Challenge is an open competition to promote the development of meaningful innovation to address complex healthcare challenges.",Boston_Scientific_Performance_Report_2018.pdf
"The 2018 competition, co-sponsored by Google Cloud, focused on the role of the Internet of Things in influencing patient outcomes.",Boston_Scientific_Performance_Report_2018.pdf
"The winner, XcellCure, a startup biotechnology company, developed the AmiAware cardiac microarray concept to detect early warning signs of a heart attack in patients with chest pain.",Boston_Scientific_Performance_Report_2018.pdf
The award enabled the company to further develop the platform and clinical strategy.,Boston_Scientific_Performance_Report_2018.pdf
Boston Scientific leaders demonstrate their commitment to innovation though the ImagineIF Innovation Fund.,Boston_Scientific_Performance_Report_2018.pdf
Employees are encouraged to participate in a venture-style contest that solicits breakthrough ideas across the organization.,Boston_Scientific_Performance_Report_2018.pdf
This program helps to continuously reinforce our meaningful innovation core value.,Boston_Scientific_Performance_Report_2018.pdf
"Since the 2014 launch, we’ve funded more than 50 projects.",Boston_Scientific_Performance_Report_2018.pdf
"Focus on Innovation Celebrating Our Teams Recognizing Development Excellence Improving Patient Care with Digital Health OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.46RECOGNITION FOR INNOVATION EXCELLENCE IN 2018 Forbes Most Innovative Companies: Boston Scientific named to Forbes' list of The World's Most Innovative Companies Clarivate: Boston Scientific recognized for the third consecutive year as a Derwent Top 100 Global Innovator by Clarivate Analytics Prix Galien: The Boston Scientific WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device received the Prix Galien USA 2018 Award for Best Medical Technology, one of the global health innovation industry’s most prized honors Every employee makes an impact on the quality of patient care and has an opportunity to innovate so that we can keep improving.",Boston_Scientific_Performance_Report_2018.pdf
We will never be satisfied with the status quo.,Boston_Scientific_Performance_Report_2018.pdf
OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.47 Collaborating on Solutions to Improve Patient Care The Boston Scientific ADVANTICS™ Innovative Healthcare Solutions portfolio helps customers solve complex challenges.,Boston_Scientific_Performance_Report_2018.pdf
"Using clinical and operational expertise, our team works together with cardiovascular staff to improve the patient experience, grow their Structural Heart programs and optimize cardiovascular lab performance.",Boston_Scientific_Performance_Report_2018.pdf
"Recent collaborations include: A 300+ bed hospital that offers advanced services in cardiovascular medicine where we identified improvement opportunities within the Structural Heart program, including increasing patient access to care and efficiency of care.",Boston_Scientific_Performance_Report_2018.pdf
"As a result, the hospital has been able to treat more patients who benefited from a streamlined referral process and operational improvements.",Boston_Scientific_Performance_Report_2018.pdf
A 500+ bed hospital where we facilitated same-day discharges for patients who under - went percutaneous coronary intervention (PCI).,Boston_Scientific_Performance_Report_2018.pdf
"Within 12 months, more than 30 percent of patients who would have previously required an overnight stay were discharged the same day and able to recover in the comfort of their own homes.",Boston_Scientific_Performance_Report_2018.pdf
"This resulted in decreased costs and increased inpatient bed capacity.QUALITY AND SAFETY Quality is integrated into every aspect of our work to ensure we design, test, manufacture and distribute high-quality, safe and effective devices.",Boston_Scientific_Performance_Report_2018.pdf
"Our commitment to quality begins with our Quality Policy, a one-line statement that is highly visible in our facilities: “I improve the quality of patient care and all things Boston Scientific.” This commitment is supported by Quality Systems Basics training for all Boston Scientific employees.",Boston_Scientific_Performance_Report_2018.pdf
"The following key elements are included in our approach to quality: A Quality Master Plan that helps us strategically plan and prioritize quality improvement projects that emphasize prevention and will lead to higher quality products, with better patient outcomes and fewer customer complaints A strategy we call Best4, with the goal of delivering industry-leading performance in (1) compliance, (2) outcomes, (3) efficiency and (4) agility A Global Quality System that integrates customer feedback and regulatory requirements into our processesFocus on Quality: Connecting our teams to customers and patients Annual employee events are held at Boston Scientific sites to celebrate the impact our work has on improving the quality of patient care.",Boston_Scientific_Performance_Report_2018.pdf
"The theme of these events is “Everyone Makes an Impact,” reinforcing the importance of every employee’s role.",Boston_Scientific_Performance_Report_2018.pdf
"Patients and physicians attend as guest speakers to share personal experiences, and employees participate in activities to reaffirm their commitment to the Boston Scientific Quality Policy.",Boston_Scientific_Performance_Report_2018.pdf
"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.48 Our Quality Mission, ""We exceed expectations with customer-centric quality solutions that transform patient lives,"" is at the forefront of our product development process and complements our Quality Policy.",Boston_Scientific_Performance_Report_2018.pdf
"Our Global Design Controls process, integrated with Risk Management and Usability Engineering helps us leverage complex technologies to create safe and effective solutions.",Boston_Scientific_Performance_Report_2018.pdf
We use an iterative process that centers on the needs of the final user at every stage of design and development.,Boston_Scientific_Performance_Report_2018.pdf
Our employees are encouraged to spend time outside our offices to observe procedures and talk to patients as well as healthcare providers.,Boston_Scientific_Performance_Report_2018.pdf
A key aspect of product quality includes the materials used in our manufacturing processes.,Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific has globally harmonized processes and systems to provide an efficient, flexible and comprehensive approach to compliance with medical, environmental and other material regulations.",Boston_Scientific_Performance_Report_2018.pdf
This includes component material and device material assessment.,Boston_Scientific_Performance_Report_2018.pdf
We carefully select the materials used in our products as well as our suppliers so that we can provide safe and effective solutions.,Boston_Scientific_Performance_Report_2018.pdf
"Our teams continually monitor and comply with global regulations to ensure our products continue to meet all applicable requirements.Continually Improving with Quality Initiatives Each year we undertake several targeted quality and compliance initiatives to ensure ongoing compliance with changing global industry regulations, while also focusing on continuously improving our products.",Boston_Scientific_Performance_Report_2018.pdf
Highlights of our 2018 accomplishments include: Implemented a global design controls process that fully integrates usability engineering and risk management for effective new product develop- ment as well as customer-centric product designs.,Boston_Scientific_Performance_Report_2018.pdf
Enabled innovation and expansion into new technologies with the launch of our new Global Process for Digital Health Development and Validation.,Boston_Scientific_Performance_Report_2018.pdf
Adapted to the evolving regulatory environment with programs to implement General Data Protection Regulation (GDPR) and continued to prepare for the European Union Medical Device Regulation (MDR).,Boston_Scientific_Performance_Report_2018.pdf
Executed enterprise training for both initiatives and implemented new policies and procedure updates to ensure compliance.,Boston_Scientific_Performance_Report_2018.pdf
"Invested in advancements in Post Market Quality assurance , including implementation of a global complaint management system that will enable continued evolution in post market surveillance.",Boston_Scientific_Performance_Report_2018.pdf
Launched Workstation Built-in Quality prevention program to enable quality at the source where the product is being built.,Boston_Scientific_Performance_Report_2018.pdf
"Implemented new lab management system for our Pathology franchise that provides end-to-end specimen processing and traceability with slide printing, barcode scanning technology and enhanced quality control processes.",Boston_Scientific_Performance_Report_2018.pdf
"SUSTAINABLE SUPPLY CHAIN With approximately 15,000 life-changing products, our manufacturing and supply chain teams play a critical role in ensuring that we plan, source, manufacture and distribute a reliable supply of high-quality products to meet our customers’ evolving needs.",Boston_Scientific_Performance_Report_2018.pdf
"To guide our work, we use a strategic quality process to prioritize, execute and monitor manufacturing and supply chain efforts.",Boston_Scientific_Performance_Report_2018.pdf
The process enables our global teams to work toward a common set of objectives.,Boston_Scientific_Performance_Report_2018.pdf
Maintaining the highest-quality component supply requires a rigorous supply chain and supplier risk-management approach.,Boston_Scientific_Performance_Report_2018.pdf
Our sourcing team monitors supplier risk level to ensure that we partner with long-term suppliers that share our customer focus.,Boston_Scientific_Performance_Report_2018.pdf
Our supply chain team facilitates planning for Boston Scientific products across divisions and regions.,Boston_Scientific_Performance_Report_2018.pdf
Both teams enable our network of manufacturing plants and global distribution centers to provide the right product at the right place and the right time.,Boston_Scientific_Performance_Report_2018.pdf
Partnering to Set Industry Standards for Quality and Compliance We collaborate with trade associations and regulatory bodies around the world to set new standards in quality and to anticipate and address changing regulatory guidelines.,Boston_Scientific_Performance_Report_2018.pdf
"We are committed to having patient-focused, high-performing quality systems and helping influence industry and regulatory approaches to quality.In the U.S., we participate in the Case for Quality Voluntary Improvement Program, a multi-year initiative led by the U.S. Food and Drug Administration (FDA) in conjunction with the Medical Device Innovation Consortium (MDIC) to improve product quality using best practices, standards, tools and metrics.",Boston_Scientific_Performance_Report_2018.pdf
"In 2017, we were one of the first companies invited to participate in the agency’s Voluntary Medical Device Manufacturing and Product Quality Program.",Boston_Scientific_Performance_Report_2018.pdf
This pilot program uses an independent assessment to evaluate the capability of medical device organizations to produce high quality devices and improve patient safety.,Boston_Scientific_Performance_Report_2018.pdf
"To date, we’ve had four successful year-one and one successful year-two appraisals: Year One Appraisals: Arden Hills, Minnesota; Clonmel, Ireland; Maple Grove, Minnesota; Galway, Ireland Year Two Appraisal: Arden Hills, Minnesota We also participate in the FDA 510K improvement and Software for Digital Health programs.",Boston_Scientific_Performance_Report_2018.pdf
"In May 2017, new European Union MDR was published with the goal of strengthening the regulatory platform across the EU to further enhance patient safety.",Boston_Scientific_Performance_Report_2018.pdf
"By May 2020, companies must demonstrate compliance with the MDR for all products that require CE mark, including existing commercialized products that must apply for CE mark renewal.",Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific global quality and regulatory teams have continued to collaborate with industry trade group MedTech Europe and OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.49 “ Usability is a critical design component for a safe and effective device.” — Roz Burke, Senior Vice President, Global Quality and Regulatory Affairs “ Usability engineering helps us understand what customers do, why they do it and what they’re trying to accomplish.",Boston_Scientific_Performance_Report_2018.pdf
"With this knowledge, we can create innovative solutions that drive healthcare forward.” — David Feygin, Chief Digital Health Officer OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.50 other working groups to ensure we are prepared for the implementation of MDR requirements.",Boston_Scientific_Performance_Report_2018.pdf
"Effective May 25, 2018, the GDPR, a new European Union (EU) law, governs how companies use person- al data (customer, employee and patient data).",Boston_Scientific_Performance_Report_2018.pdf
"The GDPR broadly impacts our company since EU per - sonal data is collected, processed and stored globally.",Boston_Scientific_Performance_Report_2018.pdf
Our global privacy team collaborated with MedTech Europe as part of the data protection working group as well as the trade association AdvaMed in its new Data Stewardship and Privacy Working Group as part of our effort to comply with the new regulation.,Boston_Scientific_Performance_Report_2018.pdf
Measuring and Monitoring Effectiveness of Quality and Compliance Boston Scientific conducts internal audits to verify that our Global Quality System conforms to internal and external requirements and is effectively implemented and maintained.,Boston_Scientific_Performance_Report_2018.pdf
We plan and execute internal audits and conduct follow-up actions including re-audit of prior observations and the verification of actions taken.,Boston_Scientific_Performance_Report_2018.pdf
"External regulatory agencies also review our performance to ensure quality and compliance, with the following results in 2018: External Regulatory Inspections* 79 Percent External Regulatory Inspections Resulting in No Findings* 67% Average Findings per External Regulatory Inspection* 0.71 Average Findings per FDA Inspection 0.70 *Includes Notified Body, Competent Authority, FDAProduct Performance Boston Scientific reviews customer feedback as well as experience with our devices.",Boston_Scientific_Performance_Report_2018.pdf
This information provides valuable inputs for our Quality System as well as future product iterations and innovations.,Boston_Scientific_Performance_Report_2018.pdf
Our Corrective and Preventive Action (CAPA) process establishes a system to collect and analyze data to find root causes for potential compliance and quality problems.,Boston_Scientific_Performance_Report_2018.pdf
Our teams are then able to address any potential issues and prevent future issues or recurrences.,Boston_Scientific_Performance_Report_2018.pdf
"We initiate field actions (product advisories, product advisory updates, product retrievals), including follow-up and closure, to ensure regulatory or field safety issues are quickly and effectively addressed.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, Boston Scientific had zero Class I recalls and zero Open FDA Warning Letters.",Boston_Scientific_Performance_Report_2018.pdf
"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.51 PACKAGING AND LABELING Packaging of our medical devices ensures protection during sterilization, distribution, storage and use.",Boston_Scientific_Performance_Report_2018.pdf
We collaborate with our customers to understand their needs and requirements with usability assessments.,Boston_Scientific_Performance_Report_2018.pdf
"Additionally, we have a global Sustainability Packaging and Labeling Steering Committee that works with our CSR Council to develop our strategy and prioritize global goals and projects.",Boston_Scientific_Performance_Report_2018.pdf
"We continuously evaluate our packaging and supply chain practices to optimize design, reduce waste and limit emissions.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, with key improvements, our global packaging teams: Eliminated 120 tons of packaging from landfills Avoided 2,500 pallet shipments Repurposed 1,000 products during development Boston Scientific also ensures that we have the controls in place to initiate, review and finalize product labeling to meet global labeling regulations.",Boston_Scientific_Performance_Report_2018.pdf
Our labeling ensures proper identification and prevents mix-ups by remaining legible and attached to the product throughout its lifecycle.,Boston_Scientific_Performance_Report_2018.pdf
This additional focus on our packaging and labeling design enables us to meet the needs of our customers while reducing our overall environmental footprint.,Boston_Scientific_Performance_Report_2018.pdf
"Reducing corrugated material Final packaging and labeling processes of our Microspheres product lines were relocated from our Cork, Ireland manufacturing facility to our Kerkrade European Distribution Center, allowing sterile pack units to be packed and shipped without shelf cartons.",Boston_Scientific_Performance_Report_2018.pdf
This resulted in a 73 percent reduction of annual corrugated material consumption.,Boston_Scientific_Performance_Report_2018.pdf
"Eliminating pallet shipments Our teams updated our Electrophysiology catheter thermoformed tray design to enable local sourcing of components in Heredia, Costa Rica.",Boston_Scientific_Performance_Report_2018.pdf
This eliminated the shipment of over 47 pallets annually.,Boston_Scientific_Performance_Report_2018.pdf
"2018 WorldStar Packaging Award Winner The development of a new package design for Ureteral Stents met customers’ expectations, eliminated the need for 120,000 pounds of plastic per year, optimized storage, use and post-surgical waste in healthcare facilities and maintained product functionality.",Boston_Scientific_Performance_Report_2018.pdf
"The WorldStar Packaging Awards Competition is one of the major events of the World Packaging Organization and is the pre- eminent international award in packaging.Packaging Reduction OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.52 SUPPORTING SMALL BUSINESS AND SUPPLIER DIVERSITY Boston Scientific builds diversity and inclusion into every aspect of our business, including our supply chain.",Boston_Scientific_Performance_Report_2018.pdf
"As part of our procurement process, we strive to partner with certified companies that share our dedication to improving the quality of patient care.",Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we worked with more than 700 diverse supplier businesses, including: Minority-owned Small Small disadvantaged Veteran-owned Service disabled veteran-owned HUBZone Disability-owned LGBT-owned In 2018, $322 million of our spend was attributed to our work with diverse suppliers, a 6 percent increase from 2017.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, we conducted more than 120 capability assessments with diverse suppliers and participated in trade shows that promoted diverse suppliers.",Boston_Scientific_Performance_Report_2018.pdf
"Additionally, we strengthened our commitment to supplier diversity in 2018 by establishing a full-time management role to focus on this aspect of our operations.",Boston_Scientific_Performance_Report_2018.pdf
"Our Manager of Supplier Diversity is charged with setting our approach, policies, goals and targets to align with our values and business objectives.",Boston_Scientific_Performance_Report_2018.pdf
"In 2019, we expect to increase spending with diverse suppliers by 5 percent and to conduct an additional 100 capability assessments.Working with Responsible Suppliers We have robust standards for the more than 10,000 global suppliers with which we work to deliver our innovative medical solutions to physicians and patients.",Boston_Scientific_Performance_Report_2018.pdf
"We actively look for suppliers that deliver industry-leading quality, reliability and value as we work to meet our customers’ needs.",Boston_Scientific_Performance_Report_2018.pdf
"Quality is the most important aspect of our supplier relationships, and all direct materials suppliers are required to comply with Boston Scientific quality standards.",Boston_Scientific_Performance_Report_2018.pdf
We seek partnerships with suppliers that share our commitment to strong ethics and full compliance with all applicable laws.,Boston_Scientific_Performance_Report_2018.pdf
"In 2018, we further standardized our supplier performance assessment tools and expanded our robust criteria to include key corporate social responsibility topics among key strategic business requirements.",Boston_Scientific_Performance_Report_2018.pdf
"While this evaluation process takes time, it allows us to foster relationships with responsible suppliers that support our business continuity and risk mitigation strategy.",Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific representatives attending a 2018 Massachusetts LGBT Chamber of Commerce event. """,Boston_Scientific_Performance_Report_2018.pdf
"Embracing differences in perspectives and cultures of our suppliers furthers our goals in innovation and positively impacts the economies in which we live and work.” — Ed Mackey, Executive Vice President, Global OperationsIn 2018, we spent $322 million with 700+ diverse suppliers, a 6% increase from 2017.",Boston_Scientific_Performance_Report_2018.pdf
NON-GAAP RECONCILIATIONS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.53 This Performance Report contains forward-looking statements within the meaning of the federal securities laws.,Boston_Scientific_Performance_Report_2018.pdf
"See the discussion under “Safe Harbor for Forward-Looking Statements” in the Annual Report on Form 10-K for the year ended December 31, 2018, for matters to be considered in this regard.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, please see our Annual Report on Form 10-K for a description of our Non-GAAP adjustments and the reasons for excluding each item.",Boston_Scientific_Performance_Report_2018.pdf
"YEAR ENDED DECEMBER 31, 5-Year PERCENTAGE CHANGE IN NET SALES 2018 2017 2016 2015 2014 Average Percentage change in net sales, as reported 8.6 % 7.9 % 12 % 1 % 3 % 7 % Less: Impact of foreign currency fluctuations 0.6 % 0.1 % — % (7)% (3)% (1)% Percentage change in net sales, operational 8.0 % 7.8 % 12 % 8 % 6 % 8 % Less: Impact of certain acquisitions 0.8 % 1.2 % 2 % 3 % 2 % 1 % Percentage change in net sales, organic 7.2 % 6.6 % 10 % 5 % 4 % 7 % YEAR ENDED DECEMBER 31, OPERATING MARGIN 2 0 1 8 2017 2016 2015 2014 Operating margin, reported 15.3 % 14.2 % 5.3 % (3.8)% (4.1)% Less: Non-GAAP adjustments (10.2)% (10.8)% (18.8)% (26.1)% (24.3)% Operating margin, adjusted 25.5 % 25.0 % 24.1 % 22.3 % 20.2 % Basis Point Improvement from 2017 50 Basis Point Improvement from 2014 530 Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.",Boston_Scientific_Performance_Report_2018.pdf
Amounts may not add due to rounding.,Boston_Scientific_Performance_Report_2018.pdf
"NON-GAAP RECONCILIATIONS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.54 YEAR ENDED DECEMBER 31, 2018 Less: Impact of Less: Impact PERCENTAGE CHANGE IN NET SALES Reported Foreign Currency Operational of Certain Organic BY BUSINESS AND SEGMENT Basis Fluctuations Basis Acquisitions Basis Endoscopy 8.8 % 0.5 % 8.3 % — % 8.3 % Urology and Pelvic Health 10.8 % 0.2 % 10.6 % 2.5 % 8.1 % MedSurg† 9.7 % 0.4 % 9.3 % 1.1 % 8.2 % Cardiac Rhythm Management 2.9 % 0.8 % 2.1 % — % 2.1 % Electrophysiology 12.1 % 1.2 % 10.9 % — % 10.9 % Neuromodulation 22.7 % 0.2 % 22.5 % — % 22.5 % Rhythm and Neuro† 8.3 % 0.7 % 7.6 % — % 7.6 % Interventional Cardiology 7.1 % 0.5 % 6.6 % 2.1 % 4.5 % Peripheral Interventions 9.8 % 0.6 % 9.2 % — % 9.2 % Cardiovascular 7.9 % 0.5 % 7.4 % 1.4 % 6.0 % YEAR ENDED DECEMBER 31, 2018 Less: Impact of Reported Foreign Currency Operational PERCENTAGE CHANGE IN NET SALES BY REGION Basis Fluctuations Basis U.S. 7.3% — % 7.3% EMEA† (Europe, Middle East and Africa) 12.2% 3.2 % 9.0% APAC† (Asia-Pacific) 8.8% 1.3 % 7.5% LACA (Latin America and Canada) 6.8% (9.0)% 15.8% Emerging Markets 18.0% (3.4)% 21.4% Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.",Boston_Scientific_Performance_Report_2018.pdf
Amounts may not add due to rounding.,Boston_Scientific_Performance_Report_2018.pdf
"NON-GAAP RECONCILIATIONS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.55 YEAR ENDED DECEMBER 31, EARNINGS PER SHARE 2018 2017 2016 2015 2014 2013 GAAP earnings (loss) per share (EPS) $ 1.19 $0.08 $0.25 $(0.18) $(0.09) $(0.09) Non-GAAP adjustments 0.28 1.18 0.86 1.11a 0.93b 0.82c Adjusted EPS $ 1.47 $ 1.26 $ 1.11 $ 0.93 $ 0.84 $ 0.73 Less: Impact of 2018 net tax benefitd 0.07 — Adjusted EPS, excluding 2018 net tax benefit $1.40 $ 1.26 Adjusted EPS growth from prior year 17% 13% 20% 11% 15% Adjusted EPS growth from prior year, excluding net tax benefit 11% 5-Year Average Adjusted EPS growth, excluding net tax benefit 14% a Assumes dilution of 21.5 million shares for the year ended December 31, 2015. b Assumes dilution of 23.7 million shares for the year ended December 31, 2014. c Assumes dilution of 19.5 million shares for the year ended December 31, 2013. d Full year 2018 net tax benefit of $0.07 includes a second quarter $0.06 benefit from settling the IRS Stipulation of Settled Issues for the 2001 through 2010 tax years, offset by a fourth quarter $0.05 charge for our previously announced tax reinvestment strategy.",Boston_Scientific_Performance_Report_2018.pdf
"In addition, the net benefit includes a $0.06 benefit in the fourth quarter for the settlement with the IRS of our 2011 through 2013 tax years.",Boston_Scientific_Performance_Report_2018.pdf
"YEAR ENDED DECEMBER 31, ADJUSTED FREE CASH FLOW (IN MILLIONS) 2018 2017 Operating cash flow, reported $ 310 $1,426 Less: Purchases of property, plant and equipment 316 319 Add: Proceed on disposals of property, plant and equipment 14 — Free cash flow, reported 8 1,107 Plus: Restructuring and restructuring-related payments 89 72 Plus: Acquisition-related payments 205 95 Plus: Certain discrete tax payments 977 (239) Plus: Litigation-related settlements 791 694 Adjusted free cash flow $2,070 $1,729 Adjusted free cash flow growth from prior year 20% Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.",Boston_Scientific_Performance_Report_2018.pdf
Amounts may not add due to rounding.,Boston_Scientific_Performance_Report_2018.pdf
"Boston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-1234 bostonscientific.com© 2019 Boston Scientific Corporation or its affiliates.",Boston_Scientific_Performance_Report_2018.pdf
All rights reserved.,Boston_Scientific_Performance_Report_2018.pdf
PR2018,Boston_Scientific_Performance_Report_2018.pdf
Science.,2020_boston_scientific_performance_report.pdf
Humanity.,2020_boston_scientific_performance_report.pdf
Purpose.,2020_boston_scientific_performance_report.pdf
2020 PERFORMANCE REPORT Boston Scientific 2020 Performance Report 1 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.,2020_boston_scientific_performance_report.pdf
"When science, humanity and purpose connect, lives can be transformed.",2020_boston_scientific_performance_report.pdf
"Advancing science for lifePURPOSE A deep caring for human lifeHUMANITY Pushing the boundaries of what’s possibleSCIENCE Boston Scientific 2020 Performance Report 2 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly At Boston Scientific, our 2020 story unfolded through the experiences of health care professionals, patients, our employees and communities during a global pandemic.",2020_boston_scientific_performance_report.pdf
"As we saw humanity tested, our people stepped up in unforeseen ways to work safely as they served customers and navigated the complexities of delivering critical solutions to patients everywhere.",2020_boston_scientific_performance_report.pdf
"In a year of reckoning, we were compelled to act — inside and outside the company — as we came face to face with deep social unrest, inequities and health disparities.",2020_boston_scientific_performance_report.pdf
Our people cared for one another and our communities in ways never imagined as they stayed true to our values and focused on addressing the needs of patients.,2020_boston_scientific_performance_report.pdf
Pamela Chang is one of those patients.,2020_boston_scientific_performance_report.pdf
"Her experience exemplifies why we are dedicated to advancing science for life and why — when science, humanity and purpose come together — we can change and save lives.",2020_boston_scientific_performance_report.pdf
“ We’re focused on delivering meaningful innovations and making sure everyone who needs quality care gets it.,2020_boston_scientific_performance_report.pdf
That objective became very real for my family in 2020.,2020_boston_scientific_performance_report.pdf
"The hard work of people across Boston Scientific saved my mom’s life.” Camille Chang Gilmore , global chief diversity, equity and inclusion officer, Boston Scientific, and Pamela’s daughter ” I feel much better.",2020_boston_scientific_performance_report.pdf
"I don’t know if I could run a marathon, but I could try!” Pamela Chang , Boston Scientific patient, and Camille’s momPamela Chang is a survivor.",2020_boston_scientific_performance_report.pdf
"The 73-year-old has a long, complex history of heart disease, but to her family, she is a pillar of strength.",2020_boston_scientific_performance_report.pdf
"After immigrating to the United States from Jamaica, she worked as a nurse for 40 years and took on multiple shifts to ensure her children, including our Chief Diversity, Equity and Inclusion Officer Camille Chang Gilmore, could go to college.",2020_boston_scientific_performance_report.pdf
"Over the years, Pamela has been treated with several coronary therapies from Boston Scientific.",2020_boston_scientific_performance_report.pdf
"But recently, after experiencing painful swelling in her right leg, physicians discovered blockages there.",2020_boston_scientific_performance_report.pdf
"Pamela underwent a peripheral vascular procedure, in which doctors used Boston Scientific technology to open the blood vessels in her lower leg and foot.",2020_boston_scientific_performance_report.pdf
"Now, once again, Pamela is back enjoying a full life with her family.",2020_boston_scientific_performance_report.pdf
Watch Pamela’s story Boston Scientific 2020 Performance Report 3 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Table of Contents This report has been prepared in accordance with the Global Reporting Initiative guidelines.,2020_boston_scientific_performance_report.pdf
"Unless otherwise indicated, data in the 2020 Performance Report Addendum are as of December 31, 2020, or for the one-year period ending in December 31, 2020, as applicable.1 OUR MISSION 2 PATIENT SPOTLIGHT: PAMELA CHANG 4 A MESSAGE FROM OUR CHAIRMAN, PRESIDENT AND CEO 7 COMPANY PROFILE 7 Boston Scientific at a Glance 8 Meaningful Innovation 9 Boston Scientific by the Numbers 10 Corporate Social Responsibility at Boston Scientific 11 TRANSFORMING CARE 12 Our Approach to Innovative and Quality Products 17 Building Digital Capability 19 Collaborating with Customers 23 INVESTING IN OUR PEOPLE 24 Talent and Company Culture 27 Fostering a Diverse, Equitable and Inclusive Culture 32 Benefits to Fit People’s Lives 34 Prioritizing Employee Health and Safety35 ADVANCING POSSIBILITIES 36 Confronting Health Inequities 38 Playing Our Part: Combating Racism 39 Supporting Our Communities 46 PROTECTING THE ENVIRONMENT 47 Responding to Climate Change 50 Our Environmental Impact 55 CREATING VALUE RESPONSIBLY 56 Compliance, Ethics and Integrity 58 Risk Management and Global Security 60 Governance 62 Sustainable Supply Chain Boston Scientific 2020 Performance Report 4 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Mike Mahoney, Chairman, President and CEO 2020 has been a year unlike any we could have imagined.",2020_boston_scientific_performance_report.pdf
"As a society, we confronted COVID-19 and its economic fallout.",2020_boston_scientific_performance_report.pdf
"We watched the pandemic take a disproportionate toll on communities of color, and we saw long-standing inequities and systemic racism painfully exposed.",2020_boston_scientific_performance_report.pdf
We experienced political unrest as well as the continued devastating effects of climate change.,2020_boston_scientific_performance_report.pdf
"Amid this disruption, Boston Scientific was guided and united by our mission to transform lives through medical solutions that improve the health of patients around the world.",2020_boston_scientific_performance_report.pdf
"Our 38,000 employees were led by our values, and we fulfilled our mission — as a global business and as a global corporate citizen.",2020_boston_scientific_performance_report.pdf
"A Message from Our Chairman, President and CEO 2020 taught us that when science, humanity and purpose connect, we can make a meaningful difference in the world.",2020_boston_scientific_performance_report.pdf
"We measure our progress by the ways in which we transform care, invest in our people, advance possibilities, protect the environment and create value responsibly.",2020_boston_scientific_performance_report.pdf
"In a year without precedent our teams were resilient and agile, and as a result of their hard work our business remains strong.",2020_boston_scientific_performance_report.pdf
We invested more than $1 billion in research and development and brought to market 69 new products to advance patient care.,2020_boston_scientific_performance_report.pdf
Our teams conducted 119 clinical studies and pursued opportunities to expand access to health care in emerging markets.,2020_boston_scientific_performance_report.pdf
"We increased our digital investments in customer and patient engagement, medical education, and remote support for clinical trials.",2020_boston_scientific_performance_report.pdf
"Most important, we touched the lives of nearly 30 million patients, took care of one another and supported communities in need.",2020_boston_scientific_performance_report.pdf
Responding to COVID-19 Boston Scientific mobilized quickly to protect our employees and support global COVID-19 relief efforts.,2020_boston_scientific_performance_report.pdf
We helped communities by contributing more than $18 million in aid through monetary and supply donations and by volunteering and providing expertise and resources in engineering and manufacturing.,2020_boston_scientific_performance_report.pdf
Here are some noteworthy examples of what we accomplished: Assembled more than one million face shields and donated them to health care providers.,2020_boston_scientific_performance_report.pdf
"Worked with the University of Minnesota Bakken Medical Devices Center and others in the industry to create the Coventor , an emergency resuscitator that can be used when traditional ventilators are not available.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 5 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Collaborated with an international coalition of medical experts, clinicians and industry leaders to design and develop the Pneumask ™ Face Shield, a reusable full-face mask that was authorized by the Food and Drug Administration (FDA) for use as personal protective equipment in clinical settings.",2020_boston_scientific_performance_report.pdf
Tapped our supply chain capabilities to help source and produce parts for commercial ventilators and to enable increased global production of transportable ventilators.,2020_boston_scientific_performance_report.pdf
"We did all this while making significant changes to our global workforce operations to keep employees, customers and patients safe.",2020_boston_scientific_performance_report.pdf
"Our employees rose to every challenge, and we added resources to support their physical, mental and financial health during this uncertain time.Building a More Diverse, Equitable and Inclusive Workplace and Society The challenges of COVID-19 and the racial injustice and social unrest we experienced in 2020 underscore how important it is that we address the root causes of racism and build a more equitable, inclusive society — within Boston Scientific and our communities.",2020_boston_scientific_performance_report.pdf
"In 2020, we made progress against our goals and took the following actions to support diversity, equity and inclusion: Expanded on our 2017 diversity and inclusion goals with 3Up by 2023 , an initiative to increase representation of multicultural talent and women at the supervisory and managerial levels to 23 percent and 43 percent, respectively.",2020_boston_scientific_performance_report.pdf
"Achieved 99+ percent pay equity for gender globally and 99+ percent pay equity for multicultural talent in the United States, including Puerto Rico.",2020_boston_scientific_performance_report.pdf
"Announced a $3.5 million multiyear investment to combat racism in the United States, with a focus on advocacy in five areas: community, economic empowerment, education, health care disparities and government policy.",2020_boston_scientific_performance_report.pdf
"Through Close the Gap , launched a public service advertising campaign to increase awareness of health disparities and promote resources to help health care providers address them.",2020_boston_scientific_performance_report.pdf
Supported diverse representation among health care professionals through scholarships for Black graduate- level healthcare students.,2020_boston_scientific_performance_report.pdf
"Funded primary and secondary school grants to encourage the next generation to achieve in science, technology, engineering and math (STEM).",2020_boston_scientific_performance_report.pdf
"Our work is guided by core values; they define the culture at Boston Scientific and empower our employees CARING We act with integrity and compassion to support patients, customers, our communities and each other.",2020_boston_scientific_performance_report.pdf
"GLOBAL COLLABORATION We work collaboratively to pursue global opportunities that extend the reach of our medical solutions.MEANINGFUL INNOVATION We foster the creativity to transform new ideas into breakthrough services and solutions that create value for patients, customers and employees.DIVERSITY We embrace diversity and value unique talents, ideas and experiences of our employees.HIGH PERFORMANCE We strive for high performance to benefit our patients, clinicians and shareholders.WINNING SPIRIT We adapt to change and act with speed, agility and accountability to further improve patient care.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 6 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyWorking Together to Create a Better, More Equitable Future I am grateful for the passion and commitment of our global team and proud of the progress we have made.",2020_boston_scientific_performance_report.pdf
"There is much work to be done, but I continue to be optimistic about the future of our world and the future of Boston Scientific.",2020_boston_scientific_performance_report.pdf
We have a strong pipeline and an extraordinarily talented and caring team that is committed to achieving our mission by sustaining ethical and inclusive business practices.,2020_boston_scientific_performance_report.pdf
I look forward to continuing our work together to meet the challenges ahead and to build a better and more equitable future for all.,2020_boston_scientific_performance_report.pdf
"Sincerely, Mike Mahoney Chairman, President and CEO April 15, 2021Adopting Environmentally Sustainable Business Practices Fulfilling our mission comes with a responsibility to protect our planet.",2020_boston_scientific_performance_report.pdf
"That’s why we have set aggressive environmental goals and consistently achieve reductions in energy use, greenhouse gas emissions, waste and water use.",2020_boston_scientific_performance_report.pdf
"In 2017, we committed to achieving carbon neutrality — net zero carbon emissions — across our manufacturing and key distribution sites by 2030.",2020_boston_scientific_performance_report.pdf
"To date, we’ve reduced our carbon footprint by 50 percent.",2020_boston_scientific_performance_report.pdf
"Our manufacturing sites in Heredia and Coyol, Costa Rica use hydroelectric, wind and solar power and have been carbon-neutral since 2016.",2020_boston_scientific_performance_report.pdf
"Our facilities in Clonmel, Cork and Galway, Ireland, as well as Kerkrade, the Netherlands source only 100 percent renewable energy.",2020_boston_scientific_performance_report.pdf
"By 2024, we expect to source or generate 100 percent of our electricity from renewable energy sources.",2020_boston_scientific_performance_report.pdf
"Although Boston Scientific is already a low-intensity water user, we’ve reduced water usage by 23 percent over the last decade.",2020_boston_scientific_performance_report.pdf
"And in 2020 we diverted 94 percent of landfill solid waste through recycling, plastic segregation, redesigning packaging and other environmentally responsible measures.",2020_boston_scientific_performance_report.pdf
"“ 2020 taught us that when science, humanity and purpose connect, we can make a meaningful difference in the world.",2020_boston_scientific_performance_report.pdf
"We measure our progress by the ways in which we transform care, invest in our people, advance possibilities, protect the environment and create value responsibly.” transform invest protectcreateadvance Boston Scientific 2020 Performance Report 7 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyPERIPHERAL INTERVENTIONS $1,577 million Devices for diagnosis and minimally invasive treatments of peripheral vascular disease and cancerELECTROPHYSIOLOGY $287 million A broad range of mapping and treatment technologies for diagnosing and treating heart rhythm disordersENDOSCOPY $1,780 million Minimally invasive devices for diagnosing and treating gastrointestinal and pulmonary conditionsCARDIAC RHYTHM MANAGEMENT $1,704 million Technologies that treat irregular heart rhythms and heart failure and help protect against sudden cardiac death INTERVENTIONAL CARDIOLOGY $2,299 million Minimally invasive innovations that help improve the lives of patients living with heart and vascular conditionsNEUROMODULATION $761 million Electronic implantable technologies that help patients manage debilitating chronic pain and neurological conditionsCARDIOVASCULAR RHYTHM + NEURO UROLOGY + PELVIC HEALTH $1,286 million Solutions for urological diseases including stone disease, men’s health and women’s healthMEDSURG Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.",2020_boston_scientific_performance_report.pdf
"As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care.",2020_boston_scientific_performance_report.pdf
"Boston Scientific at a Glance NET SALES BY PRODUCT CATEGOR Y2 (dollars in millions) NET SALES BY REGION (dollars in millions) $9,913 1 We have three reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices).",2020_boston_scientific_performance_report.pdf
We have included the results of BTG’s Interventional Medicine business in our Peripheral Interventions operating segment since the date of acquisition.,2020_boston_scientific_performance_report.pdf
"2 As part of our acquisition of BTG, we acquired a specialty pharmaceuticals business (Specialty Pharmaceuticals), a stand-alone operating segment presented alongside our Medical Device reportable segments.",2020_boston_scientific_performance_report.pdf
"On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L.",2020_boston_scientific_performance_report.pdf
"and SERB SAS, affiliates of SERB, for a purchase price of $800 million.",2020_boston_scientific_performance_report.pdf
"U.S. $5,508 EMEA (Europe, Middle East and Africa) 2,097 APAC (Asia-Pacific) 1,781 LACA (Latin America and Canada) 307 Medical Devices1 9,694 Specialty Pharmaceuticals2 219 Net Sales $9,913 Boston Scientific 2020 Performance Report 8 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Meaningful InnovationBoston Scientific collaborates with health care professionals to develop meaningful innovations that help more people live longer, healthier lives.",2020_boston_scientific_performance_report.pdf
"We invest in bringing new products to large, high-growth markets while building our unique pipeline of technologies to expand our category leadership and address unmet patient needs.",2020_boston_scientific_performance_report.pdf
Our innovative culture has enabled us to serve approximately 30 million patients annually.,2020_boston_scientific_performance_report.pdf
"KEY PRODUCTS WATCHMAN FLX™ Left Atrial Appendage Closure Device ACURATE neo2 ™ Aortic Valve System ROTAPRO™ Rotational Atherectomy System ELUVIA ™ Drug-Eluting Vascular Stent System and Ranger™ Drug Coated Balloon TheraSphere ™ Y-90 Glass Microspheres AngioJet™ Peripheral Thrombectomy System EkoSonic™ Endovascular System HeartLogic™ Heart Failure Diagnostic LUX-Dx™ Insertable Cardiac Monitor System POLARx™ Cryoablation System WaveWriter Alpha™ Spinal Cord Stimulation System Vertiflex™ Procedure, Superion™ Indirect Decompression System Vercise Genus ™ Deep Brain Stimulation System EXALT™ Model D Single-use Duodenoscope, SpyGlass™ Discover Digital Catheter A X I O S ™ Stent and Electrocautery-Enhanced Delivery System O R I S E ™ Gel Submucosal Lifting Agent and ORISE ™ ProKnife Electrosurgical Knife LithoVue™ Single-Use Digital Flexible Ureteroscope SpaceOAR ™ Hydrogel Prostate Spacer SpaceOAR Vue ™ Hydrogel Radiopaque Perirectal Spacer Rezūm ™ Water Vapor Therapy BUSINESS SEGMENTS BUSINESS UNITS Cardiovascular Interventional Cardiology Peripheral Interventions Rhythm and Neuro Rhythm Management (CRM and EP) Neuromodulation MedSurg Endoscopy Urology and Pelvic HealthHEART SOUNDS THORACIC IMPEDANCE RESPIRATION HEART RATE ACTIVITY COMPOSITE INDEX % LV PACED AT/AF BURDEN WEIGHT SLEEP INCLINE V THERAPYBLOOD PRESSUREHEART RATE VARIABILITY (SDANN)RV RATE DURING AT/AF Boston Scientific 2020 Performance Report 9 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly 100% renewable electricity by 2024 Carbon neutrality in manufacturing and key distribution sites by 2030 ADVANCING POSSIBILITIES +$70 million medical research, fellowships, educational and charitable giving +$18 million COVID-19 relief 15 years closing the health disparity gap United by our core values, we are dedicated to transforming lives through innovative medical solutions, while also making measurable contributions to the world we share.",2020_boston_scientific_performance_report.pdf
Here are some highlights.,2020_boston_scientific_performance_report.pdf
"Boston Scientific by the Numbers +$1 billion invested in R&D ~30 million patients servedNewsweek America’s Most Responsible Companies Member of Dow Jones Sustainability Indices Powered by the S&P Global CSA Forbes America’s Most JUST Companies Culture Champion 2020 MIT Sloan Management Review/Glassdoor TRANSFORMING CARE PROTECTING THE ENVIRONMENT CREATING VALUE RESPONSIBLY +99% pay equity Top 10% globally recognized leader for workplace inclusionINVESTING IN OUR PEOPLE Boston Scientific 2020 Performance Report 10 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly SUSTAINABLE DEVELOPMENT GOALS AND MATERIAL TOPICS At Boston Scientific, corporate social responsibility (CSR) underpins all our business practices, and our approach is aligned with the United Nations Sustainable Development Goals (SDGs).",2020_boston_scientific_performance_report.pdf
"CSR Strategy and Practices Our CSR strategy, material topics and practices are informed by conversations with diverse stakeholders inside and outside the company — locally, nationally and globally.",2020_boston_scientific_performance_report.pdf
"In our collaborations and other business relationships, we work with organizations that share our commitment to better understand and improve environmental, social and economic progress.",2020_boston_scientific_performance_report.pdf
"In more than 100 countries, our people work with an awareness of the world’s most pressing challenges, including inequity, economic disparity, climate change and environmental protection.",2020_boston_scientific_performance_report.pdf
Their efforts are supported by: Our cross-functional CSR Council.,2020_boston_scientific_performance_report.pdf
Environmental Health and Safety (EH&S) policies.,2020_boston_scientific_performance_report.pdf
Global Council for Inclusion.,2020_boston_scientific_performance_report.pdf
"Local, regional and national employee and community programs.",2020_boston_scientific_performance_report.pdf
Corporate Social Responsibility at Boston Scientific The CSR Council includes subject matter experts from throughout the company who help define our CSR strategy and ensure accountability.,2020_boston_scientific_performance_report.pdf
An executive steering committee oversees the Council and champions sustainable practices across the business.,2020_boston_scientific_performance_report.pdf
"Within this framework, everyone in the company contributes to our social responsibility.",2020_boston_scientific_performance_report.pdf
"Each year, we participate in several widely recognized environmental-, social- and governance-rating surveys.",2020_boston_scientific_performance_report.pdf
"In 2020, we initiated a climate risk scenario analysis based on the Task Force on Climate-related Financial Disclosures framework.",2020_boston_scientific_performance_report.pdf
"TRANSFORMING CARE Material topics: Innovative products INVESTING IN OUR PEOPLE Material topics: Career, culture and talent Diversity, equity and inclusion Worker health and safety ADVANCING POSSIBILITIES Material topics: Community engagement PROTECTING THE ENVIRONMENT Material topics: Environmental impact Climate change CREATING VALUE RESPONSIBLY Material topics: Governance Compliance and ethics Sustainable supply chain Boston Scientific 2020 Performance Report 11 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Transforming carePURPOSE Advancing standards of careHUMANITY Pursuing breakthrough ideasSCIENCE Transforming Care Our commitment to improving the lives of patients requires high levels of research, quality and innovation in every aspect of our operations.",2020_boston_scientific_performance_report.pdf
Boston Scientific teams collaborate across the company and with health care providers and other trusted external experts to design and make solutions for the health care challenges that matter the most.,2020_boston_scientific_performance_report.pdf
"We are inspired by the people who have been helped by our products, and we are driven to serve those who need breakthroughs that have not yet been invented.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 12 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Our Approach to Innovative and Quality Products Boston Scientific product development teams follow a uniform, global approach that combines business, technical and quality processes.",2020_boston_scientific_performance_report.pdf
"This allows us to monitor products over their life cycles, from concept and commercialization through next-generation designs.",2020_boston_scientific_performance_report.pdf
The data we gather and analyze helps us pursue new solutions that advance standards of care and address unmet customer and patient needs.,2020_boston_scientific_performance_report.pdf
"We have research and development sites in the United States, the European Union, Costa Rica, India and China.",2020_boston_scientific_performance_report.pdf
Some of the sites also serve as R&D Centers of Excellence where we identify successful practices and share them across the company to strengthen our overall R&D capability.SUSTAINABLE DEVELOPMENT GOALS: Katie Crawford helps lead global processes that ensure quality and safety are incorporated into everything we do.,2020_boston_scientific_performance_report.pdf
“ The global reach of our quality system is critical.,2020_boston_scientific_performance_report.pdf
Boston Scientific employees everywhere know they share responsibility for the quality and safety of our products.,2020_boston_scientific_performance_report.pdf
"Each site has a comprehensive system for maintaining quality, which gives us agility in meeting new requirements such as the European Union Medical Device Regulation.” Katie Crawford, manager, Quality SystemsQuality and Safety Our commitment to meaningful innovation is matched by a customer- and patient-centric focus on quality and safety.",2020_boston_scientific_performance_report.pdf
The work and expertise of Boston Scientific global quality and safety teams is supported by: Quality system training for all employees.,2020_boston_scientific_performance_report.pdf
A companywide plan that prioritizes quality improvement projects and leads to higher quality products and better patient outcomes.,2020_boston_scientific_performance_report.pdf
A global quality system that integrates customer feedback and regulatory requirements into our processes.,2020_boston_scientific_performance_report.pdf
"The Boston Scientific Best4 quality strategy for delivering industry-leading culture, compliance, performance and agility.",2020_boston_scientific_performance_report.pdf
"Innovation Leadership Our success in pursuing and developing life-changing innovations is recognized by leading institutions, as summarized on our website awards page .",2020_boston_scientific_performance_report.pdf
GLOBAL QUALITY SYSTEM: DEVELOPING INNOVATIVE AND SAFE PRODUCTS Boston Scientific 2020 Performance Report 13 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly 4Best culture: Together we sustain a culture that makes the quality policy real for every employee.,2020_boston_scientific_performance_report.pdf
Our diverse quality team reinforces the importance of each role in improving patient lives.,2020_boston_scientific_performance_report.pdf
"Best agility: We add value by reducing complexity, removing obstacles and adapting to changing business needs.",2020_boston_scientific_performance_report.pdf
This means having intentional simplicity in our systems as well as lean practices and the right technology for process efficiency.,2020_boston_scientific_performance_report.pdf
"Best performance: We provide the best products, services and solutions for patients and customers, using a quality by design approach that emphasizes continuous improvement.",2020_boston_scientific_performance_report.pdf
Best compliance: We comply with global laws and regulations using one global quality system.,2020_boston_scientific_performance_report.pdf
"This work includes ongoing risk mitigation and an effective transition to the European Union Medical Device Regulation (EU MDR).BEST4 STRATEGY To ensure the safety and efficacy of our new technologies and tools, we follow a global design controls process that incorporates risk management and usability engineering.",2020_boston_scientific_performance_report.pdf
"At every stage of development, our teams focus on the patients who will benefit from their efforts.",2020_boston_scientific_performance_report.pdf
"This includes assessing component and device materials for quality and durability, availability, safety and efficacy.",2020_boston_scientific_performance_report.pdf
Our teams also take into consideration medical and environmental requirements and other regulations.,2020_boston_scientific_performance_report.pdf
"Strategic Quality Process (SQP) Boston Scientific manufacturing processes reinforce our quality policy and our overarching SQP, which is updated yearly and encompasses: Operations strategy: How we establish our strategic goals and plans.",2020_boston_scientific_performance_report.pdf
Management systems: How we prioritize and execute our work.,2020_boston_scientific_performance_report.pdf
Continuous improvement: How we improve our work.,2020_boston_scientific_performance_report.pdf
Cascading metrics: How we measure and connect performance.,2020_boston_scientific_performance_report.pdf
Recognition and engagement: How we recognize teams and individuals.,2020_boston_scientific_performance_report.pdf
"To ensure cohesive quality throughout the enterprise, every one of our manufacturing sites uses the overarching SQP to develop its own SQP to support the facility’s focus and performance objectives.",2020_boston_scientific_performance_report.pdf
A SHARED RESPONSIBILITY FOR QUALITY AND SAFETY All Boston Scientific employees share responsibility for quality and safety in their work every day.,2020_boston_scientific_performance_report.pdf
This commitment is reinforced by: Completing a mandatory quality systems training course when hired.,2020_boston_scientific_performance_report.pdf
Completing an annual refresher training course.,2020_boston_scientific_performance_report.pdf
Signing and wearing a badge imprinted with the quality policy.,2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 14 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Our Quality Policy is printed on employee badges and is highly visible in our facilities: “ I improve the quality of patient care and all things Boston Scientific.” Our Quality Policy is complemented by our Quality Mission: “ We exceed expectations with customer-centric quality solutions that transform patient lives.”OUR QUALITY POLICY AND QUALITY MISSION 1 Quality system management 2 Documents, records and data control 3 Design controls 4 Product approvals 5 Material controls 6 Production and process controls 7 Post-market support 8 Corrective action, preventive actionGLOBAL QUALITY PROCESS: 8 PILLARS Boston Scientific 2020 Performance Report 15 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyMeasuring and Monitoring Quality and Compliance Effectiveness We conduct regular audits to verify that our global quality system meets internal and external requirements and that it is implemented and maintained effectively.",2020_boston_scientific_performance_report.pdf
We follow up with activities that include re-auditing prior observations and confirming that the requisite actions were taken.,2020_boston_scientific_performance_report.pdf
Regulatory agencies also review our performance to ensure quality and compliance.,2020_boston_scientific_performance_report.pdf
"In 2020, to adapt amid the pandemic, our global quality team acted quickly to shift from in-person to virtual audit processes.",2020_boston_scientific_performance_report.pdf
We partnered with vendors to pilot new technologies for remote auditing and obtained legal and privacy approvals for camera and recording activity.,2020_boston_scientific_performance_report.pdf
This approach meant we were able to secure key regulatory approvals safely and on time.Product Performance Boston Scientific teams review customer and patient feedback and monitor experiences with our devices.,2020_boston_scientific_performance_report.pdf
This information is valuable for our quality system and for future product iterations and innovations.,2020_boston_scientific_performance_report.pdf
"We follow a preventive action process to identify root causes for potential compliance and quality issues, and to develop preventive solutions.",2020_boston_scientific_performance_report.pdf
We initiate field actions as needed to ensure that any regulatory or field safety issues are resolved quickly and effectively.,2020_boston_scientific_performance_report.pdf
“ Customer insights are a key resource as we work to improve our products and introduce new devices.,2020_boston_scientific_performance_report.pdf
"That’s how new generations of products are born.” Alejandra Hernandez , senior engineer, Quality Systems Our annual Everyone Makes an Impact events take place at Boston Scientific sites around the world to celebrate patients who overcome health challenges and highlight how each and every employee is helping to advance patient care.",2020_boston_scientific_performance_report.pdf
"In 2020, thousands of employees across the globe attended a virtual event, and several patients joined to talk about how their lives changed after being successfully treated with Boston Scientific solutions.ELEVATING QUALITY: EVERYONE MAKES AN IMPACT Valentina Arango of Bogota, Colombia discussed how doctors used the SpyGlass™ DS Direct Visualization System to treat potentially cancerous liver fibrosis, destroy stones in her intrahepatic duct and collect a biopsy.",2020_boston_scientific_performance_report.pdf
"Rahul Mathur, an employee in our Gurgaon, India office was successfully treated for a cardiac condition with a Promus ELITE™ stent.",2020_boston_scientific_performance_report.pdf
He talked about what it feels like to be helped by a device he knows was made with quality and care.,2020_boston_scientific_performance_report.pdf
PRODUCT INNOVATION: LISTENING TO OUR CUSTOMERS Boston Scientific 2020 Performance Report 16 Pre-Clinical Sciences We conduct extensive research into the safety and efficacy of our devices before progressing to human clinical trials.,2020_boston_scientific_performance_report.pdf
"This pre-clinical research sets stringent standards that govern our training practices, product testing and regulatory compliance.",2020_boston_scientific_performance_report.pdf
"In 2020, we made significant investments in our Research and Technology Center in Minnesota, including the latest in advanced imaging technology to help ensure device compatibility — an investment that will enhance R&D initiatives across all our businesses.To meet the highest safety standards, on occasion we use animal testing in our R&D efforts.",2020_boston_scientific_performance_report.pdf
"For instance, when we use new materials in medical devices, the U.S. Food and Drug Administration (FDA) may require evidence of animal testing prior to human clinical trials.",2020_boston_scientific_performance_report.pdf
Boston Scientific is committed to the humane care and treatment of laboratory animals.,2020_boston_scientific_performance_report.pdf
"Whenever it is feasible, appropriate and scientifically valid, we use alternative testing.",2020_boston_scientific_performance_report.pdf
"Our facilities meet applicable laws and regulatory standards, often exceeding the latter.",2020_boston_scientific_performance_report.pdf
"We are routinely audited by internal experts and government agencies, including by the FDA, the U.S. Department of Agriculture, and the Association for Assessment and Accreditation of Laboratory Animal Care.",2020_boston_scientific_performance_report.pdf
Clinical Trials Our clinical trials are scientifically rigorous and generate the data we need to document that Boston Scientific products are safe and effective.,2020_boston_scientific_performance_report.pdf
"We disclose the outcome of all primary and pre-specified secondary endpoints in trials we sponsor, regardless of whether the results are positive, negative or inconclusive.",2020_boston_scientific_performance_report.pdf
Our clinical teams adhere to criteria established by the International Committee of Medical Journal Editors for authorship on clinical trial publications.,2020_boston_scientific_performance_report.pdf
"In publications pertaining to research that has been supported by Boston Scientific, our teams disclose the company’s involvement, whether as a sponsor or supporter.",2020_boston_scientific_performance_report.pdf
"In 2020, we strengthened and refined our operating procedures to ensure we meet or exceed EU MDR requirements by the required deadlines.",2020_boston_scientific_performance_report.pdf
"119 active trials in 2020 6,655 patients enrolled globallyOur Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Boston Scientific 2020 Performance Report 17 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyBuilding Digital Capability Our recent investments in digital platforms gave us capabilities that were critical for providing remote customer support in 2020.",2020_boston_scientific_performance_report.pdf
Highlights include: Aided practitioners remotely using our augmented reality platform to offer expert guidance on product use and assist with setup and troubleshooting for devices and procedures.,2020_boston_scientific_performance_report.pdf
"Partnered with a wearable technology company to pilot a smart glasses device that enables 225 customers in Latin America to receive real-time remote guidance from Boston Scientific clinical specialists — assistance that helped nearly 1,200 patients.",2020_boston_scientific_performance_report.pdf
Developed and launched provider tools and resources for re-engaging with patients in the wake of the pandemic.,2020_boston_scientific_performance_report.pdf
"Offered on-demand webinars and telehealth resources for providers on COVID-19-related legislation, regulations and protocols.",2020_boston_scientific_performance_report.pdf
"Used our Heart Connect ™ system to conduct over 13,000 remote follow-up device checks with customers.",2020_boston_scientific_performance_report.pdf
The company’s digital capabilities also allowed many employees to work remotely during the pandemic.,2020_boston_scientific_performance_report.pdf
We established new operating procedures and launched online tools so our employees could collaborate virtually with colleagues inside and outside the company.,2020_boston_scientific_performance_report.pdf
We are working closely with the FDA on their new Digital Health Software Precertification Pilot Program .,2020_boston_scientific_performance_report.pdf
The goal of the program is to offer precertified companies a streamlined premarket review that will ultimately result in faster patient access to safe and effective software-based medical innovations.ACCELERATING DIGITAL SOLUTIONS Our augmented reality platform connects customers to expert live support.,2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 18 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Innovation in a Virtual World Throughout 2020, we remained steadfast in our commitment to transform lives.",2020_boston_scientific_performance_report.pdf
"Using virtual platforms, we continued internal innovation initiatives such as: Recognize Success , a program that celebrates contributions by teams that have innovated to improve quality, efficiency and agility at Boston Scientific.",2020_boston_scientific_performance_report.pdf
"Recognize Development Excellence , an initiative that honors cross-functional teams that develop meaningful innovations for customers, patients and our company.",2020_boston_scientific_performance_report.pdf
"ImagineIF , an internal venture capital-style approach to funding breakthrough employee ideas which could have a positive impact on any aspect of our company.",2020_boston_scientific_performance_report.pdf
"In addition, Boston Scientific launched the COVIDea portal in March to collect employee ideas on how to help slow the spread of the coronavirus and support relief efforts.",2020_boston_scientific_performance_report.pdf
"We received more than 100 submissions and pursued several proposals to develop and donate personal protective equipment and medical equipment, many of which are featured in this report.",2020_boston_scientific_performance_report.pdf
SUPPORTING DIGITAL INNOVATION: THE CONNECTED PATIENT CHALLENGE Digital health solutions that improve patient and caregiver quality of life at home was the theme of the fifth annual Boston Scientific Connected Patient Challenge .,2020_boston_scientific_performance_report.pdf
"The external competition, co-sponsored by Massachusetts Life Sciences Center and others, promotes the development of digital innovation to address complex health care challenges.",2020_boston_scientific_performance_report.pdf
"In early 2020, six finalists participated in a live pitch event with life science professionals and industry experts.",2020_boston_scientific_performance_report.pdf
"The winning submission was the VaGenie , a connected pelvic floor muscle training device that can help prevent issues related to having a weak pelvic floor, including incontinence and lower back pain.In October, Boston Scientific hosted our annual Recognize Success event, where we celebrated cross- functional teams that are making outstanding contributions to improve quality, patient care and operational effectiveness.",2020_boston_scientific_performance_report.pdf
Boston Scientific 2020 Performance Report 19 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyCollaborating with Customers Boston Scientific is deeply committed to helping health care providers meet patient needs.,2020_boston_scientific_performance_report.pdf
We gather customer feedback in several ways to inspire future product iterations and develop solutions collaboratively.,2020_boston_scientific_performance_report.pdf
"For example, our anatomical model lab in Minnesota enables engineers and physicians to evaluate new product concepts on-site or remotely using new collaboration and visualization tools.",2020_boston_scientific_performance_report.pdf
"Through the Motion Medical joint innovation accelerator with the Mayo Clinic, we made progress developing minimally invasive treatments for conditions that impede quality and longevity of life.",2020_boston_scientific_performance_report.pdf
"In 2020, we refined two prototype devices, one for patients with cancer and another for patients with structural heart disease.",2020_boston_scientific_performance_report.pdf
"In 2021, these projects are proceeding to final verification, validation and preclinical testing.To support demand for ventilators and personal protective equipment (PPE), we teamed up with customers and health care industry peers to develop and distribute innovative solutions to address critical medical needs in our communities.",2020_boston_scientific_performance_report.pdf
"Nearly 3,000 Coventor resuscitators were delivered to health care providers INNOVATING WITH URGENCY DURING THE PANDEMIC Ventilator Alternatives.",2020_boston_scientific_performance_report.pdf
"We collaborated with the University of Minnesota Bakken Medical Device Center and industry partners to bring the Coventor resuscitator to market, with less than 60 days from concept meeting to production completion.",2020_boston_scientific_performance_report.pdf
"The machine pumps a resuscitation bag at regular intervals, replacing the need for manual respiration in emergency settings.",2020_boston_scientific_performance_report.pdf
"After receiving FDA Emergency Use Authorization in April 2020, our partnership delivered nearly 3,000 Coventor resuscitators to health care providers.",2020_boston_scientific_performance_report.pdf
PPE.,2020_boston_scientific_performance_report.pdf
"Working with Stanford University and an international coalition of medical experts, clinicians and industry leaders, we developed the Pneumask ™ Face Shield in 38 days and received FDA Emergency Use Authorization shortly thereafter.",2020_boston_scientific_performance_report.pdf
The device combines a full-face mask and a Boston Scientific custom-molded adapter that attaches to a medical-grade air filter.,2020_boston_scientific_performance_report.pdf
"We donated over 1,500 Pneumask Face Shields to hospitals across the United States and have given other manufacturers access to design details for future production.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 20 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyINNOVATION COLLABORATION Boston Scientific collaborates with a variety of academic institutions, research organizations and accelerators around the globe to promote innovations in health care, including: gBETA Medtech , a free Minnesota-based accelerator that helps early-stage health care startups.",2020_boston_scientific_performance_report.pdf
"MEDX Xelerator , a medical device and digital health incubator, based in Israel, that’s focused on innovations across multiple disease states.",2020_boston_scientific_performance_report.pdf
"PracticePoint , a membership-based health care R&D facility operating at Worcester Polytechnic Institute in Massachusetts.",2020_boston_scientific_performance_report.pdf
"BioInnovate , a program at the National University of Ireland Galway that fosters medical device innovation using a needs based approach from Stanford University Biodesign.",2020_boston_scientific_performance_report.pdf
"Avicenna Alliance , an industry and academic collaboration to promote an EU framework embracing in-silico methods, computer modeling and simulation.",2020_boston_scientific_performance_report.pdf
"HuaXi-Boston Scientific Joint Innovation Center , a collaboration with Huaxi Hospital in Chengdu, China launched in September 2020 to bring innovative solutions to patients via remote education.",2020_boston_scientific_performance_report.pdf
"Medical Device Innovation Consortium , a public- private partnership with the FDA to advance solutions that promote patient access to innovative medical technologies.",2020_boston_scientific_performance_report.pdf
"Boston Scientific R&D employees testing new components for the ROTAPRO™ Rotational Atherectomy System in the anatomical model lab.Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyGlobal Customer Care In 2020, our global customer care team expanded its framework and capabilities to improve customer support.",2020_boston_scientific_performance_report.pdf
"These enhancements enabled us to shift more resources to manage customer relationships, anticipate product needs and advise on solutions.",2020_boston_scientific_performance_report.pdf
We introduced Salesforce.com Service Cloud in 16 countries to better serve customers and increase online collaboration.,2020_boston_scientific_performance_report.pdf
"In the EU, we invested in technology to increase automated ordering to more than 80 percent of volume, allowing employees to spend less time handling orders and more time talking with customers about their needs.",2020_boston_scientific_performance_report.pdf
"Using robotic process automation shipping, we reduced cycle time for sales and sales support agents and improved field inventory levels.",2020_boston_scientific_performance_report.pdf
PERSPECTIVES ON ADVANCING CUSTOMER CARE: HANS WILLEMS More than 750 dedicated Customer Care team members across 40 unique sites“ Technology solutions represent a huge opportunity for our customers to provide better care to patients.,2020_boston_scientific_performance_report.pdf
"Our teams are focused on what’s going to help providers and patients the most.” Hans Willems , vice president, Global Customer Care and EMEA Supply Chain Boston Scientific 2020 Performance Report 21 Boston Scientific 2020 Performance Report 22 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyValue-Based Health Care A global Boston Scientific team is dedicated to studying health economics to demonstrate the value of our technologies and increase market access for providers and patients through policy and reimbursement advocacy.",2020_boston_scientific_performance_report.pdf
Chronic conditions among an aging population present challenges to health care access and affordability.,2020_boston_scientific_performance_report.pdf
"A study in the Journal of the American Heart Association showed significant cost savings when patients who are at risk for stroke due to atrial fibrillation undergo a one-time, minimally invasive procedure to implant the WATCHMAN™ Left Atrial Appendage Closure Device rather than receive lifelong anticoagulant treatment.",2020_boston_scientific_performance_report.pdf
"We use a combination of science and technology to help identify patients who are likely to become sick or experience a sudden health event, giving providers more opportunities to take preventive action and keep patients healthier at more affordable costs.",2020_boston_scientific_performance_report.pdf
The Boston Scientific HeartLogic™ Heart Failure Diagnostic technology is embedded within implantable defibrillators and uses multiple sensors to collect and analyze patient physiological data.,2020_boston_scientific_performance_report.pdf
"The technology has been proven to predict heart failure events an average of 34 days before they happen , which enables proactive care and helps reduce patient hospitalizations and readmissions.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 23 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Investing in Our People At Boston Scientific, we are fortunate to have approximately 38,000 employees around the world whose constant focus is developing solutions that change and save lives.",2020_boston_scientific_performance_report.pdf
"Their talent and collective passion define us as a company, and our performance as a business is built on their diversity of thought and experiences.",2020_boston_scientific_performance_report.pdf
"Our business practices reflect our belief that innovation thrives when employees are highly engaged in their jobs and communities, and with one another.",2020_boston_scientific_performance_report.pdf
"We invest in our people so they can solve problems and advance promising ideas, and we recognize and reward them for their contributions.",2020_boston_scientific_performance_report.pdf
"Inspiring possibilityPURPOSE Innovating through diversityHUMANITY Discovering through collaborationSCIENCE Boston Scientific 2020 Performance Report 24 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly In 2020, Stephanie Pittman, who has been with Boston Scientific for 10 years, took on the role of vice president of Global Talent Management and HR Planning in 2020.",2020_boston_scientific_performance_report.pdf
“ Our global workforce expects meaningful work with career advancement opportunities.,2020_boston_scientific_performance_report.pdf
We are enhancing our workforce planning strategy and development capabilities to meet those needs both now and in the future.,2020_boston_scientific_performance_report.pdf
"This includes expanding virtual learning offerings, investing in digitally enabled analytics and increasing the ways we listen to gain insight and take action.” Stephanie Pittman , vice president, Global Talent Management and HR PlanningSUSTAINABLE DEVELOPMENT GOALS: meaningful innovation high performancediversityglobal collaborationTalent and Company Culture Our competitive edge comes from our employees’ collective talent and shared sense of purpose.",2020_boston_scientific_performance_report.pdf
"We foster a values-driven culture where engagement and inclusion thrive and diversity of thought, background and perspective elevate collaboration.",2020_boston_scientific_performance_report.pdf
This culture helps produce our greatest breakthroughs and is the foundation of our success.,2020_boston_scientific_performance_report.pdf
The core values we demonstrate across the company are embedded in our talent management systems.,2020_boston_scientific_performance_report.pdf
"winning spirit caringOur Core ValuesTALENT MANAGEMENT INSIGHTS: STEPHANIE PITTMAN Boston Scientific 2020 Performance Report 25 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyGlobal Strategic Talent Management and Planning Our efforts to recruit, promote and retain diverse talent are focused on cultivating inclusive behaviors and building an organization that prioritizes continuous learning and the following: Talent management and planning: apply analytics and insights to hire and develop diverse, high-potential talent and facilitate their movement to new roles.",2020_boston_scientific_performance_report.pdf
"Manager development: improve managers’ performance and career coaching capabilities, inclusive leadership behaviors and agility in adapting to change.",2020_boston_scientific_performance_report.pdf
Culture and engagement: measure the employee experience through data and ongoing dialogue and act on the results.,2020_boston_scientific_performance_report.pdf
"Employee growth and development: provide development opportunities for all employees, as well as tailored programs for top leaders and key talent; this includes accelerating meaningful advancement opportunities for women and multicultural talent.",2020_boston_scientific_performance_report.pdf
"Our progress in talent management included the transition to what we have named, “Performance Development Coaching (PDC) 2.0,” an ongoing people development approach.",2020_boston_scientific_performance_report.pdf
"Slated for companywide adoption in 2021, PDC 2.0 enables employees to receive continuous coaching and to request performance feedback from supervisors and colleagues as projects are completed and evaluated.",2020_boston_scientific_performance_report.pdf
Recruit.,2020_boston_scientific_performance_report.pdf
Develop.,2020_boston_scientific_performance_report.pdf
Promote.,2020_boston_scientific_performance_report.pdf
Retain.,2020_boston_scientific_performance_report.pdf
"PIVOTING TO PDC 2.0 FROM: Formal review meetings twice a year Comprehensive feedback limited to scheduled reviews Companywide timing Structured review eventsTO: Ongoing feedback as needed Brief feedback and coaching conversations relevant to current work Supervisor or direct report initiates discussions as needed Feedback and coaching intervals integrated into regular work meetings, reinforcing ongoing development conversations Boston Scientific 2020 Performance Report 26 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Employee Growth and Development Boston Scientific provides tools and training for continuous learning so every employee can envision greater possibilities for their career.",2020_boston_scientific_performance_report.pdf
"We offer more than 150 professional and technical courses , including on-the-job training, skills-based education and programs for employees who have the potential to hold leadership positions.",2020_boston_scientific_performance_report.pdf
"Responding to the realities of the pandemic, the company ramped up virtual training and development .",2020_boston_scientific_performance_report.pdf
"People at all levels of the company now have access to more than 100 new and expanded webinars, online courses and on-demand training.",2020_boston_scientific_performance_report.pdf
"564K hours spent by non-manufacturing employees in 2020 virtual and classroom training 150+ professional and technical courses offered 100+ new and expanded webinars, online courses and on-demand training Boston Scientific 2020 Performance Report 27 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Multicultural (U.S. and Puerto Rico) 2017 201817.8%19.6% 201920.8% 202021.4%Fostering a Diverse, Equitable and Inclusive Culture To promote equity and cultivate an enduring culture of inclusion, we must hold ourselves accountable as an organization.",2020_boston_scientific_performance_report.pdf
"We have made steady progress , and at the beginning of 2020, we set our diversity, equity and inclusion goals even higher with three new bold measures to accelerate the representation of women and multicultural talent in our workforce.",2020_boston_scientific_performance_report.pdf
"Based on our belief that the only acceptable trajectory for diverse representation is up, we call these goals “3Up by 2023.” Increase our goal of representation of women at the supervisory and managerial level to at least 43 percent — an increase of 3 percentage pointsIncrease our goal of representation of multicultural talent at the supervisory and managerial level to at least 23 percent — an increase of 3 percentage pointsTop 10%: Continue to be in the top 10 percent globally as a recognized leader for workplace inclusion3UP BY 2023 REPRESENTATION AT ALL LEVELS SUPERVISORY AND MANAGERIAL LEVEL REPRESENTATIONDE&I EFFORTS ACROSS BOSTON SCIENTIFIC ALIGN WITH FOUR STRATEGIC PILLARS Multicultural (U.S. and Puerto Rico) 2017 201830.7%31.7% 201933.2% 202034.0% Women (Global) 2017 201837.4%38.4% 201938.1% 202039.9% 2020Women (Global) 2017 201845.5%46.5% 201947.0% 202047.4%Greater representation and inclusivity is about progress over time, not overnight.",2020_boston_scientific_performance_report.pdf
Learn more about why DE&I is a business imperative for Boston Scientific.,2020_boston_scientific_performance_report.pdf
"CAREER CULTURE COMMERCE COMMUNITY Boston Scientific 2020 Performance Report 28 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly In 2020, four Boston Scientific employees were selected to participate in the CEO Action for Racial Equity , a fellowship that provides representatives of CEO Action for Diversity & Inclusion signatories an opportunity to advance racial equity through public policy.",2020_boston_scientific_performance_report.pdf
"The fellowship is governed by the CEO Action for Racial Equity Governing Committee, a group of 20 CEOs who represent multiple industries and regions, including Boston Scientific Chairman and CEO Mike Mahoney, a founding signatory of CEO Action.",2020_boston_scientific_performance_report.pdf
"“ This fellowship aligns with my own values and enables me to take responsibility — as a white woman of privilege — in the journey to advance racial equity.” Caroline Jacobsen , manager, Health EconomicsCEO ACTION FOR RACIAL EQUITY FELLOWSHIP Our ability to fulfill our mission will always depend on a team that includes a diversity of people, ideas and skills.",2020_boston_scientific_performance_report.pdf
The company took steps to accelerate DE&I progress in 2020 by expanding many of our programs to ensure individuals have equitable opportunities for growth.,2020_boston_scientific_performance_report.pdf
"Unconscious bias training is mandatory for all employees, as is expanded diverse hiring practices.",2020_boston_scientific_performance_report.pdf
"To help our organization be more deliberate in our approach to DE&I, we increased training for all leaders on topics such as microagressions, modeling inclusive behaviors, history of racism, allyship and moving from “color blind to color brave.” CHAMPIONING DE&I Boston Scientific 2020 Performance Report 29 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Advancing Multicultural Talent To address the need for more Black, Hispanic and Latinx employees at the manager and supervisor levels, we expanded our diverse hiring and training programs and increased our investment in ally and mentorship initiatives.",2020_boston_scientific_performance_report.pdf
"We also designed new programs specifically for Black, Hispanic and Latinx employees who build our medical devices to prepare them for business roles.",2020_boston_scientific_performance_report.pdf
These programs are expected to launch in 2021.,2020_boston_scientific_performance_report.pdf
Inclusion Resources The DE&I dashboard we developed in 2019 proved to be a valuable analytics tool in 2020 as we took stock of where we can address shortcomings and make measurable improvements.,2020_boston_scientific_performance_report.pdf
"Our leaders use DE&I analytics to better understand representation trends in their organizations and identify ways to improve hiring, promotion and attrition metrics.",2020_boston_scientific_performance_report.pdf
"Over the course of the year, we expanded our virtual inclusion resources.",2020_boston_scientific_performance_report.pdf
Inclusion toolkit.,2020_boston_scientific_performance_report.pdf
The online toolkit encourages employees to take the I Act On Pledge and complete an assessment to determine their inclusion IQ.,2020_boston_scientific_performance_report.pdf
"It offers on-demand DE&I tools as well as learning modules on topics such as unconscious bias training, modeling inclusive behaviors and anti-racism.",2020_boston_scientific_performance_report.pdf
Candid conversations.,2020_boston_scientific_performance_report.pdf
The Candid Conversations podcast is an interview series that builds on our inclusion training and Real Talk listening sessions.,2020_boston_scientific_performance_report.pdf
"In 2020, we expanded opportunities for people at all levels of the organization to tell their stories and offer perspectives on handling issues such as parenting during the pandemic, racial injustice and mental health.",2020_boston_scientific_performance_report.pdf
"As racial inequity and injustice dominated the dialogue in and outside the company, we took steps to engage in necessary, sometimes uncomfortable, conversations to break the silence about race and identity.",2020_boston_scientific_performance_report.pdf
"Leaders and our HR and DE&I teams led more than 200 hours of Real Talk listening sessions, engaging employees throughout the organization in dialogue on the root causes of racism.",2020_boston_scientific_performance_report.pdf
"We covered topics such as what it’s like to be Black in corporate America, white privilege as well as disparities in the workplace and barriers to diversity.",2020_boston_scientific_performance_report.pdf
"Rob Morton (left), and his mentor Matt Lavelle, vice president, Operations (right) held one of the first Real Talk sessions.",2020_boston_scientific_performance_report.pdf
Employees engaged in 200+ hours of “Real Talk” REAL TALK IN 2020 ” Things like race have a negative stigma associated with being talked about at work.,2020_boston_scientific_performance_report.pdf
"If sharing our conversation influences just one person then it was a success.” Rob Morton , senior scientific communications specialist, Medical Affairs Boston Scientific 2020 Performance Report 30 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Learning from our Employee Resource Groups Employee Resource Groups (ERGs) are vital collaborators in our DE&I strategy.",2020_boston_scientific_performance_report.pdf
"ERGs are voluntary, company-sponsored groups of employees who champion opportunity for all in our work environment and provide feedback to executive leaders through the company’s Global Council for Inclusion.",2020_boston_scientific_performance_report.pdf
"ERGs are typically formed around specific dimensions of diversity, for example, gender, race, veteran status, sexual orientation or life stage.",2020_boston_scientific_performance_report.pdf
All employees are welcome and encouraged to join any ERG.,2020_boston_scientific_performance_report.pdf
"In 2020, Boston Scientific leaders and employees participated in our first global ERG summit.",2020_boston_scientific_performance_report.pdf
"We examined the impact that the pandemic has had on our employees, particularly through the lens of diversity, equity and inclusion.",2020_boston_scientific_performance_report.pdf
"More than 850 members of the company gathered virtually for panels and breakout sessions to share perspectives on inclusion and belonging.GLOBAL ERG SUMMIT: INCLUSION AND BELONGING DURING THE COVID-19 PANDEMIC 6,000+ employees across nine ERGs 110 chapters globally 42 chapters outside the U.S. 11 virtual chapters Precious Morton joined Boston Scientific in 2007 and founded the Spencer, Indiana chapter of Bridge, our ERG focused on developing a community of Black leaders.",2020_boston_scientific_performance_report.pdf
"She is now a quality manager in Alpharetta, Georgia and the global lead of Bridge.",2020_boston_scientific_performance_report.pdf
"To recognize her contributions to DE&I, the Boston Scientific Global Council for Inclusion honored Precious with a 2020 Diversity, Equity and Inclusion Impact Award for her leadership and courage in bringing Black employees together to support one another and give voice to racism and injustice to drive meaningful change inside and outside the company.",2020_boston_scientific_performance_report.pdf
“ Everyone should be heard and accepted for who they are.,2020_boston_scientific_performance_report.pdf
People need a sense of belonging and purpose.,2020_boston_scientific_performance_report.pdf
"I affectionately call my Bridge colleagues The Fam, because they are my family.",2020_boston_scientific_performance_report.pdf
The ERGs at Boston Scientific give us a safe space in a not-so-safe world.,2020_boston_scientific_performance_report.pdf
"We learn from one another, and we make a positive impact on the company and on our communities.” Precious Morton , quality manager, PathologyERG PERSPECTIVE FROM BRIDGE: DEVELOPING A COMMUNITY OF BLACK LEADERS Boston Scientific 2020 Performance Report 31 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly The COVID-19 pulse survey gauged whether employees felt supported during the pandemic and allowed us to quickly adapt companywide efforts as necessary.",2020_boston_scientific_performance_report.pdf
"Distributed to a representative sampling of approximately 9,000 indirect labor * employees , and with an 80 percent participation rate , feedback showed that employees: Trust senior leaders and believe they care about employee well-being.",2020_boston_scientific_performance_report.pdf
"Value frequent, transparent COVID-19 communications.Feel they have access to helpful resources and information, although some had difficulty finding certain well-being resources.Appreciate the flexibility in where and when they work, although some expressed workload concerns.",2020_boston_scientific_performance_report.pdf
"COVID-19 PULSE SURVEY PEOPLE LEADERSHIP SURVEY 2020: EMPLOYEES RATE MANAGERS ON LEADERSHIP BEHAVIORS *Those with one or more direct reports responding Each year, we offer employees an opportunity to rate their manager’s performance against a range of leadership behaviors.",2020_boston_scientific_performance_report.pdf
"More than 26,000 employees invited to give survey feedback on 4,800 people leaders .",2020_boston_scientific_performance_report.pdf
77% employee response rate .,2020_boston_scientific_performance_report.pdf
95% of participating managers * received a personalized feedback report.,2020_boston_scientific_performance_report.pdf
* Indirect labor includes employees who are not directly involved in the manufacturing of products.,2020_boston_scientific_performance_report.pdf
Listening to Our People Our people have a prominent voice in how we conduct business and the actions we take as a global citizen.,2020_boston_scientific_performance_report.pdf
"To support this work, we invested in an on-demand, pulse survey tool that allows us to gather feedback on timely topics that can quickly be turned into action.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 32 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Benefits to Fit People’s Lives Employee benefits at Boston Scientific reflect our belief that well-being, financial health and security are essential for a productive and collaborative workforce.",2020_boston_scientific_performance_report.pdf
"We strive to offer benefits that are valued by our employees, promote well-being and support life-work integration.",2020_boston_scientific_performance_report.pdf
Our Global Benefits to Fit Your Life program provides employees with a broad range of offerings to support and improve their lives.,2020_boston_scientific_performance_report.pdf
"Compensation At Boston Scientific, we pay for performance.",2020_boston_scientific_performance_report.pdf
"Where it is relevant to an employee’s responsibilities and in compliance with applicable law, we offer both a base salary and variable compensation.",2020_boston_scientific_performance_report.pdf
"Our variable pay components include annual bonus programs, long-term incentive stock awards, and one-time performance and recognition rewards for highly successful projects and breakthrough performance.",2020_boston_scientific_performance_report.pdf
Equal Pay for Equal Work: Pay Equity We pay people equally for equal work .,2020_boston_scientific_performance_report.pdf
Our compensation experts regularly benchmark salaries and conduct companywide and external parity audits.,2020_boston_scientific_performance_report.pdf
We contract with an independent third party to assess pay equity across all positions using regression analysis.,2020_boston_scientific_performance_report.pdf
"This data-driven approach controls for variables that influence compensation such as job position, tenure, years of experience and location.",2020_boston_scientific_performance_report.pdf
"We use the results to identify any potential pay disparities, and we address these accordingly.",2020_boston_scientific_performance_report.pdf
"In our last assessment, conducted in 2019, we continued to see 99+ percent pay equity for gender globally and 99+ percent pay equity for multicultural talent in the United States, including Puerto Rico.",2020_boston_scientific_performance_report.pdf
Our compensation team will conduct another third-party global pay assessment in 2021.,2020_boston_scientific_performance_report.pdf
99%+ pay equity Employer of Choice Awards Boston Scientific is committed to be an employer of choice for globally diverse talent.,2020_boston_scientific_performance_report.pdf
We participate in external benchmarking surveys that candidly assess our progress and ensure we are doing all we can to achieve our goals.,2020_boston_scientific_performance_report.pdf
Visit our awards page to learn more about the recognition we received in 2020.,2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 33 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly As employees adjusted to life and work during the pandemic, we moved quickly to help them and their families by shortening meeting times, holding managers accountable for supporting their teams with flexible hours, and regularly communicating available resources.",2020_boston_scientific_performance_report.pdf
"Through employee surveys and listening session s with working parents and other caregivers, we continued to assess how best to support our workforce.",2020_boston_scientific_performance_report.pdf
"As a result, we added new benefits and expanded other offerings: expanded no-cost, virtual offerings for general medicine and mental health support.",2020_boston_scientific_performance_report.pdf
"doubled the time available under our Personal Leave of Absence policy, and made it available to use in half- or full-day increments.",2020_boston_scientific_performance_report.pdf
"increased child and adult care-giving benefits, including adding more caregiver resources and offering home schooling support such as virtual tutoring, learning pods and return-to-school guides.",2020_boston_scientific_performance_report.pdf
modified our financial benefits for people facing economic hardship.,2020_boston_scientific_performance_report.pdf
launched an internal well-being website and well- being circles to provide employees opportunities to connect over shared interests and circumstances.A BOOST IN PANDEMIC BENEFITS Covered COVID-19 testing .,2020_boston_scientific_performance_report.pdf
Doubled backup child care and elder care days.,2020_boston_scientific_performance_report.pdf
Upheld flex work hours and U.S. Flex Fridays.,2020_boston_scientific_performance_report.pdf
Revised policies to support workplace flexibility.,2020_boston_scientific_performance_report.pdf
Expanded personal leave .,2020_boston_scientific_performance_report.pdf
Enhanced global employee assistance programs .,2020_boston_scientific_performance_report.pdf
Expanded counseling benefit.,2020_boston_scientific_performance_report.pdf
"Introduced well-being tools and resources, including podcasts, webinars and interaction opportunities.",2020_boston_scientific_performance_report.pdf
Launched virtual well-being circles .,2020_boston_scientific_performance_report.pdf
Expanded telehealth options.,2020_boston_scientific_performance_report.pdf
"Expanded 24/7 emotional support .COVID-19: BENEFITS EXPANSION AND UPDATES Boston Scientific 2020 Performance Report 34 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyWORKPLACE STRATEGY: NOEL FINNERTY “ The dual challenges of climate change and a global pandemic have made designing safe, sustainable and efficient workplaces even more important for companies and their employees.” Noel Finnerty , director, Global Real Estate and Facilities Prioritizing Employee Health and Safety Boston Scientific takes a global approach to prioritizing, delivering and monitoring employee safety at all our offices and facilities.",2020_boston_scientific_performance_report.pdf
We set health and safety goals called Total Recordable Incident Rate (TRIR) targets for every Boston Scientific operations site.,2020_boston_scientific_performance_report.pdf
"Our global Employee Health and Safety (EHS) Operations Council reviews their performance monthly to discuss trends and risks, as well as opportunities for improvement.",2020_boston_scientific_performance_report.pdf
"In accordance with the Boston Scientific Environment, Health and Safety Policy , we integrate multiple health and safety metrics in our monitoring systems at the local and global levels.",2020_boston_scientific_performance_report.pdf
"The policy is supported by our global EHS Essentials, which sets 143 specific expectations across 25 health- and safety-related programs.",2020_boston_scientific_performance_report.pdf
Our Occupational Health Council provided valuable employee assistance during the pandemic.,2020_boston_scientific_performance_report.pdf
"They established a centralized helpline, staffed by Boston Scientific physicians and occupational health nurses to help guide employees with COVID-19-related queries.",2020_boston_scientific_performance_report.pdf
We also offered voluntary COVID-19 testing to our on-site employees to help reassure them of the effectiveness of our protective processes.,2020_boston_scientific_performance_report.pdf
"We conducted a workplace survey of more than 25,000 employees to ask about their remote work experience during the pandemic and their preferences moving forward.",2020_boston_scientific_performance_report.pdf
Responses showed that working remotely has changed many employees’ thinking about their ability to work effectively from home and has made them more receptive to different types of office environments.,2020_boston_scientific_performance_report.pdf
We incorporated survey insights into a Global Design Guidelines Update that addresses on-site protocols as well as work-from-home practices.,2020_boston_scientific_performance_report.pdf
"In 2020, we navigated the ongoing challenges of the pandemic in the various countries where our employees live and work.",2020_boston_scientific_performance_report.pdf
"Boston Scientific took immediate action to develop global COVID-19 guidance, restrictions and workplace protocols , including: Flexible work arrangements for employees who could work from home.",2020_boston_scientific_performance_report.pdf
Travel restrictions and protocols .,2020_boston_scientific_performance_report.pdf
Company and site safety protocols .,2020_boston_scientific_performance_report.pdf
Workstation reconfiguration .,2020_boston_scientific_performance_report.pdf
Limited sales visits to critical cases.,2020_boston_scientific_performance_report.pdf
Accelerated capabilities to provide remote physician support .,2020_boston_scientific_performance_report.pdf
Advanced cleaning protocols .,2020_boston_scientific_performance_report.pdf
COVID-19 employee resources website.,2020_boston_scientific_performance_report.pdf
Office space modifications and new building procedures .,2020_boston_scientific_performance_report.pdf
COVID-19 testing and personal protective equipment (PPE) for employees.,2020_boston_scientific_performance_report.pdf
COVID-19 contact tracing .,2020_boston_scientific_performance_report.pdf
Augmented platforms for remote practitioner case support .,2020_boston_scientific_performance_report.pdf
"TOTAL RECORDABLE INCIDENT RATE (TRIR) 2020: 0.47 TRIR (0.47 injuries per 100 employees)2030 Goal: 0.25 TRIR (0.25 injuries per 100 employees) 4,655 employee calls to our physicians and nurses in 2020 5,482 COVID-19 tests for on-site employees in 2020 Boston Scientific 2020 Performance Report 35 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Advancing possibilitiesPURPOSE Combating inequitiesHUMANITY Improving outcomesSCIENCE Advancing Possibilities Our commitment to transforming lives inspires us to address inequities in the world around us.",2020_boston_scientific_performance_report.pdf
"Boston Scientific collaborates with local communities, nonprofit organizations and providers to understand and address disparities within underrepresented populations.",2020_boston_scientific_performance_report.pdf
"Whether we are improving treatment disparities for Black, Hispanic and Latinx people, providing students access to STEM opportunities, or empowering employees to take action in their communities, we are advancing possibilities for societal good.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 36 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Confronting Health Inequities For more than 15 years, Boston Scientific has worked to eliminate health care inequities in underserved communities through our industry-leading program Close the Gap .",2020_boston_scientific_performance_report.pdf
"More recently, and as the pandemic exposed the severity of treatment disparities and systemic barriers to care, we stepped up our efforts to help providers identify and serve diverse populations.",2020_boston_scientific_performance_report.pdf
"Through Close the Gap, Boston Scientific launched a public awareness campaign focused on health inequities related to heart and vascular disease outcomes in the U.S.",2020_boston_scientific_performance_report.pdf
The campaign augments the work we’re doing with local health care providers and major health systems.,2020_boston_scientific_performance_report.pdf
This includes sharing community-specific disparity data and patient education materials to help address the treatment gaps among patients who identify as women and people of color.,2020_boston_scientific_performance_report.pdf
"SUSTAINABLE DEVELOPMENT GOALS: HEALTH EQUITY CHAMPION: PAIGE BINGHAM In 2020, Paige Bingham became the national program director of Close the Gap.",2020_boston_scientific_performance_report.pdf
"A longtime health equity champion, Paige offers insights on the team’s work to address treatment disparities and increase diversity in clinical trials .",2020_boston_scientific_performance_report.pdf
“ The Boston Scientific Close the Gap program empowers physicians with data and epidemiological insights to identify local treatment gaps and customizable resources to reach vulnerable populations.,2020_boston_scientific_performance_report.pdf
"This approach helps to inform and activate measurable change to save lives.” Paige Bingham , national program director, Close the Gap In 2020, Boston Scientific launched a public awareness campaign focused on health inequity awareness.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 37 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Addressing the Gaps: COVID-19 Heart Study The most vulnerable populations are at the greatest risk for conditions such as heart disease, but they are the least studied in large-scale clinical trials.",2020_boston_scientific_performance_report.pdf
"According to census data, Black Americans represent 13.4 percent of the U.S. population, yet peer-reviewed research shows they make up only 5 to 7 percent of clinical trial participants.1 In 2020, we began work with Yale/Yale-New Haven Hospital Center for Outcomes Research and Evaluation (Yale-CORE) to increase the diversity of representation in the Boston Scientific COVID-19 Heart Study , developed to better understand how COVID-19 affects people with heart conditions.",2020_boston_scientific_performance_report.pdf
"1 Clark LT, Watkins L, Piña IL, et al.",2020_boston_scientific_performance_report.pdf
Increasing diversity in clinical trials: Overcoming critical barriers.,2020_boston_scientific_performance_report.pdf
Curr Probl Cardiol .,2020_boston_scientific_performance_report.pdf
2019 May;44(5):148-72.,2020_boston_scientific_performance_report.pdf
"Paul Underwood, MD, and medical director at Boston Scientific, has been working to reduce health disparities for women and people of color since 1990.",2020_boston_scientific_performance_report.pdf
He made it his mission to fight racism .,2020_boston_scientific_performance_report.pdf
“ The data show that the most vulnerable populations have the greatest risk of heart disease but are the least studied in large-scale clinical trials.,2020_boston_scientific_performance_report.pdf
The opportunities to make an impact are fantastic when we use objective data to guide the way.,2020_boston_scientific_performance_report.pdf
"I am so proud to be working for a company taking tangible actions to battle systemic racism.” Paul Underwood, MD , medical director, Boston ScientificIN THE UNITED STATES: 13.4% of the population is Black Only 5-7% of clinical trial participants are BlackA 40-YEAR BATTLE AGAINST RACISM Boston Scientific 2020 Performance Report 38 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Playing Our Part: Combating Racism Racism in the United States and around the world was front and center in 2020 as we witnessed the tragic death of George Floyd, preceded by those of Breonna Taylor, Ahmaud Arbery and so many others.",2020_boston_scientific_performance_report.pdf
The Boston Scientific Executive Committee issued an open letter reaffirming the company’s commitment to contribute to a more equitable and inclusive society where all people feel safe and valued and have a voice.,2020_boston_scientific_performance_report.pdf
"As part of that pledge, Boston Scientific is donating $3.5 million over a multiyear period to combat inequity, systemic racism and injustice in our communities.",2020_boston_scientific_performance_report.pdf
"We are also accelerating our internal diversity, equity and inclusion programs, which include initiatives that address discrimination and racism.$3.5 million to combat racism and advance social justiceCOMBATING RACISM STRATEGY Community Expand the conversation on anti-racism and support social justice organizations Economic Empowerment Accelerate the development of Black-owned businesses Education Educate and create professional opportunities for Black youth Health Care Disparities Address health care disparities in the community Government/Policies Advocate for change Boston Scientific 2020 Performance Report 39 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblySupporting Our Communities The work we do is about caring for human life, and it draws us into the communities where we live and work.",2020_boston_scientific_performance_report.pdf
Our employees help us shape the way we care for the world around us.,2020_boston_scientific_performance_report.pdf
"In 2020, employee engagement expanded to 54 countries and philanthropic contributions focused on the coronavirus pandemic, social justice and natural disasters.",2020_boston_scientific_performance_report.pdf
"Our global community engagement is focused on three key areas: BSC CONTRIBUTIONS AND ENGAGEMENT 54 countries Employee community engagement $70 million Contributions for medical research, fellowships, educational and charitable giving $1.2 million Boston Scientific Foundation contributions +1,700 nonprofits supported with donations or grant funding Advancing education To develop diverse talent who will create health solutions for generations to come, we support science, technology, engineering and math (STEM) programming for underserved 5- to 18-year-old students around the world.",2020_boston_scientific_performance_report.pdf
"Advancing health To decrease health disparities in chronic diseases among underserved communities, we aim to provide access to quality care, support disease prevention and help prepare children for a healthy journey into adulthood.",2020_boston_scientific_performance_report.pdf
"Advancing community To improve life in their local communities, we empower our employees to donate their talent and resources through our strategic matching gifts and volunteer programs.",2020_boston_scientific_performance_report.pdf
"1 2 3 Boston Scientific 2020 Performance Report 40 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Relief Efforts When an event occurs that devastates one of our communities, Boston Scientific works to ensure employee safety, assess impact and determine how the company can support relief efforts.",2020_boston_scientific_performance_report.pdf
"For example, in 2020, the company coordinated and encouraged employee donations to help people affected by the wildfires in Australia and California, Hurricane Laura, the explosion in Beirut, the coronavirus epidemic as well as victims of social injustice and racial inequity.",2020_boston_scientific_performance_report.pdf
"Employees who chose to donate to these efforts received a matching financial contribution from Boston Scientific.EMPLOYEE ACTION AFTER BEIRUT BLAST In August 2020, an explosion in Beirut killed more than 200 people, injured more than 7,500 and left an estimated 300,000 people homeless.",2020_boston_scientific_performance_report.pdf
"Boston Scientific Peripheral Interventions Training Manager Rawad Abou Dihn, who has a nursing background, quickly rallied colleagues and friends to turn the entrance of a local building into an emergency wound clinic.",2020_boston_scientific_performance_report.pdf
The team provided critical aid to an average of 100 people daily and helped reduce the tremendous strain on hospitals overwhelmed with critically wounded people and COVID-19 patients.,2020_boston_scientific_performance_report.pdf
Boston Scientific 2020 Performance Report 4035% annual increase of employees participating in global matching gifts program Tarek El Rahbani led local efforts to support Boston Scientific employees and operations in Beirut following the explosion.,2020_boston_scientific_performance_report.pdf
"“ As a Lebanese Boston Scientific employee, I am grateful for the support we received from colleagues around the world and proud of the quick actions taken by Rawad and volunteers.",2020_boston_scientific_performance_report.pdf
"Our commitment to our caring core value is evidenced by how our employees responded with compassion and integrity.” Tarek El Rahbani, managing director, Middle East, North Africa, Turkey and Central AsiaPERSPECTIVE FROM BEIRUT TAREK EL RAHBANI Boston Scientific 2020 Performance Report 41 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly In Marlborough, Massachusetts , employees made and donated masks and other items to local nursing homes, hospitals and homeless shelters.",2020_boston_scientific_performance_report.pdf
"In Galway, Ireland , employees lifted spirits by donating critical supplies, including gloves, masks, coveralls and boxes of chocolate Easter eggs, to local nursing homes.In Singapore , employees packed and donated more than 350 kits filled with essential items such as hand sanitizer, face shields and healthy snacks to local nursing home residents and health care workers.+ + =$18 million+ Global relief efforts$1 million+ Charitable donations$13 million + Face shields, other innovations$4 million+ Personal Protective Equipment (PPE) PITCHING IN WITH PPE GLOBALLYCOVID-19 RELIEF BY THE NUMBERS Boston Scientific 2020 Performance Report 42 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly In an urgent 2020 undertaking called Project Shield , Boston Scientific employees assembled and donated one million face shields in just over one month.",2020_boston_scientific_performance_report.pdf
Urology Research and Development (R&D) Project Manager Alissa Brandon came up with the idea and collaborated with colleagues to launch the initiative .,2020_boston_scientific_performance_report.pdf
The effort rapidly expanded to include: 12 Boston Scientific sites.,2020_boston_scientific_performance_report.pdf
More than 400 employees around the world contributing their time and expertise.,2020_boston_scientific_performance_report.pdf
"They also collaborated with the grassroots organization GetUsPPE , to deliver the PPE to health care facilities in more than 40 U.S. states and territories.",2020_boston_scientific_performance_report.pdf
“ This shows what can be accomplished when a team with a lot of heart and know-how comes together to collaborate.,2020_boston_scientific_performance_report.pdf
So many people stepped up to contribute and help scale this project to where it is today.,2020_boston_scientific_performance_report.pdf
"I am grateful for our caring team who demonstrated heroic hustle.” Alissa Brandon , R&D manager, Urology COMMUNITY ENGAGEMENT SPOTLIGHT: PROTECTING OUR HEALTH CARE HEROES Boston Scientific 2020 Performance Report 43 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Global Signature Health Grant Program The World Health Organization is estimating a shortage of 19 million health care workers in low- and lower-middle income countries by 2030.",2020_boston_scientific_performance_report.pdf
"Recognizing this crisis early on, Boston Scientific launched a Global Signature Health Grant Program in 2016.",2020_boston_scientific_performance_report.pdf
"Since then, we have partnered with nonprofit organizations that are working globally to increase the number of trained health care workers and improve the quality and availability of chronic disease screenings.",2020_boston_scientific_performance_report.pdf
"The World Health Organization is estimating a shortage of 19 million health care workers in low- and lower-middle income countries by 2030 MEXICO: Boston Scientific supported Partners in Health between 2017 and 2019 and trained newly graduated Mexican physicians in the diagnosis and treatment of chronic disease.COLOMBIA: New in 2020, we support Project HOPE in its work with the Ministry of Health and local universities to deliver chronic disease training for providers caring for millions of Venezuelan refugees.SOUTH AFRICA: Our grant to Project HOPE funded work that trained health care workers and created screening protocols for diabetes and hypertension from 2016 to 2018.",2020_boston_scientific_performance_report.pdf
"INDIA: Beginning in 2016, we collaboratively developed training tools with Project HOPE that support the diagnosis and treatment of chronic disease.",2020_boston_scientific_performance_report.pdf
"New in 2020, our grant to Population Services International funds the creation of digital tools that better identify and follow patients living with chronic disease.MALAYSIA: Since 2018, we have supported Children’s HeartLink to help create a regional center of excellence for the diagnosis and treatment of congenital heart disease in children.GLOBAL SIGNATURE HEALTH GRANT COLLABORATIONS SINCE 2016 “ We are incredibly thankful for Boston Scientific’s commitment to improving the world’s health and for a partnership that is helping people around the world access the care they need.” Rabih Torbay , president and CEO, Project HOPE Project HOPE Project HOPEProject HOPE, Population Services InternationalPartners in Health Children’s HeartLink Boston Scientific 2020 Performance Report 44 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyProject HOPE Aid in Colombia When Colombia declared COVID-19 a health emergency, Project HOPE redirected its efforts, and a portion of grant funding, to work with the Ministry of Health, Departmental Health Institute and local hospitals to train health care workers and non-medical staff, conduct COVID-19 screenings and distribute PPE.",2020_boston_scientific_performance_report.pdf
"5,616 people screened for COVID-19.",2020_boston_scientific_performance_report.pdf
94 health care workers trained.,2020_boston_scientific_performance_report.pdf
"238 non-medical staff and local volunteers trained in hygiene promotion, infection protection and control, and contact tracing.",2020_boston_scientific_performance_report.pdf
"7,543 health consultations provided.",2020_boston_scientific_performance_report.pdf
415+ full sets of PPE distributed.,2020_boston_scientific_performance_report.pdf
"1,500 gloves provided.",2020_boston_scientific_performance_report.pdf
500+ protective lenses distributed.,2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 45 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly STEM Education On-site events and in-person mentoring were put on hold for much of the year, but Boston Scientific found innovative ways to continue to bring STEM education to underrepresented youth.",2020_boston_scientific_performance_report.pdf
"Around the world, STEM volunteers used new technology to expose students to careers in industries like ours.",2020_boston_scientific_performance_report.pdf
"China: In honor of Children’s Day, our STEM team created “Know Your Body” videos, including How does air pollution harm your lungs?",2020_boston_scientific_performance_report.pdf
and Why lip color turns darker when your heart does not feel well .,2020_boston_scientific_performance_report.pdf
Puerto Rico: Employee volunteers gave elementary school students a virtual tour of our Dorado plant that featured an interactive pH experiment.,2020_boston_scientific_performance_report.pdf
High school students also had the opportunity to interact with an online panel of STEM experts and watch a video simulating a product being implanted.,2020_boston_scientific_performance_report.pdf
"Ireland: To recognize Engineering Day, the team held a contest in which 8- to 12-year-old students had the chance to win a “STEM Day in a Box” that featured content and experiments in chemistry, engineering, physics and battery technology.",2020_boston_scientific_performance_report.pdf
More than 750 youngsters representing 46 schools in 25 towns participated in the contest.,2020_boston_scientific_performance_report.pdf
"Our Community Engagement team launched BSC Buddies, a program that connects employees’ school-aged children online across different geographies, cultures and languages.",2020_boston_scientific_performance_report.pdf
"The 2020 pilot paired 400 children from more than 20 countries.34,000 kits packed that provided STEM activities, health and wellness essentials, and other necessities to populations in need around the world BSC BUDDIES Boston Scientific 2020 Performance Report 46 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Prioritizing our planetPURPOSE Making a global commitmentHUMANITY Reducing our climate impactsSCIENCEProtecting the Environment Our commitment to improving patient health comes with a responsibility to protect the planet we all share.",2020_boston_scientific_performance_report.pdf
"As we work to solve health care’s toughest challenges, we are taking decisive action to reduce our environmental impacts and achieve carbon neutrality.",2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 47 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Responding to Climate Change Boston Scientific sets ambitious climate change goals, and we are on track to meet our commitment to achieve carbon neutrality in all manufacturing and key distribution sites by 2030.",2020_boston_scientific_performance_report.pdf
We became the first medical device manufacturer to make such a pledge in 2017.,2020_boston_scientific_performance_report.pdf
"Since the start of 2017, we have reduced our carbon footprint by 50 percent.SUSTAINABLE DEVELOPMENT GOALS: Ronan Coffey has led our Global Energy Management System (GEMS) since 2018.",2020_boston_scientific_performance_report.pdf
"“ Carbon neutrality is the right thing to do, and our C3 strategy is the right way to do it.",2020_boston_scientific_performance_report.pdf
Our Global Energy Management System has grown from being a new way to look at energy consumption to being the actual language we use to talk about energy management and carbon emissions.,2020_boston_scientific_performance_report.pdf
GEMS is built into how we work.,2020_boston_scientific_performance_report.pdf
"Our teams are making great progress around the world.” Ronan Coffey, global energy manager, Boston Scientific C3 STRATEGY Cut energy use emissions.Convert to renewable energy sources instead of relying on fossil fuels.Compensate with carbon credits and offset projects for any remaining unavoidable emissions.A central component of the company’s carbon neutrality approach is our C3 energy strategy.",2020_boston_scientific_performance_report.pdf
"Global and site teams collaborate across Boston Scientific to meet its objectives: ACHIEVING CARBON NEUTRALITY: RONAN COFFEY Boston Scientific 2020 Performance Report 48 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly 2013123k 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030Greenhouse Gas Emis sions: Tonnes C O₂ Equiv alents • Renew able thermal • Electriﬁc ation • Renew able ener gy cr edit pur chases • Supplier r enew ables • On-site solar installations • Power pur chase agr eements Scope 2: Electricity Scope 1: Natur al Gas% Renewable Energy2013–2030: RAMP TO CARBON NEUTRALITY Interim Goals: 50% renewable electricity by 2021100% renewable electricity by 202490% renewable energy (all sources) by 2027Boston Scientific is on track to achieving carbon neutrality in all manufacturing and key distribution sites by 2030 2020 HONORS In 2020, Boston Scientific was named to the Dow Jones Sustainability Index (DJSI) for North America, a well- respected global benchmark for corporate responsibility.",2020_boston_scientific_performance_report.pdf
"The list recognizes companies that deliver outstanding economic, social and environmental performance.",2020_boston_scientific_performance_report.pdf
Visit our online awards page to read more about our environmental honors and distinctions.,2020_boston_scientific_performance_report.pdf
"Boston Scientific 2020 Performance Report 49 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyGEMS KEY PERFORMANCE INDICATORS Using the GEMS approach developed in conjunction with the National University of Ireland, Galway, Boston Scientific is making measurable strides toward carbon neutrality.",2020_boston_scientific_performance_report.pdf
We track progress and report it publicly using five GEMS key performance indicators (KPIs).,2020_boston_scientific_performance_report.pdf
"2015 2016 2017 2018 2019 2020 Carbon Footprint Total amount of Scope 1 and Scope 2 greenhouse gas emissions 118,327 108,694 94,946 85,127 84,778 53,730 (MT CO2eq) emitted into the atmosphere from manufacturing and distribution sites.",2020_boston_scientific_performance_report.pdf
Measured in tonnes of carbon equivalent.,2020_boston_scientific_performance_report.pdf
Energy Use Total energy Boston Scientific Total MWh 370k 367k 364k 355k 368k 381k (MWh) consumes annually to manufacture our products.,2020_boston_scientific_performance_report.pdf
Normalized MWh/ 49 44 40 36 34 38 Million $ Revenue EM3 An energy management maturity model to establish where in 2.7 3.2 3.6 3.7 3.9 4.1 the “energy journey” each manufacturing site resides on a scale of 0 to 5: (Minimal/Emerging/Developing/Advancing/Leading) Green Real Estate Percentage of Boston Scientific real estate that is independently 27% 28% 32% 32%* 41%* 42% (% of total) certified for energy efficiency by industry-leading bodies such as LEED for design and Energy Star or ISO 50001 for building operations.,2020_boston_scientific_performance_report.pdf
"Renewable Energy Percentage of total energy Electricity Percent — — — 5% 11% 71% (% of total) consumed, generated from renewable sources, with BSC owning the renewable All Sources Percent — — — 3% 6% 35% attributes.",2020_boston_scientific_performance_report.pdf
"* Prior year numbers restated Boston Scientific 2020 Performance Report 50 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly2020 ENVIRONMENTAL ADVANCES Our Environmental Impact In 2020, we made significant progress in our C³ energy strategy to achieve carbon neutrality across our manufacturing and key distribution sites.",2020_boston_scientific_performance_report.pdf
"By addressing the company’s energy consumption, carbon emissions and environmental designs, we are reducing our climate impacts.",2020_boston_scientific_performance_report.pdf
"67% reduction in greenhouse gas emissions since 2009 71% of purchased electricity from renewable sources 94% of solid waste diverted from landfills Working with sustainability-minded customers, since 2017 , we increased the number of patients reached by 20% while reducing our carbon footprint by 50% BIGGER REACH, SMALLER FOOTPRINT Boston Scientific 2020 Performance Report 51 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyCutting Our Carbon Footprint Tackling energy use is the first tier of our C3 approach.",2020_boston_scientific_performance_report.pdf
"To improve energy use in our existing sites and develop new construction in an environmentally responsible manner, we adhere to internationally recognized programs such as Leadership in Energy and Environmental Design (LEED) or the ISO 50001 energy management system.",2020_boston_scientific_performance_report.pdf
"In 2020, Boston Scientific green real estate increased to 42%, up from 27% in 2015, representing more than 3.8 million square feet of total company real estate.",2020_boston_scientific_performance_report.pdf
"At a minimum, all newly constructed Boston Scientific buildings are LEED certified.OUR GREEN REAL ESTATE EXPANDS Energy Management System ISO 50001: 5 manufacturing sites, 1 distribution center Leadership in Energy and Environmental Design (LEED): 15 buildings 42% of Boston Scientific real estate is green — representing 3.8+ million square feet New commercial hub in Madrid, Spain .",2020_boston_scientific_performance_report.pdf
"Renovated flexible, collaborative workspace in Galway, Ireland .New administration block in Clonmel, Ireland .",2020_boston_scientific_performance_report.pdf
Boston Scientific 2020 Performance Report 52 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyConverting to Renewable Energy Investing in and converting to renewable energy sources is the second action area of the C3 strategy.,2020_boston_scientific_performance_report.pdf
"We monitor the percentage of the company’s energy generated from renewable sources, whether the energy is generated on-site or purchased from outside suppliers.",2020_boston_scientific_performance_report.pdf
"In 2020, we stayed on track to meet our objective of sourcing or generating 100 percent of our electricity from renewable sources by 2024.",2020_boston_scientific_performance_report.pdf
"We expect that by 2027, 90 percent of all energy at Boston Scientific facilities, including electricity and natural gas, will be renewable.",2020_boston_scientific_performance_report.pdf
"Our Clonmel, Cork and Galway, Ireland facilities and our Kerkrade, the Netherlands distribution center source 100 percent renewable energy.",2020_boston_scientific_performance_report.pdf
"Using hydroelectric, wind and solar power, our manufacturing sites in Heredia and Coyol, Costa Rica have been carbon-neutral since 2016.",2020_boston_scientific_performance_report.pdf
"In our Marlborough and Quincy, Massachusetts locations, we have on-site solar installations that generated a total of 3.2 million kilowatt-hours of renewable electricity in 2020.",2020_boston_scientific_performance_report.pdf
"An on-site solar installation at our Dorado, Puerto Rico facility, slated for completion in mid-2021, will deliver approximately 17 percent of the site’s electricity needs.Compensating With Carbon Offsets Carbon offsetting is the final step we consider taking to reach carbon neutrality.",2020_boston_scientific_performance_report.pdf
"While our primary focus is on cutting energy use and converting to clean energy sources, we compensate with carbon offset projects when we have unavoidable carbon emissions or cannot yet rely on renewable energy options.",2020_boston_scientific_performance_report.pdf
Potential projects are carefully assessed to ensure the results will negate our remaining carbon emissions.,2020_boston_scientific_performance_report.pdf
"For example, Boston Scientific collaborated with the eco-conscious platform Treedom in 2020 to plant more than 5,000 trees in Kenya.",2020_boston_scientific_performance_report.pdf
The initiative will benefit local communities and contribute to cleaner air in the region.,2020_boston_scientific_performance_report.pdf
Climate Risk Management Boston Scientific has begun integrating climate-related financial disclosures into the way we manage climate- related risks and opportunities.,2020_boston_scientific_performance_report.pdf
"In 2021, we will complete a comprehensive assessment of our business risks associated with climate change.",2020_boston_scientific_performance_report.pdf
"By 2027 , we expect 90% of all energy used in Boston Scientific facilities will be renewable Boston Scientific 2020 Performance Report 53 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Conserving Water Water is a critical shared resource, and we are committed to managing its use responsibly.",2020_boston_scientific_performance_report.pdf
"While Boston Scientific operations are not water intensive, we work to minimize consumption and prepare for water supply challenges.",2020_boston_scientific_performance_report.pdf
"Based on an assessment using the World Resources Institute Aqueduct risk-mapping tool, we have determined that 11 company locations are at low overall water-related risk, and six facilities are in the low-to-medium risk category.",2020_boston_scientific_performance_report.pdf
Our efforts to assess water-related risks and opportunities will expand in 2021 to include the company’s significant commercial operations.,2020_boston_scientific_performance_report.pdf
"Water usage at Boston Scientific manufacturing and major distribution centers is predominantly associated with employees, which accounts for 69 percent of our total water consumption.",2020_boston_scientific_performance_report.pdf
Waste Management and Recycling We are working to divert all non-hazardous waste from landfills and incineration by 2030.,2020_boston_scientific_performance_report.pdf
Boston Scientific facilities will participate in the TRUE (Total Resource Use and Efficiency) certification program to meet this objective.,2020_boston_scientific_performance_report.pdf
"TRUE strives to change the way materials flow through society so that all products are eventually reused and diverted from landfills, incineration and the environment.2020 RECYCLING AND RECOVERY 79% 7 ,922 metric tons total non-hazardous waste recycled 52% 509 metric tons of hazardous and regulated waste recovered or recycled Boston Scientific 2020 Performance Report 54 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Results from Cork: Taking Recycling to the Next Level After achieving a recycling rate of more than 90 percent, our Cork, Ireland team extended their success by recovering reusable materials.",2020_boston_scientific_performance_report.pdf
"In 2020, they began setting aside plastic packaging made from Polyethylene Terephthalate, a material that can be ground into flakes and reused if properly isolated in the collection process.This approach also results in less processing energy than recycling.",2020_boston_scientific_performance_report.pdf
"By taking this extra step, the team diverted 20 metric tons of plastic for recovery.",2020_boston_scientific_performance_report.pdf
Our Cork site made significant progress toward waste avoidance in 2020 — their recycling initiatives resulted in 20 metric tons of plastic recovered.,2020_boston_scientific_performance_report.pdf
Success in Cork: 90% recycling rate achieved 20 metric tons of plastic recovered “ Focusing on avoidance and reuse is key to reducing our environmental impact.,2020_boston_scientific_performance_report.pdf
"For the future of our planet, we have a duty to go beyond standard recycling.” Seamus Gethins , global director, Global Environment, Health and SafetyGLOBAL WASTE MANAGEMENT PERSPECTIVE: SEAMUS GETHINS Boston Scientific 2020 Performance Report 55 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Boston Scientific is committed to conducting business with unwavering ethics, strong corporate governance and regulatory compliance.",2020_boston_scientific_performance_report.pdf
We insist on integrity in all our working relationships inside and outside the company.,2020_boston_scientific_performance_report.pdf
"Our practices protect human rights, promote accountability and ensure that we act responsibly as a global citizen.",2020_boston_scientific_performance_report.pdf
Creating value responsiblyPURPOSE Respecting human rightsHUMANITY Innovating with integritySCIENCE Creating Value Responsibly Boston Scientific 2020 Performance Report 56 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Jessica Pill leads our efforts to ensure compliance with regulatory requirements while acting with integrity and living our core values.,2020_boston_scientific_performance_report.pdf
"“ Despite how we’ve had to change the way we work this year, we are doing our part to keep each other safe and live our values while continuing to serve patients and navigate challenges together.” Jessica Pill , chief compliance officer and vice president, Compliance Compliance, Ethics and Integrity Our work contributes value to the lives of patients, employees and people in communities around the world.",2020_boston_scientific_performance_report.pdf
"Social responsibility is built into how we deliver innovations, collaborate and operate.",2020_boston_scientific_performance_report.pdf
Our employees have a shared commitment to: Act honestly and ethically in all company matters.,2020_boston_scientific_performance_report.pdf
"Protect the privacy of patients, customers and employees.",2020_boston_scientific_performance_report.pdf
Treat one another with respect and fairness.,2020_boston_scientific_performance_report.pdf
"Hold one another accountable to ensure quality in everything we do.The Boston Scientific global compliance team provides employees with the resources and training they need to do business with integrity, treat customers and suppliers fairly, and report ethics concerns when they arise.",2020_boston_scientific_performance_report.pdf
"Led by our chief compliance officer, the team collaborates across the company to monitor our activities and performance.",2020_boston_scientific_performance_report.pdf
The chief compliance officer reports quarterly to the risk committee of our board of directors and more frequently as needed.,2020_boston_scientific_performance_report.pdf
"Code of Conduct Every employee is required to read and understand the Boston Scientific Code of Conduct , which is the foundation for all our business practices and relationships.",2020_boston_scientific_performance_report.pdf
"Employees complete annual training on the Code of Conduct, as well as multiple mandatory training courses throughout SUSTAINABLE DEVELOPMENT GOALS: the year that reinforce company policies, explain corruption- and compliance-related risks and provide resources for reporting concerns.",2020_boston_scientific_performance_report.pdf
Many of these trainings offer scenario-based content that help people respond ethically to issues they may face in their daily work.,2020_boston_scientific_performance_report.pdf
"We continually assess opportunities to adapt our Code of Conduct in light of developments in the global marketplace, including emerging technologies and business practices.",2020_boston_scientific_performance_report.pdf
"In January 2020, we released an updated Code of Conduct with greater specificity about privacy rights, new language about maintaining a safe and healthy work environment, additional details about data privacy and expanded guidance on conflicts of interest.GLOBAL COMPLIANCE: LEADING WITH INTEGRITY Boston Scientific 2020 Performance Report 57 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Non-Retaliation Policy The Boston Scientific Non-Retaliation Policy is an essential component of our compliance program.",2020_boston_scientific_performance_report.pdf
"It prohibits any form of retaliation, direct or indirect, against an individual who raises a concern in good faith.",2020_boston_scientific_performance_report.pdf
"This protection extends to anyone who assists with, or cooperates in, an investigation or report of misconduct.",2020_boston_scientific_performance_report.pdf
Advice Line All employees are responsible for immediately reporting any suspected violation of the Code of Conduct and related company policies.,2020_boston_scientific_performance_report.pdf
Ethics concerns may be confidentially reported through the Boston Scientific Advice Line.,2020_boston_scientific_performance_report.pdf
"The toll-free, 24-hour service is operated by a third party seven days a week in multiple languages.“INTEGRITY TOGETHER” CAMPAIGN We regularly promote employee awareness of the Code of Conduct and Non-Retaliation Policy.",2020_boston_scientific_performance_report.pdf
"In 2020, our week-long integrity campaign featured video messages from senior leaders and interactive virtual events that emphasized the importance of working ethically.",2020_boston_scientific_performance_report.pdf
"In addition, regional and country leaders reinforced the campaign through local email messages, videos and online roundtables.Global Human Rights and Labor Standards We adhere to human rights and labor laws in every location where our company operates.",2020_boston_scientific_performance_report.pdf
"In 2020, we finalized the Boston Scientific Human Rights Policy , which articulates our commitment to promoting human rights principles as recognized and understood by the international community.",2020_boston_scientific_performance_report.pdf
"These principles include vigilance against modern slavery, human trafficking, bribery, discrimination and harassment.",2020_boston_scientific_performance_report.pdf
Our human rights policy supports and is guided by the principles of the United Nations (UN) International Bill of Rights as well as: The Universal Declaration of Human Rights.,2020_boston_scientific_performance_report.pdf
The UN Guiding Principles on Business and Human Rights.,2020_boston_scientific_performance_report.pdf
"The International Covenant on Economic, Social and Cultural Rights.",2020_boston_scientific_performance_report.pdf
The International Labor Organization Declaration on Fundamental Principles and Rights at Work.,2020_boston_scientific_performance_report.pdf
Global Reporting Initiative Sustainability Reporting Standards.,2020_boston_scientific_performance_report.pdf
We also adhere to disclosure requirements under the California Transparency in Supply Chains Act and the U.K. Modern Slavery Act.,2020_boston_scientific_performance_report.pdf
"As the pandemic changed how we work, we continued our Open Doors initiative using online resources to ensure managers could maintain a virtual open door with employees, including those with compliance concerns.",2020_boston_scientific_performance_report.pdf
EQUIPPING LEADERS TO ADDRESS EMPLOYEE CONCERNS Boston Scientific 2020 Performance Report 58 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly BEST-IN-CLASS GLOBAL SECURITY The Boston Scientific global security and resiliency team was ranked in the top 10 of all U.S. manufacturers’ security departments in Security magazine’s 2020 Security 500 rankings .,2020_boston_scientific_performance_report.pdf
"The team’s leadership has also been recognized for its commitment to diversity, equity and inclusion.",2020_boston_scientific_performance_report.pdf
"Risk Management and Global Security Under the oversight of our board of directors, our enterprise risk management team supports company leadership with guidance to achieve performance objectives.",2020_boston_scientific_performance_report.pdf
"The team analyzes strategic, operational, financial, legal and compliance risks to ensure we can adapt to challenges, pursue opportunities to help patients and meet commitments to stockholders.",2020_boston_scientific_performance_report.pdf
"Led by our vice president of global internal audit, our risk management experts identify enterprise-level developments that could be barriers to meeting customer and patient needs or preserving and growing stockholder value.",2020_boston_scientific_performance_report.pdf
"Any issue that presents a potential risk to the company’s financial results, operations or reputation is reported by management to the Board of Directors or one of its committees.",2020_boston_scientific_performance_report.pdf
Matt Sprague leads our team of risk management experts that identify enterprise- level developments that could be barriers to meeting customer and patient needs.,2020_boston_scientific_performance_report.pdf
"“ The COVID-19 pandemic has broadened our definition of risk and expanded the scenarios we plan for in our risk manage - ment approach and processes, resulting in sharper action plans, escalation paths and lines of communication.” Matt Sprague, vice president, Global Internal AuditRISK MANAGEMENT: PREPARING TO HANDLE ANY SITUATION Boston Scientific 2020 Performance Report 59 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Business Resiliency The Boston Scientific business resiliency strategy ensures that we can sustain operations and secure our facilities in the event of a crisis.",2020_boston_scientific_performance_report.pdf
"Our global security and resiliency team plans and prepares for a range of potential threats, including wildfires, tornados, earthquakes, hurricanes and the effects of climate change.",2020_boston_scientific_performance_report.pdf
"They use risk and impact assessments to plan for disasters or events that could interfere with our ability to deliver products for patients or jeopardize the safety of our people, suppliers or communities.",2020_boston_scientific_performance_report.pdf
The team also works closely with our IT disaster recovery experts to identify technology vulnerabilities so we can make the right investments to keep company operations secure.,2020_boston_scientific_performance_report.pdf
"When COVID-19 cases first emerged, our security, resiliency and medical teams acted quickly to protect our people and business operations while taking steps to ensure that our devices and therapies would continue to reach patients.",2020_boston_scientific_performance_report.pdf
"Our employees provided on-site support to customers in accordance with guidance from local health authorities, as well as hospital protocols.",2020_boston_scientific_performance_report.pdf
"To prevent on-site outbreaks and ensure extra safety, employees who could perform their job functions from home worked remotely with flexible work arrangements.",2020_boston_scientific_performance_report.pdf
"We also shipped personal protective equipment (PPE) to company locations for employees’ use, provided COVID-19 testing for employees and issued pandemic guidance for teams globally.",2020_boston_scientific_performance_report.pdf
"Based on virus-tracking data, we implemented new safety protocols, adapted facilities for social distancing and rolled out plans for the tiered resumption of manufacturing operations in locations where case counts subsided.",2020_boston_scientific_performance_report.pdf
Ty Harris leads the company’s business resiliency efforts to help ensure continuity in operations and safety for our employees.,2020_boston_scientific_performance_report.pdf
“ We have a strong global resiliency model to protect the enterprise in the event of a crisis.,2020_boston_scientific_performance_report.pdf
"In early January, when our global intelligence team alerted us to the COVID-19 outbreak in Wuhan, we were able to act immediately to anticipate the extent of the threat and keep employees safe.",2020_boston_scientific_performance_report.pdf
"With new protocols and work streams, we kept critical operations intact and created work environments without community-spread at our sites.” Ty Harris, director, Global Security and Resiliency Protecting Global Assets Our global security and resiliency team ensures the safety of our people as well as enterprise assets and operations.",2020_boston_scientific_performance_report.pdf
"The team uses industry-standard protocols and global situational awareness tactics to manage our security posture and to maintain a global security operations center 24 hours a day, seven days a week.",2020_boston_scientific_performance_report.pdf
"Their work to maintain and enhance physical security and cybersecurity is supported by a network of partners specializing in cybersecurity, environment, health and safety, supply chain, global regulation and data privacy.BUSINESS CONTINUITY: RESILIENCY AND THE GLOBAL PANDEMIC Boston Scientific 2020 Performance Report 60 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyGovernance The Boston Scientific Board of Directors has well-estab - lished corporate governance guidelines and adopted written charters for each of its standing committees (audit, executive compensation and human resources, risk, nominating and governance).",2020_boston_scientific_performance_report.pdf
Our Code of Conduct reflects the company’s commitment to good corporate governance and compliance with the rules and listing standards of the New York Stock Exchange and other legal requirements.,2020_boston_scientific_performance_report.pdf
"Global Tax Strategy and Compliance Our business makes a positive economic and social impact around the world, strengthening the communities where our people live and work.",2020_boston_scientific_performance_report.pdf
"In keeping with our commitment to social responsibility, we prioritize our role as a responsible taxpayer.",2020_boston_scientific_performance_report.pdf
"We comply with all applicable tax laws, regulations and related disclosure requirements in every jurisdiction where we operate.",2020_boston_scientific_performance_report.pdf
Our tax professionals are committed to the highest compliance standards and use processes based on standardization and automation to minimize our tax risk.,2020_boston_scientific_performance_report.pdf
"Political Involvement and Contributions Boston Scientific supports public policies that promote diversity, equity and inclusion and improve patient health, our employees’ lives and the communities we serve.",2020_boston_scientific_performance_report.pdf
We advocate for policies that focus on increasing patient access to life-changing and life-saving technologies.,2020_boston_scientific_performance_report.pdf
"The company posts annual updates on contributions to political action committees, corporate contributions to state officials and memberships in associations that engage in public policy advocacy.",2020_boston_scientific_performance_report.pdf
"To advance sound public policy, the Boston Scientific Corporation Political Action Committee (PAC) facilitates voluntary political contributions by eligible employees and our board of directors in accordance with federal law.",2020_boston_scientific_performance_report.pdf
"While the PAC supports our company values, it does not accept any contributions made on behalf of any corporations, including Boston Scientific, nor does it contribute to presidential campaigns.",2020_boston_scientific_performance_report.pdf
The PAC is run by a governing board of senior employees who represent our primary businesses.,2020_boston_scientific_performance_report.pdf
The nominating and governance committee of our board of directors annually reviews political contributions made by our company and the PAC.,2020_boston_scientific_performance_report.pdf
"Contributions to political candidates are bipartisan, and to be eligible for funding, candidates must meet one or more of the following criteria: Policy alignment: The candidate is aligned with the company’s top public policy priorities; or, Leadership and jurisdiction: The candidate serves in elected leadership within the Congress and/or sits on a congressional committee with jurisdiction over issues impacting our business; or, Constituency: The candidate represents a district or state in which a company facility exists and/or serves a significant population of our employees; or, Values and reputation: The candidate’s character and integrity align with BSC’s corporate reputation and values.",2020_boston_scientific_performance_report.pdf
Boston Scientific 2020 Performance Report 61 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblySetting Industry Standards Boston Scientific collaborates with trade associations and regulatory bodies around the world to set new standards in quality and stay informed about regulatory developments so we can be agile in our response.,2020_boston_scientific_performance_report.pdf
We make it a priority to help shape industry and regulatory approaches to quality by sharing the best practices behind our patient-centric systems.,2020_boston_scientific_performance_report.pdf
FDA Digital Health: We are working closely with the FDA through the Digital Health Software Precertification Pilot Program to expedite patient access to safe and effective software-based medical innovations.,2020_boston_scientific_performance_report.pdf
Medical Device Innovation Consortium: We are part of this public-private partnership with the FDA to advance solutions that promote patient access to innovative medical technologies.,2020_boston_scientific_performance_report.pdf
Responsible Marketing Boston Scientific is committed to ethical and responsible marketing and promotion.,2020_boston_scientific_performance_report.pdf
"Our Code of Conduct and other employee policies emphasize the importance of fair and honest communications with patients, customers and the public.",2020_boston_scientific_performance_report.pdf
"The company’s sales and marketing training for all customer-facing employees covers fair and honest marketing practices, respect for intellectual property, interactions with physicians and public officials, and conflicts of interest.",2020_boston_scientific_performance_report.pdf
"2020 Responsible Sales and Marketing Training: $1.9 million invested in sales and marketing training programs +12,000 hours of training for customer-facing employees Boston Scientific 2020 Performance Report 62 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly Supporting Supplier Diversity Our approach to supplier selection involves building diversity, equity and inclusion throughout the Boston Scientific supplier network.",2020_boston_scientific_performance_report.pdf
"In 2020, as part of our combating racism strategy, we took steps to further expand the number of Black-owned enterprises that provide supply chain services for our business in the United States.",2020_boston_scientific_performance_report.pdf
"We also supported small and diverse vendors during the pandemic by shortening payment terms for those whose business with us is under $250,000.",2020_boston_scientific_performance_report.pdf
"We prioritize partnerships with certified companies that share our dedication to improving the quality of patient care, including businesses that are: Minority-owned Women-owned Small or disadvantaged Service-disabled Veteran-owned LGBTQ-owned Disability-owned “ I’ve never been more impressed by our diverse network of suppliers than I was in 2020.",2020_boston_scientific_performance_report.pdf
Each came through to ensure our products were available wherever they were needed in the world.,2020_boston_scientific_performance_report.pdf
"We are proud to partner with businesses with so much diversity of talent and perspective.” Saken Khokhar, manager, Supplier DiversityPROTECTING SUPPLY CHAIN STABILITY IN 2020 In early 2020, the Boston Scientific global sourcing team shifted resources to keep our supply chain stable; as a result, we did not experience manufacturing outages amid the pandemic.",2020_boston_scientific_performance_report.pdf
The interventions we took included: Tracking supplier status and inventory in risk areas and taking action to prevent shortages.,2020_boston_scientific_performance_report.pdf
Monitoring safety stock levels and building up product supplies as warranted.,2020_boston_scientific_performance_report.pdf
Mitigating risk for technology and material shortages by identifying new vendors.,2020_boston_scientific_performance_report.pdf
"Analyzing continuity risks by product family.Sustainable Supply Chain The company’s manufacturing and supply chain teams lead our efforts to plan, source, manufacture and distribute more than 17,000 products to customers and patients worldwide.",2020_boston_scientific_performance_report.pdf
"More than 22,000 indirect and direct suppliers meet the highest quality standards for materials and service, ethical conduct, and compliance with all applicable laws and regulations.",2020_boston_scientific_performance_report.pdf
"To identify supply chain partners supporting product development and ongoing supply for manufacturing, we use a standardized supplier performance tool that assesses each organization’s business practices and corporate citizenship.",2020_boston_scientific_performance_report.pdf
"This protocol enables us to build relationships with responsible, high-performing suppliers who make significant contributions to our work.",2020_boston_scientific_performance_report.pdf
"2020 Supplier Diversity: Worked with 3,200 diverse suppliers Spent $599 million on the services of diverse suppliers PERSPECTIVE ON SUPPORTING SUPPLIER DIVERSITY: SAKEN KHOKHAR Boston Scientific 2020 Performance Report 63 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment Responsibly The new SYNERGY™ XD Bioabsorbable Polymer Stent single-barrier packaging system reduced total shipping weight by 26.9 metric tons globally.",2020_boston_scientific_performance_report.pdf
"Packaging and Labeling Packaging practices at Boston Scientific reflect the critical need to ensure the highest quality sterilization, distribution, storage and use of our medical devices.",2020_boston_scientific_performance_report.pdf
We collaborate with customers and conduct usability assessments to ensure we are meeting their needs and requirements.,2020_boston_scientific_performance_report.pdf
The company has controls in place to verify that our product labeling meets global labeling regulations and all internal quality standards.Sustainability in Packaging and Labeling We develop packaging sustainability goals under the guidance of a global sustainability packaging and labeling steering committee.,2020_boston_scientific_performance_report.pdf
"Our packaging and labeling practices include optimizing design, reducing waste and limiting emissions from shipping.",2020_boston_scientific_performance_report.pdf
"In 2020, we conducted a global survey with customers to learn more about their sustainability practices and how we can work together to reduce waste and emissions.",2020_boston_scientific_performance_report.pdf
"As a member of the Healthcare Plastics Recycling Council, we participated in its work to increase the recycling of plastics in clinical settings.",2020_boston_scientific_performance_report.pdf
This work has improved our ability to trace raw materials and learn how our customers dispose of the plastics used to safely deliver our products.,2020_boston_scientific_performance_report.pdf
Boston Scientific packaging teams routinely share case studies to communicate the company’s support for sustainability and to share successful practices with our global teams.,2020_boston_scientific_performance_report.pdf
"In 2020, we shared the following accomplishments: Packaging consolidation: By consolidating sterile barrier systems and sourcing more packaging materials locally in Clonmel, Ireland, the Neuromodulation team avoided using 755 kg of plastic and 1.03 metric tons of carbon emissions.",2020_boston_scientific_performance_report.pdf
"Cold chain packaging redesign: By developing new packaging for SpaceOAR™ Hydrogel and SpaceOAR Vue™ Hydrogel that uses cold chain technology, we shipped more product per pallet and extended the time products can spend in transport.",2020_boston_scientific_performance_report.pdf
"Packaging material efficiency: By shifting from two-pouch packaging to a single-pouch and thinner carton for the SYNERGY™ XD Bioabsorbable Polymer Stent, we reduced total shipping weight by 26.9 metric tons worldwide.",2020_boston_scientific_performance_report.pdf
"REDUCING WASTE WITH ELECTRONIC INSTRUCTIONS To reduce paper waste, we host an eLabeling website where customers can download Instructions for Use (IFU) for an increasing number of Boston Scientific products.",2020_boston_scientific_performance_report.pdf
Many IFU booklets that were previously printed and shipped with devices are now available online in multiple languages.,2020_boston_scientific_performance_report.pdf
"By converting to electronic-only instructions for customers in Korea and Russia, we cut paper waste in the region by 35 metric tons in 2020.",2020_boston_scientific_performance_report.pdf
"2020 Packaging Sustainability Snapshot: 164 metric tons of packaging removed from waste stream 1,100 acres of forest saved 5,300 products diverted from landfills during development 697 pallet shipments avoidedPACKAGING MATERIAL EFFICIENCY Boston Scientific 2020 Performance Report 64 Our Mission Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in Advancing Protecting the Creating Value Stakeholders Our People Possibilities Environment ResponsiblyBoston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-1234 bostonscientific.com© 2021 Boston Scientific Corporation or its affiliates.",2020_boston_scientific_performance_report.pdf
All rights reserved.,2020_boston_scientific_performance_report.pdf
PR2020,2020_boston_scientific_performance_report.pdf
